PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
28710036-3	2017	Carriers of the ABCC4 934CC and ABCB1 1236TT genotypes received a lower percentage of the protocol-recommended starting dose of MTX (62.1 vs. 81.3% for 934CA carriers, p=0.001) and 6MP (73.1 vs. 87.7% for 1236CC/CT carriers; p=0.026), respectively.	Methotrexate	128-131	ATP binding cassette subfamily C member 4	Homo sapiens	16-21
28710036-3	2017	Carriers of the ABCC4 934CC and ABCB1 1236TT genotypes received a lower percentage of the protocol-recommended starting dose of MTX (62.1 vs. 81.3% for 934CA carriers, p=0.001) and 6MP (73.1 vs. 87.7% for 1236CC/CT carriers; p=0.026), respectively.	Mercaptopurine	181-184	ATP binding cassette subfamily C member 4	Homo sapiens	16-21
28735070-0	2017	Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo.	Irinotecan	112-122	ATP binding cassette subfamily C member 4	Homo sapiens	52-57
28630284-10	2017	Taken together, OAT1 and OAT3 interact with the MRP4 inhibitors dantrolene, glafenine, nalidixic acid, and prazosin, indicating overlapping specificities.	Dantrolene	64-74	ATP binding cassette subfamily C member 4	Homo sapiens	48-52
28630284-10	2017	Taken together, OAT1 and OAT3 interact with the MRP4 inhibitors dantrolene, glafenine, nalidixic acid, and prazosin, indicating overlapping specificities.	Glafenine	76-85	ATP binding cassette subfamily C member 4	Homo sapiens	48-52
28630284-2	2017	We hypothesized that recently identified MRP4 inhibitors dantrolene, glafenine, nalidixic acid, and prazosin also interact with human OAT1 and/or OAT3 stably transfected in human embryonic kidney 293 cells.	Dantrolene	57-67	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
28479361-5	2017	Inhibitory affinity of suramin to OATP2A1 was the highest (IC50,2A1 of 0.17 muM), and its IC50 values to MRP4-mediated PGE2 transport (IC50,MRP4) and PGE2 synthesis in human U-937 cells treated with phorbol 12-myristate 13-acetate (IC50,Syn) were 73.6 and 336.7 times higher than IC50,2A1, respectively.	Suramin	23-30	ATP binding cassette subfamily C member 4	Homo sapiens	105-109
28630284-10	2017	Taken together, OAT1 and OAT3 interact with the MRP4 inhibitors dantrolene, glafenine, nalidixic acid, and prazosin, indicating overlapping specificities.	Nalidixic Acid	87-101	ATP binding cassette subfamily C member 4	Homo sapiens	48-52
28479361-5	2017	Inhibitory affinity of suramin to OATP2A1 was the highest (IC50,2A1 of 0.17 muM), and its IC50 values to MRP4-mediated PGE2 transport (IC50,MRP4) and PGE2 synthesis in human U-937 cells treated with phorbol 12-myristate 13-acetate (IC50,Syn) were 73.6 and 336.7 times higher than IC50,2A1, respectively.	Suramin	23-30	ATP binding cassette subfamily C member 4	Homo sapiens	140-144
28630284-2	2017	We hypothesized that recently identified MRP4 inhibitors dantrolene, glafenine, nalidixic acid, and prazosin also interact with human OAT1 and/or OAT3 stably transfected in human embryonic kidney 293 cells.	Glafenine	69-78	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
28630284-2	2017	We hypothesized that recently identified MRP4 inhibitors dantrolene, glafenine, nalidixic acid, and prazosin also interact with human OAT1 and/or OAT3 stably transfected in human embryonic kidney 293 cells.	Nalidixic Acid	80-94	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
28630284-10	2017	Taken together, OAT1 and OAT3 interact with the MRP4 inhibitors dantrolene, glafenine, nalidixic acid, and prazosin, indicating overlapping specificities.	Prazosin	107-115	ATP binding cassette subfamily C member 4	Homo sapiens	48-52
28630284-2	2017	We hypothesized that recently identified MRP4 inhibitors dantrolene, glafenine, nalidixic acid, and prazosin also interact with human OAT1 and/or OAT3 stably transfected in human embryonic kidney 293 cells.	Prazosin	100-108	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
28479361-5	2017	Inhibitory affinity of suramin to OATP2A1 was the highest (IC50,2A1 of 0.17 muM), and its IC50 values to MRP4-mediated PGE2 transport (IC50,MRP4) and PGE2 synthesis in human U-937 cells treated with phorbol 12-myristate 13-acetate (IC50,Syn) were 73.6 and 336.7 times higher than IC50,2A1, respectively.	Dinoprostone	119-123	ATP binding cassette subfamily C member 4	Homo sapiens	105-109
28479361-5	2017	Inhibitory affinity of suramin to OATP2A1 was the highest (IC50,2A1 of 0.17 muM), and its IC50 values to MRP4-mediated PGE2 transport (IC50,MRP4) and PGE2 synthesis in human U-937 cells treated with phorbol 12-myristate 13-acetate (IC50,Syn) were 73.6 and 336.7 times higher than IC50,2A1, respectively.	Dinoprostone	119-123	ATP binding cassette subfamily C member 4	Homo sapiens	140-144
28627473-9	2017	These synergistic actions were primarily due to the inhibitory effect of GA on MRP4 and BCRP, which transport ETV out of hepatocytes.	Glycyrrhetinic Acid	73-75	ATP binding cassette subfamily C member 4	Homo sapiens	79-83
28627473-9	2017	These synergistic actions were primarily due to the inhibitory effect of GA on MRP4 and BCRP, which transport ETV out of hepatocytes.	entecavir	110-113	ATP binding cassette subfamily C member 4	Homo sapiens	79-83
28627473-10	2017	In conclusion, GA interacted with ETV at cellular and subcellular levels in the liver through MRP4 and BCRP inhibition, which enhanced the antiviral activity of ETV.	Glycyrrhetinic Acid	15-17	ATP binding cassette subfamily C member 4	Homo sapiens	94-98
28627473-10	2017	In conclusion, GA interacted with ETV at cellular and subcellular levels in the liver through MRP4 and BCRP inhibition, which enhanced the antiviral activity of ETV.	entecavir	34-37	ATP binding cassette subfamily C member 4	Homo sapiens	94-98
28627473-10	2017	In conclusion, GA interacted with ETV at cellular and subcellular levels in the liver through MRP4 and BCRP inhibition, which enhanced the antiviral activity of ETV.	entecavir	161-164	ATP binding cassette subfamily C member 4	Homo sapiens	94-98
27778300-3	2017	Gd-BOPTA can return to sinusoids via the sinusoidal transporters MRP3/MRP4.	gadobenic acid	0-8	ATP binding cassette subfamily C member 4	Homo sapiens	70-74
28371506-12	2017	A rare population-specific allele (P1036L) with predicted strong functional consequence reduced the uric acid transport activity of ABCC4 by 30%.	Uric Acid	100-109	ATP binding cassette subfamily C member 4	Homo sapiens	132-137
28765596-0	2017	A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients.	Fluorouracil	50-54	ATP binding cassette subfamily C member 4	Homo sapiens	18-23
28765596-0	2017	A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients.	Capecitabine	55-67	ATP binding cassette subfamily C member 4	Homo sapiens	18-23
28765596-4	2017	Statistical analysis showed that a polymorphism rs3742106 in the 3"-UTR of ATP-binding cassette subfamily C member 4 (ABCC4) gene was significantly associated with the efficacy of 5-FU/capecitabine-based chemotherapy in CRC.	Fluorouracil	180-184	ATP binding cassette subfamily C member 4	Homo sapiens	75-116
28765596-4	2017	Statistical analysis showed that a polymorphism rs3742106 in the 3"-UTR of ATP-binding cassette subfamily C member 4 (ABCC4) gene was significantly associated with the efficacy of 5-FU/capecitabine-based chemotherapy in CRC.	Fluorouracil	180-184	ATP binding cassette subfamily C member 4	Homo sapiens	118-123
28765596-4	2017	Statistical analysis showed that a polymorphism rs3742106 in the 3"-UTR of ATP-binding cassette subfamily C member 4 (ABCC4) gene was significantly associated with the efficacy of 5-FU/capecitabine-based chemotherapy in CRC.	Capecitabine	185-197	ATP binding cassette subfamily C member 4	Homo sapiens	75-116
28765596-4	2017	Statistical analysis showed that a polymorphism rs3742106 in the 3"-UTR of ATP-binding cassette subfamily C member 4 (ABCC4) gene was significantly associated with the efficacy of 5-FU/capecitabine-based chemotherapy in CRC.	Capecitabine	185-197	ATP binding cassette subfamily C member 4	Homo sapiens	118-123
29108246-3	2017	In human endometrial epithelial cells, MRP4 expression is upregulated by ENaC activation and the inhibition of MRP4 blocks ENaC-dependent PGE2 release as well as phosphorylation of CREB.	Dinoprostone	138-142	ATP binding cassette subfamily C member 4	Homo sapiens	39-43
29108246-3	2017	In human endometrial epithelial cells, MRP4 expression is upregulated by ENaC activation and the inhibition of MRP4 blocks ENaC-dependent PGE2 release as well as phosphorylation of CREB.	Dinoprostone	138-142	ATP binding cassette subfamily C member 4	Homo sapiens	111-115
28863172-11	2017	In HBEC-6KT, production of uric acid was sensitive to the xanthine dehydrogenase (XDH) inhibitor, allopurinol, and the ATP Binding Cassette C4 (ABCC4) inhibitor, MK-571.	Uric Acid	27-36	ATP binding cassette subfamily C member 4	Homo sapiens	119-142
28863172-11	2017	In HBEC-6KT, production of uric acid was sensitive to the xanthine dehydrogenase (XDH) inhibitor, allopurinol, and the ATP Binding Cassette C4 (ABCC4) inhibitor, MK-571.	Uric Acid	27-36	ATP binding cassette subfamily C member 4	Homo sapiens	144-149
28863172-11	2017	In HBEC-6KT, production of uric acid was sensitive to the xanthine dehydrogenase (XDH) inhibitor, allopurinol, and the ATP Binding Cassette C4 (ABCC4) inhibitor, MK-571.	verlukast	162-168	ATP binding cassette subfamily C member 4	Homo sapiens	119-142
28863172-11	2017	In HBEC-6KT, production of uric acid was sensitive to the xanthine dehydrogenase (XDH) inhibitor, allopurinol, and the ATP Binding Cassette C4 (ABCC4) inhibitor, MK-571.	verlukast	162-168	ATP binding cassette subfamily C member 4	Homo sapiens	144-149
28677646-4	2017	3-(4,5-Dimethyl-2-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay clearly indicated that the EC50 values of azathioprine against cells expressing ABCC4 (WT) were 1.4-1.7-fold higher than those against cells expressing SNP variants of ABCC4 (M184K; N297S; K304N or E757K).	3-(4,5-dimethyl-2-thiazol-2-yl)-2,5-diphenyl-2h-tetrazolium bromide	0-67	ATP binding cassette subfamily C member 4	Homo sapiens	160-165
28677646-4	2017	3-(4,5-Dimethyl-2-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay clearly indicated that the EC50 values of azathioprine against cells expressing ABCC4 (WT) were 1.4-1.7-fold higher than those against cells expressing SNP variants of ABCC4 (M184K; N297S; K304N or E757K).	3-(4,5-dimethyl-2-thiazol-2-yl)-2,5-diphenyl-2h-tetrazolium bromide	0-67	ATP binding cassette subfamily C member 4	Homo sapiens	248-253
28677646-4	2017	3-(4,5-Dimethyl-2-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay clearly indicated that the EC50 values of azathioprine against cells expressing ABCC4 (WT) were 1.4-1.7-fold higher than those against cells expressing SNP variants of ABCC4 (M184K; N297S; K304N or E757K).	monooxyethylene trimethylolpropane tristearate	69-72	ATP binding cassette subfamily C member 4	Homo sapiens	160-165
28677646-4	2017	3-(4,5-Dimethyl-2-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay clearly indicated that the EC50 values of azathioprine against cells expressing ABCC4 (WT) were 1.4-1.7-fold higher than those against cells expressing SNP variants of ABCC4 (M184K; N297S; K304N or E757K).	monooxyethylene trimethylolpropane tristearate	69-72	ATP binding cassette subfamily C member 4	Homo sapiens	248-253
28677646-4	2017	3-(4,5-Dimethyl-2-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay clearly indicated that the EC50 values of azathioprine against cells expressing ABCC4 (WT) were 1.4-1.7-fold higher than those against cells expressing SNP variants of ABCC4 (M184K; N297S; K304N or E757K).	Azathioprine	122-134	ATP binding cassette subfamily C member 4	Homo sapiens	160-165
28677646-4	2017	3-(4,5-Dimethyl-2-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay clearly indicated that the EC50 values of azathioprine against cells expressing ABCC4 (WT) were 1.4-1.7-fold higher than those against cells expressing SNP variants of ABCC4 (M184K; N297S; K304N or E757K).	Azathioprine	122-134	ATP binding cassette subfamily C member 4	Homo sapiens	248-253
28677646-5	2017	EC50 values of 6-mercaptopurine or 7-Ethyl-10-hydroxy-camptothecin (SN-38) against cells expressing ABCC4 (WT) were also 1.4-2.0- or 1.9-fold higher than those against cells expressing the SNP variants of ABCC4 (K304N or E757K) or (K304N; P403L or E757K); respectively.	Mercaptopurine	15-31	ATP binding cassette subfamily C member 4	Homo sapiens	100-105
28677646-5	2017	EC50 values of 6-mercaptopurine or 7-Ethyl-10-hydroxy-camptothecin (SN-38) against cells expressing ABCC4 (WT) were also 1.4-2.0- or 1.9-fold higher than those against cells expressing the SNP variants of ABCC4 (K304N or E757K) or (K304N; P403L or E757K); respectively.	Mercaptopurine	15-31	ATP binding cassette subfamily C member 4	Homo sapiens	205-210
28677646-5	2017	EC50 values of 6-mercaptopurine or 7-Ethyl-10-hydroxy-camptothecin (SN-38) against cells expressing ABCC4 (WT) were also 1.4-2.0- or 1.9-fold higher than those against cells expressing the SNP variants of ABCC4 (K304N or E757K) or (K304N; P403L or E757K); respectively.	Irinotecan	68-73	ATP binding cassette subfamily C member 4	Homo sapiens	100-105
28677646-5	2017	EC50 values of 6-mercaptopurine or 7-Ethyl-10-hydroxy-camptothecin (SN-38) against cells expressing ABCC4 (WT) were also 1.4-2.0- or 1.9-fold higher than those against cells expressing the SNP variants of ABCC4 (K304N or E757K) or (K304N; P403L or E757K); respectively.	Irinotecan	68-73	ATP binding cassette subfamily C member 4	Homo sapiens	205-210
28371506-13	2017	CONCLUSION: An association between ABCC4 and gout and fractional excretion of uric acid is consistent with the established role of MRP4 as a unidirectional renal uric acid efflux pump.	Uric Acid	78-87	ATP binding cassette subfamily C member 4	Homo sapiens	35-40
28371506-13	2017	CONCLUSION: An association between ABCC4 and gout and fractional excretion of uric acid is consistent with the established role of MRP4 as a unidirectional renal uric acid efflux pump.	Uric Acid	78-87	ATP binding cassette subfamily C member 4	Homo sapiens	131-135
28371506-13	2017	CONCLUSION: An association between ABCC4 and gout and fractional excretion of uric acid is consistent with the established role of MRP4 as a unidirectional renal uric acid efflux pump.	Uric Acid	162-171	ATP binding cassette subfamily C member 4	Homo sapiens	35-40
28371506-13	2017	CONCLUSION: An association between ABCC4 and gout and fractional excretion of uric acid is consistent with the established role of MRP4 as a unidirectional renal uric acid efflux pump.	Uric Acid	162-171	ATP binding cassette subfamily C member 4	Homo sapiens	131-135
27737931-1	2017	Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3].	Rosuvastatin Calcium	0-12	ATP binding cassette subfamily C member 4	Homo sapiens	355-359
28258008-11	2017	Using purified HEK293 membrane vesicles overexpressing MRP1, MRP2, MRP3, and MRP4, we also demonstrated that the identified compounds exert differential and selective response on the uptake of estradiol glucuronide, an endogenous MRP substrate.	estradiol-17 beta-glucuronide	193-214	ATP binding cassette subfamily C member 4	Homo sapiens	77-81
26927285-3	2017	Moreover, a common variant in the multidrug resistance protein-4 coding gene (ABCC4, rs17268282) was associated with weight loss with furosemide use (P=0.0001).	Furosemide	134-144	ATP binding cassette subfamily C member 4	Homo sapiens	78-83
28029661-0	2017	Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.	Dinoprostone	59-75	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
28029661-0	2017	Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.	Dinoprostone	77-81	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
28029661-5	2017	Genetic or pharmacologic suppression of MRP4 expression or activity in basal cell lines led to less extracellular PGE2.	Dinoprostone	114-118	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
28029661-8	2017	In addition to the well-established role of high COX-2 in promoting metastasis, these data identify an additional mechanism to achieve high PGE2 in the tumor microenvironment; high MRP4, low PGT, and low 15-PGDH.	Dinoprostone	140-144	ATP binding cassette subfamily C member 4	Homo sapiens	181-185
27761583-1	2017	The multidrug resistance protein 4 (MRP4/ABCC4) has been identified as an important transporter for signalling molecules including cyclic nucleotides and several lipid mediators in platelets and may thus represent a novel target to interfere with platelet function.	Nucleotides, Cyclic	131-149	ATP binding cassette subfamily C member 4	Homo sapiens	36-40
27761583-1	2017	The multidrug resistance protein 4 (MRP4/ABCC4) has been identified as an important transporter for signalling molecules including cyclic nucleotides and several lipid mediators in platelets and may thus represent a novel target to interfere with platelet function.	Nucleotides, Cyclic	131-149	ATP binding cassette subfamily C member 4	Homo sapiens	41-46
28249282-6	2017	ATP-dependent efflux transporters localized to the basolateral (sinusoidal) hepatocyte membrane, particularly MRP3 (ABCC3) and MRP4 (ABCC4), pump substances from hepatocytes into sinusoidal blood.	Adenosine Triphosphate	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	127-131
28249282-6	2017	ATP-dependent efflux transporters localized to the basolateral (sinusoidal) hepatocyte membrane, particularly MRP3 (ABCC3) and MRP4 (ABCC4), pump substances from hepatocytes into sinusoidal blood.	Adenosine Triphosphate	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	133-138
28249282-7	2017	Bile acids are substrates for human MRP4 in the presence of physiological concentrations of reduced glutathione, which undergoes co-transport.	Bile Acids and Salts	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	36-40
28249282-7	2017	Bile acids are substrates for human MRP4 in the presence of physiological concentrations of reduced glutathione, which undergoes co-transport.	Glutathione	100-111	ATP binding cassette subfamily C member 4	Homo sapiens	36-40
28493713-6	2017	Methotrexate inhibited OAT-mediated fluorescein uptake and decreased efflux of Hoechst33342 and glutathione-methylfluorescein (GS-MF), which suggested involvement of OAT1/3, BCRP, and MRP4 in transepithelial transport, respectively.	Methotrexate	0-12	ATP binding cassette subfamily C member 4	Homo sapiens	184-188
27649261-4	2016	With regard to B-cell ALL, we have previously found rs56103835 in miR-323b that targets ABCC4 associated with MTX plasma levels.	Methotrexate	110-113	ATP binding cassette subfamily C member 4	Homo sapiens	88-93
28659663-11	2017	A functional polymorphism in the ABCC4 promoter, -1508A>G, may increase extracellular 15-hydroxyeicosatetraenoic acid, sphingosine-1-phosphate, and periostin levels, contributing to airway inflammation in asthmatics.	Eicosatetraenoic acid, 15-hydroxy-	89-120	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
28659663-11	2017	A functional polymorphism in the ABCC4 promoter, -1508A>G, may increase extracellular 15-hydroxyeicosatetraenoic acid, sphingosine-1-phosphate, and periostin levels, contributing to airway inflammation in asthmatics.	sphingosine 1-phosphate	122-145	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
28883280-0	2017	Susceptibility to 6-mercaptopurine toxicity related with NUDT15 and ABCC4 variants in Japanese childhood acute lymphoblastic leukemia.	Mercaptopurine	18-34	ATP binding cassette subfamily C member 4	Homo sapiens	68-73
28883280-5	2017	Therefore, we hypothesized that the combination of NUDT15 genotype with ABCC4 genotype, which is associated with 6-MP efflux, might enable to accurately predict 6-MP intolerability.	Mercaptopurine	113-117	ATP binding cassette subfamily C member 4	Homo sapiens	72-77
27659809-0	2016	Polymorphic variants of MRP4/ABCC4 differentially modulate the transport of methylated arsenic metabolites and physiological organic anions.	Arsenic	87-94	ATP binding cassette subfamily C member 4	Homo sapiens	24-28
27659809-0	2016	Polymorphic variants of MRP4/ABCC4 differentially modulate the transport of methylated arsenic metabolites and physiological organic anions.	Arsenic	87-94	ATP binding cassette subfamily C member 4	Homo sapiens	29-34
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	Cacodylic Acid	119-139	ATP binding cassette subfamily C member 4	Homo sapiens	61-65
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	Cacodylic Acid	119-139	ATP binding cassette subfamily C member 4	Homo sapiens	66-71
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	Dimethylarsinate	141-145	ATP binding cassette subfamily C member 4	Homo sapiens	61-65
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	Dimethylarsinate	141-145	ATP binding cassette subfamily C member 4	Homo sapiens	66-71
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	Arsenic	166-173	ATP binding cassette subfamily C member 4	Homo sapiens	61-65
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	Arsenic	166-173	ATP binding cassette subfamily C member 4	Homo sapiens	66-71
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	diglutathione	204-217	ATP binding cassette subfamily C member 4	Homo sapiens	61-65
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	diglutathione	204-217	ATP binding cassette subfamily C member 4	Homo sapiens	66-71
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	monomethylarsonous acid	248-271	ATP binding cassette subfamily C member 4	Homo sapiens	61-65
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	monomethylarsonous acid	248-271	ATP binding cassette subfamily C member 4	Homo sapiens	66-71
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	mma	273-276	ATP binding cassette subfamily C member 4	Homo sapiens	61-65
27659809-2	2016	We recently identified human multidrug resistance protein 4 (MRP4/ABCC4) as a novel pathway for the cellular export of dimethylarsinic acid (DMAV), the major urinary arsenic metabolite in humans, and the diglutathione conjugate of the highly toxic monomethylarsonous acid [MMA(GS)2].	mma	273-276	ATP binding cassette subfamily C member 4	Homo sapiens	66-71
27659809-3	2016	These findings, together with the basolateral and apical membrane localization of MRP4 in hepatocytes and renal proximal tubule cells, respectively, suggest a role for MRP4 in the urinary elimination of hepatic arsenic metabolites.	Arsenic	211-218	ATP binding cassette subfamily C member 4	Homo sapiens	82-86
27659809-3	2016	These findings, together with the basolateral and apical membrane localization of MRP4 in hepatocytes and renal proximal tubule cells, respectively, suggest a role for MRP4 in the urinary elimination of hepatic arsenic metabolites.	Arsenic	211-218	ATP binding cassette subfamily C member 4	Homo sapiens	168-172
27659809-6	2016	Characterization of the six correctly localized mutants revealed that MMA(GS)2 transport by C171G-, G187W-, and K304N-MRP4 was 180%, 73%, and 30% of WT-MRP4 activity, respectively, whereas DMAV transport by K304N- and Y556C-MRP4 was 30% and 184% of WT-MRP4, respectively.	Dimethylarsinate	189-193	ATP binding cassette subfamily C member 4	Homo sapiens	118-122
27659809-7	2016	Transport of the prototypical physiological MRP4 substrates prostaglandin E2 and 17beta-estradiol 17-(beta-d-glucuronide) by the six variants was also differentially affected.	Dinoprostone	60-76	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
27659809-7	2016	Transport of the prototypical physiological MRP4 substrates prostaglandin E2 and 17beta-estradiol 17-(beta-d-glucuronide) by the six variants was also differentially affected.	17beta-estradiol 17-(	81-102	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
27659809-7	2016	Transport of the prototypical physiological MRP4 substrates prostaglandin E2 and 17beta-estradiol 17-(beta-d-glucuronide) by the six variants was also differentially affected.	beta-d-glucuronide	102-120	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
27659809-8	2016	Thus, MRP4 variants have differing abilities to transport arsenic and endogenous metabolites through both altered function and membrane localization.	Arsenic	58-65	ATP binding cassette subfamily C member 4	Homo sapiens	6-10
27659809-9	2016	Further investigation is warranted to determine if genetic variations in ABCC4 contribute to inter-individual differences in susceptibility to arsenic-induced (and potentially other) diseases.	Arsenic	143-150	ATP binding cassette subfamily C member 4	Homo sapiens	73-78
28204955-9	2017	Besides PDEs, the transporters MRP4 and 5 are of major importance for cAMP and cGMP disposal.	Cyclic AMP	70-74	ATP binding cassette subfamily C member 4	Homo sapiens	31-41
28204955-9	2017	Besides PDEs, the transporters MRP4 and 5 are of major importance for cAMP and cGMP disposal.	Cyclic GMP	79-83	ATP binding cassette subfamily C member 4	Homo sapiens	31-41
28042832-0	2016	R-Flurbiprofen Traps Prostaglandins within Cells by Inhibition of Multidrug Resistance-Associated Protein-4.	Flurbiprofen	0-14	ATP binding cassette subfamily C member 4	Homo sapiens	66-107
28042832-0	2016	R-Flurbiprofen Traps Prostaglandins within Cells by Inhibition of Multidrug Resistance-Associated Protein-4.	Prostaglandins	21-35	ATP binding cassette subfamily C member 4	Homo sapiens	66-107
28042832-3	2016	Here, we show that R-flurbiprofen acts through a dual mechanism: (i) it inhibits the translocation of cPLA2alpha to the plasma membrane and thereby curtails the availability of arachidonic acid and (ii) R-flurbiprofen traps PGE2 inside of the cells by inhibiting multidrug resistance-associated protein 4 (MRP4, ABCC4), which acts as an outward transporter for prostaglandins.	Flurbiprofen	19-33	ATP binding cassette subfamily C member 4	Homo sapiens	263-304
28042832-3	2016	Here, we show that R-flurbiprofen acts through a dual mechanism: (i) it inhibits the translocation of cPLA2alpha to the plasma membrane and thereby curtails the availability of arachidonic acid and (ii) R-flurbiprofen traps PGE2 inside of the cells by inhibiting multidrug resistance-associated protein 4 (MRP4, ABCC4), which acts as an outward transporter for prostaglandins.	Flurbiprofen	19-33	ATP binding cassette subfamily C member 4	Homo sapiens	306-310
28042832-3	2016	Here, we show that R-flurbiprofen acts through a dual mechanism: (i) it inhibits the translocation of cPLA2alpha to the plasma membrane and thereby curtails the availability of arachidonic acid and (ii) R-flurbiprofen traps PGE2 inside of the cells by inhibiting multidrug resistance-associated protein 4 (MRP4, ABCC4), which acts as an outward transporter for prostaglandins.	Flurbiprofen	19-33	ATP binding cassette subfamily C member 4	Homo sapiens	312-317
28042832-4	2016	Consequently, the effects of R-flurbiprofen were mimicked by RNAi-mediated knockdown of MRP4.	Flurbiprofen	29-43	ATP binding cassette subfamily C member 4	Homo sapiens	88-92
28042832-5	2016	Our data show a novel mechanism by which R-flurbiprofen reduces extracellular PGs at physiological concentrations, particularly in cancers with high levels of MRP4, but the mechanism may also contribute to its anti-inflammatory and immune-modulating properties and suggests that it reduces PGs in a site- and context-dependent manner.	Flurbiprofen	41-55	ATP binding cassette subfamily C member 4	Homo sapiens	159-163
28042832-5	2016	Our data show a novel mechanism by which R-flurbiprofen reduces extracellular PGs at physiological concentrations, particularly in cancers with high levels of MRP4, but the mechanism may also contribute to its anti-inflammatory and immune-modulating properties and suggests that it reduces PGs in a site- and context-dependent manner.	Phosphatidylglycerols	78-81	ATP binding cassette subfamily C member 4	Homo sapiens	159-163
27683757-0	2016	Enhanced platelet MRP4 expression and correlation with platelet function in patients under chronic aspirin treatment.	Aspirin	99-106	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
27683757-1	2016	Platelet multidrug resistance protein4 (MRP4)-overexpression has a role in reducing aspirin action.	Aspirin	84-91	ATP binding cassette subfamily C member 4	Homo sapiens	9-38
27683757-1	2016	Platelet multidrug resistance protein4 (MRP4)-overexpression has a role in reducing aspirin action.	Aspirin	84-91	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
27683757-2	2016	Aspirin in vivo treatment enhances platelet MRP4 expression and MRP4 mediated transport inhibition reduces platelet function and delays thrombus formation.	Aspirin	0-7	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
27683757-3	2016	The aim of our work was to verify whether MRP4 expression is enhanced in platelets obtained from patients under chronic aspirin treatment and whether it correlates with residual platelet reactivity.	Aspirin	120-127	ATP binding cassette subfamily C member 4	Homo sapiens	42-46
27683757-6	2016	Platelets obtained from ASA>2 months patients that present high levels of platelet MRP4, have higher serum TxB2 levels and collagen-induced platelet aggregation compared to patient with low levels of MRP4 in platelets.	Aspirin	24-27	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
27683757-6	2016	Platelets obtained from ASA>2 months patients that present high levels of platelet MRP4, have higher serum TxB2 levels and collagen-induced platelet aggregation compared to patient with low levels of MRP4 in platelets.	Aspirin	24-27	ATP binding cassette subfamily C member 4	Homo sapiens	203-207
27683757-8	2016	We can assert that, in patients under chronic aspirin treatment, platelets that present high MRP4 levels have an increase of residual platelet reactivity, which is due in part to incomplete COX-1 inhibition, and in part to COX-1-independent mechanism.	Aspirin	46-53	ATP binding cassette subfamily C member 4	Homo sapiens	93-97
27754421-9	2016	Fluciclovine inhibited P-gp, MRP4, OAT1, OCT2, and OATP1B1 (IC50 > 2.95 mM).	fluciclovine F-18	0-12	ATP binding cassette subfamily C member 4	Homo sapiens	29-33
27664577-10	2016	We found up-regulation of ABCG2/BCRP and ABCC4 proteins only in paclitaxel-resistant SK-BR-3 cells.	Paclitaxel	64-74	ATP binding cassette subfamily C member 4	Homo sapiens	41-46
27432651-7	2016	In addition, shbeta-catenin abolished the DVL2-induced the expression of BCRP, MRP4, and Survivin.	shbeta-catenin	13-27	ATP binding cassette subfamily C member 4	Homo sapiens	79-83
27628421-0	2016	Influence of Genetic Polymorphisms in Prostaglandin E2 Pathway (COX-2/HPGD/SLCO2A1/ABCC4) on the Risk for Colorectal Adenoma Development and Recurrence after Polypectomy.	Dinoprostone	38-54	ATP binding cassette subfamily C member 4	Homo sapiens	83-88
27628421-2	2016	Our aim was to evaluate the influence of the genetic variability in COX-2/HPGD/SLCO2A1/ABCC4 PGE2 pathway genes on the development and recurrence of colorectal adenomas.	Dinoprostone	93-97	ATP binding cassette subfamily C member 4	Homo sapiens	87-92
27402191-0	2016	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients.	Ganciclovir	58-69	ATP binding cassette subfamily C member 4	Homo sapiens	0-41
27402191-0	2016	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients.	Ganciclovir	58-69	ATP binding cassette subfamily C member 4	Homo sapiens	43-47
27402191-0	2016	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients.	Ganciclovir	116-127	ATP binding cassette subfamily C member 4	Homo sapiens	0-41
27402191-0	2016	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients.	Ganciclovir	116-127	ATP binding cassette subfamily C member 4	Homo sapiens	43-47
27402191-7	2016	In both cohorts, we found a variant in ABCC4 (rs11568658) associated with decreased neutrophil counts following valganciclovir (GCV prodrug) administration (exploratory cohort: beta+-SD=-0.68+-0.28, p=0.029; replication cohort: beta+-SD=-0.84+-0.29, p=0.0078).	Valganciclovir	112-126	ATP binding cassette subfamily C member 4	Homo sapiens	39-44
27402191-7	2016	In both cohorts, we found a variant in ABCC4 (rs11568658) associated with decreased neutrophil counts following valganciclovir (GCV prodrug) administration (exploratory cohort: beta+-SD=-0.68+-0.28, p=0.029; replication cohort: beta+-SD=-0.84+-0.29, p=0.0078).	Ganciclovir	128-131	ATP binding cassette subfamily C member 4	Homo sapiens	39-44
27402191-8	2016	MRP4-expressing cells showed decreased GCV accumulation as compared to negative control cells (transfected with an empty vector) (-61%; p<0.0001).	Ganciclovir	39-42	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
26950035-3	2016	Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds.	Irinotecan	117-127	ATP binding cassette subfamily C member 4	Homo sapiens	53-94
26950035-3	2016	Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds.	Irinotecan	117-127	ATP binding cassette subfamily C member 4	Homo sapiens	96-100
26950035-3	2016	Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds.	Platinum	234-242	ATP binding cassette subfamily C member 4	Homo sapiens	53-94
26950035-3	2016	Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds.	Platinum	234-242	ATP binding cassette subfamily C member 4	Homo sapiens	96-100
27274832-13	2016	SNPs in other SLC (e.g. SLC22A8 or OAT3) and ABC (e.g. ABCC4 or MRP4) genes appear to make a weak gender-dependent contribution to uric acid homeostasis in CKD.	Uric Acid	131-140	ATP binding cassette subfamily C member 4	Homo sapiens	55-60
27274832-13	2016	SNPs in other SLC (e.g. SLC22A8 or OAT3) and ABC (e.g. ABCC4 or MRP4) genes appear to make a weak gender-dependent contribution to uric acid homeostasis in CKD.	Uric Acid	131-140	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
27206740-9	2016	Additionally, the activity of multidrug-resistance-associated protein-4 (MRP4; cGMP-membrane transporter) was significantly lower in ESRD-RBCs, suggesting a possible compromised efflux of cGMP across the ESRD-RBCs membrane.	Cyclic GMP	79-83	ATP binding cassette subfamily C member 4	Homo sapiens	30-71
27206740-9	2016	Additionally, the activity of multidrug-resistance-associated protein-4 (MRP4; cGMP-membrane transporter) was significantly lower in ESRD-RBCs, suggesting a possible compromised efflux of cGMP across the ESRD-RBCs membrane.	Cyclic GMP	79-83	ATP binding cassette subfamily C member 4	Homo sapiens	73-77
27206740-9	2016	Additionally, the activity of multidrug-resistance-associated protein-4 (MRP4; cGMP-membrane transporter) was significantly lower in ESRD-RBCs, suggesting a possible compromised efflux of cGMP across the ESRD-RBCs membrane.	Cyclic GMP	188-192	ATP binding cassette subfamily C member 4	Homo sapiens	30-71
27206740-9	2016	Additionally, the activity of multidrug-resistance-associated protein-4 (MRP4; cGMP-membrane transporter) was significantly lower in ESRD-RBCs, suggesting a possible compromised efflux of cGMP across the ESRD-RBCs membrane.	Cyclic GMP	188-192	ATP binding cassette subfamily C member 4	Homo sapiens	73-77
27063943-1	2016	This review focuses on multidrug resistance protein 4 (MRP4 or ABCC4) that has recently been shown to play a role in cAMP homeostasis, a key-pathway in vascular biology and in platelet functions.	Cyclic AMP	117-121	ATP binding cassette subfamily C member 4	Homo sapiens	55-59
27257388-0	2016	Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer.	Dinoprostone	33-49	ATP binding cassette subfamily C member 4	Homo sapiens	78-123
27257388-0	2016	Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer.	Dinoprostone	33-49	ATP binding cassette subfamily C member 4	Homo sapiens	125-129
27257388-0	2016	Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer.	Dinoprostone	57-61	ATP binding cassette subfamily C member 4	Homo sapiens	78-123
27257388-0	2016	Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer.	Dinoprostone	57-61	ATP binding cassette subfamily C member 4	Homo sapiens	125-129
27257388-3	2016	PGE2 is produced by COX-2 and actively exported by multiple drug resistance-associated protein 4 (MRP4) into the extracellular microenvironment, where PGE2 can bind four cognate EP receptors (EP1-EP4) and initiate diverse biological signaling pathways.	Dinoprostone	0-4	ATP binding cassette subfamily C member 4	Homo sapiens	51-96
27257388-3	2016	PGE2 is produced by COX-2 and actively exported by multiple drug resistance-associated protein 4 (MRP4) into the extracellular microenvironment, where PGE2 can bind four cognate EP receptors (EP1-EP4) and initiate diverse biological signaling pathways.	Dinoprostone	0-4	ATP binding cassette subfamily C member 4	Homo sapiens	98-102
27257388-3	2016	PGE2 is produced by COX-2 and actively exported by multiple drug resistance-associated protein 4 (MRP4) into the extracellular microenvironment, where PGE2 can bind four cognate EP receptors (EP1-EP4) and initiate diverse biological signaling pathways.	Dinoprostone	151-155	ATP binding cassette subfamily C member 4	Homo sapiens	51-96
27257388-3	2016	PGE2 is produced by COX-2 and actively exported by multiple drug resistance-associated protein 4 (MRP4) into the extracellular microenvironment, where PGE2 can bind four cognate EP receptors (EP1-EP4) and initiate diverse biological signaling pathways.	Dinoprostone	151-155	ATP binding cassette subfamily C member 4	Homo sapiens	98-102
27257388-6	2016	In triple-negative breast cancer, the observed gene expression pattern (high COX-2, high MRP4, low PGT, and low 15-PGDH) would favor high levels of tumor-promoting PGE2 in the tumor microenvironment that may contribute to the overall poor prognosis of triple-negative breast cancer.	Dinoprostone	164-168	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
27285126-1	2016	Multidrug resistance protein 4 (MRP4) is a member of the ATP-binding cassette family of membrane transporters and is an endogenous efflux transporter of cyclic nucleotides.	Nucleotides, Cyclic	153-171	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
27285126-1	2016	Multidrug resistance protein 4 (MRP4) is a member of the ATP-binding cassette family of membrane transporters and is an endogenous efflux transporter of cyclic nucleotides.	Nucleotides, Cyclic	153-171	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
27285126-2	2016	By modulating intracellular cyclic nucleotide concentration, MRP4 can regulate multiple cyclic nucleotide-dependent cellular events including cell migration.	Nucleotides, Cyclic	28-45	ATP binding cassette subfamily C member 4	Homo sapiens	61-65
27285126-2	2016	By modulating intracellular cyclic nucleotide concentration, MRP4 can regulate multiple cyclic nucleotide-dependent cellular events including cell migration.	Nucleotides, Cyclic	88-105	ATP binding cassette subfamily C member 4	Homo sapiens	61-65
27001813-7	2016	Micafungin uniquely inhibited all transporters, with strong inhibition of MRP4 (4 muM).	Micafungin	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	74-78
27063943-1	2016	This review focuses on multidrug resistance protein 4 (MRP4 or ABCC4) that has recently been shown to play a role in cAMP homeostasis, a key-pathway in vascular biology and in platelet functions.	Cyclic AMP	117-121	ATP binding cassette subfamily C member 4	Homo sapiens	63-68
27063943-7	2016	The localization of MRP4 underlines the emerging concept of cAMP compartmentalization in platelets, which is a major regulatory mechanism in other cells.	Cyclic AMP	60-64	ATP binding cassette subfamily C member 4	Homo sapiens	20-24
26758854-0	2016	Efflux Transport Characterization of Resveratrol Glucuronides in UDP-Glucuronosyltransferase 1A1 Transfected HeLa Cells: Application of a Cellular Pharmacokinetic Model to Decipher the Contribution of Multidrug Resistance-Associated Protein 4.	resveratrol glucuronides	37-61	ATP binding cassette subfamily C member 4	Homo sapiens	201-242
26758854-7	2016	Likewise, short-hairpin RNA (shRNA)-mediated silencing of MRP4 caused a significant reduction in glucuronide excretion but an elevation in glucuronide accumulation.	Glucuronides	97-108	ATP binding cassette subfamily C member 4	Homo sapiens	58-62
26758854-7	2016	Likewise, short-hairpin RNA (shRNA)-mediated silencing of MRP4 caused a significant reduction in glucuronide excretion but an elevation in glucuronide accumulation.	Glucuronides	139-150	ATP binding cassette subfamily C member 4	Homo sapiens	58-62
26758854-10	2016	It was found that a large percentage of glucuronide excretion (43%-46%) was attributed to MRP4.	Glucuronides	40-51	ATP binding cassette subfamily C member 4	Homo sapiens	90-94
26659924-6	2016	Notably, NSAIDs-Glu potently inhibited MTX uptake via MRP2 and MRP4 compared with the corresponding parent NSAIDs except for naproxen in MRP2 and S-flurbiprofen in MRP4.	Glutamic Acid	16-19	ATP binding cassette subfamily C member 4	Homo sapiens	63-67
26659924-5	2016	Results confirm that all NSAIDs and NSAIDs-Glu examined exhibited stereoselective and concentration-dependent inhibitory effects on MTX uptake via MRP2 and MRP4.	Glutamic Acid	43-46	ATP binding cassette subfamily C member 4	Homo sapiens	156-160
27045542-1	2016	AIM: Determine if individuals with beta-lactam induced neutropenia have polymorphisms that impair function of MRP4 or OAT1/OAT3.	beta-Lactams	35-46	ATP binding cassette subfamily C member 4	Homo sapiens	110-114
27045542-6	2016	CONCLUSION: MRP4 3348 A to G should be further studied for potential contribution to the development of beta-lactam induced neutropenia.	beta-Lactams	104-115	ATP binding cassette subfamily C member 4	Homo sapiens	12-16
26842729-3	2016	The uptake of cytarabine and its monophosphate metabolite was found to be facilitated in ABCC4-expressing vesicles and intracellular retention was significantly impaired by overexpression of human ABCC4 or mouse Abcc4 (P < 0.05).	Cytarabine	14-24	ATP binding cassette subfamily C member 4	Homo sapiens	89-94
26842729-3	2016	The uptake of cytarabine and its monophosphate metabolite was found to be facilitated in ABCC4-expressing vesicles and intracellular retention was significantly impaired by overexpression of human ABCC4 or mouse Abcc4 (P < 0.05).	Cytarabine	14-24	ATP binding cassette subfamily C member 4	Homo sapiens	197-202
26842729-3	2016	The uptake of cytarabine and its monophosphate metabolite was found to be facilitated in ABCC4-expressing vesicles and intracellular retention was significantly impaired by overexpression of human ABCC4 or mouse Abcc4 (P < 0.05).	monophosphate	33-46	ATP binding cassette subfamily C member 4	Homo sapiens	89-94
26659924-5	2016	Results confirm that all NSAIDs and NSAIDs-Glu examined exhibited stereoselective and concentration-dependent inhibitory effects on MTX uptake via MRP2 and MRP4.	Methotrexate	132-135	ATP binding cassette subfamily C member 4	Homo sapiens	156-160
26659924-6	2016	Notably, NSAIDs-Glu potently inhibited MTX uptake via MRP2 and MRP4 compared with the corresponding parent NSAIDs except for naproxen in MRP2 and S-flurbiprofen in MRP4.	Methotrexate	39-42	ATP binding cassette subfamily C member 4	Homo sapiens	63-67
26659924-7	2016	The present results support that the glucuronides of NSAIDs, as well as the parent NSAIDs, are involved in the inhibition of urinary excretion of MTX via MRP2 and MRP4.	Glucuronides	37-49	ATP binding cassette subfamily C member 4	Homo sapiens	163-167
26659924-7	2016	The present results support that the glucuronides of NSAIDs, as well as the parent NSAIDs, are involved in the inhibition of urinary excretion of MTX via MRP2 and MRP4.	Methotrexate	146-149	ATP binding cassette subfamily C member 4	Homo sapiens	163-167
26807589-0	2016	A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.	Tenofovir	61-70	ATP binding cassette subfamily C member 4	Homo sapiens	36-41
26141932-1	2016	Platelet Multidrug Resistance Protein 4 (MRP4)-overexpression has a role in reducing aspirin action in patients after by-pass surgery.	Aspirin	85-92	ATP binding cassette subfamily C member 4	Homo sapiens	9-39
27354267-0	2016	ABCC4, ABCC5 and SLC28A1 polymorphisms: host genome on responses of chronic hepatitis B patients with entecavir treatment.	entecavir	102-111	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
26497925-0	2016	Multidrug resistance-associated protein 4 is a determinant of arsenite resistance.	Arsenic Trioxide	62-70	ATP binding cassette subfamily C member 4	Homo sapiens	0-41
26497925-3	2016	Due to its characteristic localization, MRP4 is proposed as a candidate in the elimination of arsenic and may contribute to resistance to As(III).	Arsenic	94-101	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
26497925-3	2016	Due to its characteristic localization, MRP4 is proposed as a candidate in the elimination of arsenic and may contribute to resistance to As(III).	as(iii)	138-145	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
26497925-5	2016	The IC50 values of As(III) in MRP4 cells were approximately 6-fold higher than those in MRP2 cells, supporting an important role for MRP4 in resistance to As(III).	Arsenic	19-21	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
26497925-5	2016	The IC50 values of As(III) in MRP4 cells were approximately 6-fold higher than those in MRP2 cells, supporting an important role for MRP4 in resistance to As(III).	Arsenic	19-21	ATP binding cassette subfamily C member 4	Homo sapiens	133-137
26497925-6	2016	The capacity of MRP4 to confer resistance to As(III) was further confirmed by a dramatic decrease in the IC50 values with the addition of MK571, an MRP4 inhibitor, and cyclosporine A, a well-known broad-spectrum inhibitor of ABC transporters.	verlukast	138-143	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
26497925-6	2016	The capacity of MRP4 to confer resistance to As(III) was further confirmed by a dramatic decrease in the IC50 values with the addition of MK571, an MRP4 inhibitor, and cyclosporine A, a well-known broad-spectrum inhibitor of ABC transporters.	verlukast	138-143	ATP binding cassette subfamily C member 4	Homo sapiens	148-152
26497925-6	2016	The capacity of MRP4 to confer resistance to As(III) was further confirmed by a dramatic decrease in the IC50 values with the addition of MK571, an MRP4 inhibitor, and cyclosporine A, a well-known broad-spectrum inhibitor of ABC transporters.	Cyclosporine	168-182	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
26497925-8	2016	Given that MRP4 is a major contributor to arsenic resistance in vitro, further investigation into the correlation between MRP4 expression and treatment outcome of leukemia patients treated with arsenic-based regimens is warranted.	Arsenic	42-49	ATP binding cassette subfamily C member 4	Homo sapiens	11-15
26497925-8	2016	Given that MRP4 is a major contributor to arsenic resistance in vitro, further investigation into the correlation between MRP4 expression and treatment outcome of leukemia patients treated with arsenic-based regimens is warranted.	Arsenic	194-201	ATP binding cassette subfamily C member 4	Homo sapiens	122-126
26340566-10	2016	CAB is an inhibitor of OAT1 (IC50 0.81 microM) and OAT3 (IC50 0.41 microM) but did not or only weakly inhibited Pgp, BCRP, MRP2, MRP4, MATE1, MATE2-K, OATP1B1, OATP1B3, OCT1, OCT2 or BSEP.	cabotegravir	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	129-133
26141932-1	2016	Platelet Multidrug Resistance Protein 4 (MRP4)-overexpression has a role in reducing aspirin action in patients after by-pass surgery.	Aspirin	85-92	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
26141932-2	2016	Aspirin induces platelet MRP4 over-expression, through megakaryocytes genomic modulation.	Aspirin	0-7	ATP binding cassette subfamily C member 4	Homo sapiens	25-29
26141932-7	2016	DAMI cells treated with celecoxib, diclofenac, and naproxen showed a significant increase in MRP4-mRNA expression compared to the mock culture.	Celecoxib	24-33	ATP binding cassette subfamily C member 4	Homo sapiens	93-97
26141932-7	2016	DAMI cells treated with celecoxib, diclofenac, and naproxen showed a significant increase in MRP4-mRNA expression compared to the mock culture.	Diclofenac	35-45	ATP binding cassette subfamily C member 4	Homo sapiens	93-97
26141932-7	2016	DAMI cells treated with celecoxib, diclofenac, and naproxen showed a significant increase in MRP4-mRNA expression compared to the mock culture.	Naproxen	51-59	ATP binding cassette subfamily C member 4	Homo sapiens	93-97
26499190-9	2015	Overexpression of ABCC4 by lentivirus transfection induced chemotherapy resistance to epirubicin (EPI) and cisplatin (DDP) in YTS cells.	Epirubicin	86-96	ATP binding cassette subfamily C member 4	Homo sapiens	18-23
26611713-12	2015	Silencing of MRP4 by shRNA led to a substantial alteration in sulfate disposition (i.e., 28.6-37.8% reductions in sulfate excretion, 30.5-59.3% elevations in intracellular sulfates, and 44.8-47.7% deceases in CLef,app values).	Sulfates	62-69	ATP binding cassette subfamily C member 4	Homo sapiens	13-17
26611713-12	2015	Silencing of MRP4 by shRNA led to a substantial alteration in sulfate disposition (i.e., 28.6-37.8% reductions in sulfate excretion, 30.5-59.3% elevations in intracellular sulfates, and 44.8-47.7% deceases in CLef,app values).	Sulfates	114-121	ATP binding cassette subfamily C member 4	Homo sapiens	13-17
26611713-12	2015	Silencing of MRP4 by shRNA led to a substantial alteration in sulfate disposition (i.e., 28.6-37.8% reductions in sulfate excretion, 30.5-59.3% elevations in intracellular sulfates, and 44.8-47.7% deceases in CLef,app values).	Sulfates	172-180	ATP binding cassette subfamily C member 4	Homo sapiens	13-17
26611713-14	2015	Cellular excretion of the raloxifene sulfates was mainly mediated by BCRP and MRP4.	raloxifene sulfates	26-45	ATP binding cassette subfamily C member 4	Homo sapiens	78-82
26499190-9	2015	Overexpression of ABCC4 by lentivirus transfection induced chemotherapy resistance to epirubicin (EPI) and cisplatin (DDP) in YTS cells.	Cisplatin	107-116	ATP binding cassette subfamily C member 4	Homo sapiens	18-23
26291395-9	2015	By contrast, MRP4 knock-down led to moderate decreases (17.1-20.6%, p<0.05) in sulfate excretion and increases (125-135%, p<0.05) in sulfate accumulation.	Sulfates	82-89	ATP binding cassette subfamily C member 4	Homo sapiens	13-17
26400418-10	2015	The basolateral efflux of baicalin is likely mediated by MRP3 and MRP4 both in enterocytes and hepatocytes.	baicalin	26-34	ATP binding cassette subfamily C member 4	Homo sapiens	66-70
26600514-6	2015	Western blot analysis indicated that meloxicam reduced the expression of MRP1 and MRP4.	Meloxicam	37-46	ATP binding cassette subfamily C member 4	Homo sapiens	82-86
26600514-7	2015	The results reported in the present study demonstrate for the first time that the specific COX-2 inhibitor meloxicam can increase the intracellular accumulation of doxorubicin and enhance doxorubicin-induced cytotoxicity in A549 cancer cells by reducing the expression of MRP1 and MRP4.	Meloxicam	107-116	ATP binding cassette subfamily C member 4	Homo sapiens	281-285
26291395-9	2015	By contrast, MRP4 knock-down led to moderate decreases (17.1-20.6%, p<0.05) in sulfate excretion and increases (125-135%, p<0.05) in sulfate accumulation.	Sulfates	139-146	ATP binding cassette subfamily C member 4	Homo sapiens	13-17
26291395-10	2015	In conclusion, MRP4 was identified as an exporter for chrysin and apigenin sulfates.	apigenin sulfates	66-83	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
26291395-11	2015	The SULT1A3 modified HEK293 cells were an appropriate tool to study SULT1A3-mediated sulfonation and to characterize BCRP/MRP4-mediated sulfate transport.	Sulfates	136-143	ATP binding cassette subfamily C member 4	Homo sapiens	122-126
26102310-2	2015	The multidrug resistance-associated protein (Mrp) 4 is an export pump which transports metabolites that were recently suggested to play a major role in the pathogenesis of HE such as neurosteroids and cyclic nucleotides.	Nucleotides, Cyclic	201-219	ATP binding cassette subfamily C member 4	Homo sapiens	4-51
26102310-3	2015	We therefore studied Mrp4 expression changes in ammonia-exposed cultured astrocytes and postmortem human brain samples of cirrhotic patients with HE.	Ammonia	48-55	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
26102310-4	2015	NH4 Cl increased Mrp4 mRNA and protein levels in astrocytes in a dose- and time-dependent manner up to threefold after 72 h of exposure and concurrently inhibited N-glycosylation of Mrp4 protein.	Nitrogen	0-1	ATP binding cassette subfamily C member 4	Homo sapiens	17-21
26102310-4	2015	NH4 Cl increased Mrp4 mRNA and protein levels in astrocytes in a dose- and time-dependent manner up to threefold after 72 h of exposure and concurrently inhibited N-glycosylation of Mrp4 protein.	Nitrogen	0-1	ATP binding cassette subfamily C member 4	Homo sapiens	182-186
26102310-5	2015	Upregulation of Mrp4 mRNA and protein as well as impaired N-glycosylation of Mrp4 protein by ammonia were sensitive towards the glutamine-synthetase inhibitor l-methionine-S-sulfoximine and were not induced by CH3 NH3 Cl (5 mmol/L).	Ammonia	93-100	ATP binding cassette subfamily C member 4	Homo sapiens	77-81
26102310-5	2015	Upregulation of Mrp4 mRNA and protein as well as impaired N-glycosylation of Mrp4 protein by ammonia were sensitive towards the glutamine-synthetase inhibitor l-methionine-S-sulfoximine and were not induced by CH3 NH3 Cl (5 mmol/L).	l-methionine-s-sulfoximine	159-185	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
26102310-5	2015	Upregulation of Mrp4 mRNA and protein as well as impaired N-glycosylation of Mrp4 protein by ammonia were sensitive towards the glutamine-synthetase inhibitor l-methionine-S-sulfoximine and were not induced by CH3 NH3 Cl (5 mmol/L).	l-methionine-s-sulfoximine	159-185	ATP binding cassette subfamily C member 4	Homo sapiens	77-81
26102310-5	2015	Upregulation of Mrp4 mRNA and protein as well as impaired N-glycosylation of Mrp4 protein by ammonia were sensitive towards the glutamine-synthetase inhibitor l-methionine-S-sulfoximine and were not induced by CH3 NH3 Cl (5 mmol/L).	ch3 nh3 cl	210-220	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
26102310-5	2015	Upregulation of Mrp4 mRNA and protein as well as impaired N-glycosylation of Mrp4 protein by ammonia were sensitive towards the glutamine-synthetase inhibitor l-methionine-S-sulfoximine and were not induced by CH3 NH3 Cl (5 mmol/L).	ch3 nh3 cl	210-220	ATP binding cassette subfamily C member 4	Homo sapiens	77-81
26102310-6	2015	Upregulation of Mrp4 mRNA required ammonia-induced activation of nitric oxide synthases or NADPH oxidase and p38MAPK -dependent activation of PPARalpha.	Ammonia	35-42	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
26102310-9	2015	The data show that Mrp4 is upregulated in HE, which may be relevant for the handling of neurosteroids and cyclic nucleotides in response to ammonia.	Nucleotides, Cyclic	106-124	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
26102310-9	2015	The data show that Mrp4 is upregulated in HE, which may be relevant for the handling of neurosteroids and cyclic nucleotides in response to ammonia.	Ammonia	140-147	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
26216510-3	2015	Here, we investigated the role of the efflux transporters Multidrug Resistance Protein 4 (MRP4) and Breast Cancer Resistance Protein (BCRP) in pCS and pCG excretion, and studied the impact of both solutes on the phenotype of human conditionally immortalized renal proximal tubule epithelial cells (ciPTEC).	4-cresylglucuronide	151-154	ATP binding cassette subfamily C member 4	Homo sapiens	58-88
26239185-8	2015	Further, H-3"-S and H-7-S were good substrates for transport by MRP4 according to the vesicular transport assay.	h-3"-s	9-15	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
26239185-0	2015	Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Controls Efflux Transport of Hesperetin Sulfates in Sulfotransferase 1A3-Overexpressing Human Embryonic Kidney 293 Cells.	hesperetin sulfates	84-103	ATP binding cassette subfamily C member 4	Homo sapiens	0-41
26239185-0	2015	Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Controls Efflux Transport of Hesperetin Sulfates in Sulfotransferase 1A3-Overexpressing Human Embryonic Kidney 293 Cells.	hesperetin sulfates	84-103	ATP binding cassette subfamily C member 4	Homo sapiens	43-47
26239185-0	2015	Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Controls Efflux Transport of Hesperetin Sulfates in Sulfotransferase 1A3-Overexpressing Human Embryonic Kidney 293 Cells.	hesperetin sulfates	84-103	ATP binding cassette subfamily C member 4	Homo sapiens	48-53
26239185-8	2015	Further, H-3"-S and H-7-S were good substrates for transport by MRP4 according to the vesicular transport assay.	h-7-s	20-25	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
26239185-9	2015	Moreover, sulfonation of hesperetin and excretion of its metabolites were well characterized by a two-compartment pharmacokinetic model that integrated drug uptake and sulfonation with MRP4-mediated sulfate excretion.	hesperetin	25-35	ATP binding cassette subfamily C member 4	Homo sapiens	185-189
26239185-9	2015	Moreover, sulfonation of hesperetin and excretion of its metabolites were well characterized by a two-compartment pharmacokinetic model that integrated drug uptake and sulfonation with MRP4-mediated sulfate excretion.	Sulfates	199-206	ATP binding cassette subfamily C member 4	Homo sapiens	185-189
26239185-10	2015	In conclusion, the exporter MRP4 controlled efflux transport of hesperetin sulfates in HEK293 cells.	hesperetin sulfates	64-83	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
26239185-11	2015	Due to significant expression in various organs/tissues (including the liver and kidney), MRP4 should be a determining factor for the elimination and body distribution of hesperetin sulfates.	hesperetin sulfates	171-190	ATP binding cassette subfamily C member 4	Homo sapiens	90-94
26216510-5	2015	Moreover, pCS inhibited the activity of MRP4 by 40% and BCRP by 25%, whereas pCG only reduced MRP4 activity by 75%.	4-cresol sulfate	10-13	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
26216510-5	2015	Moreover, pCS inhibited the activity of MRP4 by 40% and BCRP by 25%, whereas pCG only reduced MRP4 activity by 75%.	4-cresylglucuronide	77-80	ATP binding cassette subfamily C member 4	Homo sapiens	94-98
25403995-0	2015	Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.	Mercaptopurine	63-79	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
26148204-11	2015	In candidate gene analysis for tenofovir clearance, most polymorphisms evaluated were in ABCC4.	Tenofovir	31-40	ATP binding cassette subfamily C member 4	Homo sapiens	89-94
25403995-0	2015	Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.	Mercaptopurine	63-79	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
25403995-1	2015	Multidrug resistance protein 4 (MRP4) is involved in the efflux of nucleoside derivatives and has a role in the determination of drug sensitivity.	Nucleosides	67-77	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
25403995-1	2015	Multidrug resistance protein 4 (MRP4) is involved in the efflux of nucleoside derivatives and has a role in the determination of drug sensitivity.	Nucleosides	67-77	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
25403995-2	2015	We investigated the relationship between MRP4 genetic polymorphisms and doses of the 6-mercaptopurine (6-MP) and methotrexate.	Mercaptopurine	85-101	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
25403995-2	2015	We investigated the relationship between MRP4 genetic polymorphisms and doses of the 6-mercaptopurine (6-MP) and methotrexate.	Mercaptopurine	103-107	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
25403995-2	2015	We investigated the relationship between MRP4 genetic polymorphisms and doses of the 6-mercaptopurine (6-MP) and methotrexate.	Methotrexate	113-125	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
25403995-5	2015	Patients with homozygous variant allele in any of MRP4 G2269A, C912A and G559T required high frequency of 6-MP dose reduction compared with non-homozygous individuals.	Mercaptopurine	106-110	ATP binding cassette subfamily C member 4	Homo sapiens	50-54
25403995-7	2015	Therefore, MRP4 genotyping may be useful for personalizing the therapeutic dose of 6-MP during the ALL maintenance therapy in Japanese.	Mercaptopurine	83-87	ATP binding cassette subfamily C member 4	Homo sapiens	11-15
25841995-1	2015	Multidrug resistance protein 4 (MRP4), a member of the ATP binding cassette transporter family, functions as a plasma membrane exporter of cyclic nucleotides.	Nucleotides, Cyclic	139-157	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
26206993-14	2015	Two transporters, ABCC4 and ABCC5, are involved in the transport of cAMP outside the cells.	Cyclic AMP	68-72	ATP binding cassette subfamily C member 4	Homo sapiens	18-23
26066637-0	2015	Decreased Expression of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Leads to Reduced Glucuronidation of Flavonoids in UGT1A1-Overexpressing HeLa Cells: The Role of Futile Recycling.	Flavonoids	115-125	ATP binding cassette subfamily C member 4	Homo sapiens	24-65
26066637-0	2015	Decreased Expression of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Leads to Reduced Glucuronidation of Flavonoids in UGT1A1-Overexpressing HeLa Cells: The Role of Futile Recycling.	Flavonoids	115-125	ATP binding cassette subfamily C member 4	Homo sapiens	67-71
26066637-0	2015	Decreased Expression of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Leads to Reduced Glucuronidation of Flavonoids in UGT1A1-Overexpressing HeLa Cells: The Role of Futile Recycling.	Flavonoids	115-125	ATP binding cassette subfamily C member 4	Homo sapiens	72-77
26066637-5	2015	Furthermore, glucuronide excretion and total glucuronidation were significantly reduced in MRP4 knocked-down as compared to control cells.	Glucuronides	13-24	ATP binding cassette subfamily C member 4	Homo sapiens	91-95
25841995-1	2015	Multidrug resistance protein 4 (MRP4), a member of the ATP binding cassette transporter family, functions as a plasma membrane exporter of cyclic nucleotides.	Nucleotides, Cyclic	139-157	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
25841995-2	2015	Recently, we demonstrated that fibroblasts lacking the Mrp4 gene migrate faster and contain higher cyclic-nucleotide levels.	Nucleotides, Cyclic	99-116	ATP binding cassette subfamily C member 4	Homo sapiens	55-59
25841995-3	2015	Here, we show that cAMP accumulation and protein kinase A (PKA) activity are higher and polarized in Mrp4(-/-) fibroblasts, versus Mrp4(+/+) cells.	Cyclic AMP	19-23	ATP binding cassette subfamily C member 4	Homo sapiens	101-105
25841995-6	2015	Our data further indicated that the enhanced accumulation of cAMP in Mrp4(-/-) fibroblasts facilitates cortical actin polymerization in a PKA-dependent manner at the leading edge, which in turn increases the overall rate of cell migration to accelerate the process of wound healing.	Cyclic AMP	61-65	ATP binding cassette subfamily C member 4	Homo sapiens	69-73
25841995-8	2015	Together, our findings suggest a novel cAMP-dependent mechanism for MRP4-mediated regulation of fibroblast migration whereby PKA and actin play critical roles as downstream effectors.	Cyclic AMP	39-43	ATP binding cassette subfamily C member 4	Homo sapiens	68-72
26102284-9	2015	Dapivirine also significantly downregulated tenofovir substrate MRP4 in cervical cell lines.	Dapivirine	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
25677905-0	2015	Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.	Cyclophosphamide	73-89	ATP binding cassette subfamily C member 4	Homo sapiens	20-25
25677905-0	2015	Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.	epirubicin-5-fluorouracil	90-115	ATP binding cassette subfamily C member 4	Homo sapiens	20-25
26102284-9	2015	Dapivirine also significantly downregulated tenofovir substrate MRP4 in cervical cell lines.	Tenofovir	44-53	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
25446850-9	2015	Among genes involved in PGF2alpha biosynthesis, metabolism and action PLA2G2A, PTGS2/COX-2, ABCC4 and PTGFR were up-regulated, mRNA levels of SLCO2A, PTGDS and HPGDS were unchanged, and genes PLA2G4A and HPGD were down-regulated in diseased tissue.	Dinoprost	24-33	ATP binding cassette subfamily C member 4	Homo sapiens	92-97
26136652-6	2015	The presence of MK571 (inhibitor of MRP1 and multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 h period.	verlukast	16-21	ATP binding cassette subfamily C member 4	Homo sapiens	45-75
26136652-6	2015	The presence of MK571 (inhibitor of MRP1 and multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 h period.	verlukast	16-21	ATP binding cassette subfamily C member 4	Homo sapiens	77-81
26136652-6	2015	The presence of MK571 (inhibitor of MRP1 and multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 h period.	Vincristine	112-123	ATP binding cassette subfamily C member 4	Homo sapiens	45-75
26136652-6	2015	The presence of MK571 (inhibitor of MRP1 and multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 h period.	Vincristine	112-123	ATP binding cassette subfamily C member 4	Homo sapiens	77-81
26136652-6	2015	The presence of MK571 (inhibitor of MRP1 and multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 h period.	Etoposide	128-137	ATP binding cassette subfamily C member 4	Homo sapiens	45-75
26136652-6	2015	The presence of MK571 (inhibitor of MRP1 and multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 h period.	Etoposide	128-137	ATP binding cassette subfamily C member 4	Homo sapiens	77-81
25583749-12	2015	CONCLUSIONS: In this population of mostly female HIV-1-infected African patients, tenofovir plasma overexposure was associated with PI/ritonavir and a time-dependent decrease in eGFR, probably via an inhibition of MRP2/MRP4 efflux transporters.	Tenofovir	82-91	ATP binding cassette subfamily C member 4	Homo sapiens	219-223
25348617-7	2015	From 17 single-nucleotide polymorphisms in the MTX pathway, only patients with the wild-type variant of rs7317112 SNP in the ABCC4 gene had more mucositis (AA (39%) vs AG/GG (15%), P=0.016).	Methotrexate	47-50	ATP binding cassette subfamily C member 4	Homo sapiens	125-130
25762723-0	2015	Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea.	Cyclic AMP	34-38	ATP binding cassette subfamily C member 4	Homo sapiens	57-87
25762723-0	2015	Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea.	Cyclic AMP	34-38	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
25752797-4	2015	A potentially important human hepatic basolateral transporter is the ATP-binding cassette (ABC) transporter multidrug resistance protein 4 (MRP4/ABCC4) that in vitro is a high-affinity transporter of DMA(V) and the diglutathione conjugate of MMA(III) [MMA(GS)(2)].	N-myristoyl-alaninol	200-203	ATP binding cassette subfamily C member 4	Homo sapiens	140-144
25752797-4	2015	A potentially important human hepatic basolateral transporter is the ATP-binding cassette (ABC) transporter multidrug resistance protein 4 (MRP4/ABCC4) that in vitro is a high-affinity transporter of DMA(V) and the diglutathione conjugate of MMA(III) [MMA(GS)(2)].	N-myristoyl-alaninol	200-203	ATP binding cassette subfamily C member 4	Homo sapiens	145-150
25752797-4	2015	A potentially important human hepatic basolateral transporter is the ATP-binding cassette (ABC) transporter multidrug resistance protein 4 (MRP4/ABCC4) that in vitro is a high-affinity transporter of DMA(V) and the diglutathione conjugate of MMA(III) [MMA(GS)(2)].	diglutathione	215-228	ATP binding cassette subfamily C member 4	Homo sapiens	140-144
25752797-4	2015	A potentially important human hepatic basolateral transporter is the ATP-binding cassette (ABC) transporter multidrug resistance protein 4 (MRP4/ABCC4) that in vitro is a high-affinity transporter of DMA(V) and the diglutathione conjugate of MMA(III) [MMA(GS)(2)].	diglutathione	215-228	ATP binding cassette subfamily C member 4	Homo sapiens	145-150
25752797-11	2015	Treatment of SCHH with oltipraz (Nrf2 activator) increased MRP4 levels and basolateral efflux of arsenic.	oltipraz	23-31	ATP binding cassette subfamily C member 4	Homo sapiens	59-63
25752797-13	2015	These results suggest arsenic basolateral transport prevails over biliary excretion and is mediated at least in part by MRPs, most likely including MRP4.	Arsenic	22-29	ATP binding cassette subfamily C member 4	Homo sapiens	148-152
25735837-10	2015	Both MRP4 and BSEP inhibitor pharmacophore models were characterized by hydrophobic and hydrogen-bond acceptor features, albeit in distinct spatial arrangements.	Hydrogen	88-96	ATP binding cassette subfamily C member 4	Homo sapiens	5-9
25762723-3	2015	Several drugs are either substrates or inhibitors of multidrug resistance protein 4 (MRP4), such as the anti-colon cancer drug irinotecan and an anti-retroviral used to treat HIV infection, 3"-azido-3"-deoxythymidine (AZT).	Irinotecan	127-137	ATP binding cassette subfamily C member 4	Homo sapiens	53-83
25790437-0	2015	Dual role of cAMP in the transcriptional regulation of multidrug resistance-associated protein 4 (MRP4) in pancreatic adenocarcinoma cell lines.	Cyclic AMP	13-17	ATP binding cassette subfamily C member 4	Homo sapiens	55-96
25762723-3	2015	Several drugs are either substrates or inhibitors of multidrug resistance protein 4 (MRP4), such as the anti-colon cancer drug irinotecan and an anti-retroviral used to treat HIV infection, 3"-azido-3"-deoxythymidine (AZT).	Irinotecan	127-137	ATP binding cassette subfamily C member 4	Homo sapiens	85-89
25762723-3	2015	Several drugs are either substrates or inhibitors of multidrug resistance protein 4 (MRP4), such as the anti-colon cancer drug irinotecan and an anti-retroviral used to treat HIV infection, 3"-azido-3"-deoxythymidine (AZT).	Zidovudine	190-216	ATP binding cassette subfamily C member 4	Homo sapiens	53-83
25762723-3	2015	Several drugs are either substrates or inhibitors of multidrug resistance protein 4 (MRP4), such as the anti-colon cancer drug irinotecan and an anti-retroviral used to treat HIV infection, 3"-azido-3"-deoxythymidine (AZT).	Zidovudine	190-216	ATP binding cassette subfamily C member 4	Homo sapiens	85-89
25762723-3	2015	Several drugs are either substrates or inhibitors of multidrug resistance protein 4 (MRP4), such as the anti-colon cancer drug irinotecan and an anti-retroviral used to treat HIV infection, 3"-azido-3"-deoxythymidine (AZT).	Zidovudine	218-221	ATP binding cassette subfamily C member 4	Homo sapiens	53-83
25762723-3	2015	Several drugs are either substrates or inhibitors of multidrug resistance protein 4 (MRP4), such as the anti-colon cancer drug irinotecan and an anti-retroviral used to treat HIV infection, 3"-azido-3"-deoxythymidine (AZT).	Zidovudine	218-221	ATP binding cassette subfamily C member 4	Homo sapiens	85-89
25762723-4	2015	These drugs activate cystic fibrosis transmembrane conductance regulator (CFTR)-mediated fluid secretion by inhibiting MRP4-mediated cAMP efflux.	Cyclic AMP	133-137	ATP binding cassette subfamily C member 4	Homo sapiens	119-123
25762723-6	2015	Importantly, HIV patients on AZT treatment demonstrate augmented MRP4-CFTR complex formation in the colon, which defines a novel paradigm of drug-induced diarrhea.	Zidovudine	29-32	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
25595598-9	2015	Furthermore, short hairpin RNA-mediated silencing of a target transporter led to a marked reduction in the excretion rate of CG (38.6% for BCRP, 39.3% for MRP1, 36.4% for MRP3, and 28.7% for MRP4; P < 0.01).	cg	125-127	ATP binding cassette subfamily C member 4	Homo sapiens	191-195
25595598-11	2015	The gene silencing results suggested that BCRP, MRP1, MRP3, and MRP4 were significant contributors to excretion of CG.	cg	115-117	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
25554564-10	2015	Intriguingly MK-571, an inhibitor of the multi-drug resistance protein MRP4, playing a pivotal role in effluxing LTB4, completely blocked PMN chemotaxis induced by IL-8, but gave conflicting results when tested for its ability to reduce LTB4 release, increasing LTB4 efflux by itself but reducing the release when in combination with IL-8.	verlukast	13-19	ATP binding cassette subfamily C member 4	Homo sapiens	71-75
25741749-7	2015	Knock-down of a MRP transporter led to substantial decreases in excretion of GG (32.3% for MRP1, 36.7% for MRP3, and 36.6% for MRP4; p < 0.01) and AG (59.3% for MRP1, 24.7% for MRP3, and 34.1% for MRP4; p < 0.01).	gg	77-79	ATP binding cassette subfamily C member 4	Homo sapiens	127-131
25741749-7	2015	Knock-down of a MRP transporter led to substantial decreases in excretion of GG (32.3% for MRP1, 36.7% for MRP3, and 36.6% for MRP4; p < 0.01) and AG (59.3% for MRP1, 24.7% for MRP3, and 34.1% for MRP4; p < 0.01).	gg	77-79	ATP binding cassette subfamily C member 4	Homo sapiens	200-204
25741749-8	2015	Also, cellular glucuronidation of genistein (38.3% for MRP1, 32.3% for MRP3, and 31.1% for MRP4; p < 0.01) and apigenin (40.6% for MRP1, 32.4% for MRP3, and 34.6% for MRP4; p < 0.001) was markedly suppressed.	Genistein	34-43	ATP binding cassette subfamily C member 4	Homo sapiens	91-95
25741749-8	2015	Also, cellular glucuronidation of genistein (38.3% for MRP1, 32.3% for MRP3, and 31.1% for MRP4; p < 0.01) and apigenin (40.6% for MRP1, 32.4% for MRP3, and 34.6% for MRP4; p < 0.001) was markedly suppressed.	Genistein	34-43	ATP binding cassette subfamily C member 4	Homo sapiens	170-174
25790437-0	2015	Dual role of cAMP in the transcriptional regulation of multidrug resistance-associated protein 4 (MRP4) in pancreatic adenocarcinoma cell lines.	Cyclic AMP	13-17	ATP binding cassette subfamily C member 4	Homo sapiens	98-102
25790437-2	2015	Intracellular cAMP levels are tightly regulated where the MRP4 transporter plays a major role.	Cyclic AMP	14-18	ATP binding cassette subfamily C member 4	Homo sapiens	58-62
25790437-3	2015	In the present study, we sought to establish whether cAMP modulated MRP4 expression in pancreatic adenocarcinoma cell lines.	Cyclic AMP	53-57	ATP binding cassette subfamily C member 4	Homo sapiens	68-72
25790437-4	2015	Quantitative PCR and western blot studies showed that cAMP-increasing agents enhanced MRP4 transcripts and protein levels in PANC-1 cells.	Cyclic AMP	54-58	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
25790437-6	2015	Present results show that cAMP regulates MRP4 promoter activity, and further indicate that the balance between intracellular and extracellular cAMP levels determines MRP4 expression.	Cyclic AMP	26-30	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
25790437-6	2015	Present results show that cAMP regulates MRP4 promoter activity, and further indicate that the balance between intracellular and extracellular cAMP levels determines MRP4 expression.	Cyclic AMP	26-30	ATP binding cassette subfamily C member 4	Homo sapiens	166-170
25790437-6	2015	Present results show that cAMP regulates MRP4 promoter activity, and further indicate that the balance between intracellular and extracellular cAMP levels determines MRP4 expression.	Cyclic AMP	143-147	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
25790437-6	2015	Present results show that cAMP regulates MRP4 promoter activity, and further indicate that the balance between intracellular and extracellular cAMP levels determines MRP4 expression.	Cyclic AMP	143-147	ATP binding cassette subfamily C member 4	Homo sapiens	166-170
25462817-3	2015	We observed that MRP4 can efflux the bioluminescence substrate d-luciferin, and exploited this phenomenon to develop a robust, high throughput, live cell-based bioluminescent screen to identify new MRP4 inhibitors.	D-luciferin	63-74	ATP binding cassette subfamily C member 4	Homo sapiens	17-21
26052533-1	2015	UNLABELLED: The ATP-binding cassette transporter MRP4 (encoded by ABCC4) regulates membrane cyclic nucleotides concentrations in arterial cells including smooth muscle cells.	Nucleotides, Cyclic	92-110	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
26052533-1	2015	UNLABELLED: The ATP-binding cassette transporter MRP4 (encoded by ABCC4) regulates membrane cyclic nucleotides concentrations in arterial cells including smooth muscle cells.	Nucleotides, Cyclic	92-110	ATP binding cassette subfamily C member 4	Homo sapiens	66-71
26052533-3	2015	We aimed to study gene transfer of a MRP4/ABCC4 silencing RNA via intratracheal delivery of aerosolized adeno-associated virus 1 (AAV1.shMRP4 or AAV1.control) in a monocrotaline-induced model of pulmonary hypertension in rats.	Monocrotaline	164-177	ATP binding cassette subfamily C member 4	Homo sapiens	37-41
25462817-3	2015	We observed that MRP4 can efflux the bioluminescence substrate d-luciferin, and exploited this phenomenon to develop a robust, high throughput, live cell-based bioluminescent screen to identify new MRP4 inhibitors.	D-luciferin	63-74	ATP binding cassette subfamily C member 4	Homo sapiens	198-202
25462817-6	2015	Selected compounds were tested for their ability to sensitize MRP4-overexpressing cell lines to the MRP4 substrate drugs 6-mercaptopurine and SN-38, with sensitization up to 6.5-fold with the ryanodine receptor antagonist dantrolene.	Mercaptopurine	121-137	ATP binding cassette subfamily C member 4	Homo sapiens	62-66
25462817-6	2015	Selected compounds were tested for their ability to sensitize MRP4-overexpressing cell lines to the MRP4 substrate drugs 6-mercaptopurine and SN-38, with sensitization up to 6.5-fold with the ryanodine receptor antagonist dantrolene.	Mercaptopurine	121-137	ATP binding cassette subfamily C member 4	Homo sapiens	100-104
25462817-6	2015	Selected compounds were tested for their ability to sensitize MRP4-overexpressing cell lines to the MRP4 substrate drugs 6-mercaptopurine and SN-38, with sensitization up to 6.5-fold with the ryanodine receptor antagonist dantrolene.	Irinotecan	142-147	ATP binding cassette subfamily C member 4	Homo sapiens	62-66
25462817-6	2015	Selected compounds were tested for their ability to sensitize MRP4-overexpressing cell lines to the MRP4 substrate drugs 6-mercaptopurine and SN-38, with sensitization up to 6.5-fold with the ryanodine receptor antagonist dantrolene.	Irinotecan	142-147	ATP binding cassette subfamily C member 4	Homo sapiens	100-104
25462817-6	2015	Selected compounds were tested for their ability to sensitize MRP4-overexpressing cell lines to the MRP4 substrate drugs 6-mercaptopurine and SN-38, with sensitization up to 6.5-fold with the ryanodine receptor antagonist dantrolene.	Dantrolene	222-232	ATP binding cassette subfamily C member 4	Homo sapiens	100-104
25640269-6	2015	Endogenous substrates of ABCC1 and ABCC4 that may be potential candidates affecting neuroblastoma biology include molecules such as prostaglandins and leukotrienes.	Prostaglandins	132-146	ATP binding cassette subfamily C member 4	Homo sapiens	35-40
25640269-6	2015	Endogenous substrates of ABCC1 and ABCC4 that may be potential candidates affecting neuroblastoma biology include molecules such as prostaglandins and leukotrienes.	Leukotrienes	151-163	ATP binding cassette subfamily C member 4	Homo sapiens	35-40
25433169-0	2015	Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer.	Dinoprostone	158-162	ATP binding cassette subfamily C member 4	Homo sapiens	0-45
25801567-0	2015	Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.	Tenofovir	46-55	ATP binding cassette subfamily C member 4	Homo sapiens	23-28
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	117-121
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	144-149
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	11-14	ATP binding cassette subfamily C member 4	Homo sapiens	117-121
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	11-14	ATP binding cassette subfamily C member 4	Homo sapiens	144-149
25801567-10	2015	In multivariate analysis, a low body weight, a low eGFR, the concomitant use of ritonavir-boosted protease inhibitors, and the ABCC4 4131T   G variation (genotype TG or GG) were independently associated with higher tenofovir plasma concentrations.	Tenofovir	215-224	ATP binding cassette subfamily C member 4	Homo sapiens	127-132
25801567-11	2015	After adjusting for weight, eGFR, and the concomitant use of ritonavir-boosted protease inhibitors, a 30% increase in the mean tenofovir plasma concentration was observed in patients having the ABCC4 4131 TG or GG genotype.	Ritonavir	61-70	ATP binding cassette subfamily C member 4	Homo sapiens	194-199
25801567-11	2015	After adjusting for weight, eGFR, and the concomitant use of ritonavir-boosted protease inhibitors, a 30% increase in the mean tenofovir plasma concentration was observed in patients having the ABCC4 4131 TG or GG genotype.	Tenofovir	127-136	ATP binding cassette subfamily C member 4	Homo sapiens	194-199
25339146-0	2015	Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients.	Latanoprost	89-100	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
25339146-1	2015	PURPOSE: The purpose of this study is to evaluate the association between variants in prostaglandin-endoperoxide synthase 1 (PTGS1), prostaglandin F (2alpha) receptor (PTGFR), and multidrug resistance protein 4 (MRP4) genes and intraocular pressure (IOP) response to latanoprost in Chinese patients with primary open-angle glaucoma (POAG).	Latanoprost	267-278	ATP binding cassette subfamily C member 4	Homo sapiens	180-210
26122863-0	2015	Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry.	Misoprostol	0-11	ATP binding cassette subfamily C member 4	Homo sapiens	85-90
26122863-6	2015	RESULTS: The ABCC4 single nucleotide polymorphism rs11568658 was associated with misoprostol-induced fever.	Misoprostol	81-92	ATP binding cassette subfamily C member 4	Homo sapiens	13-18
26122863-7	2015	Misoprostol acid was transported across a blood-brain barrier model by MRP4 and SLCO1B1.	misoprostol acid	0-16	ATP binding cassette subfamily C member 4	Homo sapiens	71-75
26122863-8	2015	CONCLUSION: Genetic variability in ABCC4 may contribute to misoprostol-induced fever in pregnant women.	Misoprostol	59-70	ATP binding cassette subfamily C member 4	Homo sapiens	35-40
26491233-0	2015	Multidrug Resistance Protein-4 Influences Aspirin Toxicity in Human Cell Line.	Aspirin	42-49	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
26491233-2	2015	We found that multidrug resistance protein-4 (MRP4) overexpression has a role in reducing aspirin action in patients after bypass surgery and, very recently, we found that aspirin enhances platelet MRP4 levels through peroxisome proliferator activated receptor-alpha (PPARalpha).	Aspirin	90-97	ATP binding cassette subfamily C member 4	Homo sapiens	14-44
26491233-2	2015	We found that multidrug resistance protein-4 (MRP4) overexpression has a role in reducing aspirin action in patients after bypass surgery and, very recently, we found that aspirin enhances platelet MRP4 levels through peroxisome proliferator activated receptor-alpha (PPARalpha).	Aspirin	90-97	ATP binding cassette subfamily C member 4	Homo sapiens	46-50
26491233-2	2015	We found that multidrug resistance protein-4 (MRP4) overexpression has a role in reducing aspirin action in patients after bypass surgery and, very recently, we found that aspirin enhances platelet MRP4 levels through peroxisome proliferator activated receptor-alpha (PPARalpha).	Aspirin	172-179	ATP binding cassette subfamily C member 4	Homo sapiens	14-44
26491233-2	2015	We found that multidrug resistance protein-4 (MRP4) overexpression has a role in reducing aspirin action in patients after bypass surgery and, very recently, we found that aspirin enhances platelet MRP4 levels through peroxisome proliferator activated receptor-alpha (PPARalpha).	Aspirin	172-179	ATP binding cassette subfamily C member 4	Homo sapiens	46-50
26491233-2	2015	We found that multidrug resistance protein-4 (MRP4) overexpression has a role in reducing aspirin action in patients after bypass surgery and, very recently, we found that aspirin enhances platelet MRP4 levels through peroxisome proliferator activated receptor-alpha (PPARalpha).	Aspirin	172-179	ATP binding cassette subfamily C member 4	Homo sapiens	198-202
26491233-3	2015	In the present paper, we verified whether exposure of human embryonic kidney-293 cells (Hek-293) to aspirin modifies MRP4 gene expression and its correlation with drug elimination and cell toxicity.	Aspirin	100-107	ATP binding cassette subfamily C member 4	Homo sapiens	117-121
26491233-5	2015	Furthermore, aspirin effects, induced at low dose, already enhance MRP4 gene expression.	Aspirin	13-20	ATP binding cassette subfamily C member 4	Homo sapiens	67-71
25433169-0	2015	Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer.	Dinoprostone	158-162	ATP binding cassette subfamily C member 4	Homo sapiens	47-51
25433169-6	2015	Multiple Drug Resistance-Associated Protein 4 (MRP4) and Prostaglandin Transporter (PGT) modulate PGE2 signaling by increasing or decreasing the levels of PGE2 available to cells.	Dinoprostone	98-102	ATP binding cassette subfamily C member 4	Homo sapiens	0-45
25433169-6	2015	Multiple Drug Resistance-Associated Protein 4 (MRP4) and Prostaglandin Transporter (PGT) modulate PGE2 signaling by increasing or decreasing the levels of PGE2 available to cells.	Dinoprostone	98-102	ATP binding cassette subfamily C member 4	Homo sapiens	47-51
25433169-6	2015	Multiple Drug Resistance-Associated Protein 4 (MRP4) and Prostaglandin Transporter (PGT) modulate PGE2 signaling by increasing or decreasing the levels of PGE2 available to cells.	Dinoprostone	155-159	ATP binding cassette subfamily C member 4	Homo sapiens	0-45
25433169-6	2015	Multiple Drug Resistance-Associated Protein 4 (MRP4) and Prostaglandin Transporter (PGT) modulate PGE2 signaling by increasing or decreasing the levels of PGE2 available to cells.	Dinoprostone	155-159	ATP binding cassette subfamily C member 4	Homo sapiens	47-51
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	Cytarabine	147-157	ATP binding cassette subfamily C member 4	Homo sapiens	76-80
25461681-4	2015	In this study, we found that multiwalled carbon nanotubes (MWCNTs) reduced transport activity and expression of ABC transporters including ABCB1/Pgp and ABCC4/MRP4 in human colon adenocarcinoma Caco-2 cells.	Carbon	41-47	ATP binding cassette subfamily C member 4	Homo sapiens	153-158
25461681-4	2015	In this study, we found that multiwalled carbon nanotubes (MWCNTs) reduced transport activity and expression of ABC transporters including ABCB1/Pgp and ABCC4/MRP4 in human colon adenocarcinoma Caco-2 cells.	Carbon	41-47	ATP binding cassette subfamily C member 4	Homo sapiens	159-163
25674464-10	2014	IN CONCLUSION: MRP4 and MRP5 overexpression confer resistance to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and troxacitabine-nucleotides in HEK/MRP4-5 cells.	troxacitabine-nucleotides	165-190	ATP binding cassette subfamily C member 4	Homo sapiens	198-202
25445042-1	2014	Intracellular cyclic nucleotides are eliminated by phosphodiesterases (PDEs) and by ATP Binding cassette transporters such as ABCC4 and ABCC5.	Nucleotides, Cyclic	14-32	ATP binding cassette subfamily C member 4	Homo sapiens	126-131
25674464-0	2014	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.	Nucleosides	73-83	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
25674464-0	2014	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.	Nucleosides	73-83	ATP binding cassette subfamily C member 4	Homo sapiens	24-29
25674464-0	2014	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.	Cytarabine	92-102	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
25674464-0	2014	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.	Cytarabine	92-102	ATP binding cassette subfamily C member 4	Homo sapiens	24-29
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	Cytarabine	147-157	ATP binding cassette subfamily C member 4	Homo sapiens	82-87
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	Cytarabine	159-164	ATP binding cassette subfamily C member 4	Homo sapiens	76-80
25674464-0	2014	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.	troxacitabine	107-120	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	Cytarabine	159-164	ATP binding cassette subfamily C member 4	Homo sapiens	82-87
25674464-0	2014	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.	troxacitabine	107-120	ATP binding cassette subfamily C member 4	Homo sapiens	24-29
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	gemcitabine	167-178	ATP binding cassette subfamily C member 4	Homo sapiens	76-80
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	gemcitabine	167-178	ATP binding cassette subfamily C member 4	Homo sapiens	82-87
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	gemcitabine	180-183	ATP binding cassette subfamily C member 4	Homo sapiens	76-80
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	gemcitabine	180-183	ATP binding cassette subfamily C member 4	Homo sapiens	82-87
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	l-nucleoside	194-206	ATP binding cassette subfamily C member 4	Homo sapiens	76-80
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	l-nucleoside	194-206	ATP binding cassette subfamily C member 4	Homo sapiens	82-87
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	troxacitabine	214-227	ATP binding cassette subfamily C member 4	Homo sapiens	76-80
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	troxacitabine	214-227	ATP binding cassette subfamily C member 4	Homo sapiens	82-87
25674464-4	2014	At 4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM.	troxacitabine	59-72	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
25674464-4	2014	At 4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM.	Cytarabine	74-79	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
25674464-4	2014	At 4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM.	adefovir	84-119	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
25674464-4	2014	At 4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM.	adefovir	121-125	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
25674464-4	2014	At 4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM.	Cytarabine	145-150	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
25674464-4	2014	At 4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM.	adefovir	155-159	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
25674464-4	2014	At 4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM.	gemcitabine	173-176	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
25674464-6	2014	After 4-hr exposure ara-C-nucleotides were 2-3-fold lower in MRP4/5 cells, in which they decreased more rapidly after washing with drug-free medium (DFM).	ara-c-nucleotides	20-37	ATP binding cassette subfamily C member 4	Homo sapiens	61-65
25674464-8	2014	Troxacitabine-nucleotides were about 25% lower in MRP4/5 cells and decreased rapidly in MRP4, but not in MRP5 cells.	troxacitabine-nucleotides	0-25	ATP binding cassette subfamily C member 4	Homo sapiens	50-54
25674464-8	2014	Troxacitabine-nucleotides were about 25% lower in MRP4/5 cells and decreased rapidly in MRP4, but not in MRP5 cells.	troxacitabine-nucleotides	0-25	ATP binding cassette subfamily C member 4	Homo sapiens	88-92
25674464-9	2014	Accumulation of GEM-nucleotides was higher in the MRP4/5 cells.	gem-nucleotides	16-31	ATP binding cassette subfamily C member 4	Homo sapiens	50-54
25674464-10	2014	IN CONCLUSION: MRP4 and MRP5 overexpression confer resistance to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and troxacitabine-nucleotides in HEK/MRP4-5 cells.	troxacitabine	65-78	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
25674464-10	2014	IN CONCLUSION: MRP4 and MRP5 overexpression confer resistance to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and troxacitabine-nucleotides in HEK/MRP4-5 cells.	troxacitabine	65-78	ATP binding cassette subfamily C member 4	Homo sapiens	198-202
25674464-10	2014	IN CONCLUSION: MRP4 and MRP5 overexpression confer resistance to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and troxacitabine-nucleotides in HEK/MRP4-5 cells.	Cytarabine	83-88	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
25674464-10	2014	IN CONCLUSION: MRP4 and MRP5 overexpression confer resistance to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and troxacitabine-nucleotides in HEK/MRP4-5 cells.	Cytarabine	83-88	ATP binding cassette subfamily C member 4	Homo sapiens	198-202
25674464-10	2014	IN CONCLUSION: MRP4 and MRP5 overexpression confer resistance to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and troxacitabine-nucleotides in HEK/MRP4-5 cells.	Cytarabine	155-160	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
25674464-10	2014	IN CONCLUSION: MRP4 and MRP5 overexpression confer resistance to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and troxacitabine-nucleotides in HEK/MRP4-5 cells.	Cytarabine	155-160	ATP binding cassette subfamily C member 4	Homo sapiens	198-202
25674464-10	2014	IN CONCLUSION: MRP4 and MRP5 overexpression confer resistance to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and troxacitabine-nucleotides in HEK/MRP4-5 cells.	troxacitabine-nucleotides	165-190	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
25275481-7	2014	RESULTS: The apparent Km values for ABCC4-mediated transport were 2.9+-0.1 microM for PGE3, 12.1+-1.3 microM for PGF(3alpha), and 11.9+-1.4 microM for TXB3 and the ATP-dependent accumulation of PGE3, PGF(3alpha), and TXB3 into vesicles was decreased by using typical substrates and inhibitors of ABCC4.	prostaglandin E3	86-90	ATP binding cassette subfamily C member 4	Homo sapiens	36-41
24902864-0	2014	Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets.	Aspirin	0-7	ATP binding cassette subfamily C member 4	Homo sapiens	78-108
24902864-1	2014	AIM: The aim of the study was to investigate whether human megakaryocytic cells have an adaptive response to aspirin treatment, leading to an enhancement of multidrug resistance protein-4 (MRP4) expression in circulating platelets responsible for a reduced aspirin action.	Aspirin	109-116	ATP binding cassette subfamily C member 4	Homo sapiens	157-187
24902864-1	2014	AIM: The aim of the study was to investigate whether human megakaryocytic cells have an adaptive response to aspirin treatment, leading to an enhancement of multidrug resistance protein-4 (MRP4) expression in circulating platelets responsible for a reduced aspirin action.	Aspirin	109-116	ATP binding cassette subfamily C member 4	Homo sapiens	189-193
24902864-1	2014	AIM: The aim of the study was to investigate whether human megakaryocytic cells have an adaptive response to aspirin treatment, leading to an enhancement of multidrug resistance protein-4 (MRP4) expression in circulating platelets responsible for a reduced aspirin action.	Aspirin	257-264	ATP binding cassette subfamily C member 4	Homo sapiens	189-193
24902864-2	2014	We recently found that platelet MRP4 overexpression has a role in reducing aspirin action in patients after by-pass surgery.	Aspirin	75-82	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
24902864-4	2014	METHODS: The effects induced by aspirin or PPARalpha agonist (WY14643) on MRP4 modulation were evaluated in vitro in a human megakaryoblastic DAMI cell line, in megakaryocytes (MKs) and in platelets obtained from human haematopoietic progenitor cell (HPC) cultures, and in vivo platelets obtained from aspirin treated healthy volunteers (HV).	Aspirin	32-39	ATP binding cassette subfamily C member 4	Homo sapiens	74-78
24902864-4	2014	METHODS: The effects induced by aspirin or PPARalpha agonist (WY14643) on MRP4 modulation were evaluated in vitro in a human megakaryoblastic DAMI cell line, in megakaryocytes (MKs) and in platelets obtained from human haematopoietic progenitor cell (HPC) cultures, and in vivo platelets obtained from aspirin treated healthy volunteers (HV).	pirinixic acid	62-69	ATP binding cassette subfamily C member 4	Homo sapiens	74-78
24902864-5	2014	RESULTS: In DAMI cells, aspirin and WY14643 treatment induced a significant increase in MRP4 and PPARalpha expression.	Aspirin	24-31	ATP binding cassette subfamily C member 4	Homo sapiens	88-92
24902864-5	2014	RESULTS: In DAMI cells, aspirin and WY14643 treatment induced a significant increase in MRP4 and PPARalpha expression.	pirinixic acid	36-43	ATP binding cassette subfamily C member 4	Homo sapiens	88-92
24902864-6	2014	In human MKs grown in the presence of either aspirin or WY14643, MRP4 and PPARalpha-mRNA were higher than in control cultures and derived platelets showed an enhancement in MRP4 protein expression.	Aspirin	45-52	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
24902864-6	2014	In human MKs grown in the presence of either aspirin or WY14643, MRP4 and PPARalpha-mRNA were higher than in control cultures and derived platelets showed an enhancement in MRP4 protein expression.	Aspirin	45-52	ATP binding cassette subfamily C member 4	Homo sapiens	173-177
24902864-6	2014	In human MKs grown in the presence of either aspirin or WY14643, MRP4 and PPARalpha-mRNA were higher than in control cultures and derived platelets showed an enhancement in MRP4 protein expression.	pirinixic acid	56-63	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
24902864-6	2014	In human MKs grown in the presence of either aspirin or WY14643, MRP4 and PPARalpha-mRNA were higher than in control cultures and derived platelets showed an enhancement in MRP4 protein expression.	pirinixic acid	56-63	ATP binding cassette subfamily C member 4	Homo sapiens	173-177
24902864-7	2014	The ability of aspirin to modulate MRP4 expression in MKs and to transfer it to platelets was also confirmed in vivo.	Aspirin	15-22	ATP binding cassette subfamily C member 4	Homo sapiens	35-39
24902864-8	2014	In fact, we found the highest MRP4 mRNA and protein expression in platelets obtained from HV after 15 days" aspirin treatment.	Aspirin	108-115	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
25275481-0	2014	Transport of eicosapentaenoic acid-derived PGE3, PGF(3alpha), and TXB3 by ABCC4.	Eicosapentaenoic Acid	13-34	ATP binding cassette subfamily C member 4	Homo sapiens	74-79
25275481-0	2014	Transport of eicosapentaenoic acid-derived PGE3, PGF(3alpha), and TXB3 by ABCC4.	prostaglandin E3	43-47	ATP binding cassette subfamily C member 4	Homo sapiens	74-79
25275481-0	2014	Transport of eicosapentaenoic acid-derived PGE3, PGF(3alpha), and TXB3 by ABCC4.	Prostaglandins F	49-52	ATP binding cassette subfamily C member 4	Homo sapiens	74-79
25275481-3	2014	We therefore investigated the contribution of ATP-binding cassette transporter C4 (ABCC4), which has been known as a prostanoids efflux transporter, to the release of PGE3, PGF(3alpha), and TXB3.	prostaglandin E3	167-171	ATP binding cassette subfamily C member 4	Homo sapiens	46-81
25275481-3	2014	We therefore investigated the contribution of ATP-binding cassette transporter C4 (ABCC4), which has been known as a prostanoids efflux transporter, to the release of PGE3, PGF(3alpha), and TXB3.	prostaglandin E3	167-171	ATP binding cassette subfamily C member 4	Homo sapiens	83-88
25275481-3	2014	We therefore investigated the contribution of ATP-binding cassette transporter C4 (ABCC4), which has been known as a prostanoids efflux transporter, to the release of PGE3, PGF(3alpha), and TXB3.	Prostaglandins F	173-176	ATP binding cassette subfamily C member 4	Homo sapiens	46-81
25275481-3	2014	We therefore investigated the contribution of ATP-binding cassette transporter C4 (ABCC4), which has been known as a prostanoids efflux transporter, to the release of PGE3, PGF(3alpha), and TXB3.	Prostaglandins F	173-176	ATP binding cassette subfamily C member 4	Homo sapiens	83-88
25275481-7	2014	RESULTS: The apparent Km values for ABCC4-mediated transport were 2.9+-0.1 microM for PGE3, 12.1+-1.3 microM for PGF(3alpha), and 11.9+-1.4 microM for TXB3 and the ATP-dependent accumulation of PGE3, PGF(3alpha), and TXB3 into vesicles was decreased by using typical substrates and inhibitors of ABCC4.	Prostaglandins F	113-116	ATP binding cassette subfamily C member 4	Homo sapiens	36-41
25275481-4	2014	MATERIALS AND METHODS: ATP-dependent transport of PGE3, PGF(3alpha), and TXB3 via ABCC4 was investigated by using inside-out membrane vesicles prepared from ABCC4-overexpressing HEK293 cells.	Adenosine Triphosphate	23-26	ATP binding cassette subfamily C member 4	Homo sapiens	82-87
25275481-4	2014	MATERIALS AND METHODS: ATP-dependent transport of PGE3, PGF(3alpha), and TXB3 via ABCC4 was investigated by using inside-out membrane vesicles prepared from ABCC4-overexpressing HEK293 cells.	Adenosine Triphosphate	23-26	ATP binding cassette subfamily C member 4	Homo sapiens	157-162
25275481-4	2014	MATERIALS AND METHODS: ATP-dependent transport of PGE3, PGF(3alpha), and TXB3 via ABCC4 was investigated by using inside-out membrane vesicles prepared from ABCC4-overexpressing HEK293 cells.	prostaglandin E3	50-54	ATP binding cassette subfamily C member 4	Homo sapiens	82-87
25275481-7	2014	RESULTS: The apparent Km values for ABCC4-mediated transport were 2.9+-0.1 microM for PGE3, 12.1+-1.3 microM for PGF(3alpha), and 11.9+-1.4 microM for TXB3 and the ATP-dependent accumulation of PGE3, PGF(3alpha), and TXB3 into vesicles was decreased by using typical substrates and inhibitors of ABCC4.	Prostaglandins F	113-116	ATP binding cassette subfamily C member 4	Homo sapiens	296-301
25275481-4	2014	MATERIALS AND METHODS: ATP-dependent transport of PGE3, PGF(3alpha), and TXB3 via ABCC4 was investigated by using inside-out membrane vesicles prepared from ABCC4-overexpressing HEK293 cells.	prostaglandin E3	50-54	ATP binding cassette subfamily C member 4	Homo sapiens	157-162
25275481-7	2014	RESULTS: The apparent Km values for ABCC4-mediated transport were 2.9+-0.1 microM for PGE3, 12.1+-1.3 microM for PGF(3alpha), and 11.9+-1.4 microM for TXB3 and the ATP-dependent accumulation of PGE3, PGF(3alpha), and TXB3 into vesicles was decreased by using typical substrates and inhibitors of ABCC4.	Adenosine Triphosphate	164-167	ATP binding cassette subfamily C member 4	Homo sapiens	36-41
25275481-4	2014	MATERIALS AND METHODS: ATP-dependent transport of PGE3, PGF(3alpha), and TXB3 via ABCC4 was investigated by using inside-out membrane vesicles prepared from ABCC4-overexpressing HEK293 cells.	Prostaglandins F	56-59	ATP binding cassette subfamily C member 4	Homo sapiens	82-87
25275481-5	2014	To evaluate the contribution of ABCC4 to the release of PGE3, PGF(3alpha), and TXB3, we measured the extracellular and intracellular levels of PGE3, PGF(3alpha), and TXB3 in A549 cells when we used ABCC4 inhibitors (dipyridamole, MK571, and probenecid) or ABCC4 siRNAs.	prostaglandin E3	56-60	ATP binding cassette subfamily C member 4	Homo sapiens	32-37
25275481-7	2014	RESULTS: The apparent Km values for ABCC4-mediated transport were 2.9+-0.1 microM for PGE3, 12.1+-1.3 microM for PGF(3alpha), and 11.9+-1.4 microM for TXB3 and the ATP-dependent accumulation of PGE3, PGF(3alpha), and TXB3 into vesicles was decreased by using typical substrates and inhibitors of ABCC4.	prostaglandin E3	194-198	ATP binding cassette subfamily C member 4	Homo sapiens	36-41
25275481-7	2014	RESULTS: The apparent Km values for ABCC4-mediated transport were 2.9+-0.1 microM for PGE3, 12.1+-1.3 microM for PGF(3alpha), and 11.9+-1.4 microM for TXB3 and the ATP-dependent accumulation of PGE3, PGF(3alpha), and TXB3 into vesicles was decreased by using typical substrates and inhibitors of ABCC4.	Prostaglandins F	200-203	ATP binding cassette subfamily C member 4	Homo sapiens	36-41
25275481-8	2014	ABCC4 inhibitors and ABCC4 knockdown showed the reduction of extracellular/intracellular ratio of PGE3 (40-60% of control) and PGF(3alpha) (60-80% of control) in A549 cells.	prostaglandin E3	98-102	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
25275481-8	2014	ABCC4 inhibitors and ABCC4 knockdown showed the reduction of extracellular/intracellular ratio of PGE3 (40-60% of control) and PGF(3alpha) (60-80% of control) in A549 cells.	prostaglandin E3	98-102	ATP binding cassette subfamily C member 4	Homo sapiens	21-26
25275481-8	2014	ABCC4 inhibitors and ABCC4 knockdown showed the reduction of extracellular/intracellular ratio of PGE3 (40-60% of control) and PGF(3alpha) (60-80% of control) in A549 cells.	Prostaglandins F	127-130	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
25275481-8	2014	ABCC4 inhibitors and ABCC4 knockdown showed the reduction of extracellular/intracellular ratio of PGE3 (40-60% of control) and PGF(3alpha) (60-80% of control) in A549 cells.	Prostaglandins F	127-130	ATP binding cassette subfamily C member 4	Homo sapiens	21-26
25275481-9	2014	CONCLUSIONS: Our results suggest that PGE3, PGF(3alpha), and TXB3 are substrates of ABCC4 and ABCC4 partially contributes to the release of PGE3 and PGF(3alpha).	prostaglandin E3	38-42	ATP binding cassette subfamily C member 4	Homo sapiens	84-89
25275481-9	2014	CONCLUSIONS: Our results suggest that PGE3, PGF(3alpha), and TXB3 are substrates of ABCC4 and ABCC4 partially contributes to the release of PGE3 and PGF(3alpha).	prostaglandin E3	38-42	ATP binding cassette subfamily C member 4	Homo sapiens	94-99
25275481-9	2014	CONCLUSIONS: Our results suggest that PGE3, PGF(3alpha), and TXB3 are substrates of ABCC4 and ABCC4 partially contributes to the release of PGE3 and PGF(3alpha).	Prostaglandins F	44-47	ATP binding cassette subfamily C member 4	Homo sapiens	84-89
25275481-9	2014	CONCLUSIONS: Our results suggest that PGE3, PGF(3alpha), and TXB3 are substrates of ABCC4 and ABCC4 partially contributes to the release of PGE3 and PGF(3alpha).	Prostaglandins F	44-47	ATP binding cassette subfamily C member 4	Homo sapiens	94-99
25275481-9	2014	CONCLUSIONS: Our results suggest that PGE3, PGF(3alpha), and TXB3 are substrates of ABCC4 and ABCC4 partially contributes to the release of PGE3 and PGF(3alpha).	prostaglandin E3	140-144	ATP binding cassette subfamily C member 4	Homo sapiens	84-89
25275481-9	2014	CONCLUSIONS: Our results suggest that PGE3, PGF(3alpha), and TXB3 are substrates of ABCC4 and ABCC4 partially contributes to the release of PGE3 and PGF(3alpha).	prostaglandin E3	140-144	ATP binding cassette subfamily C member 4	Homo sapiens	94-99
25275481-9	2014	CONCLUSIONS: Our results suggest that PGE3, PGF(3alpha), and TXB3 are substrates of ABCC4 and ABCC4 partially contributes to the release of PGE3 and PGF(3alpha).	Prostaglandins F	149-152	ATP binding cassette subfamily C member 4	Homo sapiens	84-89
25275481-9	2014	CONCLUSIONS: Our results suggest that PGE3, PGF(3alpha), and TXB3 are substrates of ABCC4 and ABCC4 partially contributes to the release of PGE3 and PGF(3alpha).	Prostaglandins F	149-152	ATP binding cassette subfamily C member 4	Homo sapiens	94-99
25121519-1	2014	Multidrug resistance protein 4 (MRP4/ABCC4) has been established as an independent regulator of cyclic AMP (cAMP) levels particularly in vascular smooth muscle cells and in hematopoietic cells.	Cyclic AMP	96-106	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
25121519-1	2014	Multidrug resistance protein 4 (MRP4/ABCC4) has been established as an independent regulator of cyclic AMP (cAMP) levels particularly in vascular smooth muscle cells and in hematopoietic cells.	Cyclic AMP	96-106	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
24973542-0	2014	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).	ceefourin 1	37-48	ATP binding cassette subfamily C member 4	Homo sapiens	99-129
24973542-0	2014	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).	ceefourin 1	37-48	ATP binding cassette subfamily C member 4	Homo sapiens	131-135
24973542-5	2014	Using high-throughput screening, we identified two chemically distinct small molecules, Ceefourin 1 and Ceefourin 2, that inhibit transport of a broad range of MRP4 substrates, yet are highly selective for MRP4 over other ABC transporters, including P-glycoprotein (P-gp), ABCG2 (Breast Cancer Resistance Protein; BCRP) and MRP1 (multidrug resistance protein 1; ABCC1).	ceefourin	88-97	ATP binding cassette subfamily C member 4	Homo sapiens	160-164
24973542-0	2014	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).	ceefourin 2	53-64	ATP binding cassette subfamily C member 4	Homo sapiens	99-129
24973542-5	2014	Using high-throughput screening, we identified two chemically distinct small molecules, Ceefourin 1 and Ceefourin 2, that inhibit transport of a broad range of MRP4 substrates, yet are highly selective for MRP4 over other ABC transporters, including P-glycoprotein (P-gp), ABCG2 (Breast Cancer Resistance Protein; BCRP) and MRP1 (multidrug resistance protein 1; ABCC1).	ceefourin	88-97	ATP binding cassette subfamily C member 4	Homo sapiens	206-210
24973542-0	2014	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).	ceefourin 2	53-64	ATP binding cassette subfamily C member 4	Homo sapiens	131-135
24973542-5	2014	Using high-throughput screening, we identified two chemically distinct small molecules, Ceefourin 1 and Ceefourin 2, that inhibit transport of a broad range of MRP4 substrates, yet are highly selective for MRP4 over other ABC transporters, including P-glycoprotein (P-gp), ABCG2 (Breast Cancer Resistance Protein; BCRP) and MRP1 (multidrug resistance protein 1; ABCC1).	ceefourin 1	88-99	ATP binding cassette subfamily C member 4	Homo sapiens	160-164
24973542-5	2014	Using high-throughput screening, we identified two chemically distinct small molecules, Ceefourin 1 and Ceefourin 2, that inhibit transport of a broad range of MRP4 substrates, yet are highly selective for MRP4 over other ABC transporters, including P-glycoprotein (P-gp), ABCG2 (Breast Cancer Resistance Protein; BCRP) and MRP1 (multidrug resistance protein 1; ABCC1).	ceefourin 1	88-99	ATP binding cassette subfamily C member 4	Homo sapiens	206-210
24870404-7	2014	MRP4 is also found at the apical membrane of renal proximal tubule cells, making it an ideal candidate for urinary arsenic elimination.	Arsenic	115-122	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
24510239-9	2014	Furthermore, inhibition of ABCC4 protein in ESCC cells decreased cell proliferation and motility via the inhibition of COX-2, PGE2 receptors and c-Myc expression; AKT, extracellular signal-regulated kinase and cAMP response element-binding protein phosphorylation; and beta-catenin nuclear translocation in ESCC cells.	Cyclic AMP	210-214	ATP binding cassette subfamily C member 4	Homo sapiens	27-32
24958844-0	2014	Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.	Enalaprilat	99-110	ATP binding cassette subfamily C member 4	Homo sapiens	8-49
24958844-6	2014	ATP-dependent uptake of enalaprilat into vesicles expressing multidrug resistance-associated protein (MRP) 4 was significantly greater (~3.8-fold) than in control vesicles.	Adenosine Triphosphate	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	61-108
24958844-6	2014	ATP-dependent uptake of enalaprilat into vesicles expressing multidrug resistance-associated protein (MRP) 4 was significantly greater (~3.8-fold) than in control vesicles.	Enalaprilat	24-35	ATP binding cassette subfamily C member 4	Homo sapiens	61-108
24958844-8	2014	The functional importance of MRP4 in the basolateral excretion of derived enalaprilat was evaluated using a novel basolateral efflux protocol developed in human sandwich-cultured hepatocytes.	Enalaprilat	74-85	ATP binding cassette subfamily C member 4	Homo sapiens	29-33
24958844-10	2014	Results suggest that hepatically derived enalaprilat is excreted across the hepatic basolateral membrane by MRP4.	Enalaprilat	41-52	ATP binding cassette subfamily C member 4	Homo sapiens	108-112
24958844-11	2014	Changes in MRP4-mediated basolateral efflux may alter the systemic concentrations of this active metabolite, and potentially the efficacy of enalapril.	Enalapril	141-150	ATP binding cassette subfamily C member 4	Homo sapiens	11-15
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	Arsenic	20-27	ATP binding cassette subfamily C member 4	Homo sapiens	79-83
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	Arsenic	20-27	ATP binding cassette subfamily C member 4	Homo sapiens	84-89
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	Cacodylic Acid	119-139	ATP binding cassette subfamily C member 4	Homo sapiens	79-83
25173977-5	2014	We show that Lkt/ABCC4 localizes to the cell membrane and exports prostaglandin E2 (PGE2), a function that is abrogated by the Lkt/ABCC4(T804M) mutant.	Dinoprostone	66-82	ATP binding cassette subfamily C member 4	Homo sapiens	17-22
25173977-5	2014	We show that Lkt/ABCC4 localizes to the cell membrane and exports prostaglandin E2 (PGE2), a function that is abrogated by the Lkt/ABCC4(T804M) mutant.	Dinoprostone	66-82	ATP binding cassette subfamily C member 4	Homo sapiens	131-136
25173977-5	2014	We show that Lkt/ABCC4 localizes to the cell membrane and exports prostaglandin E2 (PGE2), a function that is abrogated by the Lkt/ABCC4(T804M) mutant.	Dinoprostone	84-88	ATP binding cassette subfamily C member 4	Homo sapiens	17-22
25173977-5	2014	We show that Lkt/ABCC4 localizes to the cell membrane and exports prostaglandin E2 (PGE2), a function that is abrogated by the Lkt/ABCC4(T804M) mutant.	Dinoprostone	84-88	ATP binding cassette subfamily C member 4	Homo sapiens	131-136
25173977-8	2014	These findings lead us to propose that Lkt/ABCC4-mediated PGE2 signalling acts through a ciliary G-protein-coupled receptor, EP4, to upregulate cAMP synthesis and increase anterograde IFT, thereby promoting ciliogenesis.	Dinoprostone	58-62	ATP binding cassette subfamily C member 4	Homo sapiens	43-48
25173977-8	2014	These findings lead us to propose that Lkt/ABCC4-mediated PGE2 signalling acts through a ciliary G-protein-coupled receptor, EP4, to upregulate cAMP synthesis and increase anterograde IFT, thereby promoting ciliogenesis.	Cyclic AMP	144-148	ATP binding cassette subfamily C member 4	Homo sapiens	43-48
25174819-1	2014	ABCC4 is a member of the ATP-binding cassette transporter family known to transport prostaglandin E2 and other molecules across cellular membranes.	Dinoprostone	84-100	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
25174819-2	2014	A mutation in ABCC4 is now shown to cause defects in ciliogenesis, revealing a role for prostaglandin signalling in regulating cilia dynamics.	Prostaglandins	88-101	ATP binding cassette subfamily C member 4	Homo sapiens	14-19
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	Cacodylic Acid	119-139	ATP binding cassette subfamily C member 4	Homo sapiens	84-89
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	Dimethylarsinate	141-145	ATP binding cassette subfamily C member 4	Homo sapiens	79-83
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	Dimethylarsinate	141-145	ATP binding cassette subfamily C member 4	Homo sapiens	84-89
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	diglutathione	155-168	ATP binding cassette subfamily C member 4	Homo sapiens	79-83
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	diglutathione	155-168	ATP binding cassette subfamily C member 4	Homo sapiens	84-89
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	monomethylarsonous acid	182-205	ATP binding cassette subfamily C member 4	Homo sapiens	79-83
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	monomethylarsonous acid	182-205	ATP binding cassette subfamily C member 4	Homo sapiens	84-89
24870404-8	2014	In the current study, human MRP4 expressed in HEK293 cells reduced the cytotoxicity and cellular accumulation of arsenate, MMA(III), MMA(V), DMA(III), and DMA(V) while two other hepatic basolateral MRPs (MRP3 and MRP5) did not.	arsenic acid	113-121	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	monomethylarsonous acid	207-213	ATP binding cassette subfamily C member 4	Homo sapiens	79-83
24870404-0	2014	A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).	monomethylarsonous acid	207-213	ATP binding cassette subfamily C member 4	Homo sapiens	84-89
24870404-8	2014	In the current study, human MRP4 expressed in HEK293 cells reduced the cytotoxicity and cellular accumulation of arsenate, MMA(III), MMA(V), DMA(III), and DMA(V) while two other hepatic basolateral MRPs (MRP3 and MRP5) did not.	N-myristoyl-alaninol	141-144	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
24870404-8	2014	In the current study, human MRP4 expressed in HEK293 cells reduced the cytotoxicity and cellular accumulation of arsenate, MMA(III), MMA(V), DMA(III), and DMA(V) while two other hepatic basolateral MRPs (MRP3 and MRP5) did not.	N-myristoyl-alaninol	155-158	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
24870404-9	2014	Transport studies with MRP4-enriched membrane vesicles revealed that the diglutathione conjugate of MMA(III), monomethylarsenic diglutathione [MMA(GS)(2)], and DMA(V) were the transported species.	diglutathione	73-86	ATP binding cassette subfamily C member 4	Homo sapiens	23-27
24870404-9	2014	Transport studies with MRP4-enriched membrane vesicles revealed that the diglutathione conjugate of MMA(III), monomethylarsenic diglutathione [MMA(GS)(2)], and DMA(V) were the transported species.	methylarsenic diglutathione	110-141	ATP binding cassette subfamily C member 4	Homo sapiens	23-27
24870404-9	2014	Transport studies with MRP4-enriched membrane vesicles revealed that the diglutathione conjugate of MMA(III), monomethylarsenic diglutathione [MMA(GS)(2)], and DMA(V) were the transported species.	N-myristoyl-alaninol	160-163	ATP binding cassette subfamily C member 4	Homo sapiens	23-27
24870404-12	2014	These results suggest that human MRP4 could be a major player in the elimination of arsenic.	Arsenic	84-91	ATP binding cassette subfamily C member 4	Homo sapiens	33-37
24464805-3	2014	When the area under the concentration-time curve for plasma (AUC(plasma)) was used to assess systemic exposure to MTX, the rank order was Abcc4(-/-) < WT < Abcg2(-/-) < Abcg2(-/-)Abcc4(-/-).	Methotrexate	114-117	ATP binding cassette subfamily C member 4	Homo sapiens	138-143
24758594-6	2014	We show that this polymer can extract several eukaryotic ABC transporters, P-glycoprotein (ABCB1), MRP1 (multidrug-resistance protein 1; ABCC1), MRP4 (ABCC4), ABCG2 and CFTR (cystic fibrosis transmembrane conductance regulator; ABCC7), from a range of different expression systems.	Polymers	18-25	ATP binding cassette subfamily C member 4	Homo sapiens	145-149
24758594-6	2014	We show that this polymer can extract several eukaryotic ABC transporters, P-glycoprotein (ABCB1), MRP1 (multidrug-resistance protein 1; ABCC1), MRP4 (ABCC4), ABCG2 and CFTR (cystic fibrosis transmembrane conductance regulator; ABCC7), from a range of different expression systems.	Polymers	18-25	ATP binding cassette subfamily C member 4	Homo sapiens	151-156
24694755-0	2014	Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development.	Dinoprostone	36-52	ATP binding cassette subfamily C member 4	Homo sapiens	75-80
24464805-0	2014	The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.	Methotrexate	57-69	ATP binding cassette subfamily C member 4	Homo sapiens	24-29
24464805-1	2014	Methotrexate (MTX) is the cornerstone of chemotherapy for primary central nervous system lymphoma, yet how the blood-brain barrier (BBB) efflux transporters ABCG2 and ABCC4 influence the required high-dose therapy is unknown.	Methotrexate	0-12	ATP binding cassette subfamily C member 4	Homo sapiens	167-172
24343710-2	2014	We hypothesized drug transporter expression in vaginal, cervical, and colorectal tissues is a contributing factor and selected 3 efflux (ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and 3 uptake (SLC22A6/OAT1, SLC22A8/OAT3, SLCO1B1/OATP1B1) transporters to further investigate based on their affinity for 2 ARVs central to prevention (tenofovir, maraviroc).	Tenofovir	326-335	ATP binding cassette subfamily C member 4	Homo sapiens	161-166
24522246-5	2014	Also, our data indicated that silibinin, in a dose-dependent manner with applying no cytotoxic effects, inhibited cell proliferation and reduced mRNA expression levels of some transporter genes e.g. MDR1, MRP3, MRP2, MRP1, MRP5, MRP4, ABCG2, ABCB11, MRP6 and MRP7.	Silybin	30-39	ATP binding cassette subfamily C member 4	Homo sapiens	229-233
24464805-1	2014	Methotrexate (MTX) is the cornerstone of chemotherapy for primary central nervous system lymphoma, yet how the blood-brain barrier (BBB) efflux transporters ABCG2 and ABCC4 influence the required high-dose therapy is unknown.	Methotrexate	14-17	ATP binding cassette subfamily C member 4	Homo sapiens	167-172
24464805-3	2014	When the area under the concentration-time curve for plasma (AUC(plasma)) was used to assess systemic exposure to MTX, the rank order was Abcc4(-/-) < WT < Abcg2(-/-) < Abcg2(-/-)Abcc4(-/-).	Methotrexate	114-117	ATP binding cassette subfamily C member 4	Homo sapiens	188-193
24464805-7	2014	Both Abcg2 and Abcc4 limited BBB penetration of MTX; however, only when both drug efflux pumps were negated did the brain accumulation of MTX significantly increase.	Methotrexate	48-51	ATP binding cassette subfamily C member 4	Homo sapiens	15-20
24464805-7	2014	Both Abcg2 and Abcc4 limited BBB penetration of MTX; however, only when both drug efflux pumps were negated did the brain accumulation of MTX significantly increase.	Methotrexate	138-141	ATP binding cassette subfamily C member 4	Homo sapiens	15-20
24464805-8	2014	These findings indicate a contributory role of both ABCG2 and ABCC4 to limiting MTX distribution in patients.	Methotrexate	80-83	ATP binding cassette subfamily C member 4	Homo sapiens	62-67
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	adefovir	178-186	ATP binding cassette subfamily C member 4	Homo sapiens	72-76
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	adefovir	178-186	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	adefovir	178-186	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	adefovir	178-186	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	Nucleosides	190-200	ATP binding cassette subfamily C member 4	Homo sapiens	72-76
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	Nucleosides	190-200	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	Nucleosides	190-200	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	Nucleosides	190-200	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
23742099-8	2013	A multidrug-resistant protein (MRP) inhibitor and short hairpin RNA directed against MRP4 blocked H2O2 responses.	Hydrogen Peroxide	98-102	ATP binding cassette subfamily C member 4	Homo sapiens	85-89
24320552-9	2014	MPAG was a preferred substrate for the biliary excretion transporter MRP2 and the hepatic basolateral transporters MRP3 and MRP4 in conventional and metabolic/hepatobiliary transport studies using SCHH and vesicular transport studies using human MRP-expressing membrane vesicles.	mycophenolic acid glucuronide	0-4	ATP binding cassette subfamily C member 4	Homo sapiens	124-128
24036158-7	2013	With regard to the apical efflux transporters, mycophenolic acid, cyclophosphamide, hydrocortisone, and tacrolimus inhibited MRP2 and MRP4, whereas mitoxantrone and dexamethasone stimulated [(3)H]-MTX transport by both transporters.	Mycophenolic Acid	47-64	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
24036158-7	2013	With regard to the apical efflux transporters, mycophenolic acid, cyclophosphamide, hydrocortisone, and tacrolimus inhibited MRP2 and MRP4, whereas mitoxantrone and dexamethasone stimulated [(3)H]-MTX transport by both transporters.	Cyclophosphamide	66-82	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
24036158-7	2013	With regard to the apical efflux transporters, mycophenolic acid, cyclophosphamide, hydrocortisone, and tacrolimus inhibited MRP2 and MRP4, whereas mitoxantrone and dexamethasone stimulated [(3)H]-MTX transport by both transporters.	Hydrocortisone	84-98	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
24036158-7	2013	With regard to the apical efflux transporters, mycophenolic acid, cyclophosphamide, hydrocortisone, and tacrolimus inhibited MRP2 and MRP4, whereas mitoxantrone and dexamethasone stimulated [(3)H]-MTX transport by both transporters.	Tacrolimus	104-114	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
24036158-8	2013	Cyclosporine, vincristine, and vinblastine inhibited MRP2 only, whereas 6-mercaptopurine inhibited MRP4 transport activity only.	Mercaptopurine	72-88	ATP binding cassette subfamily C member 4	Homo sapiens	99-103
24006340-4	2013	N5-2OH entered cultured human CCRF-CEM cells via passive diffusion, whereas the multidrug resistance-associated protein 4 appeared to be a major mediator of N5-2OH monophosphate efflux.	n5-2oh monophosphate	157-177	ATP binding cassette subfamily C member 4	Homo sapiens	80-121
23896476-2	2013	COBI and TFV have been reported to interact with distinct transporters in renal proximal tubules; while TFV is renally eliminated by a combination of glomerular filtration and tubular secretion via anion transporters OAT1, OAT3, and MRP4, COBI inhibits renal cation transporters, particularly MATE1, resulting in a measurable decrease in the tubular secretion of creatinine.	Cobicistat	0-4	ATP binding cassette subfamily C member 4	Homo sapiens	233-237
23896476-2	2013	COBI and TFV have been reported to interact with distinct transporters in renal proximal tubules; while TFV is renally eliminated by a combination of glomerular filtration and tubular secretion via anion transporters OAT1, OAT3, and MRP4, COBI inhibits renal cation transporters, particularly MATE1, resulting in a measurable decrease in the tubular secretion of creatinine.	Tenofovir	104-107	ATP binding cassette subfamily C member 4	Homo sapiens	233-237
24624911-5	2014	RESULTS: SNPs in the thiopurine pathway genes ABCC4, ABCC5, IMPDH1, ITPA, SLC28A3 and XDH, and SNPs located within or near ATP6AP2, FRMD4B, GNG2, KCNMA1 and NME1, were associated with clinical response and measures of thiopurine metabolism.	2-mercaptopyrazine	21-31	ATP binding cassette subfamily C member 4	Homo sapiens	46-51
24454870-9	2014	Furthermore, down-regulation of ABCC4 expression enhanced intracellular cyclic adenosine monophosphate production and noticeable deficiency of G1-S phase checkpoint in cell cycle following irradiation.	Cyclic AMP	72-102	ATP binding cassette subfamily C member 4	Homo sapiens	32-37
23742099-9	2013	EP1 and EP4 agonists mimicked H2O2 in both control and MRP4 knockdown cells.	Hydrogen Peroxide	30-34	ATP binding cassette subfamily C member 4	Homo sapiens	55-59
23994649-3	2013	In this study, we investigated the contribution of MRPs, including MRP1, MRP2, and MRP4, to the release process of the prostanoids from human lung adenocarcinoma epithelial A549 cells.	Prostaglandins	119-130	ATP binding cassette subfamily C member 4	Homo sapiens	83-87
24067562-0	2013	Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.	Tenofovir	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	120-125
23994649-7	2013	The extracellular levels of PGE2 and PGF2alpha were significantly decreased after MRP4 knockdown.	Dinoprostone	28-32	ATP binding cassette subfamily C member 4	Homo sapiens	82-86
23994649-7	2013	The extracellular levels of PGE2 and PGF2alpha were significantly decreased after MRP4 knockdown.	Dinoprost	37-46	ATP binding cassette subfamily C member 4	Homo sapiens	82-86
23994649-8	2013	Our results suggest that MRPs including MRP4 contribute the release process of prostanoids in A549 cells.	Prostaglandins	79-90	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
23775562-9	2013	These results suggest that nelfinavir is both an inhibitor and substrate of MRP4.	Nelfinavir	27-37	ATP binding cassette subfamily C member 4	Homo sapiens	76-80
23775562-3	2013	We hypothesized that multidrug resistance protein 4/ATP binding cassette transporter 4 (MRP4/ABCC4), a widely expressed transporter of nucleoside-based antiviral medications as well as cancer therapeutics might interact with PIs.	Nucleosides	135-145	ATP binding cassette subfamily C member 4	Homo sapiens	88-92
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Nelfinavir	8-18	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
23775562-3	2013	We hypothesized that multidrug resistance protein 4/ATP binding cassette transporter 4 (MRP4/ABCC4), a widely expressed transporter of nucleoside-based antiviral medications as well as cancer therapeutics might interact with PIs.	Nucleosides	135-145	ATP binding cassette subfamily C member 4	Homo sapiens	93-98
23775562-4	2013	Among the PIs evaluated (nelfinavir, ritonavir, amprenavir, saquinavir, and indinavir), only nelfinavir both effectively stimulated MRP4 ATPase activity and inhibited substrate-stimulated ATPase activity.	Nelfinavir	93-103	ATP binding cassette subfamily C member 4	Homo sapiens	132-136
23775562-6	2013	MRP4 expression reduced intracellular accumulation of nelfinavir and consequently conferred survival advantage to nelfinavir cytotoxicity.	Nelfinavir	54-64	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
23775562-6	2013	MRP4 expression reduced intracellular accumulation of nelfinavir and consequently conferred survival advantage to nelfinavir cytotoxicity.	Nelfinavir	114-124	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
23775562-7	2013	Nelfinavir blocked Mrp4-mediated export, which is consistent with its ability to increase the sensitivity of MRP4-expressing cells to methotrexate.	Nelfinavir	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
23775562-7	2013	Nelfinavir blocked Mrp4-mediated export, which is consistent with its ability to increase the sensitivity of MRP4-expressing cells to methotrexate.	Nelfinavir	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	109-113
23775562-7	2013	Nelfinavir blocked Mrp4-mediated export, which is consistent with its ability to increase the sensitivity of MRP4-expressing cells to methotrexate.	Methotrexate	134-146	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Nelfinavir	8-18	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
23775562-7	2013	Nelfinavir blocked Mrp4-mediated export, which is consistent with its ability to increase the sensitivity of MRP4-expressing cells to methotrexate.	Methotrexate	134-146	ATP binding cassette subfamily C member 4	Homo sapiens	109-113
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Nelfinavir	8-18	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Nelfinavir	8-18	ATP binding cassette subfamily C member 4	Homo sapiens	70-75
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Nelfinavir	119-129	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Nelfinavir	119-129	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Nelfinavir	119-129	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Nelfinavir	119-129	ATP binding cassette subfamily C member 4	Homo sapiens	70-75
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	adefovir	194-202	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	adefovir	194-202	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	adefovir	194-202	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	adefovir	194-202	ATP binding cassette subfamily C member 4	Homo sapiens	70-75
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Methotrexate	207-219	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Methotrexate	207-219	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Methotrexate	207-219	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	Methotrexate	207-219	ATP binding cassette subfamily C member 4	Homo sapiens	70-75
23775562-11	2013	Our studies reveal, for the first time, that nelfinavir, a potent and cytotoxic PI, is both a substrate and inhibitor of MRP4.	Nelfinavir	45-55	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
23775562-12	2013	These findings suggest that HIV-infected cancer patients receiving nelfinavir might experience both enhanced antitumor efficacy and unexpected adverse toxicity given the role of MRP4/ABCC4 in exporting nucleoside-based antiretroviral medications and cancer chemotherapeutics.	Nelfinavir	67-77	ATP binding cassette subfamily C member 4	Homo sapiens	178-182
23775562-12	2013	These findings suggest that HIV-infected cancer patients receiving nelfinavir might experience both enhanced antitumor efficacy and unexpected adverse toxicity given the role of MRP4/ABCC4 in exporting nucleoside-based antiretroviral medications and cancer chemotherapeutics.	Nelfinavir	67-77	ATP binding cassette subfamily C member 4	Homo sapiens	183-188
23775562-12	2013	These findings suggest that HIV-infected cancer patients receiving nelfinavir might experience both enhanced antitumor efficacy and unexpected adverse toxicity given the role of MRP4/ABCC4 in exporting nucleoside-based antiretroviral medications and cancer chemotherapeutics.	Nucleosides	202-212	ATP binding cassette subfamily C member 4	Homo sapiens	178-182
23775562-12	2013	These findings suggest that HIV-infected cancer patients receiving nelfinavir might experience both enhanced antitumor efficacy and unexpected adverse toxicity given the role of MRP4/ABCC4 in exporting nucleoside-based antiretroviral medications and cancer chemotherapeutics.	Nucleosides	202-212	ATP binding cassette subfamily C member 4	Homo sapiens	183-188
23887631-9	2013	Nine stemness-linked genes (ABCB1, ABCC4, LMO2, SOX2, ERCC5, S100A10, IGFBP3, TCF3, and VIM) were downregulated in vorinostat-treated doxorubicin-resistant SK-N-Be(2)C cells relative to doxorubicin-resistant cells.	Vorinostat	115-125	ATP binding cassette subfamily C member 4	Homo sapiens	35-40
23462933-10	2013	The glucuronide, sulfate, and GSH conjugates are excreted by transporters in the canalicular (Mrp2 and Bcrp) and basolateral (Mrp3 and Mrp4) hepatocyte membranes.	Glucuronides	4-15	ATP binding cassette subfamily C member 4	Homo sapiens	135-139
23462933-10	2013	The glucuronide, sulfate, and GSH conjugates are excreted by transporters in the canalicular (Mrp2 and Bcrp) and basolateral (Mrp3 and Mrp4) hepatocyte membranes.	Sulfates	17-24	ATP binding cassette subfamily C member 4	Homo sapiens	135-139
23462933-10	2013	The glucuronide, sulfate, and GSH conjugates are excreted by transporters in the canalicular (Mrp2 and Bcrp) and basolateral (Mrp3 and Mrp4) hepatocyte membranes.	Glutathione	30-33	ATP binding cassette subfamily C member 4	Homo sapiens	135-139
23794731-3	2013	EXPERIMENTAL DESIGN: Transport of dasatinib was studied in cells transfected with human ABCC4 or the ortholog mouse transporter, Abcc4.	Dasatinib	34-43	ATP binding cassette subfamily C member 4	Homo sapiens	88-93
23512405-7	2013	Upon stimulation of HT29 cells by TNF-alpha, up-regulation of ABCA1, ABCB8, ABCF2 and ABCC4 was seen, and further using inhibitors we found that it was mediated through reactive oxygen species or NF-kB or both.	Reactive Oxygen Species	169-192	ATP binding cassette subfamily C member 4	Homo sapiens	86-91
23530018-0	2013	Chalcogenopyrylium dyes as differential modulators of organic anion transport by multidrug resistance protein 1 (MRP1), MRP2, and MRP4.	chalcogenopyrylium	0-18	ATP binding cassette subfamily C member 4	Homo sapiens	130-134
23472950-1	2013	OBJECTIVE: To compare the expression of the prostaglandin (PG) E(2) transporter multidrug resistance-associated protein 4 (MRP4) in eutopic and ectopic endometrial tissue from endometriosis patients with that of control subjects and to examine whether MRP4 is regulated by the antiinflammatory lipid lipoxin A(4) (LXA(4)) in endometriotic epithelial cells.	Prostaglandins	44-57	ATP binding cassette subfamily C member 4	Homo sapiens	80-121
23472950-1	2013	OBJECTIVE: To compare the expression of the prostaglandin (PG) E(2) transporter multidrug resistance-associated protein 4 (MRP4) in eutopic and ectopic endometrial tissue from endometriosis patients with that of control subjects and to examine whether MRP4 is regulated by the antiinflammatory lipid lipoxin A(4) (LXA(4)) in endometriotic epithelial cells.	Prostaglandins	44-57	ATP binding cassette subfamily C member 4	Homo sapiens	123-127
23472950-14	2013	CONCLUSION(S): We report for the first time that MRP4 is expressed in human endometrium, elevated in peritoneal endometriosis, and modulated by LXA(4) in endometriotic epithelial cells.	N-(1H-benzimidazol-2-ylmethyl)-2-methoxyacetamide	144-147	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
23075005-13	2013	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	anagliptin	164-174	ATP binding cassette subfamily C member 4	Homo sapiens	267-271
23222202-10	2013	CONCLUSION: Our results suggest that polymorphisms in ABCC4 and ABCC2 could be novel markers for MTX toxicity in pediatric ALL.	Methotrexate	97-100	ATP binding cassette subfamily C member 4	Homo sapiens	54-59
23175273-8	2013	Compared to CPZ effects, overloading of HepaRG cells with high concentrations of cholic and chenodeoxycholic acids induced a delayed oxidative stress and, similarly, after 24 hours it down-regulated BSEP and MDR3 in parallel to a decrease of NTCP and CYP8B1 and an increase of MRP4.	Cholic	81-87	ATP binding cassette subfamily C member 4	Homo sapiens	277-281
23175273-8	2013	Compared to CPZ effects, overloading of HepaRG cells with high concentrations of cholic and chenodeoxycholic acids induced a delayed oxidative stress and, similarly, after 24 hours it down-regulated BSEP and MDR3 in parallel to a decrease of NTCP and CYP8B1 and an increase of MRP4.	Chenodeoxycholic Acid	92-114	ATP binding cassette subfamily C member 4	Homo sapiens	277-281
23385799-0	2013	MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure.	Cyclic AMP	42-46	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
23385799-0	2013	MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure.	Cyclic GMP	51-55	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
23385799-1	2013	PURPOSE: Multidrug, resistance-associated protein-4 (MRP4) is a membrane transporter that regulates the cellular efflux of cyclic nucleotides (cAMP and cGMP) involved in various physiologic responses.	Nucleotides, Cyclic	123-141	ATP binding cassette subfamily C member 4	Homo sapiens	9-51
23385799-1	2013	PURPOSE: Multidrug, resistance-associated protein-4 (MRP4) is a membrane transporter that regulates the cellular efflux of cyclic nucleotides (cAMP and cGMP) involved in various physiologic responses.	Nucleotides, Cyclic	123-141	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
23385799-1	2013	PURPOSE: Multidrug, resistance-associated protein-4 (MRP4) is a membrane transporter that regulates the cellular efflux of cyclic nucleotides (cAMP and cGMP) involved in various physiologic responses.	Cyclic AMP	143-147	ATP binding cassette subfamily C member 4	Homo sapiens	9-51
23385799-1	2013	PURPOSE: Multidrug, resistance-associated protein-4 (MRP4) is a membrane transporter that regulates the cellular efflux of cyclic nucleotides (cAMP and cGMP) involved in various physiologic responses.	Cyclic AMP	143-147	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
23385799-1	2013	PURPOSE: Multidrug, resistance-associated protein-4 (MRP4) is a membrane transporter that regulates the cellular efflux of cyclic nucleotides (cAMP and cGMP) involved in various physiologic responses.	Cyclic GMP	152-156	ATP binding cassette subfamily C member 4	Homo sapiens	9-51
23385799-1	2013	PURPOSE: Multidrug, resistance-associated protein-4 (MRP4) is a membrane transporter that regulates the cellular efflux of cyclic nucleotides (cAMP and cGMP) involved in various physiologic responses.	Cyclic GMP	152-156	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
23385799-7	2013	Inhibition of MRP4 in HTM cells by MK571 or probenecid resulted in cell shape changes and decreases in actin stress fibers and MLC phosphorylation.	verlukast	35-40	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
23385799-7	2013	Inhibition of MRP4 in HTM cells by MK571 or probenecid resulted in cell shape changes and decreases in actin stress fibers and MLC phosphorylation.	Probenecid	44-54	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
23385799-11	2013	CONCLUSIONS: These observations reveal that cyclic nucleotide efflux controlling transporter-MRP4 plays a significant role in IOP homeostasis potentially by regulating the relaxation characteristics of AH outflow pathway cells.	Nucleotides, Cyclic	44-61	ATP binding cassette subfamily C member 4	Homo sapiens	93-97
22955427-3	2012	METHODS: The association between tenofovir-induced KTD and 14 single nucleotide polymorphisms (SNPs) in the ABCC2, ABCC4, ABCC10, SCL22A6, and ABCB1 genes was investigated in 190 Japanese patients.	Tenofovir	33-42	ATP binding cassette subfamily C member 4	Homo sapiens	115-120
22982073-8	2012	MK-571, chemical inhibitor of MRP2, MRP3, and MRP4, significantly reduced the efflux of glucuronide in the apical-to-basolateral (A-B) and B-A directions in a dose-dependent manner.	verlukast	0-6	ATP binding cassette subfamily C member 4	Homo sapiens	46-50
22982073-8	2012	MK-571, chemical inhibitor of MRP2, MRP3, and MRP4, significantly reduced the efflux of glucuronide in the apical-to-basolateral (A-B) and B-A directions in a dose-dependent manner.	Glucuronides	88-99	ATP binding cassette subfamily C member 4	Homo sapiens	46-50
22847220-1	2012	The inhibition potencies of aripiprazole and its active metabolite, dehydroaripiprazole, on the activities of human multidrug resistance protein 1 (MDR1/ABCB1; P-glycoprotein), breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4), that are drug efflux transporters expressed both in the intestine and at the blood-brain barrier (BBB), were investigated.	Aripiprazole	28-40	ATP binding cassette subfamily C member 4	Homo sapiens	227-268
23014861-0	2012	Reduction of cAMP and cGMP inhibitory effects in human platelets by MRP4-mediated transport.	Cyclic AMP	13-17	ATP binding cassette subfamily C member 4	Homo sapiens	68-72
23014861-0	2012	Reduction of cAMP and cGMP inhibitory effects in human platelets by MRP4-mediated transport.	Cyclic GMP	22-26	ATP binding cassette subfamily C member 4	Homo sapiens	68-72
23014861-4	2012	In some cells cyclic nucleotides are eliminated also through MRP4/5/8-dependent efflux.	Nucleotides, Cyclic	14-32	ATP binding cassette subfamily C member 4	Homo sapiens	61-69
23014861-5	2012	As only MRP4 is expressed in platelets, at high levels in dense granules, we determined its role in the elimination of cyclic nucleotides from platelet cytosol.	Nucleotides, Cyclic	119-137	ATP binding cassette subfamily C member 4	Homo sapiens	8-12
23014861-6	2012	We studied the effects of MRP4 inhibition on cAMP/cGMP effects in platelets.	Cyclic AMP	45-49	ATP binding cassette subfamily C member 4	Homo sapiens	26-30
23014861-6	2012	We studied the effects of MRP4 inhibition on cAMP/cGMP effects in platelets.	Cyclic GMP	50-54	ATP binding cassette subfamily C member 4	Homo sapiens	26-30
23014861-7	2012	Cyclic nucleotide inhibitory effects triggered by cAMP and cGMP-elevating agents on platelet aggregation are strongly enhanced by MRP4 inhibition and so is cyclic nucleotide-dependent phosphorylation of the common substrate VASP.	Nucleotides, Cyclic	0-17	ATP binding cassette subfamily C member 4	Homo sapiens	130-134
23014861-7	2012	Cyclic nucleotide inhibitory effects triggered by cAMP and cGMP-elevating agents on platelet aggregation are strongly enhanced by MRP4 inhibition and so is cyclic nucleotide-dependent phosphorylation of the common substrate VASP.	Cyclic AMP	50-54	ATP binding cassette subfamily C member 4	Homo sapiens	130-134
23014861-7	2012	Cyclic nucleotide inhibitory effects triggered by cAMP and cGMP-elevating agents on platelet aggregation are strongly enhanced by MRP4 inhibition and so is cyclic nucleotide-dependent phosphorylation of the common substrate VASP.	Cyclic GMP	59-63	ATP binding cassette subfamily C member 4	Homo sapiens	130-134
23014861-7	2012	Cyclic nucleotide inhibitory effects triggered by cAMP and cGMP-elevating agents on platelet aggregation are strongly enhanced by MRP4 inhibition and so is cyclic nucleotide-dependent phosphorylation of the common substrate VASP.	Nucleotides, Cyclic	156-173	ATP binding cassette subfamily C member 4	Homo sapiens	130-134
23014861-8	2012	MRP4 inhibition decreases cAMP concentration in platelet granules and both cAMP and cGMP compete with an established substrate of MRP4 (fluo-cAMP) for entrance in granules.	Cyclic AMP	26-30	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
23014861-8	2012	MRP4 inhibition decreases cAMP concentration in platelet granules and both cAMP and cGMP compete with an established substrate of MRP4 (fluo-cAMP) for entrance in granules.	fluo-camp	136-145	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
23014861-8	2012	MRP4 inhibition decreases cAMP concentration in platelet granules and both cAMP and cGMP compete with an established substrate of MRP4 (fluo-cAMP) for entrance in granules.	fluo-camp	136-145	ATP binding cassette subfamily C member 4	Homo sapiens	130-134
23014861-9	2012	Here we provide the first evidence of the transport of cyclic nucleotides mediated by MRP4 as part of their physiological mechanism of elimination in human platelets, which might represent a novel target to increase cyclic nucleotide-dependent inhibition.	Nucleotides, Cyclic	55-73	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
23014861-9	2012	Here we provide the first evidence of the transport of cyclic nucleotides mediated by MRP4 as part of their physiological mechanism of elimination in human platelets, which might represent a novel target to increase cyclic nucleotide-dependent inhibition.	Nucleotides, Cyclic	55-72	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
22847220-1	2012	The inhibition potencies of aripiprazole and its active metabolite, dehydroaripiprazole, on the activities of human multidrug resistance protein 1 (MDR1/ABCB1; P-glycoprotein), breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4), that are drug efflux transporters expressed both in the intestine and at the blood-brain barrier (BBB), were investigated.	Aripiprazole	28-40	ATP binding cassette subfamily C member 4	Homo sapiens	270-274
22847220-1	2012	The inhibition potencies of aripiprazole and its active metabolite, dehydroaripiprazole, on the activities of human multidrug resistance protein 1 (MDR1/ABCB1; P-glycoprotein), breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4), that are drug efflux transporters expressed both in the intestine and at the blood-brain barrier (BBB), were investigated.	Aripiprazole	28-40	ATP binding cassette subfamily C member 4	Homo sapiens	275-280
22387228-1	2012	Effects of 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), natural ligand of the VDR, on the fates of adefovir dipivoxil (P-gp substrate) and its metabolites, mono(POM)-PMEA and adefovir (MRP4 substrate), were investigated in Caco-2 cells.	Calcitriol	11-40	ATP binding cassette subfamily C member 4	Homo sapiens	185-189
22542979-0	2012	Phenylalanine 368 of multidrug resistance-associated protein 4 (MRP4/ABCC4) plays a crucial role in substrate-specific transport activity.	Phenylalanine	0-13	ATP binding cassette subfamily C member 4	Homo sapiens	21-62
22542979-0	2012	Phenylalanine 368 of multidrug resistance-associated protein 4 (MRP4/ABCC4) plays a crucial role in substrate-specific transport activity.	Phenylalanine	0-13	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
22542979-0	2012	Phenylalanine 368 of multidrug resistance-associated protein 4 (MRP4/ABCC4) plays a crucial role in substrate-specific transport activity.	Phenylalanine	0-13	ATP binding cassette subfamily C member 4	Homo sapiens	69-74
22387228-1	2012	Effects of 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), natural ligand of the VDR, on the fates of adefovir dipivoxil (P-gp substrate) and its metabolites, mono(POM)-PMEA and adefovir (MRP4 substrate), were investigated in Caco-2 cells.	Calcitriol	42-53	ATP binding cassette subfamily C member 4	Homo sapiens	185-189
22387228-3	2012	Changes in these washout studies were predicted by a catenary model for the Caco-2 monolayer that described a higher MRP4 activity with 1,25(OH)2D3 treatment, as confirmed by Western blotting.	Calcitriol	136-147	ATP binding cassette subfamily C member 4	Homo sapiens	117-121
22212563-4	2012	Furthermore, apatinib also strongly reversed multidrug resistance (MDR) in K562/ADR cells, and the primary leukemia blasts overexpressing ABCB1 while showed no synergistic interactions with chemotherapeutic agents in MRP1-, MRP4-, MRP7- and LRP-overexpressing cells.	apatinib	13-21	ATP binding cassette subfamily C member 4	Homo sapiens	224-228
22387228-8	2012	The composite data established that 1,25(OH)2D3 treatment increased both P-gp and MRP4 transport activities without affecting the metabolism of adefovir dipivoxil by esterases.	Calcitriol	36-47	ATP binding cassette subfamily C member 4	Homo sapiens	82-86
22415933-7	2012	Our results showed that 7-HC is not transported by any of the efflux transporters tested, whereas 7-HC-G was a substrate of MRP3 and MRP4.	7-hc-g	98-104	ATP binding cassette subfamily C member 4	Homo sapiens	133-137
22415933-8	2012	These results are in line with the pharmacokinetic profile of coumarin and suggest that MRP3 and MRP4 are the main transporters involved in the excretion of the coumarin metabolite 7-HC-G from liver and kidney.	coumarin	62-70	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
22415933-8	2012	These results are in line with the pharmacokinetic profile of coumarin and suggest that MRP3 and MRP4 are the main transporters involved in the excretion of the coumarin metabolite 7-HC-G from liver and kidney.	coumarin	161-169	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
22415933-8	2012	These results are in line with the pharmacokinetic profile of coumarin and suggest that MRP3 and MRP4 are the main transporters involved in the excretion of the coumarin metabolite 7-HC-G from liver and kidney.	7-hc-g	181-187	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
22337717-5	2012	An example of an ABC transporter is MRP4 (ABCC4), which facilitates ADP accumulation in dense granules.	Adenosine Diphosphate	68-71	ATP binding cassette subfamily C member 4	Homo sapiens	36-40
22337717-5	2012	An example of an ABC transporter is MRP4 (ABCC4), which facilitates ADP accumulation in dense granules.	Adenosine Diphosphate	68-71	ATP binding cassette subfamily C member 4	Homo sapiens	42-47
22337717-6	2012	MRP4 is a versatile transporter, and various additional functions have been proposed, notably lipid mediator release and a role in aspirin resistance.	Aspirin	131-138	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
22291955-6	2012	Exposure of HepG2 cells to theonellasterol antagonizes the effect of natural and synthetic FXR agonists on FXR-regulated genes, including SHP, OSTalpha, BSEP and MRP4.	7-hydroxytheonellasterol	27-42	ATP binding cassette subfamily C member 4	Homo sapiens	162-166
22837662-8	2012	The use of cells transfected with ABCC2, ABCC3 or ABCC4 showed that 3ATA was also able to modulate these transporters, though with an inhibition ratio lower than that observed for MRP1/ABCC1.	3ata	68-72	ATP binding cassette subfamily C member 4	Homo sapiens	50-55
22155354-0	2012	Multidrug resistance protein (MRP) 4 attenuates benzo[a]pyrene-mediated DNA-adduct formation in human bronchoalveolar H358 cells.	Benzo(a)pyrene	48-62	ATP binding cassette subfamily C member 4	Homo sapiens	0-36
22155354-6	2012	This suggested that MRP4 expression might contribute to the paradoxical decrease in (+)-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene-2"-deoxyguanosine ((+)-anti-trans-B[a]PDE-dGuo) DNA-adducts observed in TCDD-treated H358 cells.	(+)-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene-2"-deoxyguanosine	84-164	ATP binding cassette subfamily C member 4	Homo sapiens	20-24
22155354-6	2012	This suggested that MRP4 expression might contribute to the paradoxical decrease in (+)-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene-2"-deoxyguanosine ((+)-anti-trans-B[a]PDE-dGuo) DNA-adducts observed in TCDD-treated H358 cells.	2-amino-9-[(2R,3S,4S,5R)-3-deuterio-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one	189-193	ATP binding cassette subfamily C member 4	Homo sapiens	20-24
22155354-6	2012	This suggested that MRP4 expression might contribute to the paradoxical decrease in (+)-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene-2"-deoxyguanosine ((+)-anti-trans-B[a]PDE-dGuo) DNA-adducts observed in TCDD-treated H358 cells.	Polychlorinated Dibenzodioxins	219-223	ATP binding cassette subfamily C member 4	Homo sapiens	20-24
22155354-7	2012	We have now found that decreased MRP4 expression induced by a short hairpin RNA (shRNA), or chemical inhibition with probenecid, increased (+)-anti-trans-B[a]PDE-dGuo formation in cells treated with (-)-B[a]P-7,8-dihydrodiol, but not the ultimate carcinogen (+)-anti-trans-B[a]PDE.	Probenecid	117-127	ATP binding cassette subfamily C member 4	Homo sapiens	33-37
22155354-7	2012	We have now found that decreased MRP4 expression induced by a short hairpin RNA (shRNA), or chemical inhibition with probenecid, increased (+)-anti-trans-B[a]PDE-dGuo formation in cells treated with (-)-B[a]P-7,8-dihydrodiol, but not the ultimate carcinogen (+)-anti-trans-B[a]PDE.	7,8-dihydrodiol	209-224	ATP binding cassette subfamily C member 4	Homo sapiens	33-37
22155354-8	2012	Thus, up-regulation of MRP4 increased cellular efflux of (-)-B[a]P-7,8-dihydrodiol, which attenuated DNA-adduct formation.	(-)-b[a]p-7,8-dihydrodiol	57-82	ATP binding cassette subfamily C member 4	Homo sapiens	23-27
21741706-1	2012	CYP2B6, CYP2C19, ABCC4, and SOD2 have been implicated in adverse drug reactions and survival after cyclophosphamide (CPA) treatment.	Cyclophosphamide	99-115	ATP binding cassette subfamily C member 4	Homo sapiens	17-22
21741706-1	2012	CYP2B6, CYP2C19, ABCC4, and SOD2 have been implicated in adverse drug reactions and survival after cyclophosphamide (CPA) treatment.	Cyclophosphamide	117-120	ATP binding cassette subfamily C member 4	Homo sapiens	17-22
22291955-8	2012	Analysis of genes involved in bile acid uptake and excretion by hepatocytes revealed that theonellasterol increases the liver expression of MRP4, a basolateral transporter that is negatively regulated by FXR.	Bile Acids and Salts	30-39	ATP binding cassette subfamily C member 4	Homo sapiens	140-144
22291955-8	2012	Analysis of genes involved in bile acid uptake and excretion by hepatocytes revealed that theonellasterol increases the liver expression of MRP4, a basolateral transporter that is negatively regulated by FXR.	7-hydroxytheonellasterol	90-105	ATP binding cassette subfamily C member 4	Homo sapiens	140-144
21615622-4	2011	Among the genes involved in bile acid and bilirubin transport, the expression of SLCO1B3 was significantly elevated in HCC with CTNNB1 mutations, whereas the expression of ABCC4 was elevated in HCC with wild-type CTNNB1.	Bile Acids and Salts	28-37	ATP binding cassette subfamily C member 4	Homo sapiens	172-177
21930826-7	2011	Ciprofloxacin accumulation was lower in MRP4-HEK293 cells than in the parent line, indicating that ciprofloxacin is also a substrate for this transporter.	Ciprofloxacin	0-13	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
21930826-7	2011	Ciprofloxacin accumulation was lower in MRP4-HEK293 cells than in the parent line, indicating that ciprofloxacin is also a substrate for this transporter.	Ciprofloxacin	99-112	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
21803983-8	2011	Protection is accompanied by increased levels of glutathione and induction of multidrug resistance-associated protein 4, an organic anion efflux pump that also exports nucleoside monophosphate analogues.	nucleoside monophosphate	168-192	ATP binding cassette subfamily C member 4	Homo sapiens	78-119
21615622-4	2011	Among the genes involved in bile acid and bilirubin transport, the expression of SLCO1B3 was significantly elevated in HCC with CTNNB1 mutations, whereas the expression of ABCC4 was elevated in HCC with wild-type CTNNB1.	Bilirubin	42-51	ATP binding cassette subfamily C member 4	Homo sapiens	172-177
21526375-6	2011	The beneficial properties of rifampicin were associated with an increase in DME and export bile acid systems (multidrug resistance-associated protein 4, MRP4, and bile acid export pump to bile duct, BSEP) expression, as well as a reduction in NTCP expression.	Rifampin	29-39	ATP binding cassette subfamily C member 4	Homo sapiens	110-151
21526375-6	2011	The beneficial properties of rifampicin were associated with an increase in DME and export bile acid systems (multidrug resistance-associated protein 4, MRP4, and bile acid export pump to bile duct, BSEP) expression, as well as a reduction in NTCP expression.	Rifampin	29-39	ATP binding cassette subfamily C member 4	Homo sapiens	153-157
21816313-0	2011	Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting.	Aspirin	0-7	ATP binding cassette subfamily C member 4	Homo sapiens	47-77
21816313-1	2011	OBJECTIVES: In this study we investigate: 1) the role of multidrug resistance protein-4 (MRP4), an organic anion unidirectional transporter, in modulating aspirin action on human platelet cyclooxygenase (COX)-1; and 2) whether the impairment of aspirin-COX-1 interaction, found in coronary artery bypass grafting (CABG) patients, could be dependent on MRP4-mediated transport.	Aspirin	155-162	ATP binding cassette subfamily C member 4	Homo sapiens	57-87
21816313-1	2011	OBJECTIVES: In this study we investigate: 1) the role of multidrug resistance protein-4 (MRP4), an organic anion unidirectional transporter, in modulating aspirin action on human platelet cyclooxygenase (COX)-1; and 2) whether the impairment of aspirin-COX-1 interaction, found in coronary artery bypass grafting (CABG) patients, could be dependent on MRP4-mediated transport.	Aspirin	155-162	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
21816313-1	2011	OBJECTIVES: In this study we investigate: 1) the role of multidrug resistance protein-4 (MRP4), an organic anion unidirectional transporter, in modulating aspirin action on human platelet cyclooxygenase (COX)-1; and 2) whether the impairment of aspirin-COX-1 interaction, found in coronary artery bypass grafting (CABG) patients, could be dependent on MRP4-mediated transport.	Aspirin	155-162	ATP binding cassette subfamily C member 4	Homo sapiens	352-356
21816313-1	2011	OBJECTIVES: In this study we investigate: 1) the role of multidrug resistance protein-4 (MRP4), an organic anion unidirectional transporter, in modulating aspirin action on human platelet cyclooxygenase (COX)-1; and 2) whether the impairment of aspirin-COX-1 interaction, found in coronary artery bypass grafting (CABG) patients, could be dependent on MRP4-mediated transport.	Aspirin	245-252	ATP binding cassette subfamily C member 4	Homo sapiens	57-87
21816313-1	2011	OBJECTIVES: In this study we investigate: 1) the role of multidrug resistance protein-4 (MRP4), an organic anion unidirectional transporter, in modulating aspirin action on human platelet cyclooxygenase (COX)-1; and 2) whether the impairment of aspirin-COX-1 interaction, found in coronary artery bypass grafting (CABG) patients, could be dependent on MRP4-mediated transport.	Aspirin	245-252	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
21816313-3	2011	Aspirin is an organic anion and could be a substrate for MRP4.	Aspirin	0-7	ATP binding cassette subfamily C member 4	Homo sapiens	57-61
21816313-9	2011	CONCLUSIONS: Aspirin is a substrate for MRP4 and can be extruded from platelet through its transportation.	Aspirin	13-20	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
21816313-6	2011	RESULTS: Inhibition of MRP4-mediated transport by dipyridamole or Mk-571 increases aspirin entrapment and its in vitro effect on COX-1 activity (142.7 +- 34.6 pg/10(8) cells vs. 343.7 +- 169.3 pg/108 cells TxB2-production).	Dipyridamole	50-62	ATP binding cassette subfamily C member 4	Homo sapiens	23-27
21816313-10	2011	Aspirin effect on COX-1 is little-related to MRP4-mediated aspirin transport in HV, but in CABG patients with MRP4 over-expression, its pharmacological inhibition enhances aspirin action in an efficient way.	Aspirin	59-66	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
21816313-10	2011	Aspirin effect on COX-1 is little-related to MRP4-mediated aspirin transport in HV, but in CABG patients with MRP4 over-expression, its pharmacological inhibition enhances aspirin action in an efficient way.	Aspirin	172-179	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
21816313-10	2011	Aspirin effect on COX-1 is little-related to MRP4-mediated aspirin transport in HV, but in CABG patients with MRP4 over-expression, its pharmacological inhibition enhances aspirin action in an efficient way.	Aspirin	172-179	ATP binding cassette subfamily C member 4	Homo sapiens	110-114
21816313-6	2011	RESULTS: Inhibition of MRP4-mediated transport by dipyridamole or Mk-571 increases aspirin entrapment and its in vitro effect on COX-1 activity (142.7 +- 34.6 pg/10(8) cells vs. 343.7 +- 169.3 pg/108 cells TxB2-production).	verlukast	66-72	ATP binding cassette subfamily C member 4	Homo sapiens	23-27
21816313-6	2011	RESULTS: Inhibition of MRP4-mediated transport by dipyridamole or Mk-571 increases aspirin entrapment and its in vitro effect on COX-1 activity (142.7 +- 34.6 pg/10(8) cells vs. 343.7 +- 169.3 pg/108 cells TxB2-production).	Aspirin	83-90	ATP binding cassette subfamily C member 4	Homo sapiens	23-27
21816313-7	2011	Platelets derived from megakaryocytes transfected with MRP4 small interfering ribonucleic acid have a higher aspirin entrapment and drug COX-1 activity.	Aspirin	109-116	ATP binding cassette subfamily C member 4	Homo sapiens	55-59
21816313-8	2011	Platelets from CABG patients showed a high expression of MRP4 whose in vitro inhibition enhanced aspirin effect on COX-1 (349 +- 141 pg/108 cells vs. 1,670 +- 646 pg/108 cells TxB2-production).	Aspirin	97-104	ATP binding cassette subfamily C member 4	Homo sapiens	57-61
21359593-6	2011	Concentration of serum total bile acids (TBA) was significantly correlated with MRP4 protein in cholestasis samples (P < 0.01).	Bile Acids and Salts	29-39	ATP binding cassette subfamily C member 4	Homo sapiens	80-84
21511945-6	2011	Rimonabant inhibited MRP1 transport activity more potently than MRP4 (K(i) of 1.4 and 4 muM, respectively), whereas the 3,4-diarylpyrazolines were stronger inhibitors of MRP4- than MRP1-mediated transport.	3,4-diarylpyrazolines	120-141	ATP binding cassette subfamily C member 4	Homo sapiens	170-174
21511945-9	2011	Preliminary in vivo data suggested that for some 3,4-diarylpyrazolines the relatively lower brain efficacy may be related to their inhibitory potency against MRP4 activity.	3,4-diarylpyrazolines	49-70	ATP binding cassette subfamily C member 4	Homo sapiens	158-162
21359593-10	2011	CONCLUSION: Hepatic MRP4 levels were dramatically induced in human obstructive cholestasis, which may reduce liver injury by increasing efflux of toxic bile acids from hepatocytes into blood.	Bile Acids and Salts	152-162	ATP binding cassette subfamily C member 4	Homo sapiens	20-24
21359593-6	2011	Concentration of serum total bile acids (TBA) was significantly correlated with MRP4 protein in cholestasis samples (P < 0.01).	tba	41-44	ATP binding cassette subfamily C member 4	Homo sapiens	80-84
21296199-1	2011	Multidrug resistance protein-4 (MRP4) is a member of the multidrug resistance associated gene family that is expressed on the basolateral membrane of hepatocytes and undergoes adaptive up-regulation in response to cholestatic injury or bile acid feeding.	Bile Acids and Salts	236-245	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
21205825-0	2011	Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation.	Cyclic AMP	54-58	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
21205825-0	2011	Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation.	Cyclic AMP	54-58	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
21205825-3	2011	Here we show that intracellular cAMP levels not only in U937 cells but also in other acute myeloid leukemia cell lines are also regulated by multidrug resistance-associated proteins (MRPs), particularly MRP4.	Cyclic AMP	32-36	ATP binding cassette subfamily C member 4	Homo sapiens	203-207
21205825-9	2011	Furthermore, blockade by probenecid or MRP4 knockdown showed that increased intracellular cAMP levels induce maturation in U937 cells.	Cyclic AMP	90-94	ATP binding cassette subfamily C member 4	Homo sapiens	39-43
21403643-5	2011	In this study, the role(s) of organic anion transporter type 1 (OAT1) and multidrug-resistant protein type 4 (MRP4) in transport and regulation of tenofovir in proximal tubules were assessed.	Tenofovir	147-156	ATP binding cassette subfamily C member 4	Homo sapiens	74-108
21403643-5	2011	In this study, the role(s) of organic anion transporter type 1 (OAT1) and multidrug-resistant protein type 4 (MRP4) in transport and regulation of tenofovir in proximal tubules were assessed.	Tenofovir	147-156	ATP binding cassette subfamily C member 4	Homo sapiens	110-114
21403643-14	2011	Both OAT1 and MRP4 have a direct role in transport and efflux of tenofovir, regulating levels of tenofovir in proximal tubules.	Tenofovir	65-74	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
21403643-14	2011	Both OAT1 and MRP4 have a direct role in transport and efflux of tenofovir, regulating levels of tenofovir in proximal tubules.	Tenofovir	97-106	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
21296199-1	2011	Multidrug resistance protein-4 (MRP4) is a member of the multidrug resistance associated gene family that is expressed on the basolateral membrane of hepatocytes and undergoes adaptive up-regulation in response to cholestatic injury or bile acid feeding.	Bile Acids and Salts	236-245	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
21991497-7	2011	As for thipurine drugs, the clinical importance of multidrug-resistance protein 4 (MRP4) in Japanese patients is highlighted.	thipurine	7-16	ATP binding cassette subfamily C member 4	Homo sapiens	51-81
21727755-0	2011	Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males.	mizoribine	83-93	ATP binding cassette subfamily C member 4	Homo sapiens	55-60
21897051-0	2011	Molecular-weight-dependent, anionic-substrate-preferential transport of beta-lactam antibiotics via multidrug resistance-associated protein 4.	beta-Lactams	72-83	ATP binding cassette subfamily C member 4	Homo sapiens	100-141
21897051-2	2011	Multidrug resistance-associated protein 4 (MRP4) has been reported to transport several beta-lactam antibiotics, and its expression at the blood-brain barrier also serves to limit their distribution to the brain.	beta-Lactams	88-99	ATP binding cassette subfamily C member 4	Homo sapiens	0-41
21897051-2	2011	Multidrug resistance-associated protein 4 (MRP4) has been reported to transport several beta-lactam antibiotics, and its expression at the blood-brain barrier also serves to limit their distribution to the brain.	beta-Lactams	88-99	ATP binding cassette subfamily C member 4	Homo sapiens	43-47
21897051-3	2011	Therefore, the purpose of this study was to clarify the structure-activity relationship of MRP4-mediated transport of beta-lactam antibiotics using MRP4-expressing Sf9 membrane vesicles.	beta-Lactams	118-129	ATP binding cassette subfamily C member 4	Homo sapiens	91-95
21897051-3	2011	Therefore, the purpose of this study was to clarify the structure-activity relationship of MRP4-mediated transport of beta-lactam antibiotics using MRP4-expressing Sf9 membrane vesicles.	beta-Lactams	118-129	ATP binding cassette subfamily C member 4	Homo sapiens	148-152
21897051-5	2011	Cefotiam showed the greatest MRP4-mediated transport activity [8.90 nL/(min fmol MRP4 protein)] among the beta-lactam antibiotics examined in this study.	Cefotiam	0-8	ATP binding cassette subfamily C member 4	Homo sapiens	29-33
21897051-5	2011	Cefotiam showed the greatest MRP4-mediated transport activity [8.90 nL/(min fmol MRP4 protein)] among the beta-lactam antibiotics examined in this study.	Cefotiam	0-8	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
21897051-5	2011	Cefotiam showed the greatest MRP4-mediated transport activity [8.90 nL/(min fmol MRP4 protein)] among the beta-lactam antibiotics examined in this study.	beta-Lactams	106-117	ATP binding cassette subfamily C member 4	Homo sapiens	29-33
21991497-7	2011	As for thipurine drugs, the clinical importance of multidrug-resistance protein 4 (MRP4) in Japanese patients is highlighted.	thipurine	7-16	ATP binding cassette subfamily C member 4	Homo sapiens	83-87
20393862-1	2010	BACKGROUND: Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN).	nucleoside monophosphate	81-105	ATP binding cassette subfamily C member 4	Homo sapiens	12-42
20855458-4	2010	Those observations suggested the possible existence of a "thiopurine cellular circulation" involving nucleotide efflux by ABCC4, hydrolysis of thiopurine nucleotide monophosphates outside of the cell by NT5E, and subsequent transport of thiopurine nucleosides back into the cell by nucleoside transporters.	2-mercaptopyrazine	58-68	ATP binding cassette subfamily C member 4	Homo sapiens	122-127
20393862-1	2010	BACKGROUND: Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN).	nucleoside monophosphate	81-105	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
20393862-1	2010	BACKGROUND: Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN).	Mercaptopurine	123-139	ATP binding cassette subfamily C member 4	Homo sapiens	12-42
20393862-1	2010	BACKGROUND: Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN).	Mercaptopurine	123-139	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
20393862-1	2010	BACKGROUND: Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN).	Mercaptopurine	141-145	ATP binding cassette subfamily C member 4	Homo sapiens	12-42
20393862-1	2010	BACKGROUND: Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN).	Mercaptopurine	141-145	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
20393862-1	2010	BACKGROUND: Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN).	6-thioguanylic acid	151-175	ATP binding cassette subfamily C member 4	Homo sapiens	12-42
20393862-1	2010	BACKGROUND: Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN).	6-thioguanylic acid	151-175	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
20393862-1	2010	BACKGROUND: Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN).	6-thioguanylic acid	177-182	ATP binding cassette subfamily C member 4	Homo sapiens	12-42
20393862-1	2010	BACKGROUND: Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN).	6-thioguanylic acid	177-182	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
20393862-2	2010	A single-nucleotide polymorphism in human MRP4 (rs3765534) dramatically reduces MRP4 function and results in the intracellular accumulation of 6-TGN.	6-thioguanylic acid	143-148	ATP binding cassette subfamily C member 4	Homo sapiens	42-46
20393862-2	2010	A single-nucleotide polymorphism in human MRP4 (rs3765534) dramatically reduces MRP4 function and results in the intracellular accumulation of 6-TGN.	6-thioguanylic acid	143-148	ATP binding cassette subfamily C member 4	Homo sapiens	80-84
20393862-3	2010	In this study, we investigated the association between MRP4 G2269A polymorphism and thiopurine sensitivity in Japanese IBD patients.	2-mercaptopyrazine	84-94	ATP binding cassette subfamily C member 4	Homo sapiens	55-59
20393862-11	2010	CONCLUSIONS: These results suggest that MRP4 G2269A might be a new factor accounting for thiopurine sensitivity in Japanese patients with IBD.	2-mercaptopyrazine	89-99	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
20005867-4	2010	This feature was associated with increased expression and altered N-linked glycosylation of ATP binding cassette transporters MRP1 and MRP4.	Nitrogen	66-67	ATP binding cassette subfamily C member 4	Homo sapiens	135-139
20405259-0	2010	Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4).	oxazaphosphorines	15-32	ATP binding cassette subfamily C member 4	Homo sapiens	38-79
20405259-0	2010	Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4).	oxazaphosphorines	15-32	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
20405259-1	2010	Multidrug resistance-associated protein 4 (MRP4) is an organic anion efflux pump capable of transporting nucleoside, nucleotide analogs, and cyclic nucleotide.	Nucleosides	105-115	ATP binding cassette subfamily C member 4	Homo sapiens	0-41
20405259-1	2010	Multidrug resistance-associated protein 4 (MRP4) is an organic anion efflux pump capable of transporting nucleoside, nucleotide analogs, and cyclic nucleotide.	Nucleosides	105-115	ATP binding cassette subfamily C member 4	Homo sapiens	43-47
20405259-1	2010	Multidrug resistance-associated protein 4 (MRP4) is an organic anion efflux pump capable of transporting nucleoside, nucleotide analogs, and cyclic nucleotide.	Nucleotides, Cyclic	141-158	ATP binding cassette subfamily C member 4	Homo sapiens	0-41
20405259-1	2010	Multidrug resistance-associated protein 4 (MRP4) is an organic anion efflux pump capable of transporting nucleoside, nucleotide analogs, and cyclic nucleotide.	Nucleotides, Cyclic	141-158	ATP binding cassette subfamily C member 4	Homo sapiens	43-47
20405259-2	2010	MRP4 could have an influence on the resistance and transport of the two oxazaphosphorines, cyclophosphamide (CP) and ifosfamide (IF).	oxazaphosphorines	72-89	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
20405259-2	2010	MRP4 could have an influence on the resistance and transport of the two oxazaphosphorines, cyclophosphamide (CP) and ifosfamide (IF).	Cyclophosphamide	91-107	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
20405259-2	2010	MRP4 could have an influence on the resistance and transport of the two oxazaphosphorines, cyclophosphamide (CP) and ifosfamide (IF).	Ifosfamide	117-127	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
20405259-4	2010	HepG2 and HEK293 human kidney cells were also used to investigate the inducing potency of oxazaphosphorines on the MRP4 expression.	oxazaphosphorines	90-107	ATP binding cassette subfamily C member 4	Homo sapiens	115-119
20405259-8	2010	In addition, CP and clofibrate (CFB), a reported MRP4 inducer, in vivo significantly increased the MRP4 expression at both protein level and mRNA level in HEK293 cells at higher concentrations, while IF significantly decreased the MRP4 expression at mRNA level at lower concentration and had no effect at higher concentrations.	Clofibrate	20-30	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
20405259-8	2010	In addition, CP and clofibrate (CFB), a reported MRP4 inducer, in vivo significantly increased the MRP4 expression at both protein level and mRNA level in HEK293 cells at higher concentrations, while IF significantly decreased the MRP4 expression at mRNA level at lower concentration and had no effect at higher concentrations.	Clofibrate	20-30	ATP binding cassette subfamily C member 4	Homo sapiens	99-103
20405259-8	2010	In addition, CP and clofibrate (CFB), a reported MRP4 inducer, in vivo significantly increased the MRP4 expression at both protein level and mRNA level in HEK293 cells at higher concentrations, while IF significantly decreased the MRP4 expression at mRNA level at lower concentration and had no effect at higher concentrations.	Clofibrate	20-30	ATP binding cassette subfamily C member 4	Homo sapiens	99-103
20405259-8	2010	In addition, CP and clofibrate (CFB), a reported MRP4 inducer, in vivo significantly increased the MRP4 expression at both protein level and mRNA level in HEK293 cells at higher concentrations, while IF significantly decreased the MRP4 expression at mRNA level at lower concentration and had no effect at higher concentrations.	Clofibrate	32-35	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
20405259-8	2010	In addition, CP and clofibrate (CFB), a reported MRP4 inducer, in vivo significantly increased the MRP4 expression at both protein level and mRNA level in HEK293 cells at higher concentrations, while IF significantly decreased the MRP4 expression at mRNA level at lower concentration and had no effect at higher concentrations.	Clofibrate	32-35	ATP binding cassette subfamily C member 4	Homo sapiens	99-103
20405259-8	2010	In addition, CP and clofibrate (CFB), a reported MRP4 inducer, in vivo significantly increased the MRP4 expression at both protein level and mRNA level in HEK293 cells at higher concentrations, while IF significantly decreased the MRP4 expression at mRNA level at lower concentration and had no effect at higher concentrations.	Clofibrate	32-35	ATP binding cassette subfamily C member 4	Homo sapiens	99-103
20551216-8	2010	Cells overexpressing MDR1 P-gp, MRP3, MRP4 and MRP5 displayed low levels of resistance to atazanavir (RF: 1.3-1.7); MRP7- and MRP9-overexpressing cells to lopinavir (RF: 1.4-1.5); and MRP9-overexpressing cells to ritonavir (RF: 1.4).	Atazanavir Sulfate	90-100	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
20395535-1	2010	Multidrug resistance protein 4 (MRP4; ABCC4) is an ATP binding cassette transporter that facilitates the excretion of bile salt conjugates and other conjugated steroids in hepatocytes and renal proximal tubule epithelium.	Bile Acids and Salts	118-127	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
20395535-1	2010	Multidrug resistance protein 4 (MRP4; ABCC4) is an ATP binding cassette transporter that facilitates the excretion of bile salt conjugates and other conjugated steroids in hepatocytes and renal proximal tubule epithelium.	Bile Acids and Salts	118-127	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
20395535-1	2010	Multidrug resistance protein 4 (MRP4; ABCC4) is an ATP binding cassette transporter that facilitates the excretion of bile salt conjugates and other conjugated steroids in hepatocytes and renal proximal tubule epithelium.	Bile Acids and Salts	118-127	ATP binding cassette subfamily C member 4	Homo sapiens	38-43
20395535-1	2010	Multidrug resistance protein 4 (MRP4; ABCC4) is an ATP binding cassette transporter that facilitates the excretion of bile salt conjugates and other conjugated steroids in hepatocytes and renal proximal tubule epithelium.	Steroids	160-168	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
20395535-1	2010	Multidrug resistance protein 4 (MRP4; ABCC4) is an ATP binding cassette transporter that facilitates the excretion of bile salt conjugates and other conjugated steroids in hepatocytes and renal proximal tubule epithelium.	Steroids	160-168	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
20395535-1	2010	Multidrug resistance protein 4 (MRP4; ABCC4) is an ATP binding cassette transporter that facilitates the excretion of bile salt conjugates and other conjugated steroids in hepatocytes and renal proximal tubule epithelium.	Steroids	160-168	ATP binding cassette subfamily C member 4	Homo sapiens	38-43
20395535-7	2010	TCDD, 3-MC, and oltipraz significantly increased MRP4 expression at mRNA and protein levels.	Polychlorinated Dibenzodioxins	0-4	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
20395535-7	2010	TCDD, 3-MC, and oltipraz significantly increased MRP4 expression at mRNA and protein levels.	Methylcholanthrene	6-10	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
20395535-7	2010	TCDD, 3-MC, and oltipraz significantly increased MRP4 expression at mRNA and protein levels.	oltipraz	16-24	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
20395535-11	2010	Mutation of any of these XRE sites significantly decreased MRP4 promoter activity in reporter assays, although XRE2 demonstrated the strongest effects on both basal and TCDD-inducible activity.	Polychlorinated Dibenzodioxins	169-173	ATP binding cassette subfamily C member 4	Homo sapiens	59-63
20360301-0	2010	Vectorial transport of nucleoside analogs from the apical to the basolateral membrane in double-transfected cells expressing the human concentrative nucleoside transporter hCNT3 and the export pump ABCC4.	Nucleosides	23-33	ATP binding cassette subfamily C member 4	Homo sapiens	198-203
20530583-9	2010	Blocking multidrug resistance-associated protein-4 may be a useful therapeutic strategy to deplete COX-deficient pancreatic cancers of prostaglandins.	Prostaglandins	135-149	ATP binding cassette subfamily C member 4	Homo sapiens	9-50
20005867-5	2010	Pre-treatment with tunicamycin, which inhibits the biosynthesis of N-linked oligosaccharides, decreased the accumulation of Pt in sensitive cells exposed to oxaliplatin or cisplatin and increased the electrophoretic mobility of MRP1 and MRP4, reproducing the association between decreased glycosylation of MRP1 and MRP4 and decreased Pt accumulation observed in the resistant IGROV-1/OHP cells.	Tunicamycin	19-30	ATP binding cassette subfamily C member 4	Homo sapiens	237-241
20005867-5	2010	Pre-treatment with tunicamycin, which inhibits the biosynthesis of N-linked oligosaccharides, decreased the accumulation of Pt in sensitive cells exposed to oxaliplatin or cisplatin and increased the electrophoretic mobility of MRP1 and MRP4, reproducing the association between decreased glycosylation of MRP1 and MRP4 and decreased Pt accumulation observed in the resistant IGROV-1/OHP cells.	Tunicamycin	19-30	ATP binding cassette subfamily C member 4	Homo sapiens	315-319
20005867-8	2010	In addition, the overexpression of fully glycosylated MRP1 or MRP4 in tumor cell line of ovarian origin was associated with resistance to oxaliplatin and cisplatin.	Oxaliplatin	138-149	ATP binding cassette subfamily C member 4	Homo sapiens	62-66
20005867-8	2010	In addition, the overexpression of fully glycosylated MRP1 or MRP4 in tumor cell line of ovarian origin was associated with resistance to oxaliplatin and cisplatin.	Cisplatin	154-163	ATP binding cassette subfamily C member 4	Homo sapiens	62-66
20005867-9	2010	Our findings, showing that development of resistance to oxaliplatin results in up-regulation of MRPs, support that patients with oxaliplatin-refractory ovarian carcinomas may benefit from non-Pt-based regimens which do not contain MRP1 and MRP4 substrates.	Oxaliplatin	56-67	ATP binding cassette subfamily C member 4	Homo sapiens	240-244
19566819-9	2010	Both MRP4 and MRP5 are able to mediate the transport of cyclic nucleotides and confer resistance to certain antiviral and anticancer nucleotide analogues.	Nucleotides, Cyclic	56-74	ATP binding cassette subfamily C member 4	Homo sapiens	5-9
20133816-0	2010	Role of MRP4 (ABCC4) in platelet adenine nucleotide-storage: evidence from patients with delta-storage pool deficiencies.	Adenine Nucleotides	33-51	ATP binding cassette subfamily C member 4	Homo sapiens	8-12
20133816-0	2010	Role of MRP4 (ABCC4) in platelet adenine nucleotide-storage: evidence from patients with delta-storage pool deficiencies.	Adenine Nucleotides	33-51	ATP binding cassette subfamily C member 4	Homo sapiens	14-19
20133816-1	2010	We previously showed that the MRP4 (ABCC4) transporter is expressed in human platelet delta-granules and may be involved in ADP transport.	Adenosine Diphosphate	124-127	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
20133816-1	2010	We previously showed that the MRP4 (ABCC4) transporter is expressed in human platelet delta-granules and may be involved in ADP transport.	Adenosine Diphosphate	124-127	ATP binding cassette subfamily C member 4	Homo sapiens	36-41
20133816-2	2010	We now demonstrate by immunoblotting and immunofluorescence microscopy that platelet MRP4 is absent in two patients with a platelet delta-storage pool deficiency (delta-SPD)-like phenotype with reduced platelet adenine nucleotide (AN) but normal serotonin levels, whereas their other membrane marker proteins of platelet granules were normally expressed and localized.	Adenine Nucleotides	211-229	ATP binding cassette subfamily C member 4	Homo sapiens	85-89
20133816-2	2010	We now demonstrate by immunoblotting and immunofluorescence microscopy that platelet MRP4 is absent in two patients with a platelet delta-storage pool deficiency (delta-SPD)-like phenotype with reduced platelet adenine nucleotide (AN) but normal serotonin levels, whereas their other membrane marker proteins of platelet granules were normally expressed and localized.	Serotonin	246-255	ATP binding cassette subfamily C member 4	Homo sapiens	85-89
20200426-9	2010	Furthermore, GSTM4, GSTT1, and ABCC4 overexpression significantly decreased cisplatin sensitivity in lung cancer and HEK293T cell lines.	Cisplatin	76-85	ATP binding cassette subfamily C member 4	Homo sapiens	31-36
20200426-11	2010	ABCC4 polymorphisms, as well as GSTT1 copy number, may also help to predict cisplatin response, but further validation is required.	Cisplatin	76-85	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
19735648-0	2010	Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil.	adefovir	95-103	ATP binding cassette subfamily C member 4	Homo sapiens	39-43
19735648-0	2010	Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil.	dipivoxil	104-113	ATP binding cassette subfamily C member 4	Homo sapiens	39-43
19735648-9	2010	These cells showed reduced MRP4 protein expression and corresponding reduction in the basolateral egress of adefovir when adefovir dipivoxil was dosed on the apical side.	dipivoxil	131-140	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
19735648-10	2010	A comparison of these data with the reduction in the basolateral egress of adefovir by the general MRP inhibitor indomethacin established that MRP4, among MRPs, plays a predominant role in the basolateral egress of adefovir in Caco-2 cells.	adefovir	75-83	ATP binding cassette subfamily C member 4	Homo sapiens	143-147
19735648-10	2010	A comparison of these data with the reduction in the basolateral egress of adefovir by the general MRP inhibitor indomethacin established that MRP4, among MRPs, plays a predominant role in the basolateral egress of adefovir in Caco-2 cells.	Indomethacin	113-125	ATP binding cassette subfamily C member 4	Homo sapiens	143-147
19735648-10	2010	A comparison of these data with the reduction in the basolateral egress of adefovir by the general MRP inhibitor indomethacin established that MRP4, among MRPs, plays a predominant role in the basolateral egress of adefovir in Caco-2 cells.	adefovir	215-223	ATP binding cassette subfamily C member 4	Homo sapiens	143-147
19735648-11	2010	The results highlight the importance of MRP4 in oral absorption of adefovir dipivoxil, and suggest that significant drug-drug interactions can occur if an MRP4 inhibitor is co-administered with adefovir dipivoxil.	adefovir dipivoxil	67-85	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
19735648-11	2010	The results highlight the importance of MRP4 in oral absorption of adefovir dipivoxil, and suggest that significant drug-drug interactions can occur if an MRP4 inhibitor is co-administered with adefovir dipivoxil.	adefovir dipivoxil	67-85	ATP binding cassette subfamily C member 4	Homo sapiens	155-159
19735648-11	2010	The results highlight the importance of MRP4 in oral absorption of adefovir dipivoxil, and suggest that significant drug-drug interactions can occur if an MRP4 inhibitor is co-administered with adefovir dipivoxil.	adefovir dipivoxil	194-212	ATP binding cassette subfamily C member 4	Homo sapiens	155-159
19903828-2	2010	In these cells, a tetrodotoxin-resistant background N(+) conductance is critical for firing of action potentials, and multidrug resistance proteins (MRPs) MRP4 and MRP5 contribute to cyclic nucleotide efflux.	Nucleotides, Cyclic	183-200	ATP binding cassette subfamily C member 4	Homo sapiens	155-159
19903828-6	2010	In human embryonic kidney 293 cells stably transfected with human MRP4 or MRP5, replacement of bath Na(+) with organic cations also hyperpolarized the cell membranes and inhibited cyclic nucleotide efflux.	Nucleotides, Cyclic	180-197	ATP binding cassette subfamily C member 4	Homo sapiens	66-70
19903828-9	2010	These results indicate that the MRP4/5-mediated cyclic nucleotide efflux can be rapidly modulated by membrane potential determined by the background Na(+) conductance.	Nucleotides, Cyclic	48-65	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
19940267-7	2010	METHODS AND RESULTS: We demonstrate that the uptake transporter OATP2B1 (human organic anion transporting polypeptide 2B1) and the efflux transporters, multidrug resistance-associated protein (MRP)1, MRP4, and MRP5 are expressed on the sarcolemmal membrane of human skeletal muscle fibers and that atorvastatin and rosuvastatin are substrates of these transporters when assessed using a heterologous expression system.	Atorvastatin	298-310	ATP binding cassette subfamily C member 4	Homo sapiens	200-204
19837908-7	2010	In conclusion, drugs that are substrates of BCRP and MRP4, like zidovudine, may have an altered efficacy in newborns.	Zidovudine	64-74	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
19515727-1	2009	Methotrexate and 6-mercaptopurine, important components of acute lymphoblastic leukemia treatment, are substrates for multidrug resistance-associated protein MRP4.	Methotrexate	0-12	ATP binding cassette subfamily C member 4	Homo sapiens	158-162
19399588-7	2009	ABCC4 up-regulation further supports the assumption of its involvement in prostanoid transport.	Prostaglandins	74-84	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
19696793-0	2009	Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.	Cyclophosphamide	56-72	ATP binding cassette subfamily C member 4	Homo sapiens	45-50
19696793-5	2009	The association study revealed that one SNP, rs9561778 in ABCC4, showed a significant association with CPA-induced ADRs (Cochran-Armitage trend"s P-value=0.00031; odds ratio (OR)=2.06).	Cyclophosphamide	103-106	ATP binding cassette subfamily C member 4	Homo sapiens	58-63
19696793-8	2009	The SNPs in ABCC4 might be applicable in predicting the risk of ADRs in patients receiving CPA combination chemotherapy.	Cyclophosphamide	91-94	ATP binding cassette subfamily C member 4	Homo sapiens	12-17
19515727-1	2009	Methotrexate and 6-mercaptopurine, important components of acute lymphoblastic leukemia treatment, are substrates for multidrug resistance-associated protein MRP4.	Mercaptopurine	17-33	ATP binding cassette subfamily C member 4	Homo sapiens	158-162
19601896-1	2009	The present paper reviews and discusses selectivity of ABCC4 (MRP4), ABCC5 (MRP5) and ABCC11 (MRP8) as cellular efflux pumps for cAMP and cGMP.	Cyclic GMP	138-142	ATP binding cassette subfamily C member 4	Homo sapiens	55-60
19414624-4	2009	1,25(OH)(2)D(3) treatment significantly enhanced MRP4 protein expression by increasing protein stability without affecting mRNA expression, as confirmed in cycloheximide experiments.	Cycloheximide	156-169	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
19414624-8	2009	Higher protein expression of CYP3A4, MRP2, P-gp, and MRP4 was also observed after a 6-day treatment with other vitamin D analogs (100 nM 1alpha-hydroxyvitamin D(3),1alpha-hydroxyvitamin D(2) or Hectorol, and 25-hydroxyvitamin D(3)) in Caco-2 cells, suggesting a role of 1,25(OH)(2)D(3) and analogs in the activation of enzymes and transporters via the vitamin D receptor.	Vitamin D	111-120	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
19414624-8	2009	Higher protein expression of CYP3A4, MRP2, P-gp, and MRP4 was also observed after a 6-day treatment with other vitamin D analogs (100 nM 1alpha-hydroxyvitamin D(3),1alpha-hydroxyvitamin D(2) or Hectorol, and 25-hydroxyvitamin D(3)) in Caco-2 cells, suggesting a role of 1,25(OH)(2)D(3) and analogs in the activation of enzymes and transporters via the vitamin D receptor.	1alpha-hydroxyvitamin d	137-160	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
19414624-8	2009	Higher protein expression of CYP3A4, MRP2, P-gp, and MRP4 was also observed after a 6-day treatment with other vitamin D analogs (100 nM 1alpha-hydroxyvitamin D(3),1alpha-hydroxyvitamin D(2) or Hectorol, and 25-hydroxyvitamin D(3)) in Caco-2 cells, suggesting a role of 1,25(OH)(2)D(3) and analogs in the activation of enzymes and transporters via the vitamin D receptor.	1alpha-hydroxyvitamin d	164-187	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
19414624-8	2009	Higher protein expression of CYP3A4, MRP2, P-gp, and MRP4 was also observed after a 6-day treatment with other vitamin D analogs (100 nM 1alpha-hydroxyvitamin D(3),1alpha-hydroxyvitamin D(2) or Hectorol, and 25-hydroxyvitamin D(3)) in Caco-2 cells, suggesting a role of 1,25(OH)(2)D(3) and analogs in the activation of enzymes and transporters via the vitamin D receptor.	1 alpha-hydroxyergocalciferol	194-202	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
19414624-8	2009	Higher protein expression of CYP3A4, MRP2, P-gp, and MRP4 was also observed after a 6-day treatment with other vitamin D analogs (100 nM 1alpha-hydroxyvitamin D(3),1alpha-hydroxyvitamin D(2) or Hectorol, and 25-hydroxyvitamin D(3)) in Caco-2 cells, suggesting a role of 1,25(OH)(2)D(3) and analogs in the activation of enzymes and transporters via the vitamin D receptor.	25-hydroxyvitamin D	208-227	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
19470503-9	2009	The mechanism-of-action study showed that the efflux of 4"-Ed4T or AZT nucleoside might be due to unknown nucleoside transporters which were not related to the equilibrative nucleoside transporters, while the efflux of AZT monophosphate might be due to multidrug resistance protein 4 (MRP4/ABCC4).	4'-ethynylstavudine	56-63	ATP binding cassette subfamily C member 4	Homo sapiens	285-289
19470503-9	2009	The mechanism-of-action study showed that the efflux of 4"-Ed4T or AZT nucleoside might be due to unknown nucleoside transporters which were not related to the equilibrative nucleoside transporters, while the efflux of AZT monophosphate might be due to multidrug resistance protein 4 (MRP4/ABCC4).	4'-ethynylstavudine	56-63	ATP binding cassette subfamily C member 4	Homo sapiens	290-295
19470503-9	2009	The mechanism-of-action study showed that the efflux of 4"-Ed4T or AZT nucleoside might be due to unknown nucleoside transporters which were not related to the equilibrative nucleoside transporters, while the efflux of AZT monophosphate might be due to multidrug resistance protein 4 (MRP4/ABCC4).	azt nucleoside	67-81	ATP binding cassette subfamily C member 4	Homo sapiens	285-289
19470503-9	2009	The mechanism-of-action study showed that the efflux of 4"-Ed4T or AZT nucleoside might be due to unknown nucleoside transporters which were not related to the equilibrative nucleoside transporters, while the efflux of AZT monophosphate might be due to multidrug resistance protein 4 (MRP4/ABCC4).	azt nucleoside	67-81	ATP binding cassette subfamily C member 4	Homo sapiens	290-295
19470503-9	2009	The mechanism-of-action study showed that the efflux of 4"-Ed4T or AZT nucleoside might be due to unknown nucleoside transporters which were not related to the equilibrative nucleoside transporters, while the efflux of AZT monophosphate might be due to multidrug resistance protein 4 (MRP4/ABCC4).	azt monophosphate	219-236	ATP binding cassette subfamily C member 4	Homo sapiens	285-289
19470503-9	2009	The mechanism-of-action study showed that the efflux of 4"-Ed4T or AZT nucleoside might be due to unknown nucleoside transporters which were not related to the equilibrative nucleoside transporters, while the efflux of AZT monophosphate might be due to multidrug resistance protein 4 (MRP4/ABCC4).	azt monophosphate	219-236	ATP binding cassette subfamily C member 4	Homo sapiens	290-295
19601896-1	2009	The present paper reviews and discusses selectivity of ABCC4 (MRP4), ABCC5 (MRP5) and ABCC11 (MRP8) as cellular efflux pumps for cAMP and cGMP.	Cyclic GMP	138-142	ATP binding cassette subfamily C member 4	Homo sapiens	62-66
19001108-6	2009	Similar to acyclic nucleotides, GS-9148 was a substrate for MRP4 as evidenced by its reduced intracellular retention in cells overexpressing the efflux pump.	acyclic nucleotides	11-30	ATP binding cassette subfamily C member 4	Homo sapiens	60-64
19082692-5	2009	Transport of gaboxadol and its glucuronide was evaluated using cell lines and membrane vesicles expressing human organic anion transporters hOAT1 and hOAT3, organic cation transporter hOCT2, and the multidrug resistance proteins MRP2 and MRP4.Results.	gaboxadol	13-22	ATP binding cassette subfamily C member 4	Homo sapiens	238-242
19082692-9	2009	Gaboxadol-O-glucuronide was transported by MRP4, but not MRP2.Conlusion.	gaboxadol-o-glucuronide	0-23	ATP binding cassette subfamily C member 4	Homo sapiens	43-47
19082692-10	2009	Gaboxadol could be taken up into the kidney by hOAT1 followed by glucuronidation and efflux of the conjugate into urine via MRP4.	gaboxadol	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	124-128
19073137-1	2009	Multidrug resistance protein 4 (MRP4/ABCC4), a member of the ATP-binding cassette protein superfamily, confers resistance to nucleoside and nucleotide analogs as well as camptothecin derivatives.	Nucleosides	125-135	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
19073137-1	2009	Multidrug resistance protein 4 (MRP4/ABCC4), a member of the ATP-binding cassette protein superfamily, confers resistance to nucleoside and nucleotide analogs as well as camptothecin derivatives.	Nucleosides	125-135	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
19073137-1	2009	Multidrug resistance protein 4 (MRP4/ABCC4), a member of the ATP-binding cassette protein superfamily, confers resistance to nucleoside and nucleotide analogs as well as camptothecin derivatives.	Camptothecin	170-182	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
19073137-1	2009	Multidrug resistance protein 4 (MRP4/ABCC4), a member of the ATP-binding cassette protein superfamily, confers resistance to nucleoside and nucleotide analogs as well as camptothecin derivatives.	Camptothecin	170-182	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
19073137-2	2009	MRP4 also mediates the efflux of certain cyclic nucleotides, eicosanoids, conjugated steroids, and uric acid.	Nucleotides, Cyclic	41-59	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
19073137-2	2009	MRP4 also mediates the efflux of certain cyclic nucleotides, eicosanoids, conjugated steroids, and uric acid.	Eicosanoids	61-72	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
19073137-2	2009	MRP4 also mediates the efflux of certain cyclic nucleotides, eicosanoids, conjugated steroids, and uric acid.	Steroids	85-93	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
19073137-2	2009	MRP4 also mediates the efflux of certain cyclic nucleotides, eicosanoids, conjugated steroids, and uric acid.	Uric Acid	99-108	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
20032540-11	2009	However, MRP4 expression increased following phytohaemaglutinin and AZT treatment.	Zidovudine	68-71	ATP binding cassette subfamily C member 4	Homo sapiens	9-13
18945957-7	2008	Knocking down Mrp4 expression resulted in a reduction of transepithelial urate secretion to 35% of control with no effects on TER or Iglu.	Uric Acid	73-78	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
18930752-7	2008	PAH secretion across the monolayer consisted of the uptake of PAH across the basolateral membrane by OAT1 and OAT3 and the apical exit of PAH by a probenecid and MK571-sensitive route consistent with actions of MRP2 or MRP4.	p-Aminohippuric Acid	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	219-223
19020075-7	2008	Patch-clamp experiments show that R352 interacts with D993 in TM9 to stabilize the open-channel state; D993 is absolutely conserved between CFTRs and ABCC4s.	2-Nitro-4-thiocyanatoaniline	34-38	ATP binding cassette subfamily C member 4	Homo sapiens	150-155
18724382-4	2008	Recently, we identified the multidrug resistance protein (MRP) 4 as a luminal efflux transporter for urate in the proximal tubule.	Uric Acid	101-106	ATP binding cassette subfamily C member 4	Homo sapiens	28-64
18724382-6	2008	KEY RESULTS: Allopurinol stimulated MRP4-mediated cellular urate efflux and allopurinol and oxypurinol both markedly stimulated urate transport by MRP4 in membrane vesicles.	Allopurinol	13-24	ATP binding cassette subfamily C member 4	Homo sapiens	36-40
18724382-6	2008	KEY RESULTS: Allopurinol stimulated MRP4-mediated cellular urate efflux and allopurinol and oxypurinol both markedly stimulated urate transport by MRP4 in membrane vesicles.	Oxypurinol	92-102	ATP binding cassette subfamily C member 4	Homo sapiens	147-151
18724382-9	2008	CONCLUSIONS AND IMPLICATIONS: These data suggest that inhibition of MRP4-mediated urate efflux by furosemide and thiazide diuretics could have an important function in their hyperuricaemic mechanisms.	Furosemide	98-108	ATP binding cassette subfamily C member 4	Homo sapiens	68-72
18724382-10	2008	Furthermore, stimulation of MRP4-mediated renal urate efflux could be a new mechanism in the hypouricaemic action of allopurinol and oxypurinol.	Allopurinol	117-128	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
19077464-10	2009	Compared to parental Capan-1 cells, Capan-1 cells with acquired chemoresistance towards 5-fluorouracil showed an upregulated mRNA and protein expression of MRP3, MRP4, and MRP5.	Fluorouracil	88-102	ATP binding cassette subfamily C member 4	Homo sapiens	162-166
19077464-12	2009	CONCLUSION: MRP3, MRP4, and MRP5 are upregulated in 5-fluorouracil-resistant cells, and MRP5 contributes to 5-FU resistance in pancreatic carcinoma cells.	Fluorouracil	52-66	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
18724382-10	2008	Furthermore, stimulation of MRP4-mediated renal urate efflux could be a new mechanism in the hypouricaemic action of allopurinol and oxypurinol.	Oxypurinol	133-143	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
18945957-9	2008	However, electrical gradient-dependent vesicular urate transport was inhibited by the MRP4 inhibitor MK-571 also known to inhibit active transepithelial urate transport by cPTCs.	verlukast	101-107	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
18945957-9	2008	However, electrical gradient-dependent vesicular urate transport was inhibited by the MRP4 inhibitor MK-571 also known to inhibit active transepithelial urate transport by cPTCs.	3-Chloropropyltrichlorosilane	172-177	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
18636120-0	2008	Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation.	Cyclic AMP	52-56	ATP binding cassette subfamily C member 4	Homo sapiens	0-41
18615486-7	2008	MRP4/ABCC4 levels were significantly decreased in PCs treated with AA compared to cancers exposed to normal testosterone levels (P < 0.0001).	Testosterone	108-120	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
18615486-7	2008	MRP4/ABCC4 levels were significantly decreased in PCs treated with AA compared to cancers exposed to normal testosterone levels (P < 0.0001).	Testosterone	108-120	ATP binding cassette subfamily C member 4	Homo sapiens	5-10
18615486-9	2008	MRP4/ABCC4 protein levels increased in LNCaP cells after DHT which was partially blocked by bicalutamide.	Dihydrotestosterone	57-60	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
18615486-9	2008	MRP4/ABCC4 protein levels increased in LNCaP cells after DHT which was partially blocked by bicalutamide.	Dihydrotestosterone	57-60	ATP binding cassette subfamily C member 4	Homo sapiens	5-10
18615486-9	2008	MRP4/ABCC4 protein levels increased in LNCaP cells after DHT which was partially blocked by bicalutamide.	bicalutamide	92-104	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
18615486-9	2008	MRP4/ABCC4 protein levels increased in LNCaP cells after DHT which was partially blocked by bicalutamide.	bicalutamide	92-104	ATP binding cassette subfamily C member 4	Homo sapiens	5-10
18609448-3	2008	The renal apical transport transport of zonampanel was examined in this study using HEK293 cells expressing human organic anion transporter 4 (OAT4/SLC22A11), and membrane vesicles prepared from Sf-9 insect cells expressing human multidrug resistance-associated protein 2 (MRP2/ABCC2), MRP4 (ABCC4), and breast cancer resistance protein (BCRP/ABCG2).	YM 872	40-50	ATP binding cassette subfamily C member 4	Homo sapiens	286-290
18609448-3	2008	The renal apical transport transport of zonampanel was examined in this study using HEK293 cells expressing human organic anion transporter 4 (OAT4/SLC22A11), and membrane vesicles prepared from Sf-9 insect cells expressing human multidrug resistance-associated protein 2 (MRP2/ABCC2), MRP4 (ABCC4), and breast cancer resistance protein (BCRP/ABCG2).	YM 872	40-50	ATP binding cassette subfamily C member 4	Homo sapiens	292-297
18609448-7	2008	For MRP2, MRP4, and BCRP, zonampanel selectively inhibited the activity of MRP4 (K(i) = 41.3 microM).	YM 872	26-36	ATP binding cassette subfamily C member 4	Homo sapiens	10-14
18609448-7	2008	For MRP2, MRP4, and BCRP, zonampanel selectively inhibited the activity of MRP4 (K(i) = 41.3 microM).	YM 872	26-36	ATP binding cassette subfamily C member 4	Homo sapiens	75-79
18609448-8	2008	Marked transport of [(14)C]zonampanel was observed only for MRP4 (K(m) = 33.7 microM).	[(14)c]zonampanel	20-37	ATP binding cassette subfamily C member 4	Homo sapiens	60-64
18609448-10	2008	In conclusion, the data indicate that MRP4 was the apical efflux transporter that contributed to the active renal tubular secretion of zonampanel in humans, in concert with the apical reabsorption transporter OAT4 and basolateral uptake transporters.	YM 872	135-145	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
18612080-0	2008	Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4).	Arginine	19-27	ATP binding cassette subfamily C member 4	Homo sapiens	92-96
18612080-0	2008	Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4).	Arginine	19-27	ATP binding cassette subfamily C member 4	Homo sapiens	97-102
18612080-7	2008	Furthermore, MTX inhibition of MRP4-mediated cGMP transport was noncompetitive, and the inhibition constant was increased by introduction of the R375S mutation.	Methotrexate	13-16	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
18612080-7	2008	Furthermore, MTX inhibition of MRP4-mediated cGMP transport was noncompetitive, and the inhibition constant was increased by introduction of the R375S mutation.	Cyclic GMP	45-49	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
18625884-5	2008	The responsible MRP4 substrate remains to be identified as exogenous addition of MRP4"s known substrates prostaglandin E(2), leukotriene B(4) and D(4), or cyclic nucleotides (all previously implicated in DC migration) could not restore migration.	Dinoprostone	105-123	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
18625884-5	2008	The responsible MRP4 substrate remains to be identified as exogenous addition of MRP4"s known substrates prostaglandin E(2), leukotriene B(4) and D(4), or cyclic nucleotides (all previously implicated in DC migration) could not restore migration.	Dinoprostone	105-123	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
18625884-5	2008	The responsible MRP4 substrate remains to be identified as exogenous addition of MRP4"s known substrates prostaglandin E(2), leukotriene B(4) and D(4), or cyclic nucleotides (all previously implicated in DC migration) could not restore migration.	Leukotriene B4	125-138	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
18625884-5	2008	The responsible MRP4 substrate remains to be identified as exogenous addition of MRP4"s known substrates prostaglandin E(2), leukotriene B(4) and D(4), or cyclic nucleotides (all previously implicated in DC migration) could not restore migration.	Leukotriene B4	125-138	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
18625884-5	2008	The responsible MRP4 substrate remains to be identified as exogenous addition of MRP4"s known substrates prostaglandin E(2), leukotriene B(4) and D(4), or cyclic nucleotides (all previously implicated in DC migration) could not restore migration.	Deuterium	146-147	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
18625884-5	2008	The responsible MRP4 substrate remains to be identified as exogenous addition of MRP4"s known substrates prostaglandin E(2), leukotriene B(4) and D(4), or cyclic nucleotides (all previously implicated in DC migration) could not restore migration.	Deuterium	146-147	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
18625884-5	2008	The responsible MRP4 substrate remains to be identified as exogenous addition of MRP4"s known substrates prostaglandin E(2), leukotriene B(4) and D(4), or cyclic nucleotides (all previously implicated in DC migration) could not restore migration.	Nucleotides, Cyclic	155-173	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
18690847-3	2008	The aim of the study was to investigate the induction by celecoxib of some multidrug resistance proteins, MRP1, MRP2, MRP4 and MRP5, involved in the transport of irinotecan and 5-FU.	Celecoxib	57-66	ATP binding cassette subfamily C member 4	Homo sapiens	118-122
18690847-3	2008	The aim of the study was to investigate the induction by celecoxib of some multidrug resistance proteins, MRP1, MRP2, MRP4 and MRP5, involved in the transport of irinotecan and 5-FU.	Irinotecan	162-172	ATP binding cassette subfamily C member 4	Homo sapiens	118-122
18690847-3	2008	The aim of the study was to investigate the induction by celecoxib of some multidrug resistance proteins, MRP1, MRP2, MRP4 and MRP5, involved in the transport of irinotecan and 5-FU.	Fluorouracil	177-181	ATP binding cassette subfamily C member 4	Homo sapiens	118-122
18690847-8	2008	In both cell lines celecoxib induced MRP4 and MRP5 over-expression at RNA and protein levels.	Celecoxib	19-28	ATP binding cassette subfamily C member 4	Homo sapiens	37-41
18690847-10	2008	Cryoimmunoelectron microscopy showed increased MRP4 and MRP5 immunolabeling in celecoxib treated cells both at cytoplasmic level and along the plasma membrane.	Celecoxib	79-88	ATP binding cassette subfamily C member 4	Homo sapiens	47-51
18593894-4	2008	We show that multidrug-resistance protein 4 (Mrp4) is abundant in myeloid progenitors and tested the role of the Mrp4, an ATP transporter of monophosphorylated nucleosides, in this unexplained thiopurine sensitivity.	Adenosine Triphosphate	122-125	ATP binding cassette subfamily C member 4	Homo sapiens	113-117
18593894-4	2008	We show that multidrug-resistance protein 4 (Mrp4) is abundant in myeloid progenitors and tested the role of the Mrp4, an ATP transporter of monophosphorylated nucleosides, in this unexplained thiopurine sensitivity.	Nucleosides	160-171	ATP binding cassette subfamily C member 4	Homo sapiens	113-117
18593894-4	2008	We show that multidrug-resistance protein 4 (Mrp4) is abundant in myeloid progenitors and tested the role of the Mrp4, an ATP transporter of monophosphorylated nucleosides, in this unexplained thiopurine sensitivity.	2-mercaptopyrazine	193-203	ATP binding cassette subfamily C member 4	Homo sapiens	13-43
18593894-4	2008	We show that multidrug-resistance protein 4 (Mrp4) is abundant in myeloid progenitors and tested the role of the Mrp4, an ATP transporter of monophosphorylated nucleosides, in this unexplained thiopurine sensitivity.	2-mercaptopyrazine	193-203	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
18593894-4	2008	We show that multidrug-resistance protein 4 (Mrp4) is abundant in myeloid progenitors and tested the role of the Mrp4, an ATP transporter of monophosphorylated nucleosides, in this unexplained thiopurine sensitivity.	2-mercaptopyrazine	193-203	ATP binding cassette subfamily C member 4	Homo sapiens	113-117
18593894-6	2008	Therefore, Mrp4 protects against thiopurine-induced hematopoietic toxicity by actively exporting thiopurine nucleotides.	2-mercaptopyrazine	33-43	ATP binding cassette subfamily C member 4	Homo sapiens	11-15
18593894-6	2008	Therefore, Mrp4 protects against thiopurine-induced hematopoietic toxicity by actively exporting thiopurine nucleotides.	thiopurine nucleotides	97-119	ATP binding cassette subfamily C member 4	Homo sapiens	11-15
19138942-2	2008	It has been reported that PGE(2) is transported or passes through the cell membrane via prostaglandin-specific transporters including the prostaglandin transporter (PGT, an influx transporter) and the multidrug resistance-associated protein 4 (an efflux transporter).	Prostaglandins E	26-29	ATP binding cassette subfamily C member 4	Homo sapiens	201-242
19138942-2	2008	It has been reported that PGE(2) is transported or passes through the cell membrane via prostaglandin-specific transporters including the prostaglandin transporter (PGT, an influx transporter) and the multidrug resistance-associated protein 4 (an efflux transporter).	Prostaglandins	88-101	ATP binding cassette subfamily C member 4	Homo sapiens	201-242
18593894-8	2008	This SNP is common (>18%) in the Japanese population and indicates that the increased sensitivity of some Japanese patients to thiopurines may reflect the greater frequency of this MRP4 SNP.	thiopurines	130-141	ATP binding cassette subfamily C member 4	Homo sapiens	184-188
18513968-4	2008	The ABCC4 model may be used as a working tool for experimental studies on ABCC4 and design of more specific membrane transport modulating agents (MTMA).	mtma	146-150	ATP binding cassette subfamily C member 4	Homo sapiens	4-9
18513968-4	2008	The ABCC4 model may be used as a working tool for experimental studies on ABCC4 and design of more specific membrane transport modulating agents (MTMA).	mtma	146-150	ATP binding cassette subfamily C member 4	Homo sapiens	74-79
18364470-6	2008	The function of MRP4 variants was compared by measuring the intracellular accumulation of two antiviral agents, azidothymidine (AZT) and adefovir (PMEA).	Zidovudine	112-126	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
18559527-1	2008	Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the ATP-binding cassette superfamily of membrane transport proteins and confers resistance to nucleoside and nucleotide analogues as well as camptothecin derivatives.	Nucleosides	154-164	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
18559527-1	2008	Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the ATP-binding cassette superfamily of membrane transport proteins and confers resistance to nucleoside and nucleotide analogues as well as camptothecin derivatives.	Nucleosides	154-164	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
18559527-1	2008	Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the ATP-binding cassette superfamily of membrane transport proteins and confers resistance to nucleoside and nucleotide analogues as well as camptothecin derivatives.	Nucleosides	154-164	ATP binding cassette subfamily C member 4	Homo sapiens	38-43
18559527-1	2008	Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the ATP-binding cassette superfamily of membrane transport proteins and confers resistance to nucleoside and nucleotide analogues as well as camptothecin derivatives.	Camptothecin	201-213	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
18559527-1	2008	Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the ATP-binding cassette superfamily of membrane transport proteins and confers resistance to nucleoside and nucleotide analogues as well as camptothecin derivatives.	Camptothecin	201-213	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
18559527-1	2008	Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the ATP-binding cassette superfamily of membrane transport proteins and confers resistance to nucleoside and nucleotide analogues as well as camptothecin derivatives.	Camptothecin	201-213	ATP binding cassette subfamily C member 4	Homo sapiens	38-43
18559527-2	2008	MRP4 also mediates the transmembrane transport of several eicosanoids, conjugated estrogens, and cyclic AMP.	Eicosanoids	58-69	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
18559527-2	2008	MRP4 also mediates the transmembrane transport of several eicosanoids, conjugated estrogens, and cyclic AMP.	Cyclic AMP	97-107	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
18559527-6	2008	Increased plasma membrane MRP4 was accompanied by increased efflux function as reflected by reduced cellular accumulation of the MRP4 substrates 6-mercaptopurine and 9-[2-(phosphonylmethoxy)ethyl]-adenine.	Mercaptopurine	145-161	ATP binding cassette subfamily C member 4	Homo sapiens	26-30
18559527-6	2008	Increased plasma membrane MRP4 was accompanied by increased efflux function as reflected by reduced cellular accumulation of the MRP4 substrates 6-mercaptopurine and 9-[2-(phosphonylmethoxy)ethyl]-adenine.	Mercaptopurine	145-161	ATP binding cassette subfamily C member 4	Homo sapiens	129-133
18559527-6	2008	Increased plasma membrane MRP4 was accompanied by increased efflux function as reflected by reduced cellular accumulation of the MRP4 substrates 6-mercaptopurine and 9-[2-(phosphonylmethoxy)ethyl]-adenine.	adefovir	166-204	ATP binding cassette subfamily C member 4	Homo sapiens	26-30
18364470-6	2008	The function of MRP4 variants was compared by measuring the intracellular accumulation of two antiviral agents, azidothymidine (AZT) and adefovir (PMEA).	Zidovudine	128-131	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
18364470-6	2008	The function of MRP4 variants was compared by measuring the intracellular accumulation of two antiviral agents, azidothymidine (AZT) and adefovir (PMEA).	adefovir	137-145	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
18364470-6	2008	The function of MRP4 variants was compared by measuring the intracellular accumulation of two antiviral agents, azidothymidine (AZT) and adefovir (PMEA).	adefovir	147-151	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
18364470-10	2008	However, two variants (G187W and G487E) showed a significantly reduced function compared to reference with both substrates, as evidenced by higher intracellular accumulation of AZT and PMEA compared to the reference MRP4 (43 and 69% increase in accumulation for G187W compared with the reference MRP4, with AZT and PMEA, respectively).	Zidovudine	177-180	ATP binding cassette subfamily C member 4	Homo sapiens	296-300
18364470-10	2008	However, two variants (G187W and G487E) showed a significantly reduced function compared to reference with both substrates, as evidenced by higher intracellular accumulation of AZT and PMEA compared to the reference MRP4 (43 and 69% increase in accumulation for G187W compared with the reference MRP4, with AZT and PMEA, respectively).	adefovir	185-189	ATP binding cassette subfamily C member 4	Homo sapiens	216-220
18364470-10	2008	However, two variants (G187W and G487E) showed a significantly reduced function compared to reference with both substrates, as evidenced by higher intracellular accumulation of AZT and PMEA compared to the reference MRP4 (43 and 69% increase in accumulation for G187W compared with the reference MRP4, with AZT and PMEA, respectively).	adefovir	185-189	ATP binding cassette subfamily C member 4	Homo sapiens	296-300
18364470-10	2008	However, two variants (G187W and G487E) showed a significantly reduced function compared to reference with both substrates, as evidenced by higher intracellular accumulation of AZT and PMEA compared to the reference MRP4 (43 and 69% increase in accumulation for G187W compared with the reference MRP4, with AZT and PMEA, respectively).	Zidovudine	307-310	ATP binding cassette subfamily C member 4	Homo sapiens	296-300
18364470-10	2008	However, two variants (G187W and G487E) showed a significantly reduced function compared to reference with both substrates, as evidenced by higher intracellular accumulation of AZT and PMEA compared to the reference MRP4 (43 and 69% increase in accumulation for G187W compared with the reference MRP4, with AZT and PMEA, respectively).	adefovir	315-319	ATP binding cassette subfamily C member 4	Homo sapiens	296-300
17878487-0	2007	Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications.	Celecoxib	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	18-23
18398970-8	2008	ABCC4 3463G variants had TFV-DP concentrations 35% higher (29 fmol/10(6) cells) than wild type (P = 0.04).	dp	29-31	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
17674156-5	2008	Candesartan, losartan, and telmisartan inhibited ATP-dependent uptake of uric acid by MRP4 at 10 microM.	candesartan	0-11	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
17674156-5	2008	Candesartan, losartan, and telmisartan inhibited ATP-dependent uptake of uric acid by MRP4 at 10 microM.	Losartan	13-21	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
17674156-5	2008	Candesartan, losartan, and telmisartan inhibited ATP-dependent uptake of uric acid by MRP4 at 10 microM.	Telmisartan	27-38	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
17674156-5	2008	Candesartan, losartan, and telmisartan inhibited ATP-dependent uptake of uric acid by MRP4 at 10 microM.	Adenosine Triphosphate	49-52	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
17674156-5	2008	Candesartan, losartan, and telmisartan inhibited ATP-dependent uptake of uric acid by MRP4 at 10 microM.	Uric Acid	73-82	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
17674156-6	2008	The IC50 value of losartan for MRP4 was comparable to the estimated kidney tissue concentration of losartan.	Losartan	18-26	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
17674156-9	2008	Furthermore losartan could inhibit ATP-dependent uric acid secretion by MRP4.	Losartan	12-20	ATP binding cassette subfamily C member 4	Homo sapiens	72-76
17674156-9	2008	Furthermore losartan could inhibit ATP-dependent uric acid secretion by MRP4.	Adenosine Triphosphate	35-38	ATP binding cassette subfamily C member 4	Homo sapiens	72-76
17674156-9	2008	Furthermore losartan could inhibit ATP-dependent uric acid secretion by MRP4.	Uric Acid	49-58	ATP binding cassette subfamily C member 4	Homo sapiens	72-76
18762713-3	2008	We have demonstrated that some angiotensin II receptor blockers trans-stimulate the uptake of uric acid by human URAT1 and others inhibit the transport of uric acid mediated by human URAT1, OAT1, OAT3 and MRP4 in vitro.	Uric Acid	94-103	ATP binding cassette subfamily C member 4	Homo sapiens	205-209
18762713-3	2008	We have demonstrated that some angiotensin II receptor blockers trans-stimulate the uptake of uric acid by human URAT1 and others inhibit the transport of uric acid mediated by human URAT1, OAT1, OAT3 and MRP4 in vitro.	Uric Acid	155-164	ATP binding cassette subfamily C member 4	Homo sapiens	205-209
17855498-2	2007	Here we used confocal microscopy to investigate in killifish tubules the transport of a fluorescent cAMP analog (fluo-cAMP), a putative substrate for Mrp2 and Mrp4 (ABCC4).	Cyclic AMP	100-104	ATP binding cassette subfamily C member 4	Homo sapiens	159-163
17855498-2	2007	Here we used confocal microscopy to investigate in killifish tubules the transport of a fluorescent cAMP analog (fluo-cAMP), a putative substrate for Mrp2 and Mrp4 (ABCC4).	fluo-camp	113-122	ATP binding cassette subfamily C member 4	Homo sapiens	159-163
17855498-8	2007	Finally, in membrane vesicles from Spodoptera frugiperda (Sf9) cells containing human MRP4, ATP-dependent and specific uptake of fluo-cAMP could be demonstrated.	Adenosine Triphosphate	92-95	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
17855498-8	2007	Finally, in membrane vesicles from Spodoptera frugiperda (Sf9) cells containing human MRP4, ATP-dependent and specific uptake of fluo-cAMP could be demonstrated.	fluo-camp	129-138	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
17855498-9	2007	Thus, based on inhibitor specificity and regulatory signaling, cell-to-lumen transport of fluo-cAMP in killifish renal tubules is mediated by a transporter distinct from Mrp2, presumably a teleost form of Mrp4.	fluo-camp	90-99	ATP binding cassette subfamily C member 4	Homo sapiens	205-209
17823233-8	2007	ATP-dependent transport into membrane vesicles expressing human MRP2 and MRP4 was clearly observed, with K(m) values of 14.9 and 26.2 microM, respectively, whereas the urinary excretion of olmesartan in Mrp4-knockout mice was not different from that of control mice.	Adenosine Triphosphate	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	73-77
17823233-8	2007	ATP-dependent transport into membrane vesicles expressing human MRP2 and MRP4 was clearly observed, with K(m) values of 14.9 and 26.2 microM, respectively, whereas the urinary excretion of olmesartan in Mrp4-knockout mice was not different from that of control mice.	Adenosine Triphosphate	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	203-207
17823233-8	2007	ATP-dependent transport into membrane vesicles expressing human MRP2 and MRP4 was clearly observed, with K(m) values of 14.9 and 26.2 microM, respectively, whereas the urinary excretion of olmesartan in Mrp4-knockout mice was not different from that of control mice.	olmesartan	189-199	ATP binding cassette subfamily C member 4	Homo sapiens	73-77
17823233-8	2007	ATP-dependent transport into membrane vesicles expressing human MRP2 and MRP4 was clearly observed, with K(m) values of 14.9 and 26.2 microM, respectively, whereas the urinary excretion of olmesartan in Mrp4-knockout mice was not different from that of control mice.	olmesartan	189-199	ATP binding cassette subfamily C member 4	Homo sapiens	203-207
17534577-5	2007	RESULTS: In 61 samples, low levels of TS, GARFT, DHFR, and mrp4 gene expression significantly correlated with chemosensitivity to pemetrexed.	Pemetrexed	130-140	ATP binding cassette subfamily C member 4	Homo sapiens	59-63
17996297-0	2008	Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine.	Mercaptopurine	117-133	ATP binding cassette subfamily C member 4	Homo sapiens	17-21
17959747-0	2008	ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4).	Adenosine Triphosphate	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	86-91
17959747-0	2008	ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4).	Adenosine Triphosphate	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	93-97
17959747-0	2008	ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4).	Leukotrienes	27-39	ATP binding cassette subfamily C member 4	Homo sapiens	86-91
17959747-0	2008	ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4).	Leukotrienes	27-39	ATP binding cassette subfamily C member 4	Homo sapiens	93-97
17959747-4	2008	Here, we demonstrate that human ABCC4 mediates the ATP-dependent efflux of LTB(4) in the presence of reduced glutathione (GSH), whereby the latter can be replaced by S-methyl GSH.	Adenosine Triphosphate	51-54	ATP binding cassette subfamily C member 4	Homo sapiens	32-37
17959747-4	2008	Here, we demonstrate that human ABCC4 mediates the ATP-dependent efflux of LTB(4) in the presence of reduced glutathione (GSH), whereby the latter can be replaced by S-methyl GSH.	Glutathione	109-120	ATP binding cassette subfamily C member 4	Homo sapiens	32-37
17959747-4	2008	Here, we demonstrate that human ABCC4 mediates the ATP-dependent efflux of LTB(4) in the presence of reduced glutathione (GSH), whereby the latter can be replaced by S-methyl GSH.	Glutathione	122-125	ATP binding cassette subfamily C member 4	Homo sapiens	32-37
17959747-4	2008	Here, we demonstrate that human ABCC4 mediates the ATP-dependent efflux of LTB(4) in the presence of reduced glutathione (GSH), whereby the latter can be replaced by S-methyl GSH.	Glutathione	175-178	ATP binding cassette subfamily C member 4	Homo sapiens	32-37
17959747-8	2008	ABCC4, with its broad substrate specificity, also functioned as an ATP-dependent efflux pump for LTC(4) with a K(m) of 0.13 muM in vesicles from fibroblasts and 0.32 muM in vesicles from platelets.	Adenosine Triphosphate	67-70	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
17939016-2	2007	METHODS: Human MRP4-expressing membrane vesicles were incubated with a mixture of 50 compounds, including methotrexate, a known MRP4 substrate.	Methotrexate	106-118	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
17939016-2	2007	METHODS: Human MRP4-expressing membrane vesicles were incubated with a mixture of 50 compounds, including methotrexate, a known MRP4 substrate.	Methotrexate	106-118	ATP binding cassette subfamily C member 4	Homo sapiens	128-132
17939016-8	2007	By contrast, the uptakes of meloxicam and nateglinide did not depend on osmolarity, indicating that these compounds were not substrates, but bound to MRP4.	Meloxicam	28-37	ATP binding cassette subfamily C member 4	Homo sapiens	150-154
17939016-8	2007	By contrast, the uptakes of meloxicam and nateglinide did not depend on osmolarity, indicating that these compounds were not substrates, but bound to MRP4.	Nateglinide	42-53	ATP binding cassette subfamily C member 4	Homo sapiens	150-154
17947407-4	2007	mrp-4(+) activity is required for the extracellular mislocalization of birefringent material, body-length retraction, and NaCl sensitivity, phenotypes associated with defective gut granule biogenesis exhibited by embryos lacking the activity of GLO-1/Rab38, a putative GLO-1 guanine nucleotide exchange factor GLO-4, and the AP-3 complex.	Sodium Chloride	122-126	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
17947407-4	2007	mrp-4(+) activity is required for the extracellular mislocalization of birefringent material, body-length retraction, and NaCl sensitivity, phenotypes associated with defective gut granule biogenesis exhibited by embryos lacking the activity of GLO-1/Rab38, a putative GLO-1 guanine nucleotide exchange factor GLO-4, and the AP-3 complex.	Guanine Nucleotides	275-293	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
17894656-2	2007	AIM: To evaluate whether ursodeoxycholic acid affects MRP2, MRP3 and MRP4 expression in the placenta.	Ursodeoxycholic Acid	25-45	ATP binding cassette subfamily C member 4	Homo sapiens	69-73
17627974-5	2007	Compared with normal liver specimens, MRP1 and MRP4 mRNA levels were elevated after APAP overdose and in PBC.	Acetaminophen	84-88	ATP binding cassette subfamily C member 4	Homo sapiens	47-51
17578901-8	2007	Among ABC transporters, such as BCRP/ABCG2, multidrug resistance-associated protein (MRP) 2/ABCC2, and MRP4/ABCC4, which are candidates for the luminal efflux of methotrexate, ATP-dependent uptake of methotrexate by MRP4-expressing membrane vesicles was most potently inhibited by NSAIDs.	Methotrexate	162-174	ATP binding cassette subfamily C member 4	Homo sapiens	103-107
17578901-8	2007	Among ABC transporters, such as BCRP/ABCG2, multidrug resistance-associated protein (MRP) 2/ABCC2, and MRP4/ABCC4, which are candidates for the luminal efflux of methotrexate, ATP-dependent uptake of methotrexate by MRP4-expressing membrane vesicles was most potently inhibited by NSAIDs.	Methotrexate	162-174	ATP binding cassette subfamily C member 4	Homo sapiens	108-113
17578901-8	2007	Among ABC transporters, such as BCRP/ABCG2, multidrug resistance-associated protein (MRP) 2/ABCC2, and MRP4/ABCC4, which are candidates for the luminal efflux of methotrexate, ATP-dependent uptake of methotrexate by MRP4-expressing membrane vesicles was most potently inhibited by NSAIDs.	Methotrexate	162-174	ATP binding cassette subfamily C member 4	Homo sapiens	216-220
17578901-8	2007	Among ABC transporters, such as BCRP/ABCG2, multidrug resistance-associated protein (MRP) 2/ABCC2, and MRP4/ABCC4, which are candidates for the luminal efflux of methotrexate, ATP-dependent uptake of methotrexate by MRP4-expressing membrane vesicles was most potently inhibited by NSAIDs.	Adenosine Triphosphate	176-179	ATP binding cassette subfamily C member 4	Homo sapiens	103-107
17578901-8	2007	Among ABC transporters, such as BCRP/ABCG2, multidrug resistance-associated protein (MRP) 2/ABCC2, and MRP4/ABCC4, which are candidates for the luminal efflux of methotrexate, ATP-dependent uptake of methotrexate by MRP4-expressing membrane vesicles was most potently inhibited by NSAIDs.	Adenosine Triphosphate	176-179	ATP binding cassette subfamily C member 4	Homo sapiens	108-113
17578901-8	2007	Among ABC transporters, such as BCRP/ABCG2, multidrug resistance-associated protein (MRP) 2/ABCC2, and MRP4/ABCC4, which are candidates for the luminal efflux of methotrexate, ATP-dependent uptake of methotrexate by MRP4-expressing membrane vesicles was most potently inhibited by NSAIDs.	Adenosine Triphosphate	176-179	ATP binding cassette subfamily C member 4	Homo sapiens	216-220
17578901-8	2007	Among ABC transporters, such as BCRP/ABCG2, multidrug resistance-associated protein (MRP) 2/ABCC2, and MRP4/ABCC4, which are candidates for the luminal efflux of methotrexate, ATP-dependent uptake of methotrexate by MRP4-expressing membrane vesicles was most potently inhibited by NSAIDs.	Methotrexate	200-212	ATP binding cassette subfamily C member 4	Homo sapiens	103-107
17578901-8	2007	Among ABC transporters, such as BCRP/ABCG2, multidrug resistance-associated protein (MRP) 2/ABCC2, and MRP4/ABCC4, which are candidates for the luminal efflux of methotrexate, ATP-dependent uptake of methotrexate by MRP4-expressing membrane vesicles was most potently inhibited by NSAIDs.	Methotrexate	200-212	ATP binding cassette subfamily C member 4	Homo sapiens	108-113
17578901-8	2007	Among ABC transporters, such as BCRP/ABCG2, multidrug resistance-associated protein (MRP) 2/ABCC2, and MRP4/ABCC4, which are candidates for the luminal efflux of methotrexate, ATP-dependent uptake of methotrexate by MRP4-expressing membrane vesicles was most potently inhibited by NSAIDs.	Methotrexate	200-212	ATP binding cassette subfamily C member 4	Homo sapiens	216-220
17578901-9	2007	Salicylate and indomethacin were predicted to inhibit MRP4 at clinical plasma concentrations.	Salicylates	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	54-58
17578901-9	2007	Salicylate and indomethacin were predicted to inhibit MRP4 at clinical plasma concentrations.	Indomethacin	15-27	ATP binding cassette subfamily C member 4	Homo sapiens	54-58
17578901-11	2007	Inhibition of renal uptake (via OAT3) and efflux processes (via MRP2 and MRP4) explains the possible sites of drug-drug interaction for methotrexate with probenecid and some NSAIDs, including their glucuronides.	Methotrexate	136-148	ATP binding cassette subfamily C member 4	Homo sapiens	73-77
17578901-11	2007	Inhibition of renal uptake (via OAT3) and efflux processes (via MRP2 and MRP4) explains the possible sites of drug-drug interaction for methotrexate with probenecid and some NSAIDs, including their glucuronides.	Probenecid	154-164	ATP binding cassette subfamily C member 4	Homo sapiens	73-77
17578901-11	2007	Inhibition of renal uptake (via OAT3) and efflux processes (via MRP2 and MRP4) explains the possible sites of drug-drug interaction for methotrexate with probenecid and some NSAIDs, including their glucuronides.	Glucuronides	198-210	ATP binding cassette subfamily C member 4	Homo sapiens	73-77
17295178-2	2007	Defects of the phospholipid export pump MDR3 ( ABCC4) result in impaired biliary excretion of phosphatidylcholine and a variety of cholestatic syndromes ranging from progressive familial intrahepatic cholestasis in neonates to biliary cirrhosis in adults.	Phospholipids	15-27	ATP binding cassette subfamily C member 4	Homo sapiens	47-52
17344354-2	2007	Most of the injectable cephalosporins have an inhibitory effect on the ATP-dependent uptake of [(3)H]dehydroepiandrosterone sulfate by membrane vesicles expressing hMRP4, whereas cephaloridine, cefsulodin, and cefepime do not.	Cephalosporins	23-37	ATP binding cassette subfamily C member 4	Homo sapiens	164-169
17344354-2	2007	Most of the injectable cephalosporins have an inhibitory effect on the ATP-dependent uptake of [(3)H]dehydroepiandrosterone sulfate by membrane vesicles expressing hMRP4, whereas cephaloridine, cefsulodin, and cefepime do not.	Adenosine Triphosphate	71-74	ATP binding cassette subfamily C member 4	Homo sapiens	164-169
17344354-2	2007	Most of the injectable cephalosporins have an inhibitory effect on the ATP-dependent uptake of [(3)H]dehydroepiandrosterone sulfate by membrane vesicles expressing hMRP4, whereas cephaloridine, cefsulodin, and cefepime do not.	[(3)h]dehydroepiandrosterone sulfate	95-131	ATP binding cassette subfamily C member 4	Homo sapiens	164-169
17344354-4	2007	Significant ATP-dependent transport of ceftizoxime (K(m), 18 microM), cefazolin (K(m), 80 microM), cefotaxime, and cefmetazole has been observed only in the membrane vesicles expressing hMRP4.	Adenosine Triphosphate	12-15	ATP binding cassette subfamily C member 4	Homo sapiens	186-191
17344354-4	2007	Significant ATP-dependent transport of ceftizoxime (K(m), 18 microM), cefazolin (K(m), 80 microM), cefotaxime, and cefmetazole has been observed only in the membrane vesicles expressing hMRP4.	Ceftizoxime	39-50	ATP binding cassette subfamily C member 4	Homo sapiens	186-191
17344354-4	2007	Significant ATP-dependent transport of ceftizoxime (K(m), 18 microM), cefazolin (K(m), 80 microM), cefotaxime, and cefmetazole has been observed only in the membrane vesicles expressing hMRP4.	Cefmetazole	115-126	ATP binding cassette subfamily C member 4	Homo sapiens	186-191
17291602-4	2007	The genes encoding for organic anion uptake (NTCP, OATPs), canalicular export (BSEP, MRP2) and alternative basolateral export (MRP3, MRP4) in liver are regulated by a complex interacting network of hepatocyte nuclear factors (HNF1, 3, 4) and nuclear (orphan) receptors (e.g., FXR, PXR, CAR, RAR, LRH-1, SHP, GR).	periodate-oxidized adenosine 5'-triphosphate	51-56	ATP binding cassette subfamily C member 4	Homo sapiens	133-137
16868766-8	2007	Similar to the case for other MRPs that possess only two membrane spanning domains (MRP4 and MRP5), MRP8 is a cyclic nucleotide efflux pump that is able to confer resistance to nucleoside-based agents, such as PMEA and 5FU.	Nucleotides, Cyclic	110-127	ATP binding cassette subfamily C member 4	Homo sapiens	84-88
16868766-8	2007	Similar to the case for other MRPs that possess only two membrane spanning domains (MRP4 and MRP5), MRP8 is a cyclic nucleotide efflux pump that is able to confer resistance to nucleoside-based agents, such as PMEA and 5FU.	Nucleosides	177-187	ATP binding cassette subfamily C member 4	Homo sapiens	84-88
16868766-8	2007	Similar to the case for other MRPs that possess only two membrane spanning domains (MRP4 and MRP5), MRP8 is a cyclic nucleotide efflux pump that is able to confer resistance to nucleoside-based agents, such as PMEA and 5FU.	adefovir	210-214	ATP binding cassette subfamily C member 4	Homo sapiens	84-88
16868766-8	2007	Similar to the case for other MRPs that possess only two membrane spanning domains (MRP4 and MRP5), MRP8 is a cyclic nucleotide efflux pump that is able to confer resistance to nucleoside-based agents, such as PMEA and 5FU.	Fluorouracil	219-222	ATP binding cassette subfamily C member 4	Homo sapiens	84-88
17284667-4	2007	In this screen, we identified Drosophila CG14709 gene as a homolog of the human multidrug resistance protein 4 (MRP4/ABCC4) that is tightly regulated to oxygen.	Oxygen	153-159	ATP binding cassette subfamily C member 4	Homo sapiens	112-116
17284667-4	2007	In this screen, we identified Drosophila CG14709 gene as a homolog of the human multidrug resistance protein 4 (MRP4/ABCC4) that is tightly regulated to oxygen.	Oxygen	153-159	ATP binding cassette subfamily C member 4	Homo sapiens	117-122
17314201-2	2007	In this report, we demonstrate that sitagliptin is transported by human organic anion transporter hOAT3 (Km=162 microM), organic anion transporting polypeptide OATP4C1, and multidrug resistance (MDR) P-glycoprotein (Pgp), but not by human organic cation transporter 2 hOCT2, hOAT1, oligopeptide transporter hPEPT1, OATP2B1, and the multidrug resistance proteins MRP2 and MRP4.	Sitagliptin Phosphate	36-47	ATP binding cassette subfamily C member 4	Homo sapiens	371-375
17518506-4	2007	While erythrocytes mainly express multidrug resistance protein (MRP) 1, MRP4 and MRP5, which are discussed with regard to their involvement in glutathione homeostasis (MRP1) and in the efflux of cyclic nucleotides (MRP4 and MRP5), leukocytes also express P-glycoprotein and breast cancer resistance protein.	Glutathione	143-154	ATP binding cassette subfamily C member 4	Homo sapiens	72-76
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	38-47	ATP binding cassette subfamily C member 4	Homo sapiens	181-211
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	38-47	ATP binding cassette subfamily C member 4	Homo sapiens	213-217
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	49-52	ATP binding cassette subfamily C member 4	Homo sapiens	181-211
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	49-52	ATP binding cassette subfamily C member 4	Homo sapiens	213-217
17518506-4	2007	While erythrocytes mainly express multidrug resistance protein (MRP) 1, MRP4 and MRP5, which are discussed with regard to their involvement in glutathione homeostasis (MRP1) and in the efflux of cyclic nucleotides (MRP4 and MRP5), leukocytes also express P-glycoprotein and breast cancer resistance protein.	Glutathione	143-154	ATP binding cassette subfamily C member 4	Homo sapiens	215-219
17518506-4	2007	While erythrocytes mainly express multidrug resistance protein (MRP) 1, MRP4 and MRP5, which are discussed with regard to their involvement in glutathione homeostasis (MRP1) and in the efflux of cyclic nucleotides (MRP4 and MRP5), leukocytes also express P-glycoprotein and breast cancer resistance protein.	Nucleotides, Cyclic	195-213	ATP binding cassette subfamily C member 4	Homo sapiens	72-76
17518506-4	2007	While erythrocytes mainly express multidrug resistance protein (MRP) 1, MRP4 and MRP5, which are discussed with regard to their involvement in glutathione homeostasis (MRP1) and in the efflux of cyclic nucleotides (MRP4 and MRP5), leukocytes also express P-glycoprotein and breast cancer resistance protein.	Nucleotides, Cyclic	195-213	ATP binding cassette subfamily C member 4	Homo sapiens	215-219
18058328-13	2007	Plasma VPA distributed to erythrocytes by the inhibition of transporters (Mrp4), which efflux VPA from erythrocytes to plasma, by carbapenem antibiotics.	Carbapenems	130-152	ATP binding cassette subfamily C member 4	Homo sapiens	74-78
17579998-1	2007	The role of MRP4 and MRP5 transporters in the acyclic nucleoside phosphonate PMEDAP efflux was studied in vitro (CCRF-CEM cells) and in vivo (spontaneous transplantable T-cell lymphoma of SD/Cub inbred rats).	nucleoside phosphonate	54-76	ATP binding cassette subfamily C member 4	Homo sapiens	12-16
17229149-5	2007	Whereas cGMP transport into human vesicles was efficiently inhibited by the ABCC4-specific substrate prostaglandin E1, cGMP transport into mouse vesicles was inhibited equally by Abcg2 and Abcc4 inhibitors/substrates.	Cyclic GMP	8-12	ATP binding cassette subfamily C member 4	Homo sapiens	76-81
17229149-5	2007	Whereas cGMP transport into human vesicles was efficiently inhibited by the ABCC4-specific substrate prostaglandin E1, cGMP transport into mouse vesicles was inhibited equally by Abcg2 and Abcc4 inhibitors/substrates.	Alprostadil	101-117	ATP binding cassette subfamily C member 4	Homo sapiens	76-81
17005917-5	2007	MTX was transported by MRP2 and MRP4 with Km values of 480 +/- 90 and 220 +/- 70 microM, respectively.	Methotrexate	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
17005917-0	2007	Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport.	Methotrexate	125-137	ATP binding cassette subfamily C member 4	Homo sapiens	105-109
17005917-7	2007	Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model.	Salicylates	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
17005917-0	2007	Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport.	Methotrexate	125-137	ATP binding cassette subfamily C member 4	Homo sapiens	110-115
17005917-7	2007	Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model.	Piroxicam	12-21	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
17005917-7	2007	Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model.	Ibuprofen	23-32	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
17005917-7	2007	Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model.	Naproxen	34-42	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
17005917-7	2007	Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model.	Sulindac	44-52	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
17005917-7	2007	Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model.	Tolmetin	54-62	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
17005917-7	2007	Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model.	Etodolac	68-76	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
17005917-7	2007	Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model.	Methotrexate	111-114	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
17005917-9	2007	Inhibition of MRP4 by diclofenac and MRP2 by indomethacin and ketoprofen followed a two-site competition model.	Diclofenac	22-32	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
17005917-9	2007	Inhibition of MRP4 by diclofenac and MRP2 by indomethacin and ketoprofen followed a two-site competition model.	Indomethacin	45-57	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
17005917-9	2007	Inhibition of MRP4 by diclofenac and MRP2 by indomethacin and ketoprofen followed a two-site competition model.	Ketoprofen	62-72	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
17005917-10	2007	Phenylbutazone stimulated MRP2 and celecoxib MRP4 transport at low concentrations and inhibited both transporters at high concentration.	Phenylbutazone	0-14	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
17005917-10	2007	Phenylbutazone stimulated MRP2 and celecoxib MRP4 transport at low concentrations and inhibited both transporters at high concentration.	Celecoxib	35-44	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
17005917-11	2007	Our data suggest that the inhibition by NSAIDs of renal MTX efflux via MRP2 and MRP4 is a potential new site and mechanism contributing to the overall interaction between these drugs.	Methotrexate	56-59	ATP binding cassette subfamily C member 4	Homo sapiens	80-84
17003774-3	2007	Dihydrotestosterone induced MRP4 expression in both androgen-dependent and -independent LNCaP cells, whereas there was little detectable expression in PC-3 or normal prostate epithelial cells.	Dihydrotestosterone	0-19	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
17003774-4	2007	Disruption of MRP4 expression renders LNCaP cells more sensitive to the cytotoxic effects of methotrexate but not etoposide.	Methotrexate	93-105	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
17083032-3	2006	METHODS: Mutational screening of the genes for MRP2 (ABCC2) and MRP4 (ABCC4) was performed using genomic DNA from 13 human immunodeficiency virus type 1 (HIV-1)-infected patients (group 1) presenting with TDF-induced rPT.	Tenofovir	205-208	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
16282361-5	2006	Ursodeoxycholyltaurine and ursodeoxycholylglycine were cotransported together with GSH by ABCC4 with K(m) values of 7.8 and 12.5 microM, respectively, but no transport of ursodeoxycholate and deoxycholate was observed.	Deoxycholic Acid	175-187	ATP binding cassette subfamily C member 4	Homo sapiens	90-95
17067265-6	2006	Compared to the parental CEM cells, CEM(ZLA) cells express a high level of multidrug resistance protein 4 (MRP4), which could reduce the intracellular concentration of 3TC.	Lamivudine	168-171	ATP binding cassette subfamily C member 4	Homo sapiens	75-105
17067265-6	2006	Compared to the parental CEM cells, CEM(ZLA) cells express a high level of multidrug resistance protein 4 (MRP4), which could reduce the intracellular concentration of 3TC.	Lamivudine	168-171	ATP binding cassette subfamily C member 4	Homo sapiens	107-111
17005808-5	2006	In contrast to Pgp and MRP2, TFV was observed to be a substrate for MRP4.	Tenofovir	29-32	ATP binding cassette subfamily C member 4	Homo sapiens	68-72
17005808-6	2006	TFV accumulated to fivefold lower levels in MRP4-overexpressing cells, and its accumulation could be increased by an MRP inhibitor.	Tenofovir	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
17005808-7	2006	Furthermore, MRP4-overexpressing cells were found to be 2.0- to 2.5-fold less susceptible to cytotoxicity caused by TFV.	Tenofovir	116-119	ATP binding cassette subfamily C member 4	Homo sapiens	13-17
17005808-8	2006	ATP-dependent uptake of TFV was observed in membrane vesicles containing MRP4 but not in vesicles lacking the transporter.	Adenosine Triphosphate	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	73-77
17005808-8	2006	ATP-dependent uptake of TFV was observed in membrane vesicles containing MRP4 but not in vesicles lacking the transporter.	Tenofovir	24-27	ATP binding cassette subfamily C member 4	Homo sapiens	73-77
17005808-9	2006	On the basis of these and previous results, the molecular transport pathway for the active tubular secretion of TFV through renal proximal-tubule cells involves uptake from the blood mediated by human organic anion transporters 1 and 3 and efflux into urine by MRP4.	Tenofovir	112-115	ATP binding cassette subfamily C member 4	Homo sapiens	261-265
16614078-1	2006	The energy-dependent cyclic nucleotide cellular efflux is operative in numerous eukaryotic cells and could be mediated by multidrug resistance proteins MRP4, MRP5, and MRP8.	Nucleotides, Cyclic	21-38	ATP binding cassette subfamily C member 4	Homo sapiens	152-156
16791115-1	2006	OBJECTIVE: The aim of the study was to investigate relationships among indinavir, lamivudine-triphosphate, and zidovudine-triphosphate pharmacokinetics and pharmacodynamics with polymorphisms in CYP3A5, MDR1, MRP2, MRP4, BCRP, and UGT1A1 genes.	zidovudine triphosphate	111-134	ATP binding cassette subfamily C member 4	Homo sapiens	215-219
16791115-8	2006	Lamivudine-triphosphate concentrations were elevated 20% in MRP4 T4131G variant carriers (P = 0.004).	lamivudine triphosphate	0-23	ATP binding cassette subfamily C member 4	Homo sapiens	60-64
16791115-9	2006	A trend for elevated zidovudine-triphosphates was observed in MRP4 G3724A variant carriers (P = 0.06).	zidovudine triphosphate	21-45	ATP binding cassette subfamily C member 4	Homo sapiens	62-66
16282361-7	2006	K(m) values of the bile acids for ABCC4 were in a range similar to those reported for the canalicular bile salt export pump ABCB11.	Bile Acids and Salts	19-29	ATP binding cassette subfamily C member 4	Homo sapiens	34-39
16282361-7	2006	K(m) values of the bile acids for ABCC4 were in a range similar to those reported for the canalicular bile salt export pump ABCB11.	Bile Acids and Salts	102-111	ATP binding cassette subfamily C member 4	Homo sapiens	34-39
16282361-8	2006	Under physiological conditions, the sinusoidal ABCC4 may compete with canalicular ABCB11 for bile acids and thereby play a key role in determining the hepatocyte concentration of bile acids.	Bile Acids and Salts	93-103	ATP binding cassette subfamily C member 4	Homo sapiens	47-52
16282361-8	2006	Under physiological conditions, the sinusoidal ABCC4 may compete with canalicular ABCB11 for bile acids and thereby play a key role in determining the hepatocyte concentration of bile acids.	Bile Acids and Salts	179-189	ATP binding cassette subfamily C member 4	Homo sapiens	47-52
16282361-9	2006	In cholestatic conditions, ABCC4 may become a key pathway for efflux of bile acids from hepatocytes into blood.	Bile Acids and Salts	72-82	ATP binding cassette subfamily C member 4	Homo sapiens	27-32
16337112-7	2006	A survey of CDCF uptake by other MRPs revealed that MRP2 (ABCC2) also demonstrated ATP-dependent uptake with a Km of 19 microM and Vmax of 95.5 pmol/min/mg prot, while MRP1 (ABCC1) and MRP4 (ABCC4) had little to no uptake.	Adenosine Triphosphate	83-86	ATP binding cassette subfamily C member 4	Homo sapiens	185-189
16282361-0	2006	Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.	Bile Acids and Salts	68-78	ATP binding cassette subfamily C member 4	Homo sapiens	31-36
16282361-0	2006	Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.	Bile Acids and Salts	68-78	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
16282361-0	2006	Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.	Glutathione	91-102	ATP binding cassette subfamily C member 4	Homo sapiens	31-36
16282361-0	2006	Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.	Glutathione	91-102	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
16282361-1	2006	The multidrug resistance protein ABCC4 (MRP4), a member of the ATP-binding cassette superfamily, mediates ATP-dependent unidirectional efflux of organic anions out of cells.	Adenosine Triphosphate	63-66	ATP binding cassette subfamily C member 4	Homo sapiens	4-38
16282361-1	2006	The multidrug resistance protein ABCC4 (MRP4), a member of the ATP-binding cassette superfamily, mediates ATP-dependent unidirectional efflux of organic anions out of cells.	Adenosine Triphosphate	63-66	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
16282361-2	2006	Previous studies showed that human ABCC4 is localized to the sinusoidal membrane of hepatocytes and mediates, among other substrates, the cotransport of reduced glutathione (GSH) with bile acids.	Glutathione	161-172	ATP binding cassette subfamily C member 4	Homo sapiens	35-40
16282361-2	2006	Previous studies showed that human ABCC4 is localized to the sinusoidal membrane of hepatocytes and mediates, among other substrates, the cotransport of reduced glutathione (GSH) with bile acids.	Glutathione	174-177	ATP binding cassette subfamily C member 4	Homo sapiens	35-40
16282361-2	2006	Previous studies showed that human ABCC4 is localized to the sinusoidal membrane of hepatocytes and mediates, among other substrates, the cotransport of reduced glutathione (GSH) with bile acids.	Bile Acids and Salts	184-194	ATP binding cassette subfamily C member 4	Homo sapiens	35-40
16282361-3	2006	In the present study, using inside-out membrane vesicles, we demonstrated that human ABCC4 in the presence of physiological concentrations of GSH has a high affinity for the taurine and glycine conjugates of the common natural bile acids as well as the unconjugated bile acid cholate.	Glutathione	142-145	ATP binding cassette subfamily C member 4	Homo sapiens	85-90
16282361-3	2006	In the present study, using inside-out membrane vesicles, we demonstrated that human ABCC4 in the presence of physiological concentrations of GSH has a high affinity for the taurine and glycine conjugates of the common natural bile acids as well as the unconjugated bile acid cholate.	Taurine	174-181	ATP binding cassette subfamily C member 4	Homo sapiens	85-90
16282361-3	2006	In the present study, using inside-out membrane vesicles, we demonstrated that human ABCC4 in the presence of physiological concentrations of GSH has a high affinity for the taurine and glycine conjugates of the common natural bile acids as well as the unconjugated bile acid cholate.	Glycine	186-193	ATP binding cassette subfamily C member 4	Homo sapiens	85-90
16282361-3	2006	In the present study, using inside-out membrane vesicles, we demonstrated that human ABCC4 in the presence of physiological concentrations of GSH has a high affinity for the taurine and glycine conjugates of the common natural bile acids as well as the unconjugated bile acid cholate.	Bile Acids and Salts	227-237	ATP binding cassette subfamily C member 4	Homo sapiens	85-90
16282361-3	2006	In the present study, using inside-out membrane vesicles, we demonstrated that human ABCC4 in the presence of physiological concentrations of GSH has a high affinity for the taurine and glycine conjugates of the common natural bile acids as well as the unconjugated bile acid cholate.	Bile Acids and Salts	227-236	ATP binding cassette subfamily C member 4	Homo sapiens	85-90
16282361-3	2006	In the present study, using inside-out membrane vesicles, we demonstrated that human ABCC4 in the presence of physiological concentrations of GSH has a high affinity for the taurine and glycine conjugates of the common natural bile acids as well as the unconjugated bile acid cholate.	Cholates	276-283	ATP binding cassette subfamily C member 4	Homo sapiens	85-90
16282361-4	2006	Chenodeoxycholyltaurine and chenodeoxycholylglycine were the GSH cosubstrates with the highest affinities for ABCC4, with K(m) values of 3.6 and 5.9 microM, respectively.	Taurochenodeoxycholic Acid	0-23	ATP binding cassette subfamily C member 4	Homo sapiens	110-115
16282361-4	2006	Chenodeoxycholyltaurine and chenodeoxycholylglycine were the GSH cosubstrates with the highest affinities for ABCC4, with K(m) values of 3.6 and 5.9 microM, respectively.	Glycochenodeoxycholic Acid	28-51	ATP binding cassette subfamily C member 4	Homo sapiens	110-115
16282361-4	2006	Chenodeoxycholyltaurine and chenodeoxycholylglycine were the GSH cosubstrates with the highest affinities for ABCC4, with K(m) values of 3.6 and 5.9 microM, respectively.	Glutathione	61-64	ATP binding cassette subfamily C member 4	Homo sapiens	110-115
16282361-5	2006	Ursodeoxycholyltaurine and ursodeoxycholylglycine were cotransported together with GSH by ABCC4 with K(m) values of 7.8 and 12.5 microM, respectively, but no transport of ursodeoxycholate and deoxycholate was observed.	ursodoxicoltaurine	0-22	ATP binding cassette subfamily C member 4	Homo sapiens	90-95
16282361-5	2006	Ursodeoxycholyltaurine and ursodeoxycholylglycine were cotransported together with GSH by ABCC4 with K(m) values of 7.8 and 12.5 microM, respectively, but no transport of ursodeoxycholate and deoxycholate was observed.	glycoursodeoxycholic acid	27-49	ATP binding cassette subfamily C member 4	Homo sapiens	90-95
16282361-5	2006	Ursodeoxycholyltaurine and ursodeoxycholylglycine were cotransported together with GSH by ABCC4 with K(m) values of 7.8 and 12.5 microM, respectively, but no transport of ursodeoxycholate and deoxycholate was observed.	Glutathione	83-86	ATP binding cassette subfamily C member 4	Homo sapiens	90-95
16337112-7	2006	A survey of CDCF uptake by other MRPs revealed that MRP2 (ABCC2) also demonstrated ATP-dependent uptake with a Km of 19 microM and Vmax of 95.5 pmol/min/mg prot, while MRP1 (ABCC1) and MRP4 (ABCC4) had little to no uptake.	5-Carboxy-2',7'-dichlorofluorescein	12-16	ATP binding cassette subfamily C member 4	Homo sapiens	185-189
16337112-7	2006	A survey of CDCF uptake by other MRPs revealed that MRP2 (ABCC2) also demonstrated ATP-dependent uptake with a Km of 19 microM and Vmax of 95.5 pmol/min/mg prot, while MRP1 (ABCC1) and MRP4 (ABCC4) had little to no uptake.	5-Carboxy-2',7'-dichlorofluorescein	12-16	ATP binding cassette subfamily C member 4	Homo sapiens	191-196
16337112-7	2006	A survey of CDCF uptake by other MRPs revealed that MRP2 (ABCC2) also demonstrated ATP-dependent uptake with a Km of 19 microM and Vmax of 95.5 pmol/min/mg prot, while MRP1 (ABCC1) and MRP4 (ABCC4) had little to no uptake.	Adenosine Triphosphate	83-86	ATP binding cassette subfamily C member 4	Homo sapiens	191-196
16454695-0	2006	Topotecan is a substrate for multidrug resistance associated protein 4.	Topotecan	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	29-70
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	Topotecan	137-140	ATP binding cassette subfamily C member 4	Homo sapiens	109-113
16454695-4	2006	This study aimed to investigate whether overexpression of human MRP4 rendered resistance to TPT by examining the cytotoxicity profiles using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide (MTT) assay and cellular accumulation of TPT in HepG2 cells stably overexpressing MRP4.	Topotecan	92-95	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
16454695-9	2006	In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells.	Topotecan	33-36	ATP binding cassette subfamily C member 4	Homo sapiens	66-70
16454695-9	2006	In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells.	Topotecan	33-36	ATP binding cassette subfamily C member 4	Homo sapiens	168-172
16454695-9	2006	In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells.	Topotecan	192-195	ATP binding cassette subfamily C member 4	Homo sapiens	66-70
16454695-4	2006	This study aimed to investigate whether overexpression of human MRP4 rendered resistance to TPT by examining the cytotoxicity profiles using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide (MTT) assay and cellular accumulation of TPT in HepG2 cells stably overexpressing MRP4.	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide	145-205	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
16454695-9	2006	In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells.	Topotecan	192-195	ATP binding cassette subfamily C member 4	Homo sapiens	168-172
16454695-10	2006	Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively.	Celecoxib	67-76	ATP binding cassette subfamily C member 4	Homo sapiens	17-21
16454695-10	2006	Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively.	Celecoxib	67-76	ATP binding cassette subfamily C member 4	Homo sapiens	185-189
16454695-10	2006	Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively.	verlukast	93-99	ATP binding cassette subfamily C member 4	Homo sapiens	17-21
16454695-10	2006	Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively.	verlukast	93-99	ATP binding cassette subfamily C member 4	Homo sapiens	185-189
16454695-4	2006	This study aimed to investigate whether overexpression of human MRP4 rendered resistance to TPT by examining the cytotoxicity profiles using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide (MTT) assay and cellular accumulation of TPT in HepG2 cells stably overexpressing MRP4.	monooxyethylene trimethylolpropane tristearate	207-210	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
16454695-10	2006	Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively.	Topotecan	166-169	ATP binding cassette subfamily C member 4	Homo sapiens	17-21
16454695-10	2006	Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively.	Topotecan	166-169	ATP binding cassette subfamily C member 4	Homo sapiens	185-189
16454695-4	2006	This study aimed to investigate whether overexpression of human MRP4 rendered resistance to TPT by examining the cytotoxicity profiles using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide (MTT) assay and cellular accumulation of TPT in HepG2 cells stably overexpressing MRP4.	Topotecan	247-250	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
16454695-12	2006	MRP4 also rendered resistance to adefovir dipivoxil (bis-POM-PMEA) and methotrexate, two reported MRP4 substrates.	adefovir dipivoxil	33-51	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
16454695-12	2006	MRP4 also rendered resistance to adefovir dipivoxil (bis-POM-PMEA) and methotrexate, two reported MRP4 substrates.	bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine	53-65	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
16454695-12	2006	MRP4 also rendered resistance to adefovir dipivoxil (bis-POM-PMEA) and methotrexate, two reported MRP4 substrates.	Methotrexate	71-83	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
16454695-12	2006	MRP4 also rendered resistance to adefovir dipivoxil (bis-POM-PMEA) and methotrexate, two reported MRP4 substrates.	Methotrexate	71-83	ATP binding cassette subfamily C member 4	Homo sapiens	98-102
16454695-6	2006	The intracellular accumulation of TPT and paclitaxel (a PgP substrate) by V/HepG2 and MRP4/HepG2 cells was determined by incubation of TPT with the cells and the amounts of the drug in cells were determined by validated HPLC methods.	Topotecan	34-37	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
16454695-14	2006	These findings indicate that MRP4 confers resistance to TPT and TPT is the substrate for MRP4.	Topotecan	56-59	ATP binding cassette subfamily C member 4	Homo sapiens	29-33
16454695-14	2006	These findings indicate that MRP4 confers resistance to TPT and TPT is the substrate for MRP4.	Topotecan	64-67	ATP binding cassette subfamily C member 4	Homo sapiens	29-33
16454695-6	2006	The intracellular accumulation of TPT and paclitaxel (a PgP substrate) by V/HepG2 and MRP4/HepG2 cells was determined by incubation of TPT with the cells and the amounts of the drug in cells were determined by validated HPLC methods.	Paclitaxel	42-52	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
16454695-14	2006	These findings indicate that MRP4 confers resistance to TPT and TPT is the substrate for MRP4.	Topotecan	64-67	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
16454695-15	2006	Further studies are needed to explore the role of MRP4 in resistance to, toxicity and pharmacokinetics of TPT in cancer patients.	Topotecan	106-109	ATP binding cassette subfamily C member 4	Homo sapiens	50-54
16454695-7	2006	The study demonstrated that MRP4 conferred a 12.03- and 6.86-fold resistance to TPT in the 4- and 48-hr drug-exposure MTT assay, respectively.	Topotecan	80-83	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
16454695-7	2006	The study demonstrated that MRP4 conferred a 12.03- and 6.86-fold resistance to TPT in the 4- and 48-hr drug-exposure MTT assay, respectively.	monooxyethylene trimethylolpropane tristearate	118-121	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	verlukast	5-11	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	verlukast	5-11	ATP binding cassette subfamily C member 4	Homo sapiens	109-113
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	Celecoxib	13-22	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	Celecoxib	13-22	ATP binding cassette subfamily C member 4	Homo sapiens	109-113
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	Diclofenac	27-37	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	Diclofenac	27-37	ATP binding cassette subfamily C member 4	Homo sapiens	109-113
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	Topotecan	69-72	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
16280858-6	2005	Prostanoid transport was measured into inside-out membrane vesicles from cells expressing recombinant human MRP4.	Prostaglandins	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	108-112
16280858-0	2005	Prostanoid transport by multidrug resistance protein 4 (MRP4/ABCC4) localized in tissues of the human urogenital tract.	Prostaglandins	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	56-60
16280858-0	2005	Prostanoid transport by multidrug resistance protein 4 (MRP4/ABCC4) localized in tissues of the human urogenital tract.	Prostaglandins	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	61-66
16280858-9	2005	Transport studies established MRP4 as an efflux pump for prostaglandin E2 (Michaelis constant [Km] 3.5 muM), thromboxane B2 (Km 9.9 muM) and prostaglandin F2alpha (Km 12.6 muM).	Dinoprostone	57-73	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
16280858-3	2005	MRP4/ABCC4 (multidrug resistance protein 4 adenosine triphosphate-binding cassette, subfamily C, member 4) is an adenosine triphosphate dependent export pump for organic anions that may mediate prostanoid transport across the plasma membranes.	Adenosine Triphosphate	43-65	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
16280858-3	2005	MRP4/ABCC4 (multidrug resistance protein 4 adenosine triphosphate-binding cassette, subfamily C, member 4) is an adenosine triphosphate dependent export pump for organic anions that may mediate prostanoid transport across the plasma membranes.	Adenosine Triphosphate	43-65	ATP binding cassette subfamily C member 4	Homo sapiens	5-10
16280858-9	2005	Transport studies established MRP4 as an efflux pump for prostaglandin E2 (Michaelis constant [Km] 3.5 muM), thromboxane B2 (Km 9.9 muM) and prostaglandin F2alpha (Km 12.6 muM).	Thromboxane B2	109-123	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
16280858-3	2005	MRP4/ABCC4 (multidrug resistance protein 4 adenosine triphosphate-binding cassette, subfamily C, member 4) is an adenosine triphosphate dependent export pump for organic anions that may mediate prostanoid transport across the plasma membranes.	Prostaglandins	194-204	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
16280858-3	2005	MRP4/ABCC4 (multidrug resistance protein 4 adenosine triphosphate-binding cassette, subfamily C, member 4) is an adenosine triphosphate dependent export pump for organic anions that may mediate prostanoid transport across the plasma membranes.	Prostaglandins	194-204	ATP binding cassette subfamily C member 4	Homo sapiens	5-10
16280858-9	2005	Transport studies established MRP4 as an efflux pump for prostaglandin E2 (Michaelis constant [Km] 3.5 muM), thromboxane B2 (Km 9.9 muM) and prostaglandin F2alpha (Km 12.6 muM).	Dinoprost	141-162	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
16280858-10	2005	CONCLUSIONS: The co-expression of prostanoid synthesizing enzymes and MRP4 in epithelial cells of the human seminal vesicles and the function of MRP4 as a prostanoid efflux pump indicate that MRP4 mediates prostanoid transport from these cells, which are the main prostanoid synthesizing cells in the male urogenital tract.	Prostaglandins	34-44	ATP binding cassette subfamily C member 4	Homo sapiens	145-149
16280858-10	2005	CONCLUSIONS: The co-expression of prostanoid synthesizing enzymes and MRP4 in epithelial cells of the human seminal vesicles and the function of MRP4 as a prostanoid efflux pump indicate that MRP4 mediates prostanoid transport from these cells, which are the main prostanoid synthesizing cells in the male urogenital tract.	Prostaglandins	34-44	ATP binding cassette subfamily C member 4	Homo sapiens	145-149
16280858-10	2005	CONCLUSIONS: The co-expression of prostanoid synthesizing enzymes and MRP4 in epithelial cells of the human seminal vesicles and the function of MRP4 as a prostanoid efflux pump indicate that MRP4 mediates prostanoid transport from these cells, which are the main prostanoid synthesizing cells in the male urogenital tract.	Prostaglandins	155-165	ATP binding cassette subfamily C member 4	Homo sapiens	70-74
16280858-10	2005	CONCLUSIONS: The co-expression of prostanoid synthesizing enzymes and MRP4 in epithelial cells of the human seminal vesicles and the function of MRP4 as a prostanoid efflux pump indicate that MRP4 mediates prostanoid transport from these cells, which are the main prostanoid synthesizing cells in the male urogenital tract.	Prostaglandins	155-165	ATP binding cassette subfamily C member 4	Homo sapiens	145-149
16280858-10	2005	CONCLUSIONS: The co-expression of prostanoid synthesizing enzymes and MRP4 in epithelial cells of the human seminal vesicles and the function of MRP4 as a prostanoid efflux pump indicate that MRP4 mediates prostanoid transport from these cells, which are the main prostanoid synthesizing cells in the male urogenital tract.	Prostaglandins	155-165	ATP binding cassette subfamily C member 4	Homo sapiens	145-149
16280858-10	2005	CONCLUSIONS: The co-expression of prostanoid synthesizing enzymes and MRP4 in epithelial cells of the human seminal vesicles and the function of MRP4 as a prostanoid efflux pump indicate that MRP4 mediates prostanoid transport from these cells, which are the main prostanoid synthesizing cells in the male urogenital tract.	Prostaglandins	155-165	ATP binding cassette subfamily C member 4	Homo sapiens	70-74
16280858-10	2005	CONCLUSIONS: The co-expression of prostanoid synthesizing enzymes and MRP4 in epithelial cells of the human seminal vesicles and the function of MRP4 as a prostanoid efflux pump indicate that MRP4 mediates prostanoid transport from these cells, which are the main prostanoid synthesizing cells in the male urogenital tract.	Prostaglandins	155-165	ATP binding cassette subfamily C member 4	Homo sapiens	145-149
16280858-10	2005	CONCLUSIONS: The co-expression of prostanoid synthesizing enzymes and MRP4 in epithelial cells of the human seminal vesicles and the function of MRP4 as a prostanoid efflux pump indicate that MRP4 mediates prostanoid transport from these cells, which are the main prostanoid synthesizing cells in the male urogenital tract.	Prostaglandins	155-165	ATP binding cassette subfamily C member 4	Homo sapiens	145-149
16280858-10	2005	CONCLUSIONS: The co-expression of prostanoid synthesizing enzymes and MRP4 in epithelial cells of the human seminal vesicles and the function of MRP4 as a prostanoid efflux pump indicate that MRP4 mediates prostanoid transport from these cells, which are the main prostanoid synthesizing cells in the male urogenital tract.	Prostaglandins	155-165	ATP binding cassette subfamily C member 4	Homo sapiens	70-74
16280858-10	2005	CONCLUSIONS: The co-expression of prostanoid synthesizing enzymes and MRP4 in epithelial cells of the human seminal vesicles and the function of MRP4 as a prostanoid efflux pump indicate that MRP4 mediates prostanoid transport from these cells, which are the main prostanoid synthesizing cells in the male urogenital tract.	Prostaglandins	155-165	ATP binding cassette subfamily C member 4	Homo sapiens	145-149
16280858-10	2005	CONCLUSIONS: The co-expression of prostanoid synthesizing enzymes and MRP4 in epithelial cells of the human seminal vesicles and the function of MRP4 as a prostanoid efflux pump indicate that MRP4 mediates prostanoid transport from these cells, which are the main prostanoid synthesizing cells in the male urogenital tract.	Prostaglandins	155-165	ATP binding cassette subfamily C member 4	Homo sapiens	145-149
16132345-10	2005	Overall, overexpression of MRP4 increased the IC50 values 1.78- to 14.21-fold for various CPTs in lactone or carboxylate form.	Lactones	98-105	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
16132345-0	2005	Human multidrug resistance associated protein 4 confers resistance to camptothecins.	Camptothecin	70-83	ATP binding cassette subfamily C member 4	Homo sapiens	6-47
16132345-10	2005	Overall, overexpression of MRP4 increased the IC50 values 1.78- to 14.21-fold for various CPTs in lactone or carboxylate form.	carboxylate	109-120	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
16132345-1	2005	PURPOSE: The multidrug resistance associated protein (MRP) 4 is a member of the adenosine triphosphate (ATP)-binding cassette transporter family.	Adenosine Triphosphate	80-102	ATP binding cassette subfamily C member 4	Homo sapiens	13-60
16132345-1	2005	PURPOSE: The multidrug resistance associated protein (MRP) 4 is a member of the adenosine triphosphate (ATP)-binding cassette transporter family.	Adenosine Triphosphate	104-107	ATP binding cassette subfamily C member 4	Homo sapiens	13-60
16132345-17	2005	CPT-11 and SN-38 are substrates for MRP4.	Irinotecan	0-6	ATP binding cassette subfamily C member 4	Homo sapiens	36-40
16132345-17	2005	CPT-11 and SN-38 are substrates for MRP4.	Irinotecan	11-16	ATP binding cassette subfamily C member 4	Homo sapiens	36-40
16132345-18	2005	Further studies are needed to explore the role of MRP4 in resistance, toxicity, and pharmacokinetics of CPTs and cyclophosphamide.	Camptothecin	104-108	ATP binding cassette subfamily C member 4	Homo sapiens	50-54
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Camptothecin	34-38	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
16132345-18	2005	Further studies are needed to explore the role of MRP4 in resistance, toxicity, and pharmacokinetics of CPTs and cyclophosphamide.	Cyclophosphamide	113-129	ATP binding cassette subfamily C member 4	Homo sapiens	50-54
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Camptothecin	34-38	ATP binding cassette subfamily C member 4	Homo sapiens	215-219
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Buthionine Sulfoximine	92-123	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Buthionine Sulfoximine	92-123	ATP binding cassette subfamily C member 4	Homo sapiens	215-219
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Buthionine Sulfoximine	125-128	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Buthionine Sulfoximine	125-128	ATP binding cassette subfamily C member 4	Homo sapiens	215-219
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	verlukast	178-183	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Celecoxib	185-194	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Diclofenac	199-209	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
16132345-12	2005	In addition, the accumulation of CPT-11 and SN-38 over 120 min in MRP4/HepG2 cells was significantly reduced compared to V/HepG2 cells, whereas the addition of celecoxib, MK571, or BSO significantly increased their accumulation in MRP4/HepG2 cells.	Irinotecan	33-39	ATP binding cassette subfamily C member 4	Homo sapiens	66-70
16132345-12	2005	In addition, the accumulation of CPT-11 and SN-38 over 120 min in MRP4/HepG2 cells was significantly reduced compared to V/HepG2 cells, whereas the addition of celecoxib, MK571, or BSO significantly increased their accumulation in MRP4/HepG2 cells.	Irinotecan	33-39	ATP binding cassette subfamily C member 4	Homo sapiens	231-235
16132345-12	2005	In addition, the accumulation of CPT-11 and SN-38 over 120 min in MRP4/HepG2 cells was significantly reduced compared to V/HepG2 cells, whereas the addition of celecoxib, MK571, or BSO significantly increased their accumulation in MRP4/HepG2 cells.	Irinotecan	44-49	ATP binding cassette subfamily C member 4	Homo sapiens	66-70
16132345-12	2005	In addition, the accumulation of CPT-11 and SN-38 over 120 min in MRP4/HepG2 cells was significantly reduced compared to V/HepG2 cells, whereas the addition of celecoxib, MK571, or BSO significantly increased their accumulation in MRP4/HepG2 cells.	Irinotecan	44-49	ATP binding cassette subfamily C member 4	Homo sapiens	231-235
16132345-12	2005	In addition, the accumulation of CPT-11 and SN-38 over 120 min in MRP4/HepG2 cells was significantly reduced compared to V/HepG2 cells, whereas the addition of celecoxib, MK571, or BSO significantly increased their accumulation in MRP4/HepG2 cells.	Celecoxib	160-169	ATP binding cassette subfamily C member 4	Homo sapiens	231-235
16132345-14	2005	MRP4 also conferred resistance to cyclophosphamide and this was partially reversed by BSO.	Cyclophosphamide	34-50	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
16132345-16	2005	CONCLUSIONS: Human MRP4 rendered significant resistance to cyclophosphamide, CPT, CPT-11, SN-38, rubitecan, and 10-OH-CPT.	Cyclophosphamide	59-75	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
16132345-16	2005	CONCLUSIONS: Human MRP4 rendered significant resistance to cyclophosphamide, CPT, CPT-11, SN-38, rubitecan, and 10-OH-CPT.	Irinotecan	82-88	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
16132345-16	2005	CONCLUSIONS: Human MRP4 rendered significant resistance to cyclophosphamide, CPT, CPT-11, SN-38, rubitecan, and 10-OH-CPT.	Irinotecan	90-95	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
16132345-16	2005	CONCLUSIONS: Human MRP4 rendered significant resistance to cyclophosphamide, CPT, CPT-11, SN-38, rubitecan, and 10-OH-CPT.	rubitecan	97-106	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
16132345-16	2005	CONCLUSIONS: Human MRP4 rendered significant resistance to cyclophosphamide, CPT, CPT-11, SN-38, rubitecan, and 10-OH-CPT.	9-Hydroxycamptothecin	112-121	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
16156793-3	2005	This study investigates the interactions of six common polyphenols; quercetin, silymarin, resveratrol, naringenin, daidzein and hesperetin with the multidrug-resistance-associated proteins, MRP1, MRP4 and MRP5.	Polyphenols	55-66	ATP binding cassette subfamily C member 4	Homo sapiens	196-200
16156793-6	2005	Furthermore, most of the polyphenols showed direct inhibition of MRP1-mediated [3H]dinitrophenyl S-glutathione and MRP4-mediated [3H]cGMP transport in inside-out vesicles prepared from human erythrocytes.	Polyphenols	25-36	ATP binding cassette subfamily C member 4	Homo sapiens	115-119
16156793-6	2005	Furthermore, most of the polyphenols showed direct inhibition of MRP1-mediated [3H]dinitrophenyl S-glutathione and MRP4-mediated [3H]cGMP transport in inside-out vesicles prepared from human erythrocytes.	Cyclic GMP	133-137	ATP binding cassette subfamily C member 4	Homo sapiens	115-119
16156793-3	2005	This study investigates the interactions of six common polyphenols; quercetin, silymarin, resveratrol, naringenin, daidzein and hesperetin with the multidrug-resistance-associated proteins, MRP1, MRP4 and MRP5.	Quercetin	68-77	ATP binding cassette subfamily C member 4	Homo sapiens	196-200
16156793-7	2005	Also, both quercetin and silymarin were found to inhibit MRP1-, MRP4- and MRP5-mediated transport from intact cells with high affinity.	Quercetin	11-20	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
16156793-3	2005	This study investigates the interactions of six common polyphenols; quercetin, silymarin, resveratrol, naringenin, daidzein and hesperetin with the multidrug-resistance-associated proteins, MRP1, MRP4 and MRP5.	naringenin	103-113	ATP binding cassette subfamily C member 4	Homo sapiens	196-200
16156793-7	2005	Also, both quercetin and silymarin were found to inhibit MRP1-, MRP4- and MRP5-mediated transport from intact cells with high affinity.	Silymarin	25-34	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
16156793-3	2005	This study investigates the interactions of six common polyphenols; quercetin, silymarin, resveratrol, naringenin, daidzein and hesperetin with the multidrug-resistance-associated proteins, MRP1, MRP4 and MRP5.	hesperetin	128-138	ATP binding cassette subfamily C member 4	Homo sapiens	196-200
16156793-4	2005	At nontoxic concentrations, several of the polyphenols were able to modulate MRP1-, MRP4- and MRP5-mediated drug resistance, though to varying extents.	Polyphenols	43-54	ATP binding cassette subfamily C member 4	Homo sapiens	84-88
16156793-5	2005	The polyphenols also reversed resistance to NSC251820, a compound that appears to be a good substrate for MRP4, as predicted by data-mining studies.	Polyphenols	4-15	ATP binding cassette subfamily C member 4	Homo sapiens	106-110
15794947-6	2005	Furthermore it was apparent that different blood donors expressed on their erythrocytes different amounts of both MRP4 and MRP5, transporters that have been putatively linked to cGMP efflux across erythrocyte membranes.	Cyclic GMP	178-182	ATP binding cassette subfamily C member 4	Homo sapiens	114-118
15841457-11	2005	Several mechanisms may contribute to elevated plasma bile salts in PFIC: reduced bile salt uptake via NTCP, OATP1B1, and OATP1B3, decreased BSEP-dependent secretion into bile, and increased transport back into plasma by MRP4.	Bile Acids and Salts	53-63	ATP binding cassette subfamily C member 4	Homo sapiens	220-224
15841457-11	2005	Several mechanisms may contribute to elevated plasma bile salts in PFIC: reduced bile salt uptake via NTCP, OATP1B1, and OATP1B3, decreased BSEP-dependent secretion into bile, and increased transport back into plasma by MRP4.	Bile Acids and Salts	53-62	ATP binding cassette subfamily C member 4	Homo sapiens	220-224
15841457-12	2005	Upregulation of MRP4, but not of MRP3, might represent an important escape mechanism for bile salt extrusion in PFIC.	Bile Acids and Salts	89-98	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
15845416-4	2005	In particular, five of the 12 members of the MRP/CFTR family appear to mediate GSH export from cells namely, MRP1, MRP2, MRP4, MRP5, and CFTR.	Glutathione	79-82	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
16004972-0	2005	Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes.	Mefloquine	16-26	ATP binding cassette subfamily C member 4	Homo sapiens	63-67
16004972-0	2005	Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes.	Mefloquine	16-26	ATP binding cassette subfamily C member 4	Homo sapiens	69-74
16004972-1	2005	Human erythrocyte membranes express the multidrug resistance-associated proteins, MRP1, MRP4 and 5, that collectively can efflux oxidised glutathione, glutathione conjugates and cyclic nucleotides.	Glutathione	138-149	ATP binding cassette subfamily C member 4	Homo sapiens	88-98
16004972-1	2005	Human erythrocyte membranes express the multidrug resistance-associated proteins, MRP1, MRP4 and 5, that collectively can efflux oxidised glutathione, glutathione conjugates and cyclic nucleotides.	Glutathione	151-162	ATP binding cassette subfamily C member 4	Homo sapiens	88-98
16004972-1	2005	Human erythrocyte membranes express the multidrug resistance-associated proteins, MRP1, MRP4 and 5, that collectively can efflux oxidised glutathione, glutathione conjugates and cyclic nucleotides.	Nucleotides, Cyclic	178-196	ATP binding cassette subfamily C member 4	Homo sapiens	88-98
16004972-4	2005	Using inside-out vesicles prepared from human erythrocytes we have shown that mefloquine and MK-571 inhibit transport of 3 microM [(3)H]DNP-SG known to be mediated by MRP1 (IC(50) 127 and 1.1 microM, respectively) and of 3.3 microM [(3)H]cGMP thought but not proven to be mediated primarily by MRP4 (IC(50) 21 and 0.41 microM).	Mefloquine	78-88	ATP binding cassette subfamily C member 4	Homo sapiens	294-298
16004972-4	2005	Using inside-out vesicles prepared from human erythrocytes we have shown that mefloquine and MK-571 inhibit transport of 3 microM [(3)H]DNP-SG known to be mediated by MRP1 (IC(50) 127 and 1.1 microM, respectively) and of 3.3 microM [(3)H]cGMP thought but not proven to be mediated primarily by MRP4 (IC(50) 21 and 0.41 microM).	verlukast	93-99	ATP binding cassette subfamily C member 4	Homo sapiens	294-298
16004972-4	2005	Using inside-out vesicles prepared from human erythrocytes we have shown that mefloquine and MK-571 inhibit transport of 3 microM [(3)H]DNP-SG known to be mediated by MRP1 (IC(50) 127 and 1.1 microM, respectively) and of 3.3 microM [(3)H]cGMP thought but not proven to be mediated primarily by MRP4 (IC(50) 21 and 0.41 microM).	2,4-Dinitrophenol	136-139	ATP binding cassette subfamily C member 4	Homo sapiens	294-298
16004972-5	2005	They also inhibited transport in membrane vesicles prepared from tumour cells expressing MRP1 or MRP4 and blocked calcein efflux from MRP1-overexpressing cells and BCECF efflux from MRP4-overexpressing cells.	fluorexon	114-121	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
16004972-6	2005	Both stimulated ATPase activity in membranes prepared from MRP1 and MRP4-overexpressing cells and inhibited activity stimulated by quercetin or PGE(1), respectively.	Prostaglandins E	144-147	ATP binding cassette subfamily C member 4	Homo sapiens	68-72
15818146-2	2005	RECENT FINDINGS: Highlights include new understanding of the role of Mrp4 in bile acid homeostasis in cholestasis, new insights into the pathogenesis of specific cholestatic syndromes including primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia, and progressive familial intrahepatic cholestasis, and clinical trials of therapies for primary biliary cirrhosis, primary sclerosing cholangitis and intrahepatic cholestasis.	Bile Acids and Salts	77-86	ATP binding cassette subfamily C member 4	Homo sapiens	69-73
15827327-0	2005	Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.	Irinotecan	120-130	ATP binding cassette subfamily C member 4	Homo sapiens	36-40
15827327-0	2005	Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.	Irinotecan	120-130	ATP binding cassette subfamily C member 4	Homo sapiens	41-46
15827327-4	2005	Although MRP4 is known to transport some nucleoside analogues, it has not previously been associated with resistance to drugs used to treat solid tumors.	Nucleosides	41-51	ATP binding cassette subfamily C member 4	Homo sapiens	9-13
15454390-9	2005	We propose MRP4 as a candidate transporter for urinary urate excretion and suggest that MRP4 may also mediate hepatic export of urate into the circulation, because of its basolateral expression in the liver.	Uric Acid	128-133	ATP binding cassette subfamily C member 4	Homo sapiens	11-15
15454390-5	2005	Urate inhibited methotrexate transport (IC50 of 235 +/- 8 microM) by MRP4, did not affect cAMP transport, whereas cGMP transport was stimulated.	Methotrexate	16-28	ATP binding cassette subfamily C member 4	Homo sapiens	69-73
15454390-0	2005	Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.	purine	71-77	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
15454390-9	2005	We propose MRP4 as a candidate transporter for urinary urate excretion and suggest that MRP4 may also mediate hepatic export of urate into the circulation, because of its basolateral expression in the liver.	Uric Acid	128-133	ATP binding cassette subfamily C member 4	Homo sapiens	88-92
15454390-0	2005	Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.	purine	71-77	ATP binding cassette subfamily C member 4	Homo sapiens	38-43
15454390-0	2005	Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.	Uric Acid	93-98	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
15747503-6	2005	MRP4 also seems to be able to mediate the transport of conjugated steroids, prostaglandins, and glutathione.	Steroids	66-74	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
15454390-0	2005	Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.	Uric Acid	93-98	ATP binding cassette subfamily C member 4	Homo sapiens	38-43
15454390-3	2005	Here, we show that the renal apical organic anion efflux transporter human multidrug resistance protein 4 (MRP4), but not apical MRP2, mediates ATP-dependent urate transport via a positive cooperative mechanism (K(m) of 1.5 +/- 0.3 mM, V(max) of 47 +/- 7 pmol x mg(-1) x min(-1), and Hill coefficient of 1.7 +/- 0.2).	Adenosine Triphosphate	144-147	ATP binding cassette subfamily C member 4	Homo sapiens	75-105
15454390-3	2005	Here, we show that the renal apical organic anion efflux transporter human multidrug resistance protein 4 (MRP4), but not apical MRP2, mediates ATP-dependent urate transport via a positive cooperative mechanism (K(m) of 1.5 +/- 0.3 mM, V(max) of 47 +/- 7 pmol x mg(-1) x min(-1), and Hill coefficient of 1.7 +/- 0.2).	Adenosine Triphosphate	144-147	ATP binding cassette subfamily C member 4	Homo sapiens	107-111
15454390-3	2005	Here, we show that the renal apical organic anion efflux transporter human multidrug resistance protein 4 (MRP4), but not apical MRP2, mediates ATP-dependent urate transport via a positive cooperative mechanism (K(m) of 1.5 +/- 0.3 mM, V(max) of 47 +/- 7 pmol x mg(-1) x min(-1), and Hill coefficient of 1.7 +/- 0.2).	Uric Acid	158-163	ATP binding cassette subfamily C member 4	Homo sapiens	75-105
15454390-3	2005	Here, we show that the renal apical organic anion efflux transporter human multidrug resistance protein 4 (MRP4), but not apical MRP2, mediates ATP-dependent urate transport via a positive cooperative mechanism (K(m) of 1.5 +/- 0.3 mM, V(max) of 47 +/- 7 pmol x mg(-1) x min(-1), and Hill coefficient of 1.7 +/- 0.2).	Uric Acid	158-163	ATP binding cassette subfamily C member 4	Homo sapiens	107-111
15454390-4	2005	In HEK293 cells overexpressing MRP4, intracellular urate levels were lower than in control cells.	Uric Acid	51-56	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
15454390-5	2005	Urate inhibited methotrexate transport (IC50 of 235 +/- 8 microM) by MRP4, did not affect cAMP transport, whereas cGMP transport was stimulated.	Uric Acid	0-5	ATP binding cassette subfamily C member 4	Homo sapiens	69-73
15454390-6	2005	Urate shifted cGMP transport by MRP4 from positive cooperativity (K(m) and V(max) value of 180 +/- 20 microM and 58 +/- 4 pmol x mg(-1) x min(-1), respectively, Hill coefficient of 1.4 +/- 0.1) to single binding site kinetics (K(m) and V(max) value of 2.2 +/- 0.9 mM and 280 +/- 50 pmol x mg(-1) x min(-1), respectively).	Uric Acid	0-5	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
15454390-6	2005	Urate shifted cGMP transport by MRP4 from positive cooperativity (K(m) and V(max) value of 180 +/- 20 microM and 58 +/- 4 pmol x mg(-1) x min(-1), respectively, Hill coefficient of 1.4 +/- 0.1) to single binding site kinetics (K(m) and V(max) value of 2.2 +/- 0.9 mM and 280 +/- 50 pmol x mg(-1) x min(-1), respectively).	Cyclic GMP	14-18	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
15454390-7	2005	Finally, MRP4 could transport urate simultaneously with cAMP or cGMP.	Uric Acid	30-35	ATP binding cassette subfamily C member 4	Homo sapiens	9-13
15454390-7	2005	Finally, MRP4 could transport urate simultaneously with cAMP or cGMP.	Cyclic AMP	56-60	ATP binding cassette subfamily C member 4	Homo sapiens	9-13
15454390-7	2005	Finally, MRP4 could transport urate simultaneously with cAMP or cGMP.	Cyclic GMP	64-68	ATP binding cassette subfamily C member 4	Homo sapiens	9-13
15454390-8	2005	We conclude that human MRP4 is a unidirectional efflux pump for urate with multiple allosteric substrate binding sites.	Uric Acid	64-69	ATP binding cassette subfamily C member 4	Homo sapiens	23-27
15454390-9	2005	We propose MRP4 as a candidate transporter for urinary urate excretion and suggest that MRP4 may also mediate hepatic export of urate into the circulation, because of its basolateral expression in the liver.	Uric Acid	55-60	ATP binding cassette subfamily C member 4	Homo sapiens	11-15
16393888-15	2005	Several drug transporters, such as breast cancer resistance protein (BCRP), multidrug resistance associated proteins (MRP1, MRP2, and MRP4) are involved in the active uptake and efflux of parental oxazaphosphorines, their cytotoxic mustards and conjugates in hepatocytes and tumor cells.	oxazaphosphorines	197-214	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
15747503-6	2005	MRP4 also seems to be able to mediate the transport of conjugated steroids, prostaglandins, and glutathione.	Prostaglandins	76-90	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
15747503-6	2005	MRP4 also seems to be able to mediate the transport of conjugated steroids, prostaglandins, and glutathione.	Glutathione	96-107	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
15747503-7	2005	Furthermore, cyclic nucleotides (cyclic adenosine monophosphate and cyclic guanine monophosphate) are exported from cells by MRP4 and MRP5.	Nucleotides, Cyclic	13-31	ATP binding cassette subfamily C member 4	Homo sapiens	125-129
15747503-7	2005	Furthermore, cyclic nucleotides (cyclic adenosine monophosphate and cyclic guanine monophosphate) are exported from cells by MRP4 and MRP5.	Cyclic AMP	33-63	ATP binding cassette subfamily C member 4	Homo sapiens	125-129
15747503-7	2005	Furthermore, cyclic nucleotides (cyclic adenosine monophosphate and cyclic guanine monophosphate) are exported from cells by MRP4 and MRP5.	cyclic guanine monophosphate	68-96	ATP binding cassette subfamily C member 4	Homo sapiens	125-129
15364914-0	2004	Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state.	Adenosine Triphosphate	48-51	ATP binding cassette subfamily C member 4	Homo sapiens	32-37
16399368-3	2005	Localization of the efflux pumps ABCC3 and ABCC4 to the basolateral membrane of human hepatocytes has provided insight into the molecular mechanisms of conjugate efflux from hepatocytes into blood, as exemplified by the efflux of bilirubin glucuronosides mediated by ABCC3.	Bilirubin	230-239	ATP binding cassette subfamily C member 4	Homo sapiens	43-48
16399368-3	2005	Localization of the efflux pumps ABCC3 and ABCC4 to the basolateral membrane of human hepatocytes has provided insight into the molecular mechanisms of conjugate efflux from hepatocytes into blood, as exemplified by the efflux of bilirubin glucuronosides mediated by ABCC3.	glucuronosides	240-254	ATP binding cassette subfamily C member 4	Homo sapiens	43-48
15297306-2	2004	Possible candidates for transport proteins mediating accumulation of these mediators in granules include multidrug resistance protein 4 (MRP4, ABCC4), a transport pump for cyclic nucleotides and nucleotide analogs.	Nucleotides, Cyclic	172-190	ATP binding cassette subfamily C member 4	Homo sapiens	105-135
15297306-2	2004	Possible candidates for transport proteins mediating accumulation of these mediators in granules include multidrug resistance protein 4 (MRP4, ABCC4), a transport pump for cyclic nucleotides and nucleotide analogs.	Nucleotides, Cyclic	172-190	ATP binding cassette subfamily C member 4	Homo sapiens	137-141
15297306-2	2004	Possible candidates for transport proteins mediating accumulation of these mediators in granules include multidrug resistance protein 4 (MRP4, ABCC4), a transport pump for cyclic nucleotides and nucleotide analogs.	Nucleotides, Cyclic	172-190	ATP binding cassette subfamily C member 4	Homo sapiens	143-148
15297306-4	2004	Immunofluorescence microscopy using 2 MRP4-specific antibodies revealed staining mainly in intracellular structures, which largely colocalized with the accumulation of mepacrine as marker for delta-granules and to a lower extent at the plasma membrane.	Quinacrine	168-177	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
15297306-6	2004	Adenosine triphosphate (ATP)-dependent cyclic guanosine monophosphate (cGMP) transport codistributed with MRP4 detection in subcellular fractions, with highest activities in the dense granule and plasma membrane fractions.	Adenosine Triphosphate	0-22	ATP binding cassette subfamily C member 4	Homo sapiens	106-110
15297306-6	2004	Adenosine triphosphate (ATP)-dependent cyclic guanosine monophosphate (cGMP) transport codistributed with MRP4 detection in subcellular fractions, with highest activities in the dense granule and plasma membrane fractions.	Adenosine Triphosphate	24-27	ATP binding cassette subfamily C member 4	Homo sapiens	106-110
15297306-6	2004	Adenosine triphosphate (ATP)-dependent cyclic guanosine monophosphate (cGMP) transport codistributed with MRP4 detection in subcellular fractions, with highest activities in the dense granule and plasma membrane fractions.	Cyclic GMP	39-69	ATP binding cassette subfamily C member 4	Homo sapiens	106-110
15297306-6	2004	Adenosine triphosphate (ATP)-dependent cyclic guanosine monophosphate (cGMP) transport codistributed with MRP4 detection in subcellular fractions, with highest activities in the dense granule and plasma membrane fractions.	Cyclic GMP	71-75	ATP binding cassette subfamily C member 4	Homo sapiens	106-110
15364914-2	2004	In this study we characterize ATP hydrolysis by human MRP4 expressed in insect cells.	Adenosine Triphosphate	30-33	ATP binding cassette subfamily C member 4	Homo sapiens	54-58
15364914-3	2004	MRP4 hydrolyzes ATP (Km, 0.62 mm), which is inhibited by orthovanadate and beryllium fluoride.	Adenosine Triphosphate	16-19	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
15364914-3	2004	MRP4 hydrolyzes ATP (Km, 0.62 mm), which is inhibited by orthovanadate and beryllium fluoride.	Vanadates	57-70	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
15364914-3	2004	MRP4 hydrolyzes ATP (Km, 0.62 mm), which is inhibited by orthovanadate and beryllium fluoride.	beryllium fluoride	75-93	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
15364914-4	2004	However, unlike ATPase activity of P-glycoprotein, which is equally sensitive to both inhibitors, MRP4-ATPase is more sensitive to beryllium fluoride than to orthovanadate.	beryllium fluoride	131-149	ATP binding cassette subfamily C member 4	Homo sapiens	98-109
15364914-4	2004	However, unlike ATPase activity of P-glycoprotein, which is equally sensitive to both inhibitors, MRP4-ATPase is more sensitive to beryllium fluoride than to orthovanadate.	Vanadates	158-171	ATP binding cassette subfamily C member 4	Homo sapiens	98-109
15364914-1	2004	Multidrug resistance protein 4 (MRP4/ABCC4), transports cyclic nucleoside monophosphates, nucleoside analog drugs, chemotherapeutic agents, and prostaglandins.	Nucleosides	63-73	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
15364914-5	2004	8-Azido[alpha-32P]ATP binds to MRP4 (concentration for half-maximal binding approximately 3 microm) and is displaced by ATP or by its non-hydrolyzable analog AMPPNP (concentrations for half-maximal inhibition of 13.3 and 308 microm).	8-azido[alpha-32p]atp	0-21	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
15364914-1	2004	Multidrug resistance protein 4 (MRP4/ABCC4), transports cyclic nucleoside monophosphates, nucleoside analog drugs, chemotherapeutic agents, and prostaglandins.	Nucleosides	63-73	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
15364914-5	2004	8-Azido[alpha-32P]ATP binds to MRP4 (concentration for half-maximal binding approximately 3 microm) and is displaced by ATP or by its non-hydrolyzable analog AMPPNP (concentrations for half-maximal inhibition of 13.3 and 308 microm).	Adenosine Triphosphate	18-21	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
15364914-1	2004	Multidrug resistance protein 4 (MRP4/ABCC4), transports cyclic nucleoside monophosphates, nucleoside analog drugs, chemotherapeutic agents, and prostaglandins.	Prostaglandins	144-158	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
15364914-5	2004	8-Azido[alpha-32P]ATP binds to MRP4 (concentration for half-maximal binding approximately 3 microm) and is displaced by ATP or by its non-hydrolyzable analog AMPPNP (concentrations for half-maximal inhibition of 13.3 and 308 microm).	Adenylyl Imidodiphosphate	158-164	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
15364914-1	2004	Multidrug resistance protein 4 (MRP4/ABCC4), transports cyclic nucleoside monophosphates, nucleoside analog drugs, chemotherapeutic agents, and prostaglandins.	Prostaglandins	144-158	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
15364914-6	2004	MRP4 substrates, the prostaglandins E1 and E2, stimulate ATP hydrolysis 2- to 3-fold but do not affect the Km for ATP.	Adenosine Triphosphate	57-60	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
15312981-6	2004	Recent transfection studies suggest that members of the MRP (multidrug resistance protein) family; MRP4, MRP5 and MRP8 translocate cGMP across the cell membrane.	Cyclic GMP	131-135	ATP binding cassette subfamily C member 4	Homo sapiens	99-103
15364914-8	2004	Although both post-hydrolysis transition states MRP4.8-azido[alpha-32P]ADP.Vi and MRP4.8-azido[alpha-32P]ADP.beryllium fluoride can be generated, nucleotide trapping is approximately 4-fold higher with beryllium fluoride.	8-azido[alpha-32p]adp	53-74	ATP binding cassette subfamily C member 4	Homo sapiens	48-52
15364914-8	2004	Although both post-hydrolysis transition states MRP4.8-azido[alpha-32P]ADP.Vi and MRP4.8-azido[alpha-32P]ADP.beryllium fluoride can be generated, nucleotide trapping is approximately 4-fold higher with beryllium fluoride.	8-azido[alpha-32p]adp	87-108	ATP binding cassette subfamily C member 4	Homo sapiens	48-52
15364914-8	2004	Although both post-hydrolysis transition states MRP4.8-azido[alpha-32P]ADP.Vi and MRP4.8-azido[alpha-32P]ADP.beryllium fluoride can be generated, nucleotide trapping is approximately 4-fold higher with beryllium fluoride.	8-azido[alpha-32p]adp	87-108	ATP binding cassette subfamily C member 4	Homo sapiens	82-86
15364914-8	2004	Although both post-hydrolysis transition states MRP4.8-azido[alpha-32P]ADP.Vi and MRP4.8-azido[alpha-32P]ADP.beryllium fluoride can be generated, nucleotide trapping is approximately 4-fold higher with beryllium fluoride.	beryllium fluoride	109-127	ATP binding cassette subfamily C member 4	Homo sapiens	48-52
15364914-8	2004	Although both post-hydrolysis transition states MRP4.8-azido[alpha-32P]ADP.Vi and MRP4.8-azido[alpha-32P]ADP.beryllium fluoride can be generated, nucleotide trapping is approximately 4-fold higher with beryllium fluoride.	beryllium fluoride	109-127	ATP binding cassette subfamily C member 4	Homo sapiens	82-86
15364914-8	2004	Although both post-hydrolysis transition states MRP4.8-azido[alpha-32P]ADP.Vi and MRP4.8-azido[alpha-32P]ADP.beryllium fluoride can be generated, nucleotide trapping is approximately 4-fold higher with beryllium fluoride.	beryllium fluoride	202-220	ATP binding cassette subfamily C member 4	Homo sapiens	48-52
15364914-8	2004	Although both post-hydrolysis transition states MRP4.8-azido[alpha-32P]ADP.Vi and MRP4.8-azido[alpha-32P]ADP.beryllium fluoride can be generated, nucleotide trapping is approximately 4-fold higher with beryllium fluoride.	beryllium fluoride	202-220	ATP binding cassette subfamily C member 4	Homo sapiens	82-86
15364914-12	2004	In aggregate, our results demonstrate that MRP4 exhibits substrate-stimulated ATP hydrolysis, and we propose a kinetic scheme suggesting that ADP release from the post-hydrolysis transition state may be the rate-limiting step during the catalytic cycle.	Adenosine Triphosphate	78-81	ATP binding cassette subfamily C member 4	Homo sapiens	43-47
15364914-12	2004	In aggregate, our results demonstrate that MRP4 exhibits substrate-stimulated ATP hydrolysis, and we propose a kinetic scheme suggesting that ADP release from the post-hydrolysis transition state may be the rate-limiting step during the catalytic cycle.	Adenosine Diphosphate	142-145	ATP binding cassette subfamily C member 4	Homo sapiens	43-47
15504935-6	2004	Human MRP4 (ABCC4), which has recently been localized to the apical membrane, expressed in Sf9 cells had a much higher affinity for PAH (K(m) = 160 +/- 50 microM).	p-Aminohippuric Acid	132-135	ATP binding cassette subfamily C member 4	Homo sapiens	6-10
15504935-6	2004	Human MRP4 (ABCC4), which has recently been localized to the apical membrane, expressed in Sf9 cells had a much higher affinity for PAH (K(m) = 160 +/- 50 microM).	p-Aminohippuric Acid	132-135	ATP binding cassette subfamily C member 4	Homo sapiens	12-17
15504935-7	2004	Various inhibitors of MRP2-mediated PAH transport also inhibited MRP4.	p-Aminohippuric Acid	36-39	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
15504935-8	2004	Probenecid stimulated MRP2 at low concentrations but had no effect on MRP4; but at high probenecid concentrations, both MRP2 and MRP4 were inhibited.	Probenecid	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	129-133
15504935-9	2004	Sulfinpyrazone only stimulated MRP2, but inhibited MRP4.	Sulfinpyrazone	0-14	ATP binding cassette subfamily C member 4	Homo sapiens	51-55
15504935-11	2004	MRP4 is a novel PAH transporter that has higher affinity for PAH and is expressed more highly in kidney than MRP2, and may therefore be more important in renal PAH excretion.	p-Aminohippuric Acid	16-19	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
15504935-11	2004	MRP4 is a novel PAH transporter that has higher affinity for PAH and is expressed more highly in kidney than MRP2, and may therefore be more important in renal PAH excretion.	p-Aminohippuric Acid	61-64	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
15357833-6	2004	Hypergravity also stimulated cGMP transport in the presence of 1 microM trequinsin, an inhibitor of cGMP-binding PDE (PDE5) and of transport by multidrug resistance proteins MRP4/5, whereas 50 microM trequinsin partially inhibited cGMP transport.	Cyclic GMP	29-33	ATP binding cassette subfamily C member 4	Homo sapiens	174-180
15357833-6	2004	Hypergravity also stimulated cGMP transport in the presence of 1 microM trequinsin, an inhibitor of cGMP-binding PDE (PDE5) and of transport by multidrug resistance proteins MRP4/5, whereas 50 microM trequinsin partially inhibited cGMP transport.	trequinsin	72-82	ATP binding cassette subfamily C member 4	Homo sapiens	174-180
15357833-7	2004	Transport was further inhibited by probenecid, an inhibitor of endogenous non-selective transporters as well as of MRP4/5 and by cycloheximide as an inhibitor of de novo protein synthesis.	Probenecid	35-45	ATP binding cassette subfamily C member 4	Homo sapiens	115-121
15456083-8	2004	RESULTS: Levels of MDR1, mrp4 and mrp5 mRNA were high following AZT treatment.	Zidovudine	64-67	ATP binding cassette subfamily C member 4	Homo sapiens	25-29
15456083-15	2004	The cellular efflux of AZT probably involves MRP4 or MRP5.	Zidovudine	23-26	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
15004017-1	2004	The ABC transporter, Mrp4, transports the sulfated steroid DHEA-s, and sulfated bile acids interact with Mrp4 with high affinity.	Bile Acids and Salts	80-90	ATP binding cassette subfamily C member 4	Homo sapiens	105-109
15004017-3	2004	We therefore inferred that up-regulation of Mrp4 during cholestasis is a compensatory mechanism to protect the liver from accumulation of hydrophobic bile acids.	Bile Acids and Salts	150-160	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
15004017-1	2004	The ABC transporter, Mrp4, transports the sulfated steroid DHEA-s, and sulfated bile acids interact with Mrp4 with high affinity.	Bile Acids and Salts	80-90	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
15004017-1	2004	The ABC transporter, Mrp4, transports the sulfated steroid DHEA-s, and sulfated bile acids interact with Mrp4 with high affinity.	Steroids	51-58	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
15004017-4	2004	We determined that the nuclear receptor CAR is required to coordinately up-regulate hepatic expression of Mrp4 and an enzyme known to sulfate hydroxy-bile acids and steroids, Sult2a1.	sulfate hydroxy-bile acids	134-160	ATP binding cassette subfamily C member 4	Homo sapiens	106-110
15004017-1	2004	The ABC transporter, Mrp4, transports the sulfated steroid DHEA-s, and sulfated bile acids interact with Mrp4 with high affinity.	Steroids	51-58	ATP binding cassette subfamily C member 4	Homo sapiens	105-109
15004017-1	2004	The ABC transporter, Mrp4, transports the sulfated steroid DHEA-s, and sulfated bile acids interact with Mrp4 with high affinity.	Dehydroepiandrosterone	59-65	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
15004017-1	2004	The ABC transporter, Mrp4, transports the sulfated steroid DHEA-s, and sulfated bile acids interact with Mrp4 with high affinity.	Dehydroepiandrosterone	59-65	ATP binding cassette subfamily C member 4	Homo sapiens	105-109
15004017-4	2004	We determined that the nuclear receptor CAR is required to coordinately up-regulate hepatic expression of Mrp4 and an enzyme known to sulfate hydroxy-bile acids and steroids, Sult2a1.	Steroids	165-173	ATP binding cassette subfamily C member 4	Homo sapiens	106-110
15004017-7	2004	Based on the hydrophilic nature of sulfated bile acids and the Mrp4 capability to transport sulfated steroids, our findings suggest that Mrp4 and Sult2a1 participate in an integrated pathway mediating elimination of sulfated steroid and bile acid metabolites from the liver.	Bile Acids and Salts	44-54	ATP binding cassette subfamily C member 4	Homo sapiens	137-141
15004017-7	2004	Based on the hydrophilic nature of sulfated bile acids and the Mrp4 capability to transport sulfated steroids, our findings suggest that Mrp4 and Sult2a1 participate in an integrated pathway mediating elimination of sulfated steroid and bile acid metabolites from the liver.	Steroids	101-109	ATP binding cassette subfamily C member 4	Homo sapiens	63-67
15004017-7	2004	Based on the hydrophilic nature of sulfated bile acids and the Mrp4 capability to transport sulfated steroids, our findings suggest that Mrp4 and Sult2a1 participate in an integrated pathway mediating elimination of sulfated steroid and bile acid metabolites from the liver.	Steroids	101-109	ATP binding cassette subfamily C member 4	Homo sapiens	137-141
15004017-7	2004	Based on the hydrophilic nature of sulfated bile acids and the Mrp4 capability to transport sulfated steroids, our findings suggest that Mrp4 and Sult2a1 participate in an integrated pathway mediating elimination of sulfated steroid and bile acid metabolites from the liver.	Steroids	101-108	ATP binding cassette subfamily C member 4	Homo sapiens	63-67
15004017-7	2004	Based on the hydrophilic nature of sulfated bile acids and the Mrp4 capability to transport sulfated steroids, our findings suggest that Mrp4 and Sult2a1 participate in an integrated pathway mediating elimination of sulfated steroid and bile acid metabolites from the liver.	Steroids	101-108	ATP binding cassette subfamily C member 4	Homo sapiens	137-141
15004017-7	2004	Based on the hydrophilic nature of sulfated bile acids and the Mrp4 capability to transport sulfated steroids, our findings suggest that Mrp4 and Sult2a1 participate in an integrated pathway mediating elimination of sulfated steroid and bile acid metabolites from the liver.	Bile Acids and Salts	44-53	ATP binding cassette subfamily C member 4	Homo sapiens	137-141
15026196-2	2004	Recent work has shown that at least three members of the family of human Multidrug Resistance-associated Proteins (MRPs), MRP4, 5 and 8, are able to transport some nucleoside-monophosphate analogs.	nucleoside-monophosphate	164-188	ATP binding cassette subfamily C member 4	Homo sapiens	122-135
14639605-7	2004	We also found that exposure of HL-60 cells to cantharidin resulted in the decreased expression of multidrug resistance-associated protein genes (e.g., ABCA3, MOAT-B), suggesting that cantharidin may be used as an oncotherapy sensitizer, and the increased expression of genes in modulating cytokine production and inflammatory response (e.g., NFIL-3, N-formylpeptide receptor), which may partly explain the stimulating effects on leukocytosis.	Cantharidin	46-57	ATP binding cassette subfamily C member 4	Homo sapiens	158-164
14978246-10	2004	Finally, we have exploited MRP4 (ABCC4) to demonstrate that disulfiram can inhibit ATP binding by forming disulfide bonds between cysteines located in the vicinity of, although not in, the active site.	Disulfiram	60-70	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
14978246-10	2004	Finally, we have exploited MRP4 (ABCC4) to demonstrate that disulfiram can inhibit ATP binding by forming disulfide bonds between cysteines located in the vicinity of, although not in, the active site.	Disulfiram	60-70	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
14978246-10	2004	Finally, we have exploited MRP4 (ABCC4) to demonstrate that disulfiram can inhibit ATP binding by forming disulfide bonds between cysteines located in the vicinity of, although not in, the active site.	Adenosine Triphosphate	83-86	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
14978246-10	2004	Finally, we have exploited MRP4 (ABCC4) to demonstrate that disulfiram can inhibit ATP binding by forming disulfide bonds between cysteines located in the vicinity of, although not in, the active site.	Adenosine Triphosphate	83-86	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
14978246-10	2004	Finally, we have exploited MRP4 (ABCC4) to demonstrate that disulfiram can inhibit ATP binding by forming disulfide bonds between cysteines located in the vicinity of, although not in, the active site.	Disulfides	106-115	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
14978246-10	2004	Finally, we have exploited MRP4 (ABCC4) to demonstrate that disulfiram can inhibit ATP binding by forming disulfide bonds between cysteines located in the vicinity of, although not in, the active site.	Disulfides	106-115	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
14978246-10	2004	Finally, we have exploited MRP4 (ABCC4) to demonstrate that disulfiram can inhibit ATP binding by forming disulfide bonds between cysteines located in the vicinity of, although not in, the active site.	Cysteine	130-139	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
14978246-10	2004	Finally, we have exploited MRP4 (ABCC4) to demonstrate that disulfiram can inhibit ATP binding by forming disulfide bonds between cysteines located in the vicinity of, although not in, the active site.	Cysteine	130-139	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
14643890-0	2004	Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione.	Bimane-glutathione	63-81	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
14643890-0	2004	Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione.	Bimane-glutathione	63-81	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
14643890-3	2004	Earlier studies showed that ABCC4 functions as an ATP-driven export pump for cyclic AMP and cyclic GMP, as well as estradiol-17-beta-D-glucuronide.	Adenosine Triphosphate	50-53	ATP binding cassette subfamily C member 4	Homo sapiens	28-33
14643890-3	2004	Earlier studies showed that ABCC4 functions as an ATP-driven export pump for cyclic AMP and cyclic GMP, as well as estradiol-17-beta-D-glucuronide.	Cyclic AMP	77-87	ATP binding cassette subfamily C member 4	Homo sapiens	28-33
14643890-3	2004	Earlier studies showed that ABCC4 functions as an ATP-driven export pump for cyclic AMP and cyclic GMP, as well as estradiol-17-beta-D-glucuronide.	Cyclic GMP	92-102	ATP binding cassette subfamily C member 4	Homo sapiens	28-33
14643890-3	2004	Earlier studies showed that ABCC4 functions as an ATP-driven export pump for cyclic AMP and cyclic GMP, as well as estradiol-17-beta-D-glucuronide.	estradiol-17 beta-glucuronide	115-146	ATP binding cassette subfamily C member 4	Homo sapiens	28-33
14643890-5	2004	Hence in this study, a fluorescent substrate, bimane-glutathione (bimane-GS) was used to further examine the transport activity of ABCC4.	Bimane-glutathione	46-64	ATP binding cassette subfamily C member 4	Homo sapiens	131-136
14643890-6	2004	Using cells stably overexpressing ABCC4, this study shows that ABCC4 can facilitate the efflux of the glutathione conjugate, bimane-glutathione.	Glutathione	102-113	ATP binding cassette subfamily C member 4	Homo sapiens	34-39
14643890-6	2004	Using cells stably overexpressing ABCC4, this study shows that ABCC4 can facilitate the efflux of the glutathione conjugate, bimane-glutathione.	Glutathione	102-113	ATP binding cassette subfamily C member 4	Homo sapiens	63-68
14643890-6	2004	Using cells stably overexpressing ABCC4, this study shows that ABCC4 can facilitate the efflux of the glutathione conjugate, bimane-glutathione.	Bimane-glutathione	125-143	ATP binding cassette subfamily C member 4	Homo sapiens	34-39
14643890-6	2004	Using cells stably overexpressing ABCC4, this study shows that ABCC4 can facilitate the efflux of the glutathione conjugate, bimane-glutathione.	Bimane-glutathione	125-143	ATP binding cassette subfamily C member 4	Homo sapiens	63-68
14643890-10	2004	In addition, 100microM methotrexate, an ABCC4 substrate or 100microM 6-thioguanine (6-TG), a compound whose monophosphate metabolite is an ABCC4 substrate, reduced efflux by >40%.	Methotrexate	23-35	ATP binding cassette subfamily C member 4	Homo sapiens	40-45
14643890-10	2004	In addition, 100microM methotrexate, an ABCC4 substrate or 100microM 6-thioguanine (6-TG), a compound whose monophosphate metabolite is an ABCC4 substrate, reduced efflux by >40%.	Methotrexate	23-35	ATP binding cassette subfamily C member 4	Homo sapiens	139-144
14643890-10	2004	In addition, 100microM methotrexate, an ABCC4 substrate or 100microM 6-thioguanine (6-TG), a compound whose monophosphate metabolite is an ABCC4 substrate, reduced efflux by >40%.	Thioguanine	69-82	ATP binding cassette subfamily C member 4	Homo sapiens	139-144
14643890-10	2004	In addition, 100microM methotrexate, an ABCC4 substrate or 100microM 6-thioguanine (6-TG), a compound whose monophosphate metabolite is an ABCC4 substrate, reduced efflux by >40%.	Thioguanine	84-88	ATP binding cassette subfamily C member 4	Homo sapiens	139-144
14643890-10	2004	In addition, 100microM methotrexate, an ABCC4 substrate or 100microM 6-thioguanine (6-TG), a compound whose monophosphate metabolite is an ABCC4 substrate, reduced efflux by >40%.	monophosphate	108-121	ATP binding cassette subfamily C member 4	Homo sapiens	139-144
14643890-12	2004	The determination that ABCC4 can mediate the transport of glucuronide and glutathione conjugates indicates that ABCC4 may play a role in the cellular extrusion of Phase II detoxification metabolites.	Glucuronides	58-69	ATP binding cassette subfamily C member 4	Homo sapiens	23-28
14643890-12	2004	The determination that ABCC4 can mediate the transport of glucuronide and glutathione conjugates indicates that ABCC4 may play a role in the cellular extrusion of Phase II detoxification metabolites.	Glucuronides	58-69	ATP binding cassette subfamily C member 4	Homo sapiens	112-117
14643890-12	2004	The determination that ABCC4 can mediate the transport of glucuronide and glutathione conjugates indicates that ABCC4 may play a role in the cellular extrusion of Phase II detoxification metabolites.	Glutathione	74-85	ATP binding cassette subfamily C member 4	Homo sapiens	23-28
14643890-12	2004	The determination that ABCC4 can mediate the transport of glucuronide and glutathione conjugates indicates that ABCC4 may play a role in the cellular extrusion of Phase II detoxification metabolites.	Glutathione	74-85	ATP binding cassette subfamily C member 4	Homo sapiens	112-117
14639605-7	2004	We also found that exposure of HL-60 cells to cantharidin resulted in the decreased expression of multidrug resistance-associated protein genes (e.g., ABCA3, MOAT-B), suggesting that cantharidin may be used as an oncotherapy sensitizer, and the increased expression of genes in modulating cytokine production and inflammatory response (e.g., NFIL-3, N-formylpeptide receptor), which may partly explain the stimulating effects on leukocytosis.	Cantharidin	183-194	ATP binding cassette subfamily C member 4	Homo sapiens	158-164
14569083-7	2003	Membrane vesicles from Sf9 cells expressing human MRP2 or human MRP4 indicated that MRP2 exhibits a preferential affinity for calcein and fluo-3, whereas LY is a better substrate for MRP4.	fluorexon	126-133	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
15501592-8	2004	MRP proteins may, thus, contribute to the cellular efflux of endogenous anionic glutathione or glucuronate conjugates (substrates for MRP1), cyclic nucleotides (substrates for MRP4 and MRP5), or glutathione (co-substrate for MRP1 and MRP4); in addition, they may play an important role in the resistance of the brain to several cytotoxic and antiviral drugs.	Glutathione	80-91	ATP binding cassette subfamily C member 4	Homo sapiens	176-180
15501592-8	2004	MRP proteins may, thus, contribute to the cellular efflux of endogenous anionic glutathione or glucuronate conjugates (substrates for MRP1), cyclic nucleotides (substrates for MRP4 and MRP5), or glutathione (co-substrate for MRP1 and MRP4); in addition, they may play an important role in the resistance of the brain to several cytotoxic and antiviral drugs.	Glutathione	80-91	ATP binding cassette subfamily C member 4	Homo sapiens	234-238
15501592-8	2004	MRP proteins may, thus, contribute to the cellular efflux of endogenous anionic glutathione or glucuronate conjugates (substrates for MRP1), cyclic nucleotides (substrates for MRP4 and MRP5), or glutathione (co-substrate for MRP1 and MRP4); in addition, they may play an important role in the resistance of the brain to several cytotoxic and antiviral drugs.	Glucuronic Acid	95-106	ATP binding cassette subfamily C member 4	Homo sapiens	176-180
15501592-8	2004	MRP proteins may, thus, contribute to the cellular efflux of endogenous anionic glutathione or glucuronate conjugates (substrates for MRP1), cyclic nucleotides (substrates for MRP4 and MRP5), or glutathione (co-substrate for MRP1 and MRP4); in addition, they may play an important role in the resistance of the brain to several cytotoxic and antiviral drugs.	Glucuronic Acid	95-106	ATP binding cassette subfamily C member 4	Homo sapiens	234-238
15501592-8	2004	MRP proteins may, thus, contribute to the cellular efflux of endogenous anionic glutathione or glucuronate conjugates (substrates for MRP1), cyclic nucleotides (substrates for MRP4 and MRP5), or glutathione (co-substrate for MRP1 and MRP4); in addition, they may play an important role in the resistance of the brain to several cytotoxic and antiviral drugs.	Nucleotides, Cyclic	141-159	ATP binding cassette subfamily C member 4	Homo sapiens	176-180
15501592-8	2004	MRP proteins may, thus, contribute to the cellular efflux of endogenous anionic glutathione or glucuronate conjugates (substrates for MRP1), cyclic nucleotides (substrates for MRP4 and MRP5), or glutathione (co-substrate for MRP1 and MRP4); in addition, they may play an important role in the resistance of the brain to several cytotoxic and antiviral drugs.	Glutathione	195-206	ATP binding cassette subfamily C member 4	Homo sapiens	176-180
15501592-8	2004	MRP proteins may, thus, contribute to the cellular efflux of endogenous anionic glutathione or glucuronate conjugates (substrates for MRP1), cyclic nucleotides (substrates for MRP4 and MRP5), or glutathione (co-substrate for MRP1 and MRP4); in addition, they may play an important role in the resistance of the brain to several cytotoxic and antiviral drugs.	Glutathione	195-206	ATP binding cassette subfamily C member 4	Homo sapiens	234-238
14569083-7	2003	Membrane vesicles from Sf9 cells expressing human MRP2 or human MRP4 indicated that MRP2 exhibits a preferential affinity for calcein and fluo-3, whereas LY is a better substrate for MRP4.	Fluo-3	138-144	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
14569083-7	2003	Membrane vesicles from Sf9 cells expressing human MRP2 or human MRP4 indicated that MRP2 exhibits a preferential affinity for calcein and fluo-3, whereas LY is a better substrate for MRP4.	lucifer yellow	154-156	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
14569083-7	2003	Membrane vesicles from Sf9 cells expressing human MRP2 or human MRP4 indicated that MRP2 exhibits a preferential affinity for calcein and fluo-3, whereas LY is a better substrate for MRP4.	lucifer yellow	154-156	ATP binding cassette subfamily C member 4	Homo sapiens	183-187
12637526-0	2003	Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells.	Nucleotides, Cyclic	61-79	ATP binding cassette subfamily C member 4	Homo sapiens	24-28
12883481-0	2003	Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.	Glutathione	23-34	ATP binding cassette subfamily C member 4	Homo sapiens	54-58
12883481-0	2003	Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.	Glutathione	23-34	ATP binding cassette subfamily C member 4	Homo sapiens	60-65
12883481-0	2003	Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.	Bile Acids and Salts	40-50	ATP binding cassette subfamily C member 4	Homo sapiens	54-58
12883481-0	2003	Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.	Bile Acids and Salts	40-50	ATP binding cassette subfamily C member 4	Homo sapiens	60-65
12883481-4	2003	Recombinant human MRP4, expressed in V79 hamster fibroblasts and studied in membrane vesicles, mediated ATP-dependent cotransport of GSH or S-methyl-glutathione together with cholyltaurine, cholylglycine, or cholate.	Adenosine Triphosphate	104-107	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
12883481-4	2003	Recombinant human MRP4, expressed in V79 hamster fibroblasts and studied in membrane vesicles, mediated ATP-dependent cotransport of GSH or S-methyl-glutathione together with cholyltaurine, cholylglycine, or cholate.	Glutathione	133-136	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
12883481-4	2003	Recombinant human MRP4, expressed in V79 hamster fibroblasts and studied in membrane vesicles, mediated ATP-dependent cotransport of GSH or S-methyl-glutathione together with cholyltaurine, cholylglycine, or cholate.	S-methyl glutathione	140-160	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
12883481-4	2003	Recombinant human MRP4, expressed in V79 hamster fibroblasts and studied in membrane vesicles, mediated ATP-dependent cotransport of GSH or S-methyl-glutathione together with cholyltaurine, cholylglycine, or cholate.	Taurocholic Acid	175-188	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
12883481-4	2003	Recombinant human MRP4, expressed in V79 hamster fibroblasts and studied in membrane vesicles, mediated ATP-dependent cotransport of GSH or S-methyl-glutathione together with cholyltaurine, cholylglycine, or cholate.	Glycocholic Acid	190-203	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
12883481-4	2003	Recombinant human MRP4, expressed in V79 hamster fibroblasts and studied in membrane vesicles, mediated ATP-dependent cotransport of GSH or S-methyl-glutathione together with cholyltaurine, cholylglycine, or cholate.	Cholates	208-215	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
12883481-7	2003	Transport of bile salts by MRP4 was negligible in the absence of ATP or without S-methyl-glutathione.	Bile Acids and Salts	13-23	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
12883481-7	2003	Transport of bile salts by MRP4 was negligible in the absence of ATP or without S-methyl-glutathione.	S-methyl glutathione	80-100	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
12883481-9	2003	Moreover, MRP4-mediated bile salt transport across the basolateral membrane may function as an overflow pathway during impaired bile salt secretion across the canalicular membrane into bile.	Bile Acids and Salts	24-33	ATP binding cassette subfamily C member 4	Homo sapiens	10-14
12883481-9	2003	Moreover, MRP4-mediated bile salt transport across the basolateral membrane may function as an overflow pathway during impaired bile salt secretion across the canalicular membrane into bile.	Bile Acids and Salts	128-137	ATP binding cassette subfamily C member 4	Homo sapiens	10-14
12883481-10	2003	In conclusion, MRP4 can mediate the efflux of GSH from hepatocytes into blood by cotransport with monoanionic bile salts.	Glutathione	46-49	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
12883481-10	2003	In conclusion, MRP4 can mediate the efflux of GSH from hepatocytes into blood by cotransport with monoanionic bile salts.	monoanionic bile salts	98-120	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
12792791-0	2003	Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine.	Cisplatin	34-43	ATP binding cassette subfamily C member 4	Homo sapiens	26-30
12792791-0	2003	Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine.	Zidovudine	114-128	ATP binding cassette subfamily C member 4	Homo sapiens	26-30
12792791-8	2003	Since MRP4 is known to transport azidiothymidine (AZT) and overexpression of MRP4 confers AZT resistance, we have studied growth inhibitory effects of AZT and [3H]-AZT accumulation.	azidiothymidine	33-48	ATP binding cassette subfamily C member 4	Homo sapiens	6-10
12792791-8	2003	Since MRP4 is known to transport azidiothymidine (AZT) and overexpression of MRP4 confers AZT resistance, we have studied growth inhibitory effects of AZT and [3H]-AZT accumulation.	Zidovudine	50-53	ATP binding cassette subfamily C member 4	Homo sapiens	6-10
12792791-8	2003	Since MRP4 is known to transport azidiothymidine (AZT) and overexpression of MRP4 confers AZT resistance, we have studied growth inhibitory effects of AZT and [3H]-AZT accumulation.	Zidovudine	90-93	ATP binding cassette subfamily C member 4	Homo sapiens	77-81
12792791-8	2003	Since MRP4 is known to transport azidiothymidine (AZT) and overexpression of MRP4 confers AZT resistance, we have studied growth inhibitory effects of AZT and [3H]-AZT accumulation.	Zidovudine	90-93	ATP binding cassette subfamily C member 4	Homo sapiens	77-81
12792791-8	2003	Since MRP4 is known to transport azidiothymidine (AZT) and overexpression of MRP4 confers AZT resistance, we have studied growth inhibitory effects of AZT and [3H]-AZT accumulation.	Zidovudine	90-93	ATP binding cassette subfamily C member 4	Homo sapiens	77-81
12792791-11	2003	Thus, the increased sensitivity to AZT in SR-2 could not be solely due to mutation of MRP4.	Zidovudine	35-38	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
12950253-6	2003	It is concluded that the cGMP exporter is distinct from MRP1 and has properties similar to those reported for MRP4.	Cyclic GMP	25-29	ATP binding cassette subfamily C member 4	Homo sapiens	110-114
12835412-4	2003	In inside-out membrane vesicles derived from insect cells or HEK293 cells, MRP4 catalyzed the time- and ATP-dependent uptake of prostaglandin E1 (PGE1) and PGE2.	Adenosine Triphosphate	104-107	ATP binding cassette subfamily C member 4	Homo sapiens	75-79
12835412-4	2003	In inside-out membrane vesicles derived from insect cells or HEK293 cells, MRP4 catalyzed the time- and ATP-dependent uptake of prostaglandin E1 (PGE1) and PGE2.	Alprostadil	128-144	ATP binding cassette subfamily C member 4	Homo sapiens	75-79
12835412-4	2003	In inside-out membrane vesicles derived from insect cells or HEK293 cells, MRP4 catalyzed the time- and ATP-dependent uptake of prostaglandin E1 (PGE1) and PGE2.	Alprostadil	146-150	ATP binding cassette subfamily C member 4	Homo sapiens	75-79
12835412-4	2003	In inside-out membrane vesicles derived from insect cells or HEK293 cells, MRP4 catalyzed the time- and ATP-dependent uptake of prostaglandin E1 (PGE1) and PGE2.	Dinoprostone	156-160	ATP binding cassette subfamily C member 4	Homo sapiens	75-79
12835412-6	2003	The MRP4-mediated transport of PGE1 and PGE2 displayed saturation kinetics, with Km values of 2.1 and 3.4 microM, respectively.	Alprostadil	31-35	ATP binding cassette subfamily C member 4	Homo sapiens	4-8
12835412-6	2003	The MRP4-mediated transport of PGE1 and PGE2 displayed saturation kinetics, with Km values of 2.1 and 3.4 microM, respectively.	Dinoprostone	40-44	ATP binding cassette subfamily C member 4	Homo sapiens	4-8
12835412-7	2003	Further studies showed that PGF1alpha, PGF2alpha, PGA1, and thromboxane B2 were high-affinity inhibitors (and therefore presumably substrates) of MRP4.	prostaglandin F1	28-37	ATP binding cassette subfamily C member 4	Homo sapiens	146-150
12835412-7	2003	Further studies showed that PGF1alpha, PGF2alpha, PGA1, and thromboxane B2 were high-affinity inhibitors (and therefore presumably substrates) of MRP4.	Dinoprost	39-48	ATP binding cassette subfamily C member 4	Homo sapiens	146-150
12835412-7	2003	Further studies showed that PGF1alpha, PGF2alpha, PGA1, and thromboxane B2 were high-affinity inhibitors (and therefore presumably substrates) of MRP4.	prostaglandin A1	50-54	ATP binding cassette subfamily C member 4	Homo sapiens	146-150
12835412-7	2003	Further studies showed that PGF1alpha, PGF2alpha, PGA1, and thromboxane B2 were high-affinity inhibitors (and therefore presumably substrates) of MRP4.	Thromboxane B2	60-74	ATP binding cassette subfamily C member 4	Homo sapiens	146-150
12835412-9	2003	In cells expressing the prostaglandin transporter PGT, the steady-state accumulation of PGE1 and PGE2 was reduced proportional to MRP4 expression.	Alprostadil	88-92	ATP binding cassette subfamily C member 4	Homo sapiens	130-134
12835412-11	2003	Together, these data suggest that MRP4 can release prostaglandins from cells, and that, in addition to inhibiting prostaglandin synthesis, some nonsteroidal antiinflammatory drugs might also act by inhibiting this release.	Prostaglandins	51-65	ATP binding cassette subfamily C member 4	Homo sapiens	34-38
12835412-11	2003	Together, these data suggest that MRP4 can release prostaglandins from cells, and that, in addition to inhibiting prostaglandin synthesis, some nonsteroidal antiinflammatory drugs might also act by inhibiting this release.	Prostaglandins	51-64	ATP binding cassette subfamily C member 4	Homo sapiens	34-38
12637526-2	2003	Two recently described members of the multidrug resistance protein family, MRP4 and MRP5, might be involved in this process, because they transport the 3",5"-cyclic nucleotides, cAMP and cGMP, into inside-out membrane vesicles.	3",5"-cyclic nucleotides	152-176	ATP binding cassette subfamily C member 4	Homo sapiens	75-79
12637526-2	2003	Two recently described members of the multidrug resistance protein family, MRP4 and MRP5, might be involved in this process, because they transport the 3",5"-cyclic nucleotides, cAMP and cGMP, into inside-out membrane vesicles.	Cyclic AMP	178-182	ATP binding cassette subfamily C member 4	Homo sapiens	75-79
12637526-2	2003	Two recently described members of the multidrug resistance protein family, MRP4 and MRP5, might be involved in this process, because they transport the 3",5"-cyclic nucleotides, cAMP and cGMP, into inside-out membrane vesicles.	Cyclic GMP	187-191	ATP binding cassette subfamily C member 4	Homo sapiens	75-79
12637526-5	2003	MRP4- and MRP5-overexpressing cells effluxed more cGMP and cAMP than parental cells in an ATP-dependent manner.	Cyclic GMP	50-54	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
12637526-5	2003	MRP4- and MRP5-overexpressing cells effluxed more cGMP and cAMP than parental cells in an ATP-dependent manner.	Cyclic AMP	59-63	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
12637526-5	2003	MRP4- and MRP5-overexpressing cells effluxed more cGMP and cAMP than parental cells in an ATP-dependent manner.	Adenosine Triphosphate	90-93	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
12637526-9	2003	The efflux mediated by MRP4 and MRP5 did not lead to a proportional decrease in the intracellular cGMP or cAMP levels but reduced cGMP by maximally 2-fold over the first hour.	Cyclic GMP	130-134	ATP binding cassette subfamily C member 4	Homo sapiens	23-27
12637526-11	2003	These data indicate that MRP4 and MRP5 are low affinity cyclic nucleotide transporters that may at best function as overflow pumps, decreasing steep increases in cGMP levels under conditions where cGMP synthesis is strongly induced and phosphodiesterase activity is limiting.	Cyclic GMP	162-166	ATP binding cassette subfamily C member 4	Homo sapiens	25-29
12637526-11	2003	These data indicate that MRP4 and MRP5 are low affinity cyclic nucleotide transporters that may at best function as overflow pumps, decreasing steep increases in cGMP levels under conditions where cGMP synthesis is strongly induced and phosphodiesterase activity is limiting.	Cyclic GMP	197-201	ATP binding cassette subfamily C member 4	Homo sapiens	25-29
12695538-5	2003	MRP4 also mediated substantial resistance against other acyclic nucleoside phosphonates, whereas MRP5 did not.	acyclic	56-63	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
12695538-0	2003	Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5.	Nucleosides	37-47	ATP binding cassette subfamily C member 4	Homo sapiens	104-108
12695538-5	2003	MRP4 also mediated substantial resistance against other acyclic nucleoside phosphonates, whereas MRP5 did not.	nucleoside phosphonates	64-87	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
12695538-1	2003	The human multidrug resistance proteins MRP4 and MRP5 are organic anion transporters that have the unusual ability to transport cyclic nucleotides and some nucleoside monophosphate analogs.	Nucleotides, Cyclic	128-146	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
12695538-1	2003	The human multidrug resistance proteins MRP4 and MRP5 are organic anion transporters that have the unusual ability to transport cyclic nucleotides and some nucleoside monophosphate analogs.	nucleoside monophosphate	156-180	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
12695538-6	2003	Apart from low-level MRP4-mediated cladribine resistance, the cytotoxicity of clinically used anticancer nucleosides was not influenced by overexpression of MRP4 or MRP5.	Cladribine	35-45	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
12695538-4	2003	In cytotoxicity assays, MRP4 conferred resistance to the antiviral agent 9-(2-phosphonomethoxyethyl)adenine (PMEA) and high-performance liquid chromatography analysis showed that, like MRP5, MRP4 transported PMEA in an unmodified form.	adefovir	73-107	ATP binding cassette subfamily C member 4	Homo sapiens	24-28
12695538-4	2003	In cytotoxicity assays, MRP4 conferred resistance to the antiviral agent 9-(2-phosphonomethoxyethyl)adenine (PMEA) and high-performance liquid chromatography analysis showed that, like MRP5, MRP4 transported PMEA in an unmodified form.	adefovir	73-107	ATP binding cassette subfamily C member 4	Homo sapiens	191-195
12695538-4	2003	In cytotoxicity assays, MRP4 conferred resistance to the antiviral agent 9-(2-phosphonomethoxyethyl)adenine (PMEA) and high-performance liquid chromatography analysis showed that, like MRP5, MRP4 transported PMEA in an unmodified form.	adefovir	109-113	ATP binding cassette subfamily C member 4	Homo sapiens	24-28
12695538-4	2003	In cytotoxicity assays, MRP4 conferred resistance to the antiviral agent 9-(2-phosphonomethoxyethyl)adenine (PMEA) and high-performance liquid chromatography analysis showed that, like MRP5, MRP4 transported PMEA in an unmodified form.	adefovir	208-212	ATP binding cassette subfamily C member 4	Homo sapiens	24-28
12695538-9	2003	Cellular efflux and vesicular uptake studies were carried out to further compare transport mediated by MRP4 and MRP5 and showed that dipyridamole, dilazep, nitrobenzyl mercaptopurine riboside, sildenafil, trequinsin and MK571 inhibited MRP4 more than MRP5, whereas cyclic nucleotides and monophosphorylated nucleoside analogs were equally poor inhibitors of both pumps.	Dipyridamole	133-145	ATP binding cassette subfamily C member 4	Homo sapiens	103-107
12695538-9	2003	Cellular efflux and vesicular uptake studies were carried out to further compare transport mediated by MRP4 and MRP5 and showed that dipyridamole, dilazep, nitrobenzyl mercaptopurine riboside, sildenafil, trequinsin and MK571 inhibited MRP4 more than MRP5, whereas cyclic nucleotides and monophosphorylated nucleoside analogs were equally poor inhibitors of both pumps.	nitrobenzyl mercaptopurine riboside	156-191	ATP binding cassette subfamily C member 4	Homo sapiens	103-107
12695538-9	2003	Cellular efflux and vesicular uptake studies were carried out to further compare transport mediated by MRP4 and MRP5 and showed that dipyridamole, dilazep, nitrobenzyl mercaptopurine riboside, sildenafil, trequinsin and MK571 inhibited MRP4 more than MRP5, whereas cyclic nucleotides and monophosphorylated nucleoside analogs were equally poor inhibitors of both pumps.	Sildenafil Citrate	193-203	ATP binding cassette subfamily C member 4	Homo sapiens	103-107
12695538-9	2003	Cellular efflux and vesicular uptake studies were carried out to further compare transport mediated by MRP4 and MRP5 and showed that dipyridamole, dilazep, nitrobenzyl mercaptopurine riboside, sildenafil, trequinsin and MK571 inhibited MRP4 more than MRP5, whereas cyclic nucleotides and monophosphorylated nucleoside analogs were equally poor inhibitors of both pumps.	trequinsin	205-215	ATP binding cassette subfamily C member 4	Homo sapiens	103-107
12695538-9	2003	Cellular efflux and vesicular uptake studies were carried out to further compare transport mediated by MRP4 and MRP5 and showed that dipyridamole, dilazep, nitrobenzyl mercaptopurine riboside, sildenafil, trequinsin and MK571 inhibited MRP4 more than MRP5, whereas cyclic nucleotides and monophosphorylated nucleoside analogs were equally poor inhibitors of both pumps.	verlukast	220-225	ATP binding cassette subfamily C member 4	Homo sapiens	103-107
12695538-9	2003	Cellular efflux and vesicular uptake studies were carried out to further compare transport mediated by MRP4 and MRP5 and showed that dipyridamole, dilazep, nitrobenzyl mercaptopurine riboside, sildenafil, trequinsin and MK571 inhibited MRP4 more than MRP5, whereas cyclic nucleotides and monophosphorylated nucleoside analogs were equally poor inhibitors of both pumps.	Nucleotides, Cyclic	265-283	ATP binding cassette subfamily C member 4	Homo sapiens	103-107
12695538-9	2003	Cellular efflux and vesicular uptake studies were carried out to further compare transport mediated by MRP4 and MRP5 and showed that dipyridamole, dilazep, nitrobenzyl mercaptopurine riboside, sildenafil, trequinsin and MK571 inhibited MRP4 more than MRP5, whereas cyclic nucleotides and monophosphorylated nucleoside analogs were equally poor inhibitors of both pumps.	Nucleosides	307-317	ATP binding cassette subfamily C member 4	Homo sapiens	103-107
12679160-2	2003	We examined whether mRNA for multidrug resistance protein (MRP) 4 and MRP5, which were recently identified as ATP-dependent export pumps for cyclic nucleotides, is expressed in the porcine coronary and pulmonary arteries.	Adenosine Triphosphate	110-113	ATP binding cassette subfamily C member 4	Homo sapiens	29-65
12523936-3	2003	Since MRP4, like MRP1-3, also mediates transport of a model steroid conjugate substrate, oestradiol 17-beta-D-glucuronide (E(2)17betaG), we tested whether MRP4 may be involved in the transport of steroid and bile acid conjugates.	oestradiol 17-beta-d-glucuronide	89-121	ATP binding cassette subfamily C member 4	Homo sapiens	155-159
12523936-3	2003	Since MRP4, like MRP1-3, also mediates transport of a model steroid conjugate substrate, oestradiol 17-beta-D-glucuronide (E(2)17betaG), we tested whether MRP4 may be involved in the transport of steroid and bile acid conjugates.	Steroids	196-203	ATP binding cassette subfamily C member 4	Homo sapiens	6-10
12523936-3	2003	Since MRP4, like MRP1-3, also mediates transport of a model steroid conjugate substrate, oestradiol 17-beta-D-glucuronide (E(2)17betaG), we tested whether MRP4 may be involved in the transport of steroid and bile acid conjugates.	Bile Acids and Salts	208-217	ATP binding cassette subfamily C member 4	Homo sapiens	6-10
12523936-4	2003	Bile salts, especially sulphated derivatives, and cholestatic oestrogens inhibited the MRP4-mediated transport of E(2)17betaG.	Bile Acids and Salts	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	87-91
12523936-4	2003	Bile salts, especially sulphated derivatives, and cholestatic oestrogens inhibited the MRP4-mediated transport of E(2)17betaG.	e(2)17betag	114-125	ATP binding cassette subfamily C member 4	Homo sapiens	87-91
12523936-5	2003	Inhibition by oestradiol 3,17-disulphate and taurolithocholate 3-sulphate was competitive, suggesting that these compounds are MRP4 substrates.	oestradiol 3,17-disulphate	14-40	ATP binding cassette subfamily C member 4	Homo sapiens	127-131
12523936-5	2003	Inhibition by oestradiol 3,17-disulphate and taurolithocholate 3-sulphate was competitive, suggesting that these compounds are MRP4 substrates.	taurolithocholic acid 3-sulfate	45-73	ATP binding cassette subfamily C member 4	Homo sapiens	127-131
12523936-6	2003	Furthermore, we found that MRP4 transports dehydroepiandrosterone 3-sulphate (DHEAS), the most abundant circulating steroid in humans, which is made in the adrenal gland.	Dehydroepiandrosterone Sulfate	43-76	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
12523936-6	2003	Furthermore, we found that MRP4 transports dehydroepiandrosterone 3-sulphate (DHEAS), the most abundant circulating steroid in humans, which is made in the adrenal gland.	Steroids	116-123	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
12523936-7	2003	The ATP-dependent transport of DHEAS by MRP4 showed saturable kinetics with K (m) and V (max) values of 2 microM and 45 pmol/mg per min, respectively (at 27 degrees C).	Adenosine Triphosphate	4-7	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
12523936-11	2003	Our findings suggest a physiological role for MRP1 and MRP4 in DHEAS transport and an involvement of MRP4 in transport of conjugated steroids and bile acids.	Steroids	133-141	ATP binding cassette subfamily C member 4	Homo sapiens	101-105
12523936-11	2003	Our findings suggest a physiological role for MRP1 and MRP4 in DHEAS transport and an involvement of MRP4 in transport of conjugated steroids and bile acids.	Bile Acids and Salts	146-156	ATP binding cassette subfamily C member 4	Homo sapiens	101-105
12523936-0	2003	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4).	Steroids	0-7	ATP binding cassette subfamily C member 4	Homo sapiens	57-93
12523936-0	2003	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4).	Bile Acids and Salts	12-21	ATP binding cassette subfamily C member 4	Homo sapiens	57-93
12523936-1	2003	Human multidrug-resistance protein (MRP) 4 transports cyclic nucleotides and when overproduced in mammalian cells mediates resistance to some nucleoside analogues.	Nucleotides, Cyclic	54-72	ATP binding cassette subfamily C member 4	Homo sapiens	6-42
12523936-1	2003	Human multidrug-resistance protein (MRP) 4 transports cyclic nucleotides and when overproduced in mammalian cells mediates resistance to some nucleoside analogues.	Nucleosides	142-152	ATP binding cassette subfamily C member 4	Homo sapiens	6-42
12523936-3	2003	Since MRP4, like MRP1-3, also mediates transport of a model steroid conjugate substrate, oestradiol 17-beta-D-glucuronide (E(2)17betaG), we tested whether MRP4 may be involved in the transport of steroid and bile acid conjugates.	Steroids	60-67	ATP binding cassette subfamily C member 4	Homo sapiens	6-10
12523936-3	2003	Since MRP4, like MRP1-3, also mediates transport of a model steroid conjugate substrate, oestradiol 17-beta-D-glucuronide (E(2)17betaG), we tested whether MRP4 may be involved in the transport of steroid and bile acid conjugates.	oestradiol 17-beta-d-glucuronide	89-121	ATP binding cassette subfamily C member 4	Homo sapiens	6-10
12679160-2	2003	We examined whether mRNA for multidrug resistance protein (MRP) 4 and MRP5, which were recently identified as ATP-dependent export pumps for cyclic nucleotides, is expressed in the porcine coronary and pulmonary arteries.	Nucleotides, Cyclic	141-159	ATP binding cassette subfamily C member 4	Homo sapiens	29-65
12435799-0	2002	Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.	2-mercaptopyrazine	48-58	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
12499391-4	2003	One family member, ABCC4 (also known as MRP4) functions as a cellular efflux pump for anti-HIV drugs, such as 9-(2-phoshoenylmethoxyethyl) adenine and azido-thymidine-monophosphate, an antiviral nucleotide, ganciclovir-monophosphate, and anti-cancer agents such as thiopurines.	9-(2-phoshoenylmethoxyethyl) adenine	110-146	ATP binding cassette subfamily C member 4	Homo sapiens	19-24
12499391-4	2003	One family member, ABCC4 (also known as MRP4) functions as a cellular efflux pump for anti-HIV drugs, such as 9-(2-phoshoenylmethoxyethyl) adenine and azido-thymidine-monophosphate, an antiviral nucleotide, ganciclovir-monophosphate, and anti-cancer agents such as thiopurines.	9-(2-phoshoenylmethoxyethyl) adenine	110-146	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
12499391-4	2003	One family member, ABCC4 (also known as MRP4) functions as a cellular efflux pump for anti-HIV drugs, such as 9-(2-phoshoenylmethoxyethyl) adenine and azido-thymidine-monophosphate, an antiviral nucleotide, ganciclovir-monophosphate, and anti-cancer agents such as thiopurines.	3'-azido-3'-deoxythymidine 5'phosphate	151-180	ATP binding cassette subfamily C member 4	Homo sapiens	19-24
12499391-4	2003	One family member, ABCC4 (also known as MRP4) functions as a cellular efflux pump for anti-HIV drugs, such as 9-(2-phoshoenylmethoxyethyl) adenine and azido-thymidine-monophosphate, an antiviral nucleotide, ganciclovir-monophosphate, and anti-cancer agents such as thiopurines.	3'-azido-3'-deoxythymidine 5'phosphate	151-180	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
12499391-4	2003	One family member, ABCC4 (also known as MRP4) functions as a cellular efflux pump for anti-HIV drugs, such as 9-(2-phoshoenylmethoxyethyl) adenine and azido-thymidine-monophosphate, an antiviral nucleotide, ganciclovir-monophosphate, and anti-cancer agents such as thiopurines.	9-Dhp-GMP	207-232	ATP binding cassette subfamily C member 4	Homo sapiens	19-24
12499391-4	2003	One family member, ABCC4 (also known as MRP4) functions as a cellular efflux pump for anti-HIV drugs, such as 9-(2-phoshoenylmethoxyethyl) adenine and azido-thymidine-monophosphate, an antiviral nucleotide, ganciclovir-monophosphate, and anti-cancer agents such as thiopurines.	9-Dhp-GMP	207-232	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
12499391-4	2003	One family member, ABCC4 (also known as MRP4) functions as a cellular efflux pump for anti-HIV drugs, such as 9-(2-phoshoenylmethoxyethyl) adenine and azido-thymidine-monophosphate, an antiviral nucleotide, ganciclovir-monophosphate, and anti-cancer agents such as thiopurines.	thiopurines	265-276	ATP binding cassette subfamily C member 4	Homo sapiens	19-24
12499391-4	2003	One family member, ABCC4 (also known as MRP4) functions as a cellular efflux pump for anti-HIV drugs, such as 9-(2-phoshoenylmethoxyethyl) adenine and azido-thymidine-monophosphate, an antiviral nucleotide, ganciclovir-monophosphate, and anti-cancer agents such as thiopurines.	thiopurines	265-276	ATP binding cassette subfamily C member 4	Homo sapiens	40-44
12897433-11	2003	However, it has been revealed that MRP4 can function as an efflux pump for cyclic nucleotides and nucleoside analogues, used as anti-HIV drugs.	Nucleotides, Cyclic	75-93	ATP binding cassette subfamily C member 4	Homo sapiens	35-39
12897433-11	2003	However, it has been revealed that MRP4 can function as an efflux pump for cyclic nucleotides and nucleoside analogues, used as anti-HIV drugs.	Nucleosides	98-108	ATP binding cassette subfamily C member 4	Homo sapiens	35-39
12435799-2	2002	Overexpression of the two related multidrug resistance proteins MRP4 and MRP5 has been shown to confer some resistance against mercaptopurines, which has been attributed to extrusion of mercaptopurine metabolites by these transporters.	Mercaptopurine	127-142	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
12435799-2	2002	Overexpression of the two related multidrug resistance proteins MRP4 and MRP5 has been shown to confer some resistance against mercaptopurines, which has been attributed to extrusion of mercaptopurine metabolites by these transporters.	Mercaptopurine	127-141	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
12435799-4	2002	Incubation with 6MP led to the formation of thioinosine and thioxanthosine metabolites and we found that thio-IMP was transported by both MRP4 and MRP5; MRP5 showed the highest transport rate.	Mercaptopurine	16-19	ATP binding cassette subfamily C member 4	Homo sapiens	138-142
12435799-4	2002	Incubation with 6MP led to the formation of thioinosine and thioxanthosine metabolites and we found that thio-IMP was transported by both MRP4 and MRP5; MRP5 showed the highest transport rate.	thioxanthosine	60-74	ATP binding cassette subfamily C member 4	Homo sapiens	138-142
12435799-4	2002	Incubation with 6MP led to the formation of thioinosine and thioxanthosine metabolites and we found that thio-IMP was transported by both MRP4 and MRP5; MRP5 showed the highest transport rate.	Thioinosinic acid	105-113	ATP binding cassette subfamily C member 4	Homo sapiens	138-142
12435799-6	2002	During incubation with TG, the monophosphorylated form of thioguanosine was transported by both MRP4 and MRP5; the highest transport rate was for MRP4.	Thioguanine	23-25	ATP binding cassette subfamily C member 4	Homo sapiens	96-100
12435799-6	2002	During incubation with TG, the monophosphorylated form of thioguanosine was transported by both MRP4 and MRP5; the highest transport rate was for MRP4.	Thioguanine	23-25	ATP binding cassette subfamily C member 4	Homo sapiens	146-150
12435799-6	2002	During incubation with TG, the monophosphorylated form of thioguanosine was transported by both MRP4 and MRP5; the highest transport rate was for MRP4.	6-thioguanosine	58-71	ATP binding cassette subfamily C member 4	Homo sapiens	96-100
12435799-6	2002	During incubation with TG, the monophosphorylated form of thioguanosine was transported by both MRP4 and MRP5; the highest transport rate was for MRP4.	6-thioguanosine	58-71	ATP binding cassette subfamily C member 4	Homo sapiens	146-150
12435799-9	2002	Our results show that all major thiopurine monophosphates important in the efficacy of mercaptopurine treatment are transported by MRP4 and MRP5, although the substrate specificity of the two transporters differs in detail.	thiopurine monophosphates	32-57	ATP binding cassette subfamily C member 4	Homo sapiens	131-135
12435799-9	2002	Our results show that all major thiopurine monophosphates important in the efficacy of mercaptopurine treatment are transported by MRP4 and MRP5, although the substrate specificity of the two transporters differs in detail.	Mercaptopurine	87-101	ATP binding cassette subfamily C member 4	Homo sapiens	131-135
12105214-0	2002	Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing.	Ganciclovir	41-52	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
12105214-7	2002	In cells that overexpressed MRP4, intracellular accumulation of GCV metabolites was reduced, efflux of these metabolites was increased, and resistance to bystander killing was increased.	Ganciclovir	64-67	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
12105214-8	2002	Therefore, MRP4 can strongly reduce the susceptibility of HSV-TK-expressing cells to GCV, and its overexpression in adjacent cells protects them from bystander cell death.	Ganciclovir	85-88	ATP binding cassette subfamily C member 4	Homo sapiens	11-15
12105214-1	2002	The multidrug resistance protein MRP4, a member of the ATP-binding cassette superfamily, confers resistance to purine-based antiretroviral agents.	purine	111-117	ATP binding cassette subfamily C member 4	Homo sapiens	33-37
12105214-9	2002	These findings indicate that a nucleotide transporter, such as MRP4, modulates the cellular response to GCV and thus may influence not only the efficacy of antiviral therapy, but also prodrug-based gene therapy, which is critically dependent upon bystander cell killing.	Ganciclovir	104-107	ATP binding cassette subfamily C member 4	Homo sapiens	63-67
12105214-5	2002	Cells overexpressing MRP4 had markedly increased resistance to the cytotoxicity of GCV.	Ganciclovir	83-86	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
12036927-0	2002	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.	Methotrexate	12-24	ATP binding cassette subfamily C member 4	Homo sapiens	81-86
12036927-0	2002	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.	Methotrexate	12-24	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
12036927-0	2002	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.	Folic Acid	29-35	ATP binding cassette subfamily C member 4	Homo sapiens	81-86
12036927-0	2002	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.	Folic Acid	29-35	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
12036927-0	2002	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.	Methotrexate	116-128	ATP binding cassette subfamily C member 4	Homo sapiens	81-86
12036927-0	2002	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.	Methotrexate	116-128	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
12036927-1	2002	Human MRP4 (ABCC4, MOAT-B) is a lipophilic anion transporter that is able to confer resistance to nucleotide analogues and methotrexate (MTX).	Methotrexate	123-135	ATP binding cassette subfamily C member 4	Homo sapiens	6-10
12036927-1	2002	Human MRP4 (ABCC4, MOAT-B) is a lipophilic anion transporter that is able to confer resistance to nucleotide analogues and methotrexate (MTX).	Methotrexate	123-135	ATP binding cassette subfamily C member 4	Homo sapiens	12-17
12036927-1	2002	Human MRP4 (ABCC4, MOAT-B) is a lipophilic anion transporter that is able to confer resistance to nucleotide analogues and methotrexate (MTX).	Methotrexate	123-135	ATP binding cassette subfamily C member 4	Homo sapiens	19-25
12036927-1	2002	Human MRP4 (ABCC4, MOAT-B) is a lipophilic anion transporter that is able to confer resistance to nucleotide analogues and methotrexate (MTX).	Methotrexate	137-140	ATP binding cassette subfamily C member 4	Homo sapiens	6-10
12036927-1	2002	Human MRP4 (ABCC4, MOAT-B) is a lipophilic anion transporter that is able to confer resistance to nucleotide analogues and methotrexate (MTX).	Methotrexate	137-140	ATP binding cassette subfamily C member 4	Homo sapiens	12-17
12036927-1	2002	Human MRP4 (ABCC4, MOAT-B) is a lipophilic anion transporter that is able to confer resistance to nucleotide analogues and methotrexate (MTX).	Methotrexate	137-140	ATP binding cassette subfamily C member 4	Homo sapiens	19-25
12036927-2	2002	We previously investigated the implications of the ability of MRP4 to confer resistance to nucleotide analogues and determined that the pump is competent in the MgATP-energized transport of cyclic nucleotides and estradiol 17beta-D-glucuronide.	Adenosine Triphosphate	161-166	ATP binding cassette subfamily C member 4	Homo sapiens	62-66
12036927-2	2002	We previously investigated the implications of the ability of MRP4 to confer resistance to nucleotide analogues and determined that the pump is competent in the MgATP-energized transport of cyclic nucleotides and estradiol 17beta-D-glucuronide.	Nucleotides, Cyclic	190-208	ATP binding cassette subfamily C member 4	Homo sapiens	62-66
12036927-2	2002	We previously investigated the implications of the ability of MRP4 to confer resistance to nucleotide analogues and determined that the pump is competent in the MgATP-energized transport of cyclic nucleotides and estradiol 17beta-D-glucuronide.	estradiol-17 beta-glucuronide	213-243	ATP binding cassette subfamily C member 4	Homo sapiens	62-66
12036927-3	2002	Here we examine the potential role of MRP4 in conferring resistance to MTX and related processes by determining the selectivity of the transporter for MTX, MTX polyglutamates, and physiological folates.	Methotrexate	71-74	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
12036927-3	2002	Here we examine the potential role of MRP4 in conferring resistance to MTX and related processes by determining the selectivity of the transporter for MTX, MTX polyglutamates, and physiological folates.	Methotrexate	151-154	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
12036927-3	2002	Here we examine the potential role of MRP4 in conferring resistance to MTX and related processes by determining the selectivity of the transporter for MTX, MTX polyglutamates, and physiological folates.	methotrexate polyglutamate	156-174	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
12036927-4	2002	In so doing, it is shown that MRP4 is active in the transport of MTX as well as the physiological folates folic acid (FA) and N(5)-formyltetrahydrofolic acid (leucovorin).	Methotrexate	65-68	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
12036927-4	2002	In so doing, it is shown that MRP4 is active in the transport of MTX as well as the physiological folates folic acid (FA) and N(5)-formyltetrahydrofolic acid (leucovorin).	Folic Acid	98-105	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
12036927-4	2002	In so doing, it is shown that MRP4 is active in the transport of MTX as well as the physiological folates folic acid (FA) and N(5)-formyltetrahydrofolic acid (leucovorin).	Leucovorin	126-157	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
12036927-4	2002	In so doing, it is shown that MRP4 is active in the transport of MTX as well as the physiological folates folic acid (FA) and N(5)-formyltetrahydrofolic acid (leucovorin).	Leucovorin	159-169	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
12036927-5	2002	MTX, FA, and leucovorin are subject to high capacity [V(max(MTX)), 0.24 +/- 0.05 nmol/mg/min; V(max (FA)), 0.68 +/- 0.14 nmol/mg/min; V(max(leucovorin)), 1.95 +/- 0.18 nmol/mg/min], low affinity [K(m(MTX)), 0.22 +/- 0.01 mM; K(m(FA)), 0.17 +/- 0.02 mM; K(m (leucovorin)), 0.64 +/- 0.23 mM] transport by MRP4.	Methotrexate	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	303-307
12036927-6	2002	In addition, as would be expected were MRP4 a component of the MTX efflux system, its capacity to transport this agent is abrogated by the addition of a single glutamyl residue.	Methotrexate	63-66	ATP binding cassette subfamily C member 4	Homo sapiens	39-43
12036927-8	2002	On the basis of these transport properties, it is concluded that the efflux system for MTX includes MRP2 and MRP4, in addition to MRP1 and MRP3, and that MRP4 represents a common efflux system for both MTX and certain nucleotide analogues.	Methotrexate	87-90	ATP binding cassette subfamily C member 4	Homo sapiens	109-113
12036927-8	2002	On the basis of these transport properties, it is concluded that the efflux system for MTX includes MRP2 and MRP4, in addition to MRP1 and MRP3, and that MRP4 represents a common efflux system for both MTX and certain nucleotide analogues.	Methotrexate	202-205	ATP binding cassette subfamily C member 4	Homo sapiens	154-158
11856762-0	2002	The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP.	Cyclic AMP	136-140	ATP binding cassette subfamily C member 4	Homo sapiens	4-8
11856762-0	2002	The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP.	Cyclic AMP	136-140	ATP binding cassette subfamily C member 4	Homo sapiens	9-14
11856762-0	2002	The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP.	Cyclic GMP	145-149	ATP binding cassette subfamily C member 4	Homo sapiens	4-8
11856762-0	2002	The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP.	Cyclic GMP	145-149	ATP binding cassette subfamily C member 4	Homo sapiens	9-14
11856762-6	2002	MRP4 is localized to the proximal tubule apical membrane of human kidney, and membrane vesicles from Sf9 cells expressing human MRP4 exhibit ATP-dependent transport of [(3)H]cAMP and [(3)H]cGMP.	Adenosine Triphosphate	141-144	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
11856762-6	2002	MRP4 is localized to the proximal tubule apical membrane of human kidney, and membrane vesicles from Sf9 cells expressing human MRP4 exhibit ATP-dependent transport of [(3)H]cAMP and [(3)H]cGMP.	Adenosine Triphosphate	141-144	ATP binding cassette subfamily C member 4	Homo sapiens	128-132
11856762-6	2002	MRP4 is localized to the proximal tubule apical membrane of human kidney, and membrane vesicles from Sf9 cells expressing human MRP4 exhibit ATP-dependent transport of [(3)H]cAMP and [(3)H]cGMP.	Cyclic AMP	174-178	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
11856762-6	2002	MRP4 is localized to the proximal tubule apical membrane of human kidney, and membrane vesicles from Sf9 cells expressing human MRP4 exhibit ATP-dependent transport of [(3)H]cAMP and [(3)H]cGMP.	Cyclic AMP	174-178	ATP binding cassette subfamily C member 4	Homo sapiens	128-132
11856762-6	2002	MRP4 is localized to the proximal tubule apical membrane of human kidney, and membrane vesicles from Sf9 cells expressing human MRP4 exhibit ATP-dependent transport of [(3)H]cAMP and [(3)H]cGMP.	Cyclic GMP	189-193	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
11856762-6	2002	MRP4 is localized to the proximal tubule apical membrane of human kidney, and membrane vesicles from Sf9 cells expressing human MRP4 exhibit ATP-dependent transport of [(3)H]cAMP and [(3)H]cGMP.	Cyclic GMP	189-193	ATP binding cassette subfamily C member 4	Homo sapiens	128-132
11856762-7	2002	Both probenecid and dipyridamole are potent MRP4 inhibitors.	Probenecid	5-15	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
11856762-7	2002	Both probenecid and dipyridamole are potent MRP4 inhibitors.	Dipyridamole	20-32	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
11856762-10	2002	It is concluded that MRP4 is a novel apical organic anion transporter and the putative efflux pump for cAMP and cGMP in human kidney proximal tubules.	Cyclic AMP	103-107	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
11856762-10	2002	It is concluded that MRP4 is a novel apical organic anion transporter and the putative efflux pump for cAMP and cGMP in human kidney proximal tubules.	Cyclic GMP	112-116	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
11447229-2	2001	Human multidrug resistance protein 4 (MRP4) has recently been determined to confer resistance to the antiviral purine analog 9-(2-phosphonylmethoxyethyl)adenine and methotrexate.	purine	111-117	ATP binding cassette subfamily C member 4	Homo sapiens	6-36
12423063-4	2002	We first identified, MRP4, based on its ability to efflux antiretroviral compounds, such as azidothymidine monophosphate (AZT-MP) and 9-(2-phosphonyl methoxyethyl) adenine (PMEA), in drug-resistant and also in transfected cell lines.	3'-azido-3'-deoxythymidine 5'phosphate	92-120	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
12423063-4	2002	We first identified, MRP4, based on its ability to efflux antiretroviral compounds, such as azidothymidine monophosphate (AZT-MP) and 9-(2-phosphonyl methoxyethyl) adenine (PMEA), in drug-resistant and also in transfected cell lines.	3'-azido-3'-deoxythymidine 5'phosphate	122-128	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
12423063-4	2002	We first identified, MRP4, based on its ability to efflux antiretroviral compounds, such as azidothymidine monophosphate (AZT-MP) and 9-(2-phosphonyl methoxyethyl) adenine (PMEA), in drug-resistant and also in transfected cell lines.	adefovir	134-171	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
12423063-4	2002	We first identified, MRP4, based on its ability to efflux antiretroviral compounds, such as azidothymidine monophosphate (AZT-MP) and 9-(2-phosphonyl methoxyethyl) adenine (PMEA), in drug-resistant and also in transfected cell lines.	adefovir	173-177	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
12423063-6	2002	MRP4 and MRP5 confer resistance to cytotoxic thiopurine nucleotides, and we demonstrate MRP4 expression varies among acute lymphoblastic leukemias, suggesting this as a factor in response to chemotherapy with these agents.	thiopurine nucleotides	45-67	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
12423063-7	2002	The ability of MRP4 and MRP5 to transport 3",5"-cyclic adenosine monophosphate (cAMP) and 3",5"-cyclic guanosine monophosphate (cGMP) suggests they may play a biological role in cellular signaling by these nucleotides.	3",5"-cyclic adenosine monophosphate	42-78	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
12423063-7	2002	The ability of MRP4 and MRP5 to transport 3",5"-cyclic adenosine monophosphate (cAMP) and 3",5"-cyclic guanosine monophosphate (cGMP) suggests they may play a biological role in cellular signaling by these nucleotides.	Cyclic AMP	80-84	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
12423063-7	2002	The ability of MRP4 and MRP5 to transport 3",5"-cyclic adenosine monophosphate (cAMP) and 3",5"-cyclic guanosine monophosphate (cGMP) suggests they may play a biological role in cellular signaling by these nucleotides.	3",5"-cyclic guanosine monophosphate	90-126	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
12423063-7	2002	The ability of MRP4 and MRP5 to transport 3",5"-cyclic adenosine monophosphate (cAMP) and 3",5"-cyclic guanosine monophosphate (cGMP) suggests they may play a biological role in cellular signaling by these nucleotides.	Cyclic GMP	128-132	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
12423063-8	2002	Finally, we propose that MRP4 may also play a role in hepatic bile acid homeostasis because loss of the main bile acid efflux transporter, sister of P-glycoprotein (SPGP) aka bile-salt export pump (BSEP), leads to a strong compensatory upregulation in MRP4 expression.	Bile Acids and Salts	62-71	ATP binding cassette subfamily C member 4	Homo sapiens	25-29
11804191-5	2001	MRP4 and MRP5 resemble each other more closely than they resemble MRPs 1-3 and confer resistance to purine and nucleotide analogs which are either inherently anionic, as in the case of the anti-AIDS drug PMEA, or are phosphorylated and converted to anionic amphiphiles in the cell, as in the case of 6-MP.	purine	100-106	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
11804191-5	2001	MRP4 and MRP5 resemble each other more closely than they resemble MRPs 1-3 and confer resistance to purine and nucleotide analogs which are either inherently anionic, as in the case of the anti-AIDS drug PMEA, or are phosphorylated and converted to anionic amphiphiles in the cell, as in the case of 6-MP.	adefovir	204-208	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
11447229-0	2001	Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4.	Nucleotides, Cyclic	13-31	ATP binding cassette subfamily C member 4	Homo sapiens	71-101
11447229-0	2001	Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4.	estradiol-17 beta-glucuronide	36-67	ATP binding cassette subfamily C member 4	Homo sapiens	71-101
11802779-0	2002	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues.	Glutathione	8-19	ATP binding cassette subfamily C member 4	Homo sapiens	59-63
11802779-0	2002	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues.	Glutathione	8-19	ATP binding cassette subfamily C member 4	Homo sapiens	64-69
11802779-0	2002	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues.	Cyclic AMP	90-94	ATP binding cassette subfamily C member 4	Homo sapiens	59-63
11802779-0	2002	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues.	Cyclic AMP	90-94	ATP binding cassette subfamily C member 4	Homo sapiens	64-69
11802779-0	2002	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues.	purine	113-119	ATP binding cassette subfamily C member 4	Homo sapiens	59-63
11802779-0	2002	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues.	purine	113-119	ATP binding cassette subfamily C member 4	Homo sapiens	64-69
11802779-4	2002	Using cells stably overexpressing ABCC4, this study shows that ABCC4 exports GSH.	Glutathione	77-80	ATP binding cassette subfamily C member 4	Homo sapiens	34-39
11802779-4	2002	Using cells stably overexpressing ABCC4, this study shows that ABCC4 exports GSH.	Glutathione	77-80	ATP binding cassette subfamily C member 4	Homo sapiens	63-68
11802779-5	2002	ABCC4 also facilitates the efflux of cAMP.	Cyclic AMP	37-41	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
11802779-7	2002	ABCC4 also mediates resistance to purine analogues 9-(2-phosphonylmethoxyethyl)-adenine and 6-thioguanine.	purine	34-40	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
11802779-7	2002	ABCC4 also mediates resistance to purine analogues 9-(2-phosphonylmethoxyethyl)-adenine and 6-thioguanine.	adefovir	51-87	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
11802779-7	2002	ABCC4 also mediates resistance to purine analogues 9-(2-phosphonylmethoxyethyl)-adenine and 6-thioguanine.	Thioguanine	92-105	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
11802779-9	2002	We conclude that as well as nucleotide and nucleoside analogues, ABCC4 can mediate the export of GSH.	Glutathione	97-100	ATP binding cassette subfamily C member 4	Homo sapiens	65-70
11802779-10	2002	In addition, GSH plays an important role in the function of ABCC4.	Glutathione	13-16	ATP binding cassette subfamily C member 4	Homo sapiens	60-65
11802779-11	2002	Depletion of intracellular GSH adversely affects the export of cAMP by ABCC4.	Glutathione	27-30	ATP binding cassette subfamily C member 4	Homo sapiens	71-76
11802779-11	2002	Depletion of intracellular GSH adversely affects the export of cAMP by ABCC4.	Cyclic AMP	63-67	ATP binding cassette subfamily C member 4	Homo sapiens	71-76
11804191-5	2001	MRP4 and MRP5 resemble each other more closely than they resemble MRPs 1-3 and confer resistance to purine and nucleotide analogs which are either inherently anionic, as in the case of the anti-AIDS drug PMEA, or are phosphorylated and converted to anionic amphiphiles in the cell, as in the case of 6-MP.	Mercaptopurine	300-304	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
11804191-6	2001	Given their capacity for transporting cyclic nucleotides, MRP4 and MRP5 have also been implicated in a broad range of cellular signaling processes.	Nucleotides, Cyclic	38-56	ATP binding cassette subfamily C member 4	Homo sapiens	58-62
11447229-2	2001	Human multidrug resistance protein 4 (MRP4) has recently been determined to confer resistance to the antiviral purine analog 9-(2-phosphonylmethoxyethyl)adenine and methotrexate.	purine	111-117	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
11447229-2	2001	Human multidrug resistance protein 4 (MRP4) has recently been determined to confer resistance to the antiviral purine analog 9-(2-phosphonylmethoxyethyl)adenine and methotrexate.	adefovir	125-160	ATP binding cassette subfamily C member 4	Homo sapiens	6-36
11447229-2	2001	Human multidrug resistance protein 4 (MRP4) has recently been determined to confer resistance to the antiviral purine analog 9-(2-phosphonylmethoxyethyl)adenine and methotrexate.	adefovir	125-160	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
11447229-2	2001	Human multidrug resistance protein 4 (MRP4) has recently been determined to confer resistance to the antiviral purine analog 9-(2-phosphonylmethoxyethyl)adenine and methotrexate.	Methotrexate	165-177	ATP binding cassette subfamily C member 4	Homo sapiens	6-36
11447229-2	2001	Human multidrug resistance protein 4 (MRP4) has recently been determined to confer resistance to the antiviral purine analog 9-(2-phosphonylmethoxyethyl)adenine and methotrexate.	Methotrexate	165-177	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
11447229-5	2001	It is shown that expression of MRP4 is specifically associated with the MgATP-dependent transport of cGMP, cAMP, and estradiol 17-beta-D-glucuronide (E(2)17 beta G).	Adenosine Triphosphate	72-77	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
11447229-5	2001	It is shown that expression of MRP4 is specifically associated with the MgATP-dependent transport of cGMP, cAMP, and estradiol 17-beta-D-glucuronide (E(2)17 beta G).	Cyclic GMP	101-105	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
11447229-5	2001	It is shown that expression of MRP4 is specifically associated with the MgATP-dependent transport of cGMP, cAMP, and estradiol 17-beta-D-glucuronide (E(2)17 beta G).	Cyclic AMP	107-111	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
11447229-5	2001	It is shown that expression of MRP4 is specifically associated with the MgATP-dependent transport of cGMP, cAMP, and estradiol 17-beta-D-glucuronide (E(2)17 beta G).	estradiol-17 beta-glucuronide	117-148	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
11447229-7	2001	Consistent with its ability to transport cyclic nucleotides, it is demonstrated that the MRP4 drug resistance profile extends to 6-mercaptopurine and 6-thioguanine, two anticancer purine analogs that are converted in the cell to nucleotide analogs.	Nucleotides, Cyclic	41-59	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
11447229-7	2001	Consistent with its ability to transport cyclic nucleotides, it is demonstrated that the MRP4 drug resistance profile extends to 6-mercaptopurine and 6-thioguanine, two anticancer purine analogs that are converted in the cell to nucleotide analogs.	Mercaptopurine	129-145	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
11447229-7	2001	Consistent with its ability to transport cyclic nucleotides, it is demonstrated that the MRP4 drug resistance profile extends to 6-mercaptopurine and 6-thioguanine, two anticancer purine analogs that are converted in the cell to nucleotide analogs.	Thioguanine	150-163	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
11447229-7	2001	Consistent with its ability to transport cyclic nucleotides, it is demonstrated that the MRP4 drug resistance profile extends to 6-mercaptopurine and 6-thioguanine, two anticancer purine analogs that are converted in the cell to nucleotide analogs.	purine	139-145	ATP binding cassette subfamily C member 4	Homo sapiens	89-93
11447229-8	2001	On the basis of its capacity to transport cyclic nucleotides and E(2)17 beta G, it is concluded that MRP4 may influence diverse cellular processes regulated by cAMP and cGMP and that its substrate range is distinct from that of any other characterized MRP family member.	Nucleotides, Cyclic	42-60	ATP binding cassette subfamily C member 4	Homo sapiens	101-105
11447229-8	2001	On the basis of its capacity to transport cyclic nucleotides and E(2)17 beta G, it is concluded that MRP4 may influence diverse cellular processes regulated by cAMP and cGMP and that its substrate range is distinct from that of any other characterized MRP family member.	Cyclic AMP	160-164	ATP binding cassette subfamily C member 4	Homo sapiens	101-105
11447229-8	2001	On the basis of its capacity to transport cyclic nucleotides and E(2)17 beta G, it is concluded that MRP4 may influence diverse cellular processes regulated by cAMP and cGMP and that its substrate range is distinct from that of any other characterized MRP family member.	Cyclic GMP	169-173	ATP binding cassette subfamily C member 4	Homo sapiens	101-105
10944550-7	2000	MRP4 overexpression is associated with high-level resistance to the nucleoside analogues 9-(2-phosphonylmethoxyethyl) adenine and azidothymidine, both of which are used as anti-human immunodeficiency virus drugs.	Nucleosides	68-78	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
11477564-1	2001	To investigate the roles played by the multidrug resistance-associated protein (MRP1) homologues MRP3 and MRP4 in resistance to platinum drugs, we examined steady-state levels of mRNA for both MRP3 and MRP4 in normal lung and lung cancer specimens as well as peripheral mononuclear cells (PMN) after platinum drug exposure.	Platinum	128-136	ATP binding cassette subfamily C member 4	Homo sapiens	106-110
10944550-7	2000	MRP4 overexpression is associated with high-level resistance to the nucleoside analogues 9-(2-phosphonylmethoxyethyl) adenine and azidothymidine, both of which are used as anti-human immunodeficiency virus drugs.	adefovir	89-125	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
10944550-7	2000	MRP4 overexpression is associated with high-level resistance to the nucleoside analogues 9-(2-phosphonylmethoxyethyl) adenine and azidothymidine, both of which are used as anti-human immunodeficiency virus drugs.	Zidovudine	130-144	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
34666750-10	2021	LABA/GCS attenuation of Poly I:C or imiquimod-induced IL-6 and IL-8 were potentiated with ABCC4 and PDE4 inhibition, which was greater when ABCC4 and PDE4 inhibition was combined.	Imiquimod	36-45	ATP binding cassette subfamily C member 4	Homo sapiens	90-95
10470083-0	1999	MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs.	Nucleosides	56-66	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
10470083-6	1999	In our study of alternative or additional mechanisms of resistance operating during antiviral therapy, overexpression and amplification of the MRP4 gene correlated with ATP-dependent efflux of PMEA (9-(2-phosphonylmethoxyethyl)adenine) and azidothymidine monophosphate from cells and, thus, with resistance to these drugs.	Adenosine Triphosphate	169-172	ATP binding cassette subfamily C member 4	Homo sapiens	143-147
10470083-6	1999	In our study of alternative or additional mechanisms of resistance operating during antiviral therapy, overexpression and amplification of the MRP4 gene correlated with ATP-dependent efflux of PMEA (9-(2-phosphonylmethoxyethyl)adenine) and azidothymidine monophosphate from cells and, thus, with resistance to these drugs.	adefovir	193-197	ATP binding cassette subfamily C member 4	Homo sapiens	143-147
10470083-6	1999	In our study of alternative or additional mechanisms of resistance operating during antiviral therapy, overexpression and amplification of the MRP4 gene correlated with ATP-dependent efflux of PMEA (9-(2-phosphonylmethoxyethyl)adenine) and azidothymidine monophosphate from cells and, thus, with resistance to these drugs.	adefovir	199-234	ATP binding cassette subfamily C member 4	Homo sapiens	143-147
10470083-6	1999	In our study of alternative or additional mechanisms of resistance operating during antiviral therapy, overexpression and amplification of the MRP4 gene correlated with ATP-dependent efflux of PMEA (9-(2-phosphonylmethoxyethyl)adenine) and azidothymidine monophosphate from cells and, thus, with resistance to these drugs.	3'-azido-3'-deoxythymidine 5'phosphate	240-268	ATP binding cassette subfamily C member 4	Homo sapiens	143-147
10470083-7	1999	Overexpression of MRP4 mRNA and MRP4 protein severely impaired the antiviral efficacy of PMEA, azidothymidine and other nucleoside analogs.	adefovir	89-93	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
10470083-7	1999	Overexpression of MRP4 mRNA and MRP4 protein severely impaired the antiviral efficacy of PMEA, azidothymidine and other nucleoside analogs.	adefovir	89-93	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
10470083-7	1999	Overexpression of MRP4 mRNA and MRP4 protein severely impaired the antiviral efficacy of PMEA, azidothymidine and other nucleoside analogs.	Zidovudine	95-109	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
10470083-7	1999	Overexpression of MRP4 mRNA and MRP4 protein severely impaired the antiviral efficacy of PMEA, azidothymidine and other nucleoside analogs.	Zidovudine	95-109	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
10470083-7	1999	Overexpression of MRP4 mRNA and MRP4 protein severely impaired the antiviral efficacy of PMEA, azidothymidine and other nucleoside analogs.	Nucleosides	120-130	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
10470083-7	1999	Overexpression of MRP4 mRNA and MRP4 protein severely impaired the antiviral efficacy of PMEA, azidothymidine and other nucleoside analogs.	Nucleosides	120-130	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
10470083-8	1999	Increased resistance to PMEA and amplification of the MRP4 gene correlated with enhanced drug efflux; transfer of chromosome 13 containing the amplified MRP4 gene conferred resistance to PMEA.	adefovir	187-191	ATP binding cassette subfamily C member 4	Homo sapiens	153-157
10470083-9	1999	MRP4 is the first transporter, to our knowledge, directly linked to the efflux of nucleoside monophosphate analogs from mammalian cells.	nucleoside monophosphate	82-106	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
33802652-4	2021	Our data demonstrated that compared to PD, although endothelial-NO-synthase activation was similarly increased, HD and CT were associated to cGMP RBCs accumulation, caused by reduced activity of cGMP membrane transporter (MRP4).	Cyclic GMP	195-199	ATP binding cassette subfamily C member 4	Homo sapiens	222-226
33032192-9	2020	Examining the time activity curves for [131I]MIBG in SK-N-SH cells, higher expressions of MDR1, MRP1, MRP4, and MK-571, or probenecid loading produced significantly higher uptake than in control at most incubation times.	3-Iodobenzylguanidine	45-49	ATP binding cassette subfamily C member 4	Homo sapiens	102-106
29205871-4	2018	Our analyses associated unbound ATV disposition with multidrug resistance protein (MRP)4, RTV with P-glycoprotein (P-gp), and EFV with cytochrome P450 (CYP)2B6 and MRP4 genetic variants.	Atazanavir Sulfate	32-35	ATP binding cassette subfamily C member 4	Homo sapiens	53-88
29205871-4	2018	Our analyses associated unbound ATV disposition with multidrug resistance protein (MRP)4, RTV with P-glycoprotein (P-gp), and EFV with cytochrome P450 (CYP)2B6 and MRP4 genetic variants.	Atazanavir Sulfate	32-35	ATP binding cassette subfamily C member 4	Homo sapiens	164-168
26507107-4	2016	In this study, the ability of tolvaptan and two metabolites, DM-4103 and DM-4107, to inhibit human hepatic transporters (NTCP, BSEP, MRP2, MRP3, and MRP4) and bile acid transport in sandwich-cultured human hepatocytes (SCHH) was explored.	Tolvaptan	30-39	ATP binding cassette subfamily C member 4	Homo sapiens	149-153
26507107-4	2016	In this study, the ability of tolvaptan and two metabolites, DM-4103 and DM-4107, to inhibit human hepatic transporters (NTCP, BSEP, MRP2, MRP3, and MRP4) and bile acid transport in sandwich-cultured human hepatocytes (SCHH) was explored.	dm	61-63	ATP binding cassette subfamily C member 4	Homo sapiens	149-153
26507107-4	2016	In this study, the ability of tolvaptan and two metabolites, DM-4103 and DM-4107, to inhibit human hepatic transporters (NTCP, BSEP, MRP2, MRP3, and MRP4) and bile acid transport in sandwich-cultured human hepatocytes (SCHH) was explored.	dm	73-75	ATP binding cassette subfamily C member 4	Homo sapiens	149-153
26507107-6	2016	At the therapeutic dose of tolvaptan (90 mg), DM-4103 exhibited a C(max)/IC(50) value >0.1 for NTCP, BSEP, MRP2, MRP3, and MRP4.	UNII-B09E6IIT63	46-53	ATP binding cassette subfamily C member 4	Homo sapiens	126-130
34331561-10	2021	CONCLUSION: Four polymorphisms of the ABCC4, FPGS, SLC29A1, and MTHFR genes are likely to be potential predictive biomarkers for precision medicine in fluoropyrimidine-based treatments in the population of the Brazilian Amazon, which is constituted by a unique genetic background.	2-fluoropyrimidine	151-167	ATP binding cassette subfamily C member 4	Homo sapiens	38-43
34693929-4	2022	V458M, a novel variant not previously studied, and T1142M, showed reduced activity compared to MRP4 wildtype for E217betaG and TCA (P < 0.01), while L18I, G187W, K293E, and R531Q moderately increased activity in a substrate-dependent manner.	e217betag	113-122	ATP binding cassette subfamily C member 4	Homo sapiens	95-99
34693929-4	2022	V458M, a novel variant not previously studied, and T1142M, showed reduced activity compared to MRP4 wildtype for E217betaG and TCA (P < 0.01), while L18I, G187W, K293E, and R531Q moderately increased activity in a substrate-dependent manner.	Taurocholic Acid	127-130	ATP binding cassette subfamily C member 4	Homo sapiens	95-99
34666750-5	2021	HYPOTHESIS: Increasing intracellular cAMP during LABA/GCS combination therapy via inhibiting phosphodiesterase 4 (PDE4) and/or blocking the export of cAMP by ATP Binding Cassette Transporter C4 (ABCC4), will potentiate anti-inflammatory responses of mainstay LABA/GCS therapy.	Cyclic AMP	37-41	ATP binding cassette subfamily C member 4	Homo sapiens	158-193
34666750-5	2021	HYPOTHESIS: Increasing intracellular cAMP during LABA/GCS combination therapy via inhibiting phosphodiesterase 4 (PDE4) and/or blocking the export of cAMP by ATP Binding Cassette Transporter C4 (ABCC4), will potentiate anti-inflammatory responses of mainstay LABA/GCS therapy.	Cyclic AMP	37-41	ATP binding cassette subfamily C member 4	Homo sapiens	195-200
34666750-5	2021	HYPOTHESIS: Increasing intracellular cAMP during LABA/GCS combination therapy via inhibiting phosphodiesterase 4 (PDE4) and/or blocking the export of cAMP by ATP Binding Cassette Transporter C4 (ABCC4), will potentiate anti-inflammatory responses of mainstay LABA/GCS therapy.	Cyclic AMP	150-154	ATP binding cassette subfamily C member 4	Homo sapiens	158-193
34666750-5	2021	HYPOTHESIS: Increasing intracellular cAMP during LABA/GCS combination therapy via inhibiting phosphodiesterase 4 (PDE4) and/or blocking the export of cAMP by ATP Binding Cassette Transporter C4 (ABCC4), will potentiate anti-inflammatory responses of mainstay LABA/GCS therapy.	Cyclic AMP	150-154	ATP binding cassette subfamily C member 4	Homo sapiens	195-200
34666750-10	2021	LABA/GCS attenuation of Poly I:C or imiquimod-induced IL-6 and IL-8 were potentiated with ABCC4 and PDE4 inhibition, which was greater when ABCC4 and PDE4 inhibition was combined.	Poly I	24-30	ATP binding cassette subfamily C member 4	Homo sapiens	90-95
34666750-10	2021	LABA/GCS attenuation of Poly I:C or imiquimod-induced IL-6 and IL-8 were potentiated with ABCC4 and PDE4 inhibition, which was greater when ABCC4 and PDE4 inhibition was combined.	Imiquimod	36-45	ATP binding cassette subfamily C member 4	Homo sapiens	140-145
34666750-12	2021	CONCLUSION: Modulation of intracellular cAMP levels by PDE4 or ABCC4 inhibition potentiates LABA/GCS efficacy in human airway epithelial cells challenged with viral stimuli.	Cyclic AMP	40-44	ATP binding cassette subfamily C member 4	Homo sapiens	63-68
34703277-11	2021	Furthermore, there was a trend of higher TAF AUC and shorter tenofovir t1/2 for the rs2032582 (ABCB1) T allele and rs3742106 (ABCC4) CC variant, respectively, although not statistically significant in the multiple linear regression analysis.	Tenofovir	61-70	ATP binding cassette subfamily C member 4	Homo sapiens	126-131
34497279-7	2021	Remdesivir strongly inhibited MRP4, OATP1B1/1B3, MATE1 and OCT1.	remdesivir	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
34503865-9	2021	Conversely, loss-of-function polymorphisms in other genes that encode transporters involved in urate excretion (ABCG2, ABCC4) can lead to hyperuricaemia.	Uric Acid	95-100	ATP binding cassette subfamily C member 4	Homo sapiens	119-124
34164937-4	2021	A comprehensive PBPK model accounting for intestinal (OATP2B1, BCRP), hepatic (OATP1B, BCRP, MRP4) and renal (OAT3) transport mechanisms was developed for rosuvastatin.	Rosuvastatin Calcium	155-167	ATP binding cassette subfamily C member 4	Homo sapiens	93-97
34205602-6	2021	Sildenafil has also demonstrated inhibitory effects on the efflux activity of ATP-binding cassette (ABC) transporters such as ABCC4, ABCC5, ABCB1, and ABCG2, ultimately reversing multidrug resistance.	Sildenafil Citrate	0-10	ATP binding cassette subfamily C member 4	Homo sapiens	126-131
34162690-7	2021	MRP4 transported fluvastatin and rosuvastatin.	Fluvastatin	17-28	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
34162690-7	2021	MRP4 transported fluvastatin and rosuvastatin.	Rosuvastatin Calcium	33-45	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
34442427-2	2021	The purpose of this study was to investigate the association between genetic polymorphisms of drug-metabolizing enzymes (TPMT 719A > G (*3C), ITPA 94C > A and ITPA 123G > A) and drug transporters (MRP4 912C > A and MRP4 2269G > A) with 6-MP-related myelotoxicity and hepatotoxicity in Thai children with acute lymphoblastic leukemia (ALL).	Mercaptopurine	236-240	ATP binding cassette subfamily C member 4	Homo sapiens	197-201
34442427-2	2021	The purpose of this study was to investigate the association between genetic polymorphisms of drug-metabolizing enzymes (TPMT 719A > G (*3C), ITPA 94C > A and ITPA 123G > A) and drug transporters (MRP4 912C > A and MRP4 2269G > A) with 6-MP-related myelotoxicity and hepatotoxicity in Thai children with acute lymphoblastic leukemia (ALL).	Mercaptopurine	236-240	ATP binding cassette subfamily C member 4	Homo sapiens	215-219
35226228-0	2022	IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4.	gemcitabine	21-32	ATP binding cassette subfamily C member 4	Homo sapiens	87-92
34094932-0	2021	HOXA13, Negatively Regulated by miR-139-5p, Decreases the Sensitivity of Gastric Cancer to 5-Fluorouracil Possibly by Targeting ABCC4.	mir-139-5p	32-42	ATP binding cassette subfamily C member 4	Homo sapiens	128-133
34094932-0	2021	HOXA13, Negatively Regulated by miR-139-5p, Decreases the Sensitivity of Gastric Cancer to 5-Fluorouracil Possibly by Targeting ABCC4.	Fluorouracil	91-105	ATP binding cassette subfamily C member 4	Homo sapiens	128-133
34094932-12	2021	Mechanistically, HOXA13, directly targeted by miR-139-5p in GC, might upregulate ABCC4 expression, thereby accentuating 5-FU resistance of GC cells.	mir-139-5p	46-56	ATP binding cassette subfamily C member 4	Homo sapiens	81-86
34094932-12	2021	Mechanistically, HOXA13, directly targeted by miR-139-5p in GC, might upregulate ABCC4 expression, thereby accentuating 5-FU resistance of GC cells.	Fluorouracil	120-124	ATP binding cassette subfamily C member 4	Homo sapiens	81-86
34094932-13	2021	Conclusion: Our study suggests that HOXA13 attenuates 5-FU sensitivity of GC possibly by upregulating ABCC4.	Fluorouracil	54-58	ATP binding cassette subfamily C member 4	Homo sapiens	102-107
33610566-7	2021	Furthermore, BCRP, MRP1, and MRP4 transporters were identified as the most important contributors to glucuronides excretion in HeLa1A1 cells based on gene silencing method.	Glucuronides	101-113	ATP binding cassette subfamily C member 4	Homo sapiens	29-33
35461219-11	2022	The DNA methylase inhibitor 5-aza-2"-deoxycytidine and the histone deacetylase inhibitor trichostatin A increased the expression levels of BCRP, MRP1, MRP2, MRP3, and MRP4 transcripts in T47D/WT cells.	Decitabine	28-50	ATP binding cassette subfamily C member 4	Homo sapiens	167-171
35461219-11	2022	The DNA methylase inhibitor 5-aza-2"-deoxycytidine and the histone deacetylase inhibitor trichostatin A increased the expression levels of BCRP, MRP1, MRP2, MRP3, and MRP4 transcripts in T47D/WT cells.	trichostatin A	89-103	ATP binding cassette subfamily C member 4	Homo sapiens	167-171
35381563-10	2022	Collectively, our findings indicated that ABCC4 might be a predictive biomarker of selinexor sensitivity in MM patients, which could be enhanced if combined with immunotherapy drugs such as TIM-3 inhibitor.	selinexor	83-92	ATP binding cassette subfamily C member 4	Homo sapiens	42-47
35295075-2	2022	MRP4 represents a transporter for cyclic nucleotides as well as for certain lipid mediators.	Nucleotides, Cyclic	34-52	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
35295075-4	2022	Transport assays in isolated membrane vesicles showed a concentration-dependent inhibition of MRP4-mediated transport of cyclic nucleotides, thromboxane (Tx)B2 and fluorescein (FITC)-labeled sphingosine-1-phosphate (S1P) by the selective MRP4 inhibitor Ceefourin-1.	Nucleotides, Cyclic	121-139	ATP binding cassette subfamily C member 4	Homo sapiens	94-98
35295075-4	2022	Transport assays in isolated membrane vesicles showed a concentration-dependent inhibition of MRP4-mediated transport of cyclic nucleotides, thromboxane (Tx)B2 and fluorescein (FITC)-labeled sphingosine-1-phosphate (S1P) by the selective MRP4 inhibitor Ceefourin-1.	Nucleotides, Cyclic	121-139	ATP binding cassette subfamily C member 4	Homo sapiens	238-242
35295075-4	2022	Transport assays in isolated membrane vesicles showed a concentration-dependent inhibition of MRP4-mediated transport of cyclic nucleotides, thromboxane (Tx)B2 and fluorescein (FITC)-labeled sphingosine-1-phosphate (S1P) by the selective MRP4 inhibitor Ceefourin-1.	thromboxane (tx)b2	141-159	ATP binding cassette subfamily C member 4	Homo sapiens	94-98
35295075-4	2022	Transport assays in isolated membrane vesicles showed a concentration-dependent inhibition of MRP4-mediated transport of cyclic nucleotides, thromboxane (Tx)B2 and fluorescein (FITC)-labeled sphingosine-1-phosphate (S1P) by the selective MRP4 inhibitor Ceefourin-1.	Fluorescein	164-175	ATP binding cassette subfamily C member 4	Homo sapiens	94-98
35295075-4	2022	Transport assays in isolated membrane vesicles showed a concentration-dependent inhibition of MRP4-mediated transport of cyclic nucleotides, thromboxane (Tx)B2 and fluorescein (FITC)-labeled sphingosine-1-phosphate (S1P) by the selective MRP4 inhibitor Ceefourin-1.	Fluorescein	164-175	ATP binding cassette subfamily C member 4	Homo sapiens	238-242
35295075-4	2022	Transport assays in isolated membrane vesicles showed a concentration-dependent inhibition of MRP4-mediated transport of cyclic nucleotides, thromboxane (Tx)B2 and fluorescein (FITC)-labeled sphingosine-1-phosphate (S1P) by the selective MRP4 inhibitor Ceefourin-1.	Fluorescein-5-isothiocyanate	177-181	ATP binding cassette subfamily C member 4	Homo sapiens	94-98
35295075-4	2022	Transport assays in isolated membrane vesicles showed a concentration-dependent inhibition of MRP4-mediated transport of cyclic nucleotides, thromboxane (Tx)B2 and fluorescein (FITC)-labeled sphingosine-1-phosphate (S1P) by the selective MRP4 inhibitor Ceefourin-1.	Fluorescein-5-isothiocyanate	177-181	ATP binding cassette subfamily C member 4	Homo sapiens	238-242
35295075-4	2022	Transport assays in isolated membrane vesicles showed a concentration-dependent inhibition of MRP4-mediated transport of cyclic nucleotides, thromboxane (Tx)B2 and fluorescein (FITC)-labeled sphingosine-1-phosphate (S1P) by the selective MRP4 inhibitor Ceefourin-1.	sphingosine 1-phosphate	191-214	ATP binding cassette subfamily C member 4	Homo sapiens	94-98
35295075-4	2022	Transport assays in isolated membrane vesicles showed a concentration-dependent inhibition of MRP4-mediated transport of cyclic nucleotides, thromboxane (Tx)B2 and fluorescein (FITC)-labeled sphingosine-1-phosphate (S1P) by the selective MRP4 inhibitor Ceefourin-1.	sphingosine 1-phosphate	191-214	ATP binding cassette subfamily C member 4	Homo sapiens	238-242
35295075-4	2022	Transport assays in isolated membrane vesicles showed a concentration-dependent inhibition of MRP4-mediated transport of cyclic nucleotides, thromboxane (Tx)B2 and fluorescein (FITC)-labeled sphingosine-1-phosphate (S1P) by the selective MRP4 inhibitor Ceefourin-1.	sphingosine 1-phosphate	216-219	ATP binding cassette subfamily C member 4	Homo sapiens	94-98
35295075-4	2022	Transport assays in isolated membrane vesicles showed a concentration-dependent inhibition of MRP4-mediated transport of cyclic nucleotides, thromboxane (Tx)B2 and fluorescein (FITC)-labeled sphingosine-1-phosphate (S1P) by the selective MRP4 inhibitor Ceefourin-1.	ceefourin 1	253-264	ATP binding cassette subfamily C member 4	Homo sapiens	94-98
33964863-6	2021	Especially, the possible role of MRP4 in the excretion of xenobiotic and antiplatelet drugs such as aspirin is discussed, thus imparting platelet aspirin tolerance and correlating the protein with the ineffectiveness of aspirin antiplatelet therapy.	Aspirin	100-107	ATP binding cassette subfamily C member 4	Homo sapiens	33-37
33964863-6	2021	Especially, the possible role of MRP4 in the excretion of xenobiotic and antiplatelet drugs such as aspirin is discussed, thus imparting platelet aspirin tolerance and correlating the protein with the ineffectiveness of aspirin antiplatelet therapy.	Aspirin	146-153	ATP binding cassette subfamily C member 4	Homo sapiens	33-37
33964863-6	2021	Especially, the possible role of MRP4 in the excretion of xenobiotic and antiplatelet drugs such as aspirin is discussed, thus imparting platelet aspirin tolerance and correlating the protein with the ineffectiveness of aspirin antiplatelet therapy.	Aspirin	146-153	ATP binding cassette subfamily C member 4	Homo sapiens	33-37
35129779-5	2022	The efflux of dasatinib is also regulated by ABCC4 and ABCC6 transporters.	Dasatinib	14-23	ATP binding cassette subfamily C member 4	Homo sapiens	45-50
35342392-13	2022	It also revealed that ABCC4 might play a role in HCC by regulating epithelial-mesenchymal transition, cytidine analog pathway, met pathway, and so forth.	Cytidine	102-110	ATP binding cassette subfamily C member 4	Homo sapiens	22-27
35126121-9	2021	Further, experiments showed that the PG exporter ATP-binding cassette transporter multidrug resistance protein 4 (MRP-4) is targeted by the inhibitors and may be involved in the 5-LO inhibitor-mediated PGE2 inhibition.	Dinoprostone	202-206	ATP binding cassette subfamily C member 4	Homo sapiens	114-119
33851387-0	2021	Role of membrane lipid rafts in MRP4 (ABCC4)-dependent regulation of the cAMP pathway in blood platelets.	Cyclic AMP	73-77	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
33946595-1	2021	Multidrug resistance-associated protein 4 (MRP4), a member of the adenosine triphosphate (ATP) binding cassette transporter family, pumps various molecules out of the cell and is involved in cell communication and drug distribution.	Adenosine	66-75	ATP binding cassette subfamily C member 4	Homo sapiens	0-41
33946595-1	2021	Multidrug resistance-associated protein 4 (MRP4), a member of the adenosine triphosphate (ATP) binding cassette transporter family, pumps various molecules out of the cell and is involved in cell communication and drug distribution.	Adenosine	66-75	ATP binding cassette subfamily C member 4	Homo sapiens	43-47
33850298-5	2021	In patients with an eGFR decrement >25%, plus a decline in GFR category and TDF discontinuation, a difference was observed for ABCC4 c.*38T>G (35 subjects TG + GG vs. 18 TT, p = 0.052).	Thioguanine	155-157	ATP binding cassette subfamily C member 4	Homo sapiens	127-132
33850298-7	2021	The stronger associations were found between the tenofovir accumulation and ABCC4 c.*38T>G and c.3348G>A: the percentage of these patients was higher in the TG + GG (p = 0.011) and in the AA (p = 0.004) genotype, respectively.	Tenofovir	49-58	ATP binding cassette subfamily C member 4	Homo sapiens	76-81
33850298-10	2021	Our results show a major role for a combined determination of ABCC4/ABCC10 variants as an indicator of tenofovir toxicity in the clinical practice.	Tenofovir	103-112	ATP binding cassette subfamily C member 4	Homo sapiens	62-67
33850298-0	2021	ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment.	Tenofovir	52-81	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
33851387-0	2021	Role of membrane lipid rafts in MRP4 (ABCC4)-dependent regulation of the cAMP pathway in blood platelets.	Cyclic AMP	73-77	ATP binding cassette subfamily C member 4	Homo sapiens	38-43
33851387-3	2021	As lipid rafts have been shown to interfere on cAMP homeostasis, we evaluated the relationships between the distribution and activity of MRP4 in lipid rafts and cAMP efflux.	Cyclic AMP	161-165	ATP binding cassette subfamily C member 4	Homo sapiens	137-141
33827559-14	2021	In BeWo cells, dexamethasone induced GR translocation into the nucleus; decreased FXR, OATP2B1, and BCRP expression; and increased MRP4 expression.	Dexamethasone	15-28	ATP binding cassette subfamily C member 4	Homo sapiens	131-135
33827559-15	2021	Furthermore, GR was verified to mediate the downregulation of OATP2B1, while FXR mediated dexamethasone-altered expression of BCRP and MRP4.	Dexamethasone	90-103	ATP binding cassette subfamily C member 4	Homo sapiens	135-139
32803738-0	2021	MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation.	Nitric Oxide	49-61	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
33529712-6	2021	Genomic proximity is shared with physical proximity, with ABCC4 and CFTR physically coupled in cell membrane microenvironments of epithelial cells to orchestrate functional consequences of cyclic-adenosine monophosphate (cAMP)-dependent second messenger signaling and extracellular transport of endogenous and exogenous substrates.	Adenosine	196-205	ATP binding cassette subfamily C member 4	Homo sapiens	58-63
33529712-6	2021	Genomic proximity is shared with physical proximity, with ABCC4 and CFTR physically coupled in cell membrane microenvironments of epithelial cells to orchestrate functional consequences of cyclic-adenosine monophosphate (cAMP)-dependent second messenger signaling and extracellular transport of endogenous and exogenous substrates.	Cyclic AMP	221-225	ATP binding cassette subfamily C member 4	Homo sapiens	58-63
33472814-13	2021	The study also illustrated the major role of BSEP relative to basolateral MRP3 and MRP4 in transport of bile salts in SHH.	Bile Acids and Salts	104-114	ATP binding cassette subfamily C member 4	Homo sapiens	83-87
32803738-0	2021	MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation.	Adenosine Diphosphate	106-109	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
32803738-1	2021	The impact of inhibition of multidrug resistance protein 4 (MRP4) on nitric oxide (NO) resistance and on ADP-induced platelet aggregation is unknown.	Nitric Oxide	69-81	ATP binding cassette subfamily C member 4	Homo sapiens	60-64
32803738-2	2021	The aim of this investigation was to verify whether platelet NO resistance correlates with MRP4 expression and evaluate whether this can be reduced by in vitro MRP4 inhibition mediated by cilostazol.	Cilostazol	188-198	ATP binding cassette subfamily C member 4	Homo sapiens	160-164
32803738-3	2021	Moreover, we assessed if inhibition of MRP4-mediated transport reduces ADP-induced platelet reactivity.	Adenosine Diphosphate	71-74	ATP binding cassette subfamily C member 4	Homo sapiens	39-43
32803738-6	2021	The impact of MRP4 on ADP-induced platelet aggregation was performed in high on aspirin residual platelet reactivity (HARPR) patients and compared to healthy volunteers (HV), and a control cohort (CTR).	Adenosine Diphosphate	22-25	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
32803738-7	2021	In aspirin-treated patients with high levels of MRP4, reduced SNP inhibition was found compared to those with low levels of MRP4.	Aspirin	3-10	ATP binding cassette subfamily C member 4	Homo sapiens	48-52
32803738-7	2021	In aspirin-treated patients with high levels of MRP4, reduced SNP inhibition was found compared to those with low levels of MRP4.	Aspirin	3-10	ATP binding cassette subfamily C member 4	Homo sapiens	124-128
32803738-8	2021	MRP4 inhibition by cilostazol significantly reduced ADP-induced platelet aggregation in HARPR population, and to a lesser extent in HV and CTR populations.	Cilostazol	19-29	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
32803738-8	2021	MRP4 inhibition by cilostazol significantly reduced ADP-induced platelet aggregation in HARPR population, and to a lesser extent in HV and CTR populations.	Adenosine Diphosphate	52-55	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
32333821-0	2021	Multidrug resistance protein 4 (MRP4/ABCC4) expression is regulated by histamine in acute myeloid leukemia cells, determining cAMP efflux.	Histamine	71-80	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
33771682-0	2021	Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF-kappaB/P65 pathway.	Doxorubicin	23-33	ATP binding cassette subfamily C member 4	Homo sapiens	95-100
33417247-8	2021	Lack of Mrp4 activity in both of our in vivo and in vitro models leads to increased activation of adipose tissue cAMP response element-binding protein (Creb) and decreased plasma prostaglandin E (PGE) metabolite levels.	Prostaglandins E	179-194	ATP binding cassette subfamily C member 4	Homo sapiens	8-12
33417247-8	2021	Lack of Mrp4 activity in both of our in vivo and in vitro models leads to increased activation of adipose tissue cAMP response element-binding protein (Creb) and decreased plasma prostaglandin E (PGE) metabolite levels.	Prostaglandins E	196-199	ATP binding cassette subfamily C member 4	Homo sapiens	8-12
33441643-5	2021	Our aim was to test cyclic AMP (cAMP) modulation, through ATP Binding Cassette Transporter C4 (ABCC4) and phosphodiesterase-4 (PDE-4) inhibition, as a potential add-on therapeutic to a clinically approved CFTR modulator, VX-770, as a method for increasing CFTR activity.	Cyclic AMP	20-30	ATP binding cassette subfamily C member 4	Homo sapiens	58-93
33441643-5	2021	Our aim was to test cyclic AMP (cAMP) modulation, through ATP Binding Cassette Transporter C4 (ABCC4) and phosphodiesterase-4 (PDE-4) inhibition, as a potential add-on therapeutic to a clinically approved CFTR modulator, VX-770, as a method for increasing CFTR activity.	Cyclic AMP	20-30	ATP binding cassette subfamily C member 4	Homo sapiens	95-100
33441643-5	2021	Our aim was to test cyclic AMP (cAMP) modulation, through ATP Binding Cassette Transporter C4 (ABCC4) and phosphodiesterase-4 (PDE-4) inhibition, as a potential add-on therapeutic to a clinically approved CFTR modulator, VX-770, as a method for increasing CFTR activity.	Cyclic AMP	32-36	ATP binding cassette subfamily C member 4	Homo sapiens	58-93
33441643-5	2021	Our aim was to test cyclic AMP (cAMP) modulation, through ATP Binding Cassette Transporter C4 (ABCC4) and phosphodiesterase-4 (PDE-4) inhibition, as a potential add-on therapeutic to a clinically approved CFTR modulator, VX-770, as a method for increasing CFTR activity.	Cyclic AMP	32-36	ATP binding cassette subfamily C member 4	Homo sapiens	95-100
33441643-6	2021	Human airway epithelial cells (Calu-3) were used to test the efficacy of cAMP modulation by ABCC4 and PDE-4 inhibition through a series of concentration-response studies.	Cyclic AMP	73-77	ATP binding cassette subfamily C member 4	Homo sapiens	92-97
33510641-0	2020	Characterization of Formononetin Sulfonation in SULT1A3 Overexpressing HKE293 Cells: Involvement of Multidrug Resistance-Associated Protein 4 in Excretion of Sulfate.	Sulfates	158-165	ATP binding cassette subfamily C member 4	Homo sapiens	100-141
33307708-5	2021	Our data indicates that 4-Cl-KYN crosses the blood-brain barrier via the amino acid transporter LAT1 (SLC7A5) after which the 7-Cl-KYNA metabolite leaves the brain extracellular fluid via probenecid-sensitive organic anion transporters OAT1/3 (SLC22A6 and SLC22A8) and MRP4 (ABCC4).	4-cl	24-28	ATP binding cassette subfamily C member 4	Homo sapiens	269-273
33307708-5	2021	Our data indicates that 4-Cl-KYN crosses the blood-brain barrier via the amino acid transporter LAT1 (SLC7A5) after which the 7-Cl-KYNA metabolite leaves the brain extracellular fluid via probenecid-sensitive organic anion transporters OAT1/3 (SLC22A6 and SLC22A8) and MRP4 (ABCC4).	4-cl	24-28	ATP binding cassette subfamily C member 4	Homo sapiens	275-280
33582321-0	2021	Effect of bile acids on the MRP3 and MRP4 expression: in vitro study on HepG2 cells.	Bile Acids and Salts	10-20	ATP binding cassette subfamily C member 4	Homo sapiens	37-41
33582321-12	2021	CONCLUSION: Primary bile acids (CDCA and CA) induce overexpression of the MRP4 and MRP3 transporters in the HepG2 cell line.	Bile Acids and Salts	20-30	ATP binding cassette subfamily C member 4	Homo sapiens	74-78
33582321-12	2021	CONCLUSION: Primary bile acids (CDCA and CA) induce overexpression of the MRP4 and MRP3 transporters in the HepG2 cell line.	Chenodeoxycholic Acid	32-36	ATP binding cassette subfamily C member 4	Homo sapiens	74-78
33307708-5	2021	Our data indicates that 4-Cl-KYN crosses the blood-brain barrier via the amino acid transporter LAT1 (SLC7A5) after which the 7-Cl-KYNA metabolite leaves the brain extracellular fluid via probenecid-sensitive organic anion transporters OAT1/3 (SLC22A6 and SLC22A8) and MRP4 (ABCC4).	7-cl	126-130	ATP binding cassette subfamily C member 4	Homo sapiens	269-273
33307708-5	2021	Our data indicates that 4-Cl-KYN crosses the blood-brain barrier via the amino acid transporter LAT1 (SLC7A5) after which the 7-Cl-KYNA metabolite leaves the brain extracellular fluid via probenecid-sensitive organic anion transporters OAT1/3 (SLC22A6 and SLC22A8) and MRP4 (ABCC4).	7-cl	126-130	ATP binding cassette subfamily C member 4	Homo sapiens	275-280
33307708-5	2021	Our data indicates that 4-Cl-KYN crosses the blood-brain barrier via the amino acid transporter LAT1 (SLC7A5) after which the 7-Cl-KYNA metabolite leaves the brain extracellular fluid via probenecid-sensitive organic anion transporters OAT1/3 (SLC22A6 and SLC22A8) and MRP4 (ABCC4).	Probenecid	188-198	ATP binding cassette subfamily C member 4	Homo sapiens	269-273
33307708-5	2021	Our data indicates that 4-Cl-KYN crosses the blood-brain barrier via the amino acid transporter LAT1 (SLC7A5) after which the 7-Cl-KYNA metabolite leaves the brain extracellular fluid via probenecid-sensitive organic anion transporters OAT1/3 (SLC22A6 and SLC22A8) and MRP4 (ABCC4).	Probenecid	188-198	ATP binding cassette subfamily C member 4	Homo sapiens	275-280
33307708-8	2021	In summary, our data show that 4-Cl-KYN crosses the BBB using LAT1, while its active metabolite, 7-Cl-KYNA, is rapidly transported out of the brain via OAT1/3 and MRP4.	7-cl	97-101	ATP binding cassette subfamily C member 4	Homo sapiens	163-167
32333821-5	2021	In this study, we show that histamine treatment induces MRP4/ABCC4 expression, augmenting cAMP efflux and that histamine, in combination with MRP inhibitors, is able to reduce AML cell proliferation.	Histamine	28-37	ATP binding cassette subfamily C member 4	Homo sapiens	56-60
32333821-5	2021	In this study, we show that histamine treatment induces MRP4/ABCC4 expression, augmenting cAMP efflux and that histamine, in combination with MRP inhibitors, is able to reduce AML cell proliferation.	Histamine	28-37	ATP binding cassette subfamily C member 4	Homo sapiens	61-66
32333821-6	2021	Histamine, through histamine H2 receptor, increases i-cAMP levels and induces MRP4 transcript and protein levels in U937, KG1a, and HL-60 cells.	Histamine	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	78-82
32333821-7	2021	Moreover, histamine induces MRP4 promoter activity in HEK293T cells transfected with histamine H2 receptor (HEK293T-H2 R).	Histamine	10-19	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
32333821-8	2021	Our results support that the cAMP/Epac-PKA pathway, and not MEK/ERK nor PI3K/AKT signaling cascades, is involved in histamine mediated upregulation of MRP4 levels.	Cyclic AMP	29-33	ATP binding cassette subfamily C member 4	Homo sapiens	151-155
32333821-8	2021	Our results support that the cAMP/Epac-PKA pathway, and not MEK/ERK nor PI3K/AKT signaling cascades, is involved in histamine mediated upregulation of MRP4 levels.	Histamine	116-125	ATP binding cassette subfamily C member 4	Homo sapiens	151-155
32333821-9	2021	Finally, the addition of histamine potentiates the inhibition of U937, KG1a, and HL-60 cell proliferation induced by MRP4 inhibitors.	Histamine	25-34	ATP binding cassette subfamily C member 4	Homo sapiens	117-121
32333821-0	2021	Multidrug resistance protein 4 (MRP4/ABCC4) expression is regulated by histamine in acute myeloid leukemia cells, determining cAMP efflux.	Histamine	71-80	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
32333821-0	2021	Multidrug resistance protein 4 (MRP4/ABCC4) expression is regulated by histamine in acute myeloid leukemia cells, determining cAMP efflux.	Cyclic AMP	126-130	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
32333821-0	2021	Multidrug resistance protein 4 (MRP4/ABCC4) expression is regulated by histamine in acute myeloid leukemia cells, determining cAMP efflux.	Cyclic AMP	126-130	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
32333821-4	2021	Acting through histamine H2 receptors histamine increases cAMP production/synthesis, while MRP4/ABCC4 is responsible for the exclusion of this cyclic nucleotide.	Histamine	15-24	ATP binding cassette subfamily C member 4	Homo sapiens	96-101
32333821-4	2021	Acting through histamine H2 receptors histamine increases cAMP production/synthesis, while MRP4/ABCC4 is responsible for the exclusion of this cyclic nucleotide.	Nucleotides, Cyclic	143-160	ATP binding cassette subfamily C member 4	Homo sapiens	91-95
32333821-4	2021	Acting through histamine H2 receptors histamine increases cAMP production/synthesis, while MRP4/ABCC4 is responsible for the exclusion of this cyclic nucleotide.	Nucleotides, Cyclic	143-160	ATP binding cassette subfamily C member 4	Homo sapiens	96-101
33011162-8	2020	Silencing of hnRNPA2 decreased apigenin-induced sensitization to doxorubicin in spheroids by diminishing apoptosis and partly abrogated apigenin-mediated reduction of ABCC4 and ABCG2 efflux transporters.	Apigenin	31-39	ATP binding cassette subfamily C member 4	Homo sapiens	167-172
33127749-13	2021	Additionally, we show that coproporphyrin I and III (CP I and III) are substrates of MRP4.	coproporphyrin i and iii	27-51	ATP binding cassette subfamily C member 4	Homo sapiens	85-89
33127749-13	2021	Additionally, we show that coproporphyrin I and III (CP I and III) are substrates of MRP4.	cp i and iii	53-65	ATP binding cassette subfamily C member 4	Homo sapiens	85-89
32820679-0	2021	MRP4 is responsible for the efflux transport of mycophenolic acid beta-d glucuronide (MPAG) from hepatocytes to blood.	Mycophenolic Acid	48-65	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
32820679-0	2021	MRP4 is responsible for the efflux transport of mycophenolic acid beta-d glucuronide (MPAG) from hepatocytes to blood.	beta-d glucuronide	66-84	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
32820679-0	2021	MRP4 is responsible for the efflux transport of mycophenolic acid beta-d glucuronide (MPAG) from hepatocytes to blood.	mycophenolic acid glucuronide	86-90	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
32820679-6	2021	In vitro experiments using vesicles overexpressing MRP4 showed an ATP-dependent transport of MPAG driven by MRP4 (Michaelis-Menten constant of 233.9 +- 32.8 microM).	Adenosine Triphosphate	66-69	ATP binding cassette subfamily C member 4	Homo sapiens	51-55
32820679-6	2021	In vitro experiments using vesicles overexpressing MRP4 showed an ATP-dependent transport of MPAG driven by MRP4 (Michaelis-Menten constant of 233.9 +- 32.8 microM).	Adenosine Triphosphate	66-69	ATP binding cassette subfamily C member 4	Homo sapiens	108-112
32820679-6	2021	In vitro experiments using vesicles overexpressing MRP4 showed an ATP-dependent transport of MPAG driven by MRP4 (Michaelis-Menten constant of 233.9 +- 32.8 microM).	mycophenolic acid glucuronide	93-97	ATP binding cassette subfamily C member 4	Homo sapiens	51-55
32820679-6	2021	In vitro experiments using vesicles overexpressing MRP4 showed an ATP-dependent transport of MPAG driven by MRP4 (Michaelis-Menten constant of 233.9 +- 32.8 microM).	mycophenolic acid glucuronide	93-97	ATP binding cassette subfamily C member 4	Homo sapiens	108-112
32820679-8	2021	MRP4-mediated transport of MPAG was inhibited (from -43% to -84%) by ibuprofen, cefazolin, cefotaxime and micafungin.	mycophenolic acid glucuronide	27-31	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
32820679-8	2021	MRP4-mediated transport of MPAG was inhibited (from -43% to -84%) by ibuprofen, cefazolin, cefotaxime and micafungin.	Ibuprofen	69-78	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
32820679-8	2021	MRP4-mediated transport of MPAG was inhibited (from -43% to -84%) by ibuprofen, cefazolin, cefotaxime and micafungin.	Cefazolin	80-89	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
32820679-8	2021	MRP4-mediated transport of MPAG was inhibited (from -43% to -84%) by ibuprofen, cefazolin, cefotaxime and micafungin.	Cefotaxime	91-101	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
32820679-8	2021	MRP4-mediated transport of MPAG was inhibited (from -43% to -84%) by ibuprofen, cefazolin, cefotaxime and micafungin.	Micafungin	106-116	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
32820679-9	2021	An in silico approach based on molecular docking and molecular dynamics simulations rationalized the mode of binding of MPAG to MRP4.	mycophenolic acid glucuronide	120-124	ATP binding cassette subfamily C member 4	Homo sapiens	128-132
32820679-10	2021	The presence of the glucuronide moiety in MPAG was highlighted as key, being prone to make electrostatic and H-bond interactions with specific residues of the MRP4 protein chamber.	Glucuronides	20-31	ATP binding cassette subfamily C member 4	Homo sapiens	159-163
32820679-10	2021	The presence of the glucuronide moiety in MPAG was highlighted as key, being prone to make electrostatic and H-bond interactions with specific residues of the MRP4 protein chamber.	mycophenolic acid glucuronide	42-46	ATP binding cassette subfamily C member 4	Homo sapiens	159-163
32820679-11	2021	This explains why MPAG is a substrate of MRP4 whereas MPA is not.	mycophenolic acid glucuronide	18-22	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
33375210-0	2020	Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy.	1,4-dihydropyridine	31-51	ATP binding cassette subfamily C member 4	Homo sapiens	98-102
33375210-8	2020	All compounds showed better activities than the best known MRP4 inhibitor MK571 in an MRP4-overexpressing cell line assay, and the activities could be related to the various substitution patterns of aromatic residues within the symmetric molecular framework.	verlukast	74-79	ATP binding cassette subfamily C member 4	Homo sapiens	59-63
33375210-8	2020	All compounds showed better activities than the best known MRP4 inhibitor MK571 in an MRP4-overexpressing cell line assay, and the activities could be related to the various substitution patterns of aromatic residues within the symmetric molecular framework.	verlukast	74-79	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
31948942-5	2020	The ATP-binding cassette transporter ABCC4 was identified as a modulator of SHH-MB.	Adenosine Triphosphate	4-7	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
32648321-12	2020	CONCLUSIONS: CYP1A1 and CYP2C9, UGT1A1, UGT1A7, UGT1A8 and UGT1A9, and MRP4 all played important roles in the metabolism and disposition of bavachin.	bavachin	140-148	ATP binding cassette subfamily C member 4	Homo sapiens	71-75
33081264-1	2020	ABCC1 and ABCC4 utilize energy from ATP hydrolysis to transport many different molecules, including drugs, out of the cell and, as such, have been implicated in causing drug resistance.	Adenosine Triphosphate	36-39	ATP binding cassette subfamily C member 4	Homo sapiens	10-15
32472168-0	2020	Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates.	Acetaminophen	81-92	ATP binding cassette subfamily C member 4	Homo sapiens	6-36
32472168-0	2020	Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates.	Acetaminophen	81-92	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
32472168-0	2020	Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates.	Glutathione	93-104	ATP binding cassette subfamily C member 4	Homo sapiens	6-36
32472168-0	2020	Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates.	Glutathione	93-104	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
32472168-0	2020	Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates.	Cysteine	109-117	ATP binding cassette subfamily C member 4	Homo sapiens	6-36
32472168-0	2020	Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates.	Cysteine	109-117	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
32472168-8	2020	Whereas P-gp, BSEP, MRP3, MRP5, and BCRP did not transport any of the compounds, uptake of APAP-GSH was found for MRP1, MRP2 and MRP4.	apap-gsh	91-99	ATP binding cassette subfamily C member 4	Homo sapiens	129-133
32472168-9	2020	APAP-CYS appeared to be a substrate of MRP4 and none of the ABC proteins transported APAP.	Acetaminophen	0-4	ATP binding cassette subfamily C member 4	Homo sapiens	39-43
32472168-9	2020	APAP-CYS appeared to be a substrate of MRP4 and none of the ABC proteins transported APAP.	Cysteine	5-8	ATP binding cassette subfamily C member 4	Homo sapiens	39-43
32472168-10	2020	The results suggest that the NAPQI metabolite APAP-CYS can be excreted into plasma by MRP4, where it could be a useful biomarker for APAP exposure and toxicity.	N-acetyl-4-benzoquinoneimine	29-34	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
32472168-10	2020	The results suggest that the NAPQI metabolite APAP-CYS can be excreted into plasma by MRP4, where it could be a useful biomarker for APAP exposure and toxicity.	3-Cysteinylacetaminophen Trifluoroacetic Acid Salt	46-54	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
32472168-10	2020	The results suggest that the NAPQI metabolite APAP-CYS can be excreted into plasma by MRP4, where it could be a useful biomarker for APAP exposure and toxicity.	Acetaminophen	46-50	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
32472168-11	2020	Characterization of the cellular efflux of APAP-CYS is important for its development as a biomarker, because plasma concentrations might be influenced by drug-transporter interactions and upregulation of MRP4.	Acetaminophen	43-47	ATP binding cassette subfamily C member 4	Homo sapiens	204-208
32472168-11	2020	Characterization of the cellular efflux of APAP-CYS is important for its development as a biomarker, because plasma concentrations might be influenced by drug-transporter interactions and upregulation of MRP4.	Cysteine	48-51	ATP binding cassette subfamily C member 4	Homo sapiens	204-208
33014785-0	2020	Increased ABCC4 Expression Induced by ERRalpha Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer.	Docetaxel	56-65	ATP binding cassette subfamily C member 4	Homo sapiens	10-15
33014785-0	2020	Increased ABCC4 Expression Induced by ERRalpha Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer.	Docetaxel	91-100	ATP binding cassette subfamily C member 4	Homo sapiens	10-15
33014785-6	2020	Moreover, both ERRalpha and ABCC4 were overexpressed in the docetaxel-resistant cell, which could be reversed by ERRalpha knockdown.	Docetaxel	60-69	ATP binding cassette subfamily C member 4	Homo sapiens	28-33
33014785-10	2020	In conclusion, our study demonstrated a critical role for ERRalpha in docetaxel resistance by directly targeting ABCC4 and stressed the importance of ERRalpha as a potential therapeutic target for drug-resistant PCa.	Docetaxel	70-79	ATP binding cassette subfamily C member 4	Homo sapiens	113-118
32544819-0	2020	ATP-Binding Cassette Transporter C4 is a Prostaglandin D2 Exporter in HMC-1 cells.	Prostaglandin D2	41-57	ATP binding cassette subfamily C member 4	Homo sapiens	0-35
32544819-2	2020	Some prostaglandins (PGs), including: PGE2, PGF2alpha, PGE3, and PGF3alpha are known substrates of ABCC4, and are released from some types of cells to exert their biological effects.	Prostaglandins	5-19	ATP binding cassette subfamily C member 4	Homo sapiens	99-104
32544819-2	2020	Some prostaglandins (PGs), including: PGE2, PGF2alpha, PGE3, and PGF3alpha are known substrates of ABCC4, and are released from some types of cells to exert their biological effects.	Prostaglandins	21-24	ATP binding cassette subfamily C member 4	Homo sapiens	99-104
32544819-2	2020	Some prostaglandins (PGs), including: PGE2, PGF2alpha, PGE3, and PGF3alpha are known substrates of ABCC4, and are released from some types of cells to exert their biological effects.	Dinoprostone	38-42	ATP binding cassette subfamily C member 4	Homo sapiens	99-104
32544819-2	2020	Some prostaglandins (PGs), including: PGE2, PGF2alpha, PGE3, and PGF3alpha are known substrates of ABCC4, and are released from some types of cells to exert their biological effects.	Dinoprost	44-53	ATP binding cassette subfamily C member 4	Homo sapiens	99-104
32544819-2	2020	Some prostaglandins (PGs), including: PGE2, PGF2alpha, PGE3, and PGF3alpha are known substrates of ABCC4, and are released from some types of cells to exert their biological effects.	prostaglandin E3	55-59	ATP binding cassette subfamily C member 4	Homo sapiens	99-104
32544819-2	2020	Some prostaglandins (PGs), including: PGE2, PGF2alpha, PGE3, and PGF3alpha are known substrates of ABCC4, and are released from some types of cells to exert their biological effects.	prostaglandin F3alpha	65-74	ATP binding cassette subfamily C member 4	Homo sapiens	99-104
32544819-3	2020	In the present study, we demonstrate that PGD2 is a novel substrate of ABCC4 using a transport assay based on inside-out membrane vesicles prepared from ABCC4-overexpressing cells.	Prostaglandin D2	42-46	ATP binding cassette subfamily C member 4	Homo sapiens	71-76
32544819-3	2020	In the present study, we demonstrate that PGD2 is a novel substrate of ABCC4 using a transport assay based on inside-out membrane vesicles prepared from ABCC4-overexpressing cells.	Prostaglandin D2	42-46	ATP binding cassette subfamily C member 4	Homo sapiens	153-158
32544819-6	2020	Pharmacological inhibition and knockdown of ABCC4 significantly reduced the extracellular levels of PGD2 by at least 53% in HMC-1 cells.	Prostaglandin D2	100-104	ATP binding cassette subfamily C member 4	Homo sapiens	44-49
32544819-8	2020	Therefore, our results suggest that ABCC4 functions as a PGD2 exporter in HMC-1 cells.	Prostaglandin D2	57-61	ATP binding cassette subfamily C member 4	Homo sapiens	36-41
32855883-5	2020	Screening of GSH/GSSG efflux transporters revealed Mrp1, Mrp4, and Mrp5 to be present at the transcript level, but only Mrp5 was expressed at the protein level.	Glutathione	13-16	ATP binding cassette subfamily C member 4	Homo sapiens	57-61
32855883-5	2020	Screening of GSH/GSSG efflux transporters revealed Mrp1, Mrp4, and Mrp5 to be present at the transcript level, but only Mrp5 was expressed at the protein level.	Glutathione Disulfide	17-21	ATP binding cassette subfamily C member 4	Homo sapiens	57-61
33164984-3	2020	The folate pathway genes SLC19A1, ABCC1, ABCC4, FPGS, and MTHFD1 significantly influenced intracellular MTXPG levels (P = 2.9 x 10-3 to 3.7 x 10-8).	Folic Acid	4-10	ATP binding cassette subfamily C member 4	Homo sapiens	41-46
33164984-3	2020	The folate pathway genes SLC19A1, ABCC1, ABCC4, FPGS, and MTHFD1 significantly influenced intracellular MTXPG levels (P = 2.9 x 10-3 to 3.7 x 10-8).	mtxpg	104-109	ATP binding cassette subfamily C member 4	Homo sapiens	41-46
33261018-0	2020	Implications of ABCC4-Mediated cAMP Eflux for CRC Migration.	camp eflux	31-41	ATP binding cassette subfamily C member 4	Homo sapiens	16-21
33261018-10	2020	The results of a functional study demonstrated that, in CRC, ABCC4 can regulate cell migration in a cyclic nucleotide-dependent manner.	Nucleotides, Cyclic	100-117	ATP binding cassette subfamily C member 4	Homo sapiens	61-66
33081378-2	2020	The levels of prostaglandin E2, a key player in the hallmarks of cancer, are mainly regulated by prostaglandin-endoperoxide synthase 2 (PTGS2) and ATP-binding cassette subfamily C member 4 (ABCC4), involved in its synthesis and exportation, respectively, and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and solute carrier organic anion transporter family member 2A1 (SLCO2A1), responsible for its inactivation.	Dinoprostone	14-30	ATP binding cassette subfamily C member 4	Homo sapiens	147-188
33081378-2	2020	The levels of prostaglandin E2, a key player in the hallmarks of cancer, are mainly regulated by prostaglandin-endoperoxide synthase 2 (PTGS2) and ATP-binding cassette subfamily C member 4 (ABCC4), involved in its synthesis and exportation, respectively, and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and solute carrier organic anion transporter family member 2A1 (SLCO2A1), responsible for its inactivation.	Dinoprostone	14-30	ATP binding cassette subfamily C member 4	Homo sapiens	190-195
32553977-7	2020	In addition, using cell culture models, we observed that MRP4 pharmacological inhibition produces an imbalance in cAMP metabolism, induces cell arrest, changes in lipid composition, increase in cytoplasmic lipid droplets and finally apoptosis.	Cyclic AMP	114-118	ATP binding cassette subfamily C member 4	Homo sapiens	57-61
32807664-8	2020	Transporter inhibition study highlighted that GLUT9 strongly and MRP4 intermediately contribute to the sinusoidal efflux of UA with minor contribution of NPT1/4.	Uric Acid	124-126	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
32272108-7	2020	Conversely, inhibition of efflux transporters ABCC1, ABCC4 or ABCG2 also restrained the transport of resveratrol across these cells.	Resveratrol	101-112	ATP binding cassette subfamily C member 4	Homo sapiens	53-58
31826245-2	2020	By combining whole-exome sequencing and comparative global proteomic investigations, we found a large deletion in the ABCC4/MRP4 gene encoding an ATP-binding cassette (ABC) transporter in PEL-negative individuals.	Adenosine Triphosphate	146-149	ATP binding cassette subfamily C member 4	Homo sapiens	118-123
31704245-13	2020	Our results explain the transporter-mediated disposition of androgen glucuronides in humans, and shed light on differences between the human efflux transporters MRP2, MRP3, MRP4, BCRP and MDR1.	Glucuronides	69-81	ATP binding cassette subfamily C member 4	Homo sapiens	173-177
31826245-2	2020	By combining whole-exome sequencing and comparative global proteomic investigations, we found a large deletion in the ABCC4/MRP4 gene encoding an ATP-binding cassette (ABC) transporter in PEL-negative individuals.	Adenosine Triphosphate	146-149	ATP binding cassette subfamily C member 4	Homo sapiens	124-128
31613845-9	2020	Also, ABCC4 and ABCC6 had more expression with high doses of Daunorubicin and L-Asparginase.	Daunorubicin	61-73	ATP binding cassette subfamily C member 4	Homo sapiens	6-11
30346895-9	2020	Mrp1 may contribute to [11C]2 efflux from brain parenchymal cells, while extracellular [11C]2 is likely cleared across the BBB, partly by Oat3 and Mrp4.	Carbon-11	88-91	ATP binding cassette subfamily C member 4	Homo sapiens	147-151
32999202-4	2020	Our studies clarified the efflux transport of prostaglandin E2 (PGE2), a modulator of neural excitation and inflammatory responses, across the BBB via plasma membrane transporters such as organic anion transporter 3 (Oat3) and multidrug resistance-associated protein 4 (Mrp4).	Dinoprostone	46-62	ATP binding cassette subfamily C member 4	Homo sapiens	227-268
32999202-4	2020	Our studies clarified the efflux transport of prostaglandin E2 (PGE2), a modulator of neural excitation and inflammatory responses, across the BBB via plasma membrane transporters such as organic anion transporter 3 (Oat3) and multidrug resistance-associated protein 4 (Mrp4).	Dinoprostone	46-62	ATP binding cassette subfamily C member 4	Homo sapiens	270-274
32999202-4	2020	Our studies clarified the efflux transport of prostaglandin E2 (PGE2), a modulator of neural excitation and inflammatory responses, across the BBB via plasma membrane transporters such as organic anion transporter 3 (Oat3) and multidrug resistance-associated protein 4 (Mrp4).	Dinoprostone	64-68	ATP binding cassette subfamily C member 4	Homo sapiens	227-268
32999202-4	2020	Our studies clarified the efflux transport of prostaglandin E2 (PGE2), a modulator of neural excitation and inflammatory responses, across the BBB via plasma membrane transporters such as organic anion transporter 3 (Oat3) and multidrug resistance-associated protein 4 (Mrp4).	Dinoprostone	64-68	ATP binding cassette subfamily C member 4	Homo sapiens	270-274
31774876-0	2019	Involvement of human and canine MRP1 and MRP4 in benzylpenicillin transport.	Penicillin G	49-65	ATP binding cassette subfamily C member 4	Homo sapiens	41-45
31335591-0	2019	Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.	Tenofovir	87-96	ATP binding cassette subfamily C member 4	Homo sapiens	35-40
31381456-6	2019	Here we report a comparative study using classical detergents, calixarene-based detergents, and SMA to assess the solubilization and stabilization of the human ABC transporter MRP4 (multidrug resistance protein 4/ABCC4).	Calixarenes	63-73	ATP binding cassette subfamily C member 4	Homo sapiens	176-180
31381456-6	2019	Here we report a comparative study using classical detergents, calixarene-based detergents, and SMA to assess the solubilization and stabilization of the human ABC transporter MRP4 (multidrug resistance protein 4/ABCC4).	Calixarenes	63-73	ATP binding cassette subfamily C member 4	Homo sapiens	213-218
31381456-7	2019	We show that both SMA and calixarene-based detergents have a higher solubility efficiency (at least 80%) than conventional detergents, and show striking overstabilization features of MRP4 (up to 70  C) with at least 30  C stability improvement in comparison with the best conventional detergents.	sma	18-21	ATP binding cassette subfamily C member 4	Homo sapiens	183-187
31381456-7	2019	We show that both SMA and calixarene-based detergents have a higher solubility efficiency (at least 80%) than conventional detergents, and show striking overstabilization features of MRP4 (up to 70  C) with at least 30  C stability improvement in comparison with the best conventional detergents.	Calixarenes	26-36	ATP binding cassette subfamily C member 4	Homo sapiens	183-187
31381456-8	2019	These solubilizing agents were successfully used to purify aggregate-free, homogenous and stable MRP4, with sevenfold higher yield for C4C7 calixarene detergent in comparison with SMA.	Calixarenes	140-150	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
31381456-9	2019	This work paves the way to MRP4 structural and functional investigations and illustrates once more the high value of using calixarene-based detergent or SMA as versatile and efficient tools to study MP, and eventually enable drug discovery of challenging and highly druggable targets.	Calixarenes	123-133	ATP binding cassette subfamily C member 4	Homo sapiens	27-31
31381460-8	2019	Vesicular transport assays were used to confirm that MRP4 expressed in Sf9 was functional using a fluorescent cAMP analogue (fluo-cAMP) instead of the traditional radiolabeled substrates.	Cyclic AMP	110-114	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
31381460-8	2019	Vesicular transport assays were used to confirm that MRP4 expressed in Sf9 was functional using a fluorescent cAMP analogue (fluo-cAMP) instead of the traditional radiolabeled substrates.	fluo-camp	125-134	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
31381460-9	2019	MRP4 transported fluo-cAMP in an ATP-dependent manner.	fluo-camp	17-26	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
31381460-9	2019	MRP4 transported fluo-cAMP in an ATP-dependent manner.	Adenosine Triphosphate	33-36	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
31381460-10	2019	The specificity of functional expression of MRP4 was validated by the use of nonhydrolyzable ATP analogues and MRP4 inhibitor MK571.	Adenosine Triphosphate	93-96	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
31381460-10	2019	The specificity of functional expression of MRP4 was validated by the use of nonhydrolyzable ATP analogues and MRP4 inhibitor MK571.	verlukast	126-131	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
31381460-10	2019	The specificity of functional expression of MRP4 was validated by the use of nonhydrolyzable ATP analogues and MRP4 inhibitor MK571.	verlukast	126-131	ATP binding cassette subfamily C member 4	Homo sapiens	111-115
31774876-4	2019	The aim of this study was to investigate the possible involvement of multidrug resistance-associated protein 1 and 4 (MRP1 and MRP4), two ABC transporters, in benzylpenicillin efflux transport using wild-type (WT) MDCKII cells and cells overexpressing those human transporters, as well as non-selective and selective inhibitors.	Penicillin G	159-175	ATP binding cassette subfamily C member 4	Homo sapiens	127-131
31774876-5	2019	We found that inhibiting MRP1 or MRP4 significantly increased [3H]benzylpenicillin uptake in MDCKII-WT, -MRP1 or -MRP4 cells.	Penicillin G	62-82	ATP binding cassette subfamily C member 4	Homo sapiens	33-37
31774876-5	2019	We found that inhibiting MRP1 or MRP4 significantly increased [3H]benzylpenicillin uptake in MDCKII-WT, -MRP1 or -MRP4 cells.	Penicillin G	62-82	ATP binding cassette subfamily C member 4	Homo sapiens	114-118
31774876-7	2019	The results indicate that human and canine MRP1 and MRP4 are involved in benzylpenicillin efflux transport.	Penicillin G	73-89	ATP binding cassette subfamily C member 4	Homo sapiens	52-56
31774876-8	2019	They could be potential therapeutic targets for improving the efficacy of benzylpenicillin for treating CNS infections since both MRP1 and MRP4 express at human blood-brain barrier.	Penicillin G	74-90	ATP binding cassette subfamily C member 4	Homo sapiens	139-143
31481727-5	2019	Due to the inhibition of the MRP4/ABCC4, a cAMP-exporter confined to the CFTR macromolecular signalling-complex, PKA activation is accomplished by the subcompartmentalised elevation of cytosolic cAMP.	Cyclic AMP	43-47	ATP binding cassette subfamily C member 4	Homo sapiens	29-33
31481727-5	2019	Due to the inhibition of the MRP4/ABCC4, a cAMP-exporter confined to the CFTR macromolecular signalling-complex, PKA activation is accomplished by the subcompartmentalised elevation of cytosolic cAMP.	Cyclic AMP	43-47	ATP binding cassette subfamily C member 4	Homo sapiens	34-39
31481727-5	2019	Due to the inhibition of the MRP4/ABCC4, a cAMP-exporter confined to the CFTR macromolecular signalling-complex, PKA activation is accomplished by the subcompartmentalised elevation of cytosolic cAMP.	Cyclic AMP	195-199	ATP binding cassette subfamily C member 4	Homo sapiens	29-33
31481727-5	2019	Due to the inhibition of the MRP4/ABCC4, a cAMP-exporter confined to the CFTR macromolecular signalling-complex, PKA activation is accomplished by the subcompartmentalised elevation of cytosolic cAMP.	Cyclic AMP	195-199	ATP binding cassette subfamily C member 4	Homo sapiens	34-39
30952578-4	2019	Twelve SNPs involved in VPA transport pathways, including ABCC2, ABCC4, ABCG2, MCT1, MCT2 and OATP2B1 were genotyped in 153 Han Chinese epilepsy patients.	Valproic Acid	24-27	ATP binding cassette subfamily C member 4	Homo sapiens	65-70
31318870-9	2019	We demonstrated the under expression of the ATP-binding cassette (ABC) transporters ABCC4, ABCC5, and ABCD3 encoding proteins which pumped drugs out of the cells after 12 months of nilotinib.	nilotinib	181-190	ATP binding cassette subfamily C member 4	Homo sapiens	84-89
31410201-15	2019	Conclusion: A previously undefined role of MRP4 in stabilizing beta-catenin to sustain Wnt/beta-catenin signaling in endometrial cells is revealed for both embryo implantation and endometrial disorders, suggesting MRP4 as a theranostic target for endometrial diseases associated with Wnt/beta-catenin signaling abnormality.	wnt	87-90	ATP binding cassette subfamily C member 4	Homo sapiens	43-47
31410201-15	2019	Conclusion: A previously undefined role of MRP4 in stabilizing beta-catenin to sustain Wnt/beta-catenin signaling in endometrial cells is revealed for both embryo implantation and endometrial disorders, suggesting MRP4 as a theranostic target for endometrial diseases associated with Wnt/beta-catenin signaling abnormality.	wnt	87-90	ATP binding cassette subfamily C member 4	Homo sapiens	214-218
31043460-0	2019	Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux.	Cyclic AMP	132-136	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
31043460-0	2019	Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux.	Cyclic AMP	132-136	ATP binding cassette subfamily C member 4	Homo sapiens	23-28
31043460-3	2019	Considering that cAMP pathway is commonly activated in pancreatic ductal adenocarcinoma (PDAC) and its premalignant lesions, we aim to investigate the multidrug resistance-associated protein 4 (MRP4)-dependent cAMP extrusion process as a cause of increased cell proliferation in human PDAC cell lines.	Cyclic AMP	17-21	ATP binding cassette subfamily C member 4	Homo sapiens	151-192
31043460-3	2019	Considering that cAMP pathway is commonly activated in pancreatic ductal adenocarcinoma (PDAC) and its premalignant lesions, we aim to investigate the multidrug resistance-associated protein 4 (MRP4)-dependent cAMP extrusion process as a cause of increased cell proliferation in human PDAC cell lines.	Cyclic AMP	17-21	ATP binding cassette subfamily C member 4	Homo sapiens	194-198
31043460-3	2019	Considering that cAMP pathway is commonly activated in pancreatic ductal adenocarcinoma (PDAC) and its premalignant lesions, we aim to investigate the multidrug resistance-associated protein 4 (MRP4)-dependent cAMP extrusion process as a cause of increased cell proliferation in human PDAC cell lines.	Cyclic AMP	210-214	ATP binding cassette subfamily C member 4	Homo sapiens	151-192
31043460-3	2019	Considering that cAMP pathway is commonly activated in pancreatic ductal adenocarcinoma (PDAC) and its premalignant lesions, we aim to investigate the multidrug resistance-associated protein 4 (MRP4)-dependent cAMP extrusion process as a cause of increased cell proliferation in human PDAC cell lines.	Cyclic AMP	210-214	ATP binding cassette subfamily C member 4	Homo sapiens	194-198
31043460-5	2019	In addition, we performed in vitro experiments and identified an association between higher MRP4 expression levels and more undifferentiated and malignant models of PDAC and cAMP extrusion capacity.	Cyclic AMP	174-178	ATP binding cassette subfamily C member 4	Homo sapiens	92-96
29757761-12	2019	Main mechanisms include medication nonadherence, interaction with proton pump inhibitors, esterase-mediated ASA inactivation, post-coronary artery bypass grafting (CABG) MRP-4-mediated ASA consumption, cyclooxygenase-1 (COX-1) polymorphisms, high platelet turnover-associated regeneration of platelet COX-1, and the documented platelet ability of de novo COX-1 synthesis in response to thrombin and fibrinogen.	Aspirin	185-188	ATP binding cassette subfamily C member 4	Homo sapiens	170-175
30880686-9	2019	MRP4 inhibition, using MK571, resensitized cells with ZEB1 overexpression to docetaxel treatment.	verlukast	23-28	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
30880686-9	2019	MRP4 inhibition, using MK571, resensitized cells with ZEB1 overexpression to docetaxel treatment.	Docetaxel	77-86	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
30880686-10	2019	In addition, modulation of ZEB1 and subsequent change in MRP4 expression correlated with a lower apoptotic response to docetaxel, characterized by lower B-cell lymphoma 2 (Bcl2), high BCL2-associated X protein (Bax), and high active caspase 3 expression.	Docetaxel	119-128	ATP binding cassette subfamily C member 4	Homo sapiens	57-61
30880686-12	2019	Our results showed that modulation of MRP4 could be a mediator of ZEB1-related resistance to docetaxel in prostate cancer, making it a possible marker for chemotherapy response in patients who do not express MDR1.	Docetaxel	93-102	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
31175220-8	2019	Instead, circulating cabotegravir-glucuronide undergoes efficient renal clearance, where uptake into the proximal tubule would be mediated by OAT3 (not transported by OAT1), and subsequent secretion into urine by MRP2 (Ft = 0.66) and MRP4 (Ft = 0.34).	cabotegravir-glucuronide	21-45	ATP binding cassette subfamily C member 4	Homo sapiens	234-238
31308818-5	2019	Results: ABCC4 rs1751034 TT and rs1189437 TT were associated with increased exposure of CK and decreased exposure of 20(S)-PPD, whereas CFTR rs4148688 heterozygous carriers had the lowest maximum concentration (Cmax) of CK.	ginsenoside M1	88-90	ATP binding cassette subfamily C member 4	Homo sapiens	9-14
31308818-7	2019	ABCC4 rs1151471 and CFTR rs2283054 influenced the pharmacokinetics of 20(S)-PPD.	protopanaxadiol	72-79	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
31308818-9	2019	Quality of the best homology model of multidrug resistance protein 4 (MRP4) was assessed, and the ligand interaction plot showed the mode of interaction of CK with different MRP4 residues.	ginsenoside M1	156-158	ATP binding cassette subfamily C member 4	Homo sapiens	38-68
31308818-9	2019	Quality of the best homology model of multidrug resistance protein 4 (MRP4) was assessed, and the ligand interaction plot showed the mode of interaction of CK with different MRP4 residues.	ginsenoside M1	156-158	ATP binding cassette subfamily C member 4	Homo sapiens	70-74
31308818-9	2019	Quality of the best homology model of multidrug resistance protein 4 (MRP4) was assessed, and the ligand interaction plot showed the mode of interaction of CK with different MRP4 residues.	ginsenoside M1	156-158	ATP binding cassette subfamily C member 4	Homo sapiens	174-178
31308818-10	2019	Conlusion: ABCC4 rs1751034 and rs1189437 affected the pharmacokinetics of both CK and 20(S)-PPD.	ginsenoside M1	79-81	ATP binding cassette subfamily C member 4	Homo sapiens	11-16
31308818-10	2019	Conlusion: ABCC4 rs1751034 and rs1189437 affected the pharmacokinetics of both CK and 20(S)-PPD.	20(s)-ppd	86-95	ATP binding cassette subfamily C member 4	Homo sapiens	11-16
30959153-4	2019	Using vesicular transport assay with recombinant human MRP2, MRP3, MRP4, MDR1 and BCRP, we first identified that TG, AG, EtioG, and DHTG were primarily substrates of MRP2 and MRP3, although lower levels of transport were also observed with MDR1 and BCRP vesicles.	testosterone glucuronate	113-115	ATP binding cassette subfamily C member 4	Homo sapiens	67-71
30959153-4	2019	Using vesicular transport assay with recombinant human MRP2, MRP3, MRP4, MDR1 and BCRP, we first identified that TG, AG, EtioG, and DHTG were primarily substrates of MRP2 and MRP3, although lower levels of transport were also observed with MDR1 and BCRP vesicles.	androsterone glucuronide	121-126	ATP binding cassette subfamily C member 4	Homo sapiens	67-71
30959153-4	2019	Using vesicular transport assay with recombinant human MRP2, MRP3, MRP4, MDR1 and BCRP, we first identified that TG, AG, EtioG, and DHTG were primarily substrates of MRP2 and MRP3, although lower levels of transport were also observed with MDR1 and BCRP vesicles.	dihydrotestosterone glucuronide	132-136	ATP binding cassette subfamily C member 4	Homo sapiens	67-71
31043460-8	2019	MRP4 pharmacological inhibition or silencing abrogated cell proliferation through the activation of the cAMP/Epac/Rap1 signaling pathway.	Cyclic AMP	104-108	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
31043460-9	2019	Also, extracellular cAMP reverted the antiproliferative effect of MRP4 blockade.	Cyclic AMP	20-24	ATP binding cassette subfamily C member 4	Homo sapiens	66-70
31043460-10	2019	Our data highlight the MRP4-dependent cAMP extrusion process as a key participant in cell proliferation, indicating that MRP4 could be an exploitable therapeutic target for PDAC.	Cyclic AMP	38-42	ATP binding cassette subfamily C member 4	Homo sapiens	23-27
31043460-10	2019	Our data highlight the MRP4-dependent cAMP extrusion process as a key participant in cell proliferation, indicating that MRP4 could be an exploitable therapeutic target for PDAC.	Cyclic AMP	38-42	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
31043460-11	2019	SIGNIFICANCE STATEMENT: ABCC4/MRP4 is the main transporter responsible for cAMP efflux.	Cyclic AMP	75-79	ATP binding cassette subfamily C member 4	Homo sapiens	24-29
31043460-11	2019	SIGNIFICANCE STATEMENT: ABCC4/MRP4 is the main transporter responsible for cAMP efflux.	Cyclic AMP	75-79	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
31043460-13	2019	Findings prove the involvement of MRP4 in PDAC cell proliferation through a novel extracellular cAMP mitogenic pathway and further support MRP4 inhibition as a promising therapeutic strategy for PDAC treatment.	Cyclic AMP	96-100	ATP binding cassette subfamily C member 4	Homo sapiens	34-38
31043460-13	2019	Findings prove the involvement of MRP4 in PDAC cell proliferation through a novel extracellular cAMP mitogenic pathway and further support MRP4 inhibition as a promising therapeutic strategy for PDAC treatment.	pdac	42-46	ATP binding cassette subfamily C member 4	Homo sapiens	34-38
30983357-6	2019	In hCMEC/D3 cells, amino acid transporters SNAT1, SNAT2, SNAT5, ASCT1, CAT1, and LAT1; adenosine 5"-triphosphate-binding cassette transporters P-gp and MRP4; and GLUT1 were more highly expressed.	Adenosine	87-96	ATP binding cassette subfamily C member 4	Homo sapiens	152-156
31146764-0	2019	Uric acid transporters BCRP and MRP4 involved in chickens uric acid excretion.	Uric Acid	58-67	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
31146764-1	2019	BACKGROUND: Breast cancer resistance protein (BCRP) and multidrug resistance protein 4 (MRP4) are involved in uric acid excretion in humans and mice.	Uric Acid	110-119	ATP binding cassette subfamily C member 4	Homo sapiens	56-86
31146764-1	2019	BACKGROUND: Breast cancer resistance protein (BCRP) and multidrug resistance protein 4 (MRP4) are involved in uric acid excretion in humans and mice.	Uric Acid	110-119	ATP binding cassette subfamily C member 4	Homo sapiens	88-92
31146764-12	2019	CONCLUSION: Together, these results demonstrate that BCRP and MRP4 are involved in renal and intestinal uric acid excretion in chickens and that BCRP is positively related to MRP4 expression.	Uric Acid	104-113	ATP binding cassette subfamily C member 4	Homo sapiens	62-66
31146764-12	2019	CONCLUSION: Together, these results demonstrate that BCRP and MRP4 are involved in renal and intestinal uric acid excretion in chickens and that BCRP is positively related to MRP4 expression.	Uric Acid	104-113	ATP binding cassette subfamily C member 4	Homo sapiens	175-179
31146764-13	2019	Further, impairment of renal function results in an increase in serum uric acid as well as a compensatory increase in BCRP and MRP4 in the ileum; however, under normal renal function, renal BCRP and MRP4 are the main regulators of uric acid excretion.	Uric Acid	231-240	ATP binding cassette subfamily C member 4	Homo sapiens	199-203
31133859-10	2019	Taken together, our results indicate that MRP3 and MRP4 contribute more to the excretion of fraxetin-O-glucuronides than the other transporters do.	fraxetin-o-glucuronides	92-115	ATP binding cassette subfamily C member 4	Homo sapiens	51-55
30382560-5	2019	The transport and excretion of uric acid is a complicated procedure which is related with various transporters such as OAT1, OAT3, OAT4, URAT1, GLUT9, BCRP, MRP4, NPT1, NTP4, and so on.	Uric Acid	31-40	ATP binding cassette subfamily C member 4	Homo sapiens	157-161
30849662-5	2019	Results show that high MRP4 expression is correlated with ex vivo MTX resistance assayed by TSIA (P = 0.01).	Methotrexate	66-69	ATP binding cassette subfamily C member 4	Homo sapiens	23-27
30849662-6	2019	Moreover, elevated MRP4 and BCRP expression correlated with lower accumulation of MTX-PGs (P = 0.004 and P = 0.03, respectively).	Methotrexate	82-85	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
30849662-6	2019	Moreover, elevated MRP4 and BCRP expression correlated with lower accumulation of MTX-PGs (P = 0.004 and P = 0.03, respectively).	Phosphatidylglycerols	86-89	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
30849662-7	2019	Combined high expression of BCRP and MRP4 even further impacted reduced MTX-PG accumulation (P = 0.02).	Methotrexate	72-75	ATP binding cassette subfamily C member 4	Homo sapiens	37-41
30849662-7	2019	Combined high expression of BCRP and MRP4 even further impacted reduced MTX-PG accumulation (P = 0.02).	pg	76-78	ATP binding cassette subfamily C member 4	Homo sapiens	37-41
30849662-9	2019	These results underscore the impact of high drug efflux transporter expression, notably MRP4 and BCRP, in diminished MTX response in childhood ALL.	Methotrexate	117-120	ATP binding cassette subfamily C member 4	Homo sapiens	88-92
30807260-0	2019	Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.	Doxorubicin	63-73	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
30807260-11	2019	Our results further demonstrated that inhibition of ABCC4 expression and overexpression of miR-124-3p significantly enhanced the sensitivity to adriamycin (ADR) in MCF-7-ADR cells, and that simultaneous dual-targeting of miR-124-3p and ABCC4 had a stronger promotive effect on the sensitivity to ADR in MCF-7-ADR cells.	Doxorubicin	144-154	ATP binding cassette subfamily C member 4	Homo sapiens	52-57
29284392-0	2019	MRP4/ABCC4 As a New Therapeutic Target: Meta-Analysis to Determine cAMP Binding Sites as a Tool for Drug Design.	Cyclic AMP	67-71	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
30761271-8	2019	Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4.	Paclitaxel	143-153	ATP binding cassette subfamily C member 4	Homo sapiens	38-79
30761271-8	2019	Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4.	Paclitaxel	143-153	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
30761271-8	2019	Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4.	Paclitaxel	143-153	ATP binding cassette subfamily C member 4	Homo sapiens	235-239
30761271-9	2019	In conclusion, high-expression of CDKN2B-AS is associated with a poor response to paclitaxel of EC patients, and knockdown of CDKN2B-AS inhibits paclitaxel resistance through miR-125a-5p-Bcl2/MRP4 pathway in EC patients.	Paclitaxel	145-155	ATP binding cassette subfamily C member 4	Homo sapiens	192-196
30634695-5	2019	3-(4,5-Dimethyl-2-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay indicated that the EC50 value of the anticancer drug, SN-38, against cells expressing ABCC4 (G187W) was 1.84-fold lower than that against cells expressing ABCC4 (WT).	3-(4,5-dimethyl-2-thiazol-2-yl)-2,5-diphenyl-2h-tetrazolium bromide	0-67	ATP binding cassette subfamily C member 4	Homo sapiens	235-240
30634695-6	2019	Both azathioprine and 6-mercaptopurine showed comparable EC50 values against cells expressing ABCC4 (G187W) and those expressing ABCC4 (WT).	Azathioprine	5-17	ATP binding cassette subfamily C member 4	Homo sapiens	94-99
30634695-6	2019	Both azathioprine and 6-mercaptopurine showed comparable EC50 values against cells expressing ABCC4 (G187W) and those expressing ABCC4 (WT).	Mercaptopurine	22-38	ATP binding cassette subfamily C member 4	Homo sapiens	94-99
30634695-6	2019	Both azathioprine and 6-mercaptopurine showed comparable EC50 values against cells expressing ABCC4 (G187W) and those expressing ABCC4 (WT).	Mercaptopurine	22-38	ATP binding cassette subfamily C member 4	Homo sapiens	129-134
30634695-7	2019	These results indicate that the substitution of Gly at position 187 of ABCC4 to Trp resulted in reduced SN-38 resistance.	Glycine	48-51	ATP binding cassette subfamily C member 4	Homo sapiens	71-76
30634695-7	2019	These results indicate that the substitution of Gly at position 187 of ABCC4 to Trp resulted in reduced SN-38 resistance.	Tryptophan	80-83	ATP binding cassette subfamily C member 4	Homo sapiens	71-76
30634695-7	2019	These results indicate that the substitution of Gly at position 187 of ABCC4 to Trp resulted in reduced SN-38 resistance.	Irinotecan	104-109	ATP binding cassette subfamily C member 4	Homo sapiens	71-76
30414939-11	2019	ABCG2, ABCC4, and ABCC8 were identified as ACSL4-responsive drug resistance genes whose expression was increased in MCF-7 Tet-Off/ACSL4 cells but inhibited in MDA-MB-231 shRNA ACSL4 cells.	tetramethylenedisulfotetramine	122-125	ATP binding cassette subfamily C member 4	Homo sapiens	7-12
29284392-0	2019	MRP4/ABCC4 As a New Therapeutic Target: Meta-Analysis to Determine cAMP Binding Sites as a Tool for Drug Design.	Cyclic AMP	67-71	ATP binding cassette subfamily C member 4	Homo sapiens	5-10
29284392-7	2019	Using available homology models and mutagenesis assays, in this review we recapitulate the up-to-date knowledge about MRP structure and aligned amino acid sequences to identify the candidate MRP4 residues where cyclic nucleotides bind.	Nucleotides, Cyclic	211-229	ATP binding cassette subfamily C member 4	Homo sapiens	191-195
29284392-9	2019	This meta-analysis platform may serve as a basis for the future development of inhibitors of MRP4 cAMP specific transport.	Cyclic AMP	98-102	ATP binding cassette subfamily C member 4	Homo sapiens	93-97
30015780-4	2018	In the present study, we assessed the role of platelet miRNAs in modulating MRP4 function in response to ASA.	Aspirin	105-108	ATP binding cassette subfamily C member 4	Homo sapiens	76-80
30643796-8	2018	CCK-8 assay was conducted to detect the effect of IL-13 and ABCC4 on cell sensitivity to adriamycin (ADM) in YTS cells.	Doxorubicin	89-99	ATP binding cassette subfamily C member 4	Homo sapiens	60-65
30556891-2	2018	The transporter multidrug resistance-associated protein 4 (MRP4/ABCC4) is expressed in human endometrial tissue; it is overexpressed in ectopic endometrial tissue, and is modulated by the anti-inflammatory lipid Lipoxin A4 (LXA4).	lipoxin A4	212-222	ATP binding cassette subfamily C member 4	Homo sapiens	16-57
30556891-2	2018	The transporter multidrug resistance-associated protein 4 (MRP4/ABCC4) is expressed in human endometrial tissue; it is overexpressed in ectopic endometrial tissue, and is modulated by the anti-inflammatory lipid Lipoxin A4 (LXA4).	lipoxin A4	212-222	ATP binding cassette subfamily C member 4	Homo sapiens	59-63
30556891-2	2018	The transporter multidrug resistance-associated protein 4 (MRP4/ABCC4) is expressed in human endometrial tissue; it is overexpressed in ectopic endometrial tissue, and is modulated by the anti-inflammatory lipid Lipoxin A4 (LXA4).	lipoxin A4	212-222	ATP binding cassette subfamily C member 4	Homo sapiens	64-69
30556891-3	2018	Recently, it was demonstrated that aspirin induces platelet MRP4 over-expression, through genomic modulation in megakaryocytes.	Aspirin	35-42	ATP binding cassette subfamily C member 4	Homo sapiens	60-64
30556891-6	2018	RESULTS: In 12Z cells, aspirin and other NSAIDs enhanced MRP4 mRNA and protein expression; these treatments also induced PPARa expression.	Aspirin	23-30	ATP binding cassette subfamily C member 4	Homo sapiens	57-61
30556891-7	2018	Aspirin and diclofenac-induced increases in MRP4 expression were not observed in cells where PPARa was knocked down using siRNA.	Aspirin	0-7	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
30556891-7	2018	Aspirin and diclofenac-induced increases in MRP4 expression were not observed in cells where PPARa was knocked down using siRNA.	Diclofenac	12-22	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
30556891-8	2018	NSAIDs-induced MRP4 expression was correlated with augmented PGE2 secretion, indicating functional relevance.	Dinoprostone	61-65	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
30556891-10	2018	Elevated PGE2 levels in cell supernatants correlate with its increased transport by MRP4 after NSAID treatment.	Dinoprostone	9-13	ATP binding cassette subfamily C member 4	Homo sapiens	84-88
30176366-0	2018	Sulfation disposition of liquiritigenin in SULT1A3 overexpressing HEK293 cells: The role of breast cancer resistance protein (BCRP) and multidrug resistance-associated protein 4 (MRP4) in sulfate efflux of liquiritigenin.	Sulfates	188-195	ATP binding cassette subfamily C member 4	Homo sapiens	179-183
30321196-0	2018	Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening.	Mercaptopurine	124-140	ATP binding cassette subfamily C member 4	Homo sapiens	19-49
30321196-0	2018	Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening.	Mercaptopurine	124-140	ATP binding cassette subfamily C member 4	Homo sapiens	51-55
30321196-0	2018	Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening.	Mercaptopurine	142-146	ATP binding cassette subfamily C member 4	Homo sapiens	19-49
30321196-0	2018	Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening.	Mercaptopurine	142-146	ATP binding cassette subfamily C member 4	Homo sapiens	51-55
30321196-8	2018	Then compound Cpd23 was discovered to improve HEK293/MRP4 cell sensibility to 6-MP dramatically, and low concentration Cpd23 (5 muM) achieved the equivalent effect of 50 muM MK571.	Mercaptopurine	78-82	ATP binding cassette subfamily C member 4	Homo sapiens	53-57
30321196-9	2018	The accumulation of 6-MP was determined by validated high-performance liquid chromatography methods, and pretreatment of the HEK293/MRP4 cells with 50 muM MK571 or Cpd23 resulted in significantly increased accumulation of 6-MP by approximately 1.5 times.	Mercaptopurine	20-24	ATP binding cassette subfamily C member 4	Homo sapiens	132-136
30321196-9	2018	The accumulation of 6-MP was determined by validated high-performance liquid chromatography methods, and pretreatment of the HEK293/MRP4 cells with 50 muM MK571 or Cpd23 resulted in significantly increased accumulation of 6-MP by approximately 1.5 times.	Mercaptopurine	222-226	ATP binding cassette subfamily C member 4	Homo sapiens	132-136
30015780-5	2018	METHODS: MRP4 mRNA expression has been analyzed by RealTime PCR in platelets from patients on chronic ASA treatment versus a control group.	Aspirin	102-105	ATP binding cassette subfamily C member 4	Homo sapiens	9-13
30015780-10	2018	RESULTS: We observed a higher MRP4 mRNA expression in platelets of patients under ASA treatment compared to the control group (p&lt;0.005).	Aspirin	82-85	ATP binding cassette subfamily C member 4	Homo sapiens	30-34
30060118-0	2018	The FoxM1-ABCC4 axis mediates carboplatin resistance in human retinoblastoma Y-79 cells.	Carboplatin	30-41	ATP binding cassette subfamily C member 4	Homo sapiens	10-15
30060118-6	2018	Our study further revealed that FoxM1 enhanced carboplatin resistance in Y-79CR cells through directly up-regulating the transcription of ATP-binding cassette transporter C4 (ABCC4), an important drug efflux transporter.	Carboplatin	47-58	ATP binding cassette subfamily C member 4	Homo sapiens	138-173
30060118-6	2018	Our study further revealed that FoxM1 enhanced carboplatin resistance in Y-79CR cells through directly up-regulating the transcription of ATP-binding cassette transporter C4 (ABCC4), an important drug efflux transporter.	Carboplatin	47-58	ATP binding cassette subfamily C member 4	Homo sapiens	175-180
30060118-7	2018	Overall, our study demonstrated the novel role of FoxM1-ABCC4 axis in human RB, which provides insights into the prevention of carboplatin resistance in human RB.	Carboplatin	127-138	ATP binding cassette subfamily C member 4	Homo sapiens	56-61
30115944-9	2018	Exposure of HEK293 cells to IGF-1 resulted in a dose-dependent increase of uric acid transporters deputed to uric acid excretion (MRP4, NPT1 and BCRP), and reduction of GLUT9 expression, the major mediator of uric acid reabsorption, both at mRNA and protein level.	Uric Acid	75-84	ATP binding cassette subfamily C member 4	Homo sapiens	130-134
30115944-9	2018	Exposure of HEK293 cells to IGF-1 resulted in a dose-dependent increase of uric acid transporters deputed to uric acid excretion (MRP4, NPT1 and BCRP), and reduction of GLUT9 expression, the major mediator of uric acid reabsorption, both at mRNA and protein level.	Uric Acid	109-118	ATP binding cassette subfamily C member 4	Homo sapiens	130-134
30115944-9	2018	Exposure of HEK293 cells to IGF-1 resulted in a dose-dependent increase of uric acid transporters deputed to uric acid excretion (MRP4, NPT1 and BCRP), and reduction of GLUT9 expression, the major mediator of uric acid reabsorption, both at mRNA and protein level.	Uric Acid	109-118	ATP binding cassette subfamily C member 4	Homo sapiens	130-134
30598629-0	2018	Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia.	Mercaptopurine	63-79	ATP binding cassette subfamily C member 4	Homo sapiens	24-29
29691239-8	2018	Overall, the data indicated that BCRP, not MRP4, was responsible for the excretion of N-glucosides, whereas both BCRP and MRP4 contributed to excretion of N-glucuronides.	n-glucuronides	155-169	ATP binding cassette subfamily C member 4	Homo sapiens	122-126
29448294-5	2018	Platelet function was studied by collagen and TRAP-6-induced platelet aggregation and secretion.Cilostazol reduced the release of bimane-glutathione and enhanced aspirin entrapment demonstrating an inhibitory effect on MRP4 in platelets.	Cilostazol	96-106	ATP binding cassette subfamily C member 4	Homo sapiens	219-223
29605625-2	2018	Multidrug resistance protein 4 (MRP4) expressed in human platelets pumps cyclic nucleotides out of cells.	Nucleotides, Cyclic	73-91	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
29605625-2	2018	Multidrug resistance protein 4 (MRP4) expressed in human platelets pumps cyclic nucleotides out of cells.	Nucleotides, Cyclic	73-91	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
29605625-4	2018	This study was undertaken to investigate the pharmacological association of the sGC activator BAY 60-2770 with the MRP4 inhibitor MK571 on human washed platelets.	4-(((4-carboxybutyl) (2- (5-fluoro-2-((4'-(trifluoromethyl) biphenyl-4-yl)methoxy)phenyl)ethyl) amino)methyl)benzoic acid	94-105	ATP binding cassette subfamily C member 4	Homo sapiens	115-119
29605625-4	2018	This study was undertaken to investigate the pharmacological association of the sGC activator BAY 60-2770 with the MRP4 inhibitor MK571 on human washed platelets.	verlukast	130-135	ATP binding cassette subfamily C member 4	Homo sapiens	115-119
29605625-12	2018	Blocking the MRP4-mediated efflux of cGMP may be a potential mechanism to enhance the antiplatelet efficacy of sGC activators.	Cyclic GMP	37-41	ATP binding cassette subfamily C member 4	Homo sapiens	13-17
30046765-9	2018	In aspirin-treated volunteers, an inverse relationship between miR-21 and MRP4 platelet expression was found after aspirin treatment.	Aspirin	3-10	ATP binding cassette subfamily C member 4	Homo sapiens	74-78
30046765-9	2018	In aspirin-treated volunteers, an inverse relationship between miR-21 and MRP4 platelet expression was found after aspirin treatment.	Aspirin	115-122	ATP binding cassette subfamily C member 4	Homo sapiens	74-78
30046765-11	2018	Conclusion: The results reported in this study provide information that aspirin induces the modulation of platelet miR-21 expression levels and this modulation can be responsible for MRP4 enhancement in circulating platelets.	Aspirin	72-79	ATP binding cassette subfamily C member 4	Homo sapiens	183-187
29568871-0	2018	Involvement of multidrug resistance protein 4 in the hepatocyte efflux of lamivudine and entecavir.	Lamivudine	74-84	ATP binding cassette subfamily C member 4	Homo sapiens	15-45
29568871-0	2018	Involvement of multidrug resistance protein 4 in the hepatocyte efflux of lamivudine and entecavir.	entecavir	89-98	ATP binding cassette subfamily C member 4	Homo sapiens	15-45
29568871-1	2018	Multidrug resistance protein 4 (MRP4) is capable of transporting acyclic nucleotide phosphonates, but little is known about its role in lamivudine (LAM) and entecavir (ETV) transport.	nucleotide phosphonates	73-96	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
29568871-1	2018	Multidrug resistance protein 4 (MRP4) is capable of transporting acyclic nucleotide phosphonates, but little is known about its role in lamivudine (LAM) and entecavir (ETV) transport.	nucleotide phosphonates	73-96	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
29568871-1	2018	Multidrug resistance protein 4 (MRP4) is capable of transporting acyclic nucleotide phosphonates, but little is known about its role in lamivudine (LAM) and entecavir (ETV) transport.	entecavir	157-166	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
29568871-1	2018	Multidrug resistance protein 4 (MRP4) is capable of transporting acyclic nucleotide phosphonates, but little is known about its role in lamivudine (LAM) and entecavir (ETV) transport.	entecavir	168-171	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
29568871-1	2018	Multidrug resistance protein 4 (MRP4) is capable of transporting acyclic nucleotide phosphonates, but little is known about its role in lamivudine (LAM) and entecavir (ETV) transport.	entecavir	168-171	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
29695968-5	2018	Among the ABC transporters, especially BCRP (ABCG2) and several MRP/ABCC subfamily members (MRP1, MRP4, MRP8) are expressed in the brain and known to efflux conjugated steroids.	Steroids	168-176	ATP binding cassette subfamily C member 4	Homo sapiens	98-102
29175180-0	2018	Efflux transport of estrogen glucuronides by human MRP2, MRP3, MRP4 and BCRP.	Glucuronides	29-41	ATP binding cassette subfamily C member 4	Homo sapiens	63-67
28418010-0	2018	Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.	Mercaptopurine	73-89	ATP binding cassette subfamily C member 4	Homo sapiens	31-36
29318243-9	2018	Furthermore, shRNA-mediated silencing of a target transporter led to a marked reduction in the excretion rate of wushanicaritin glucuronides (maximal 33.8% for BCRP; 25.9% for MRP1; 26.7% for MRP3; 39.3% for MRP4).	wushanicaritin	113-127	ATP binding cassette subfamily C member 4	Homo sapiens	208-212
29318243-11	2018	In conclusion, chemical inhibition and gene silencing results suggested that BCRP, MRP1, MRP3 and MRP4 were significant contributors to excretion of wushanicaritin glucuronides.	wushanicaritin	149-163	ATP binding cassette subfamily C member 4	Homo sapiens	98-102
29318243-11	2018	In conclusion, chemical inhibition and gene silencing results suggested that BCRP, MRP1, MRP3 and MRP4 were significant contributors to excretion of wushanicaritin glucuronides.	Glucuronides	164-176	ATP binding cassette subfamily C member 4	Homo sapiens	98-102
29724614-5	2018	BCRP, MRP3 and MRP4-mediated transport of RSV was observed, and Ko143 inhibited these transporters except MRP3.	Rosuvastatin Calcium	42-45	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
29724614-6	2018	BCRP and MRP4 also mediated the transport of PTV, but the Ko143-mediated inhibition was only clear for BCRP.	pitavastatin	45-48	ATP binding cassette subfamily C member 4	Homo sapiens	9-13
30046765-1	2018	Background: A mechanism involved in high on-aspirin treatment residual platelet reactivity is platelet multidrug resistance protein 4 (MRP4) overexpression.	Aspirin	44-51	ATP binding cassette subfamily C member 4	Homo sapiens	103-133
30046765-1	2018	Background: A mechanism involved in high on-aspirin treatment residual platelet reactivity is platelet multidrug resistance protein 4 (MRP4) overexpression.	Aspirin	44-51	ATP binding cassette subfamily C member 4	Homo sapiens	135-139
30046765-2	2018	Aspirin enhances platelet MRP4 expression with a PPARalpha-dependent mechanism and reduces miR-21 expression that, in turn, downregulates PPARalpha expression.	Aspirin	0-7	ATP binding cassette subfamily C member 4	Homo sapiens	26-30
30046765-3	2018	Objective: The aim of our study was to verify the relationship between miR-21 and MRP4-PPARalpha levels induced by aspirin treatment.	Aspirin	115-122	ATP binding cassette subfamily C member 4	Homo sapiens	82-86
30046765-4	2018	Methods: We evaluated the changes in MRP4-PPARalpha, mRNA, MRP4 protein, and miR-21 expression induced by aspirin in: (i) in vitro-treated megakaryoblastic cell line (DAMI), (ii) primary megakaryocytes cultures and derived platelets, (iii) healthy volunteers" platelets treated with aspirin, and (iv) aspirinated patients (aspirin-treated patients) and in a control population (control).	Aspirin	106-113	ATP binding cassette subfamily C member 4	Homo sapiens	37-41
30046765-5	2018	Results: We observed an aspirin-induced reverse relationship between the expression of miR-21 and PPARalpha-MRP4.	Aspirin	24-31	ATP binding cassette subfamily C member 4	Homo sapiens	108-112
30046765-8	2018	In human megakaryocytes, aspirin treatment lead to a miR-21 downregulation and a MRP4 upregulation and this trend is confirmed in derived platelets.	Aspirin	25-32	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
29448294-2	2018	Platelet function and thrombus formation are impaired in MRP4 knockout mice models, and, among aspirin-treated patients, high on-aspirin residual platelet reactivity (HARPR) positively correlates with MRP4 levels.	Aspirin	95-102	ATP binding cassette subfamily C member 4	Homo sapiens	201-205
29448294-2	2018	Platelet function and thrombus formation are impaired in MRP4 knockout mice models, and, among aspirin-treated patients, high on-aspirin residual platelet reactivity (HARPR) positively correlates with MRP4 levels.	Aspirin	129-136	ATP binding cassette subfamily C member 4	Homo sapiens	201-205
29448294-3	2018	To better understand the effects of MRP4 on platelet function, the aim of this investigation was to assess the impact of cilostazol-induced inhibition of MRP4-mediated transport and assess aspirin-induced antiplatelet effects and rates of HARPR in human subjects.Cilostazol-dependent inhibition of MRP4-mediated transport was assessed with the release of the fluorescent adduct bimane-glutathione and aspirin entrapment.	Cilostazol	121-131	ATP binding cassette subfamily C member 4	Homo sapiens	154-158
29448294-3	2018	To better understand the effects of MRP4 on platelet function, the aim of this investigation was to assess the impact of cilostazol-induced inhibition of MRP4-mediated transport and assess aspirin-induced antiplatelet effects and rates of HARPR in human subjects.Cilostazol-dependent inhibition of MRP4-mediated transport was assessed with the release of the fluorescent adduct bimane-glutathione and aspirin entrapment.	Cilostazol	121-131	ATP binding cassette subfamily C member 4	Homo sapiens	154-158
29448294-7	2018	An inhibitory effect on platelet aggregation and secretion was found in activated platelets, with threshold concentration of agonists, 10 seconds after addition of cilostazol, supporting a role of MRP4 on platelet function that is cAMP independent.	Cilostazol	164-174	ATP binding cassette subfamily C member 4	Homo sapiens	197-201
29448294-7	2018	An inhibitory effect on platelet aggregation and secretion was found in activated platelets, with threshold concentration of agonists, 10 seconds after addition of cilostazol, supporting a role of MRP4 on platelet function that is cAMP independent.	Cyclic AMP	231-235	ATP binding cassette subfamily C member 4	Homo sapiens	197-201
29448294-9	2018	A reduction of platelet aggregation and secretion were observed in aspirin-treated patients with HARPR.This study supports the role of MRP4 on modulating platelet function which occurs through cAMP-independent mechanisms.	Aspirin	67-74	ATP binding cassette subfamily C member 4	Homo sapiens	135-139
29448294-9	2018	A reduction of platelet aggregation and secretion were observed in aspirin-treated patients with HARPR.This study supports the role of MRP4 on modulating platelet function which occurs through cAMP-independent mechanisms.	Cyclic AMP	193-197	ATP binding cassette subfamily C member 4	Homo sapiens	135-139
29448294-10	2018	Moreover, inhibition of MRP4 induced by cilostazol enhances aspirin-induced antiplatelet effects and reduces HARPR.	Cilostazol	40-50	ATP binding cassette subfamily C member 4	Homo sapiens	24-28
29448294-10	2018	Moreover, inhibition of MRP4 induced by cilostazol enhances aspirin-induced antiplatelet effects and reduces HARPR.	Aspirin	60-67	ATP binding cassette subfamily C member 4	Homo sapiens	24-28
28960749-3	2018	Efflux of [3 H]-9-(2-phosphonomethoxyethyl) adenine ([3 H]-PMEA), a known ABCC4 substrate in humans, was detected from PhABCC4 cRNA-injected oocytes by liquid scintillation spectrophotometric analysis and PhABCC4 expression in oocytes was confirmed using ABC transporter inhibitors.	[3 h]-9-(2-phosphonomethoxyethyl) adenine	10-51	ATP binding cassette subfamily C member 4	Homo sapiens	74-79
28960749-3	2018	Efflux of [3 H]-9-(2-phosphonomethoxyethyl) adenine ([3 H]-PMEA), a known ABCC4 substrate in humans, was detected from PhABCC4 cRNA-injected oocytes by liquid scintillation spectrophotometric analysis and PhABCC4 expression in oocytes was confirmed using ABC transporter inhibitors.	adefovir	59-63	ATP binding cassette subfamily C member 4	Homo sapiens	74-79
28960749-3	2018	Efflux of [3 H]-9-(2-phosphonomethoxyethyl) adenine ([3 H]-PMEA), a known ABCC4 substrate in humans, was detected from PhABCC4 cRNA-injected oocytes by liquid scintillation spectrophotometric analysis and PhABCC4 expression in oocytes was confirmed using ABC transporter inhibitors.	phabcc4	119-126	ATP binding cassette subfamily C member 4	Homo sapiens	74-79
28885828-0	2017	Multidrug Resistance Protein 4 (MRP4/ABCC4) Protects Cells from the Toxic Effects of Halobenzoquinones.	halobenzoquinones	85-102	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
30372692-13	2018	Expression of MRP4, a nucleoside transporter, appeared to influence the response of AML cells to ODE-adefovir, as its inhibition potentiated ODE-adefovir killing.	ode-adefovir	97-109	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
30372692-13	2018	Expression of MRP4, a nucleoside transporter, appeared to influence the response of AML cells to ODE-adefovir, as its inhibition potentiated ODE-adefovir killing.	adefovir	101-109	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
29304533-0	2018	Release of Platelet-Derived Sphingosine-1-Phosphate Involves Multidrug Resistance Protein 4 (MRP4/ABCC4) and Is Inhibited by Statins.	sphingosine 1-phosphate	28-51	ATP binding cassette subfamily C member 4	Homo sapiens	93-97
29304533-0	2018	Release of Platelet-Derived Sphingosine-1-Phosphate Involves Multidrug Resistance Protein 4 (MRP4/ABCC4) and Is Inhibited by Statins.	sphingosine 1-phosphate	28-51	ATP binding cassette subfamily C member 4	Homo sapiens	98-103
29304533-5	2018	Transport studies in membrane vesicles of Sf9 cells containing recombinant human MRP4 revealed that MRP4 mediates ATP-dependent transport of fluorescein- and tritium-labelled S1P.	Adenosine Triphosphate	114-117	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
29304533-5	2018	Transport studies in membrane vesicles of Sf9 cells containing recombinant human MRP4 revealed that MRP4 mediates ATP-dependent transport of fluorescein- and tritium-labelled S1P.	Adenosine Triphosphate	114-117	ATP binding cassette subfamily C member 4	Homo sapiens	100-104
29304533-5	2018	Transport studies in membrane vesicles of Sf9 cells containing recombinant human MRP4 revealed that MRP4 mediates ATP-dependent transport of fluorescein- and tritium-labelled S1P.	Fluorescein	141-152	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
29146910-5	2017	Specific disruption of this protein complex, either genetically or chemically, removed ABCC4 from the plasma membrane, increased drug sensitivity, and abrogated MPP1-dependent hematopoietic progenitor cell replating in methylcellulose.	Methylcellulose	219-234	ATP binding cassette subfamily C member 4	Homo sapiens	87-92
29146910-6	2017	High-throughput screening identified Antimycin A as a small molecule that disrupted the ABCC4-MPP1 protein complex and reversed drug resistance in AML cell lines and in primary patient AML cells.	Antimycin A	37-48	ATP binding cassette subfamily C member 4	Homo sapiens	88-93
29061086-4	2017	RESULTS: The estimated glomerular filtration rate calculated by the Cockcroft and Gault equation, concomitant use of lopinavir/ritonavir and ABCC4 3463A&gt;G polymorphism were associated with tenofovir apparent oral clearance (CL/F).	Tenofovir	192-201	ATP binding cassette subfamily C member 4	Homo sapiens	141-146
29061086-4	2017	RESULTS: The estimated glomerular filtration rate calculated by the Cockcroft and Gault equation, concomitant use of lopinavir/ritonavir and ABCC4 3463A&gt;G polymorphism were associated with tenofovir apparent oral clearance (CL/F).	Fluorine	230-231	ATP binding cassette subfamily C member 4	Homo sapiens	141-146
29061583-6	2018	In addition, recombinant NRF2-siRNA was effective to sensitize both 143B and MG63 cells to doxorubicin, cisplatin, and sorafenib, which was associated with significant downregulation of NRF2-targeted ATP-binding cassette (ABC) efflux transporters (ABCC3, ABCC4, and ABCG2).	Sorafenib	119-128	ATP binding cassette subfamily C member 4	Homo sapiens	255-260
29304533-5	2018	Transport studies in membrane vesicles of Sf9 cells containing recombinant human MRP4 revealed that MRP4 mediates ATP-dependent transport of fluorescein- and tritium-labelled S1P.	Fluorescein	141-152	ATP binding cassette subfamily C member 4	Homo sapiens	100-104
29304533-5	2018	Transport studies in membrane vesicles of Sf9 cells containing recombinant human MRP4 revealed that MRP4 mediates ATP-dependent transport of fluorescein- and tritium-labelled S1P.	Tritium	158-165	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
29304533-5	2018	Transport studies in membrane vesicles of Sf9 cells containing recombinant human MRP4 revealed that MRP4 mediates ATP-dependent transport of fluorescein- and tritium-labelled S1P.	Tritium	158-165	ATP binding cassette subfamily C member 4	Homo sapiens	100-104
29304533-6	2018	Also, ATP-dependent S1P transport in platelet membrane vesicles containing endogenous MRP4 was inhibited by the MRP inhibitor MK571 and the MRP4-selective compound Ceefourin-1.	Adenosine Triphosphate	6-9	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
29304533-6	2018	Also, ATP-dependent S1P transport in platelet membrane vesicles containing endogenous MRP4 was inhibited by the MRP inhibitor MK571 and the MRP4-selective compound Ceefourin-1.	Adenosine Triphosphate	6-9	ATP binding cassette subfamily C member 4	Homo sapiens	140-144
29304533-6	2018	Also, ATP-dependent S1P transport in platelet membrane vesicles containing endogenous MRP4 was inhibited by the MRP inhibitor MK571 and the MRP4-selective compound Ceefourin-1.	verlukast	126-131	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
29304533-6	2018	Also, ATP-dependent S1P transport in platelet membrane vesicles containing endogenous MRP4 was inhibited by the MRP inhibitor MK571 and the MRP4-selective compound Ceefourin-1.	ceefourin 1	164-175	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
29304533-6	2018	Also, ATP-dependent S1P transport in platelet membrane vesicles containing endogenous MRP4 was inhibited by the MRP inhibitor MK571 and the MRP4-selective compound Ceefourin-1.	ceefourin 1	164-175	ATP binding cassette subfamily C member 4	Homo sapiens	140-144
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Fluvastatin	0-11	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Fluvastatin	0-11	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Fluvastatin	0-11	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Rosuvastatin Calcium	16-28	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Rosuvastatin Calcium	16-28	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Rosuvastatin Calcium	16-28	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Adenosine Triphosphate	70-73	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Adenosine Triphosphate	70-73	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Adenosine Triphosphate	70-73	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Cyclic GMP	84-88	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Cyclic GMP	84-88	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Cyclic GMP	84-88	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Cyclic GMP	90-120	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Cyclic GMP	90-120	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
29304533-9	2018	Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo.	Cyclic GMP	90-120	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
28885828-0	2017	Multidrug Resistance Protein 4 (MRP4/ABCC4) Protects Cells from the Toxic Effects of Halobenzoquinones.	halobenzoquinones	85-102	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
28885828-8	2017	To further support MRP4-mediated detoxication of HBQs, we examined the HBQ-induced ROS levels in HEK-MRP4 and HEK-V cells.	Opaviraline	49-52	ATP binding cassette subfamily C member 4	Homo sapiens	19-23
28885828-8	2017	To further support MRP4-mediated detoxication of HBQs, we examined the HBQ-induced ROS levels in HEK-MRP4 and HEK-V cells.	Reactive Oxygen Species	83-86	ATP binding cassette subfamily C member 4	Homo sapiens	101-105
28885828-9	2017	ROS levels were significantly reduced in HEK-MRP4 cells compared with HEK-V cells after HBQ treatment.	Reactive Oxygen Species	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
28885828-9	2017	ROS levels were significantly reduced in HEK-MRP4 cells compared with HEK-V cells after HBQ treatment.	Opaviraline	88-91	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
28885828-10	2017	Furthermore, it was found that MRP4-mediated detoxication of the HBQs was GSH dependent, as the cytotoxicity of the HBQs was increased in GSH-depleted HEK-MRP4 cells in comparison to HEK-MRP4 cells.	Glutathione	74-77	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
28885828-10	2017	Furthermore, it was found that MRP4-mediated detoxication of the HBQs was GSH dependent, as the cytotoxicity of the HBQs was increased in GSH-depleted HEK-MRP4 cells in comparison to HEK-MRP4 cells.	Glutathione	74-77	ATP binding cassette subfamily C member 4	Homo sapiens	155-159
28885828-10	2017	Furthermore, it was found that MRP4-mediated detoxication of the HBQs was GSH dependent, as the cytotoxicity of the HBQs was increased in GSH-depleted HEK-MRP4 cells in comparison to HEK-MRP4 cells.	Glutathione	74-77	ATP binding cassette subfamily C member 4	Homo sapiens	155-159
28885828-10	2017	Furthermore, it was found that MRP4-mediated detoxication of the HBQs was GSH dependent, as the cytotoxicity of the HBQs was increased in GSH-depleted HEK-MRP4 cells in comparison to HEK-MRP4 cells.	Glutathione	138-141	ATP binding cassette subfamily C member 4	Homo sapiens	31-35
28885828-10	2017	Furthermore, it was found that MRP4-mediated detoxication of the HBQs was GSH dependent, as the cytotoxicity of the HBQs was increased in GSH-depleted HEK-MRP4 cells in comparison to HEK-MRP4 cells.	Glutathione	138-141	ATP binding cassette subfamily C member 4	Homo sapiens	155-159
28885828-10	2017	Furthermore, it was found that MRP4-mediated detoxication of the HBQs was GSH dependent, as the cytotoxicity of the HBQs was increased in GSH-depleted HEK-MRP4 cells in comparison to HEK-MRP4 cells.	Glutathione	138-141	ATP binding cassette subfamily C member 4	Homo sapiens	155-159
28885828-11	2017	The GSH-dependent protection of cells from HBQs supports the possibility of HBQ-GSH conjugate efflux by MRP4.	Glutathione	4-7	ATP binding cassette subfamily C member 4	Homo sapiens	104-108
28885828-11	2017	The GSH-dependent protection of cells from HBQs supports the possibility of HBQ-GSH conjugate efflux by MRP4.	Glutathione	80-83	ATP binding cassette subfamily C member 4	Homo sapiens	104-108
28850245-0	2017	Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.	Glucuronides	29-41	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
28850245-0	2017	Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.	Hymecromone	94-115	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
28850245-0	2017	Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.	naphthyl glucuronide	120-143	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
28850245-0	2017	Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.	propranolol glucuronide	181-204	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
28850245-6	2017	Our results revealed high transport rates and apparent affinity of MRP4 toward the glucuronides of 4-methylumbelliferone, 1-naphthol, and 1-hydroxypyrene (Km values of 168, 13, and 3 muM, respectively) in comparison to MRP3 (Km values of 278, 98, and 8 muM, respectively).	Glucuronides	83-95	ATP binding cassette subfamily C member 4	Homo sapiens	67-71
28850245-6	2017	Our results revealed high transport rates and apparent affinity of MRP4 toward the glucuronides of 4-methylumbelliferone, 1-naphthol, and 1-hydroxypyrene (Km values of 168, 13, and 3 muM, respectively) in comparison to MRP3 (Km values of 278, 98, and 8 muM, respectively).	Hymecromone	99-120	ATP binding cassette subfamily C member 4	Homo sapiens	67-71
28850245-6	2017	Our results revealed high transport rates and apparent affinity of MRP4 toward the glucuronides of 4-methylumbelliferone, 1-naphthol, and 1-hydroxypyrene (Km values of 168, 13, and 3 muM, respectively) in comparison to MRP3 (Km values of 278, 98, and 8 muM, respectively).	1-naphthol	122-132	ATP binding cassette subfamily C member 4	Homo sapiens	67-71
28850245-6	2017	Our results revealed high transport rates and apparent affinity of MRP4 toward the glucuronides of 4-methylumbelliferone, 1-naphthol, and 1-hydroxypyrene (Km values of 168, 13, and 3 muM, respectively) in comparison to MRP3 (Km values of 278, 98, and 8 muM, respectively).	1-hydroxypyrene	138-153	ATP binding cassette subfamily C member 4	Homo sapiens	67-71
28850245-11	2017	Our results provide new information, at the molecular level, of efflux transport of the tested glucuronides, which could explain their disposition in vivo, as well as provide new tools for in vitro studies of MRP3, MRP4, and BCRP.	Glucuronides	95-107	ATP binding cassette subfamily C member 4	Homo sapiens	215-219
29190892-8	2017	Using genetic and pharmacological approaches, we demonstrated that MDR1 and MRP4 were major effectors of H19-regulated Dox resistance in breast cancer cells as MDR1 and MRP4 expression was markedly elevated in Dox-resistant cells while dramatically reduced when H19 was knocked down.	Doxorubicin	119-122	ATP binding cassette subfamily C member 4	Homo sapiens	76-80
29190892-8	2017	Using genetic and pharmacological approaches, we demonstrated that MDR1 and MRP4 were major effectors of H19-regulated Dox resistance in breast cancer cells as MDR1 and MRP4 expression was markedly elevated in Dox-resistant cells while dramatically reduced when H19 was knocked down.	Doxorubicin	119-122	ATP binding cassette subfamily C member 4	Homo sapiens	169-173
29190892-8	2017	Using genetic and pharmacological approaches, we demonstrated that MDR1 and MRP4 were major effectors of H19-regulated Dox resistance in breast cancer cells as MDR1 and MRP4 expression was markedly elevated in Dox-resistant cells while dramatically reduced when H19 was knocked down.	Doxorubicin	210-213	ATP binding cassette subfamily C member 4	Homo sapiens	76-80
29190892-8	2017	Using genetic and pharmacological approaches, we demonstrated that MDR1 and MRP4 were major effectors of H19-regulated Dox resistance in breast cancer cells as MDR1 and MRP4 expression was markedly elevated in Dox-resistant cells while dramatically reduced when H19 was knocked down.	Doxorubicin	210-213	ATP binding cassette subfamily C member 4	Homo sapiens	169-173